

# Bibliometric analysis of ongoing projects

## 12<sup>th</sup> Report September 2021

**Copyright ©2021 Innovative Medicines Initiative**

Prepared by Clarivate on behalf of IMI Programme Office under a public procurement procedure document reference:  
IMI.2018.OP.01.

#### Disclaimer/Legal Notice

This document has been prepared solely for the Innovative Medicines Initiative (IMI). All contents may not be re-used (in whatever form and by whatever medium) by any third party without prior permission of the IMI.

## TABLE OF CONTENTS

<b>1</b>	<b>EXECUTIVE SUMMARY .....</b>	<b>5</b>
<b>2</b>	<b>INTRODUCTION .....</b>	<b>8</b>
2.1	OVERVIEW .....	8
2.2	INNOVATIVE MEDICINES INITIATIVE (IMI) JOINT UNDERTAKING .....	8
2.3	CLARIVATE .....	8
2.4	SCOPE OF THIS REPORT .....	10
<b>3</b>	<b>DATA SOURCES, INDICATORS AND INTERPRETATION .....</b>	<b>11</b>
3.1	BIBLIOMETRICS AND CITATION ANALYSIS .....	11
3.2	DATA SOURCE .....	11
3.3	METHODOLOGY .....	12
3.4	DATA COLLATION .....	14
<b>4</b>	<b>CITATION ANALYSIS – IMI SUPPORTED PUBLICATIONS OVERALL.....</b>	<b>15</b>
4.1	PUBLICATIONS FROM IMI-SUPPORTED PROJECTS .....	15
4.2	PUBLICATIONS FROM IMI PROJECTS BY DOCUMENT TYPE.....	17
4.3	TRENDS IN PUBLICATION OUTPUT .....	18
4.4	PUBLICATION OUTPUT BY COUNTRY.....	20
4.5	PUBLICATION OUTPUT BY IMI PROJECT.....	23
4.6	IS IMI PROJECT RESEARCH WELL-CITED? .....	25
4.7	IN WHICH JOURNALS DO IMI PROJECT PUBLICATIONS APPEAR MOST FREQUENTLY? .....	27
4.8	WHICH RESEARCH FIELDS ACCOUNT FOR THE HIGHEST VOLUME OF IMI PROJECT PUBLICATIONS? .....	31
4.9	IMI RESEARCH FIELDS WITH THE HIGHEST VOLUME OF PUBLICATIONS BENCHMARKED AGAINST EU-28 PUBLICATIONS OF THE SAME FIELD .....	36
<b>5</b>	<b>CITATION ANALYSIS – AT IMI PROJECT LEVEL.....</b>	<b>39</b>
5.1	TRENDS IN PUBLICATION OUTPUT BY IMI FUNDING CALL .....	39
5.2	SUMMARY BIBLIOMETRIC ANALYSES FOR IMI 1 PROJECTS – CALL 1 .....	43
5.3	SUMMARY BIBLIOMETRIC ANALYSES FOR IMI 1 PROJECTS – CALL 2 .....	45
5.4	SUMMARY BIBLIOMETRIC ANALYSES FOR IMI 1 PROJECTS – CALL 3 .....	47
5.5	SUMMARY BIBLIOMETRIC ANALYSES FOR IMI 1 PROJECTS – CALL 4 .....	49
5.6	SUMMARY BIBLIOMETRIC ANALYSES FOR IMI 1 PROJECTS – CALL 5-10.....	51
5.7	SUMMARY BIBLIOMETRIC ANALYSES FOR IMI 1 PROJECTS – CALL 11 .....	53
5.8	SUMMARY BIBLIOMETRIC ANALYSES FOR IMI 2 PROJECTS .....	55
<b>6</b>	<b>GEOGRAPHIC CLUSTERING ANALYSIS.....</b>	<b>62</b>
6.1	LOCATIONS WHERE IMI-FUNDED RESEARCH TAKES PLACE.....	62
<b>7</b>	<b>COLLABORATION ANALYSIS FOR IMI RESEARCH.....</b>	<b>76</b>

7.1	COLLABORATION ANALYSIS FOR IMI RESEARCH .....	76
7.2	COLLABORATION ANALYSIS BY IMI PROJECT .....	79
7.3	COLLABORATION METRICS FOR IMI RESEARCH.....	95
7.4	COLLABORATION INDEX.....	105
<b>8</b>	<b>BENCHMARKING ANALYSIS – IMI PROJECT RESEARCH AGAINST RESEARCH FROM SELECTED COMPARATORS .....</b>	<b>108</b>
8.1	IDENTIFYING COMPARATORS .....	108
8.2	TRENDS IN OUTPUT: IMI PROJECT RESEARCH COMPARED WITH SELECTED COMPARATORS .....	109
8.3	SUMMARY OF BIBLIOMETRIC INDICATORS: IMI PROJECT RESEARCH COMPARED WITH SELECTED COMPARATORS .....	124
	<b>ANNEX 1: BIBLIOMETRICS AND CITATION ANALYSIS.....</b>	<b>125</b>
	<b>ANNEX 2: BIOMEDICALLY RELATED JOURNAL CATEGORIES.....</b>	<b>134</b>
	<b>ANNEX 3: TOTAL NUMBER OF WEB OF SCIENCE PUBLICATIONS FROM IMI PROJECTS BETWEEN 2010 AND 2019 BY COUNTRY .....</b>	<b>135</b>
	<b>ANNEX 4: TOTAL NUMBER OF WEB OF SCIENCE PUBLICATIONS, PAPERS AND OPEN- ACCESS PUBLICATIONS BETWEEN 2010 AND 2019 BY PROJECT .....</b>	<b>138</b>
	<b>ANNEX 5: COLLABORATION INDEX FOR ALL IMI SUPPORTED RESEARCH PROJECTS .....</b>	<b>142</b>
	<b>ANNEX 6: BIBLIOGRAPHY OF HOT PAPERS AND HIGHLY-CITED PAPERS.....</b>	<b>146</b>

# 1 EXECUTIVE SUMMARY

This report presents a bibliometric analysis of the Innovative Medicine Initiative Joint Undertaking's (IMI JU) research published between 2010 and 2020, using citations as an index of academic impact and co-authorship as an index of collaboration. This is the twelfth report commissioned by IMI from Clarivate.

The data show that IMI continues to perform well. To date, IMI projects have produced 7,177 publications which have been matched to the Clarivate Web of Science™. This represents a 21% increase from the 5,943 publications matched to the Web of Science in the eleventh report, which covered IMI project research published between 2010 and 2019.

The number of IMI research publications has generally increased year on year, except for the year 2019 where output fell by almost 8% as noted in the eleventh report. Publication growth has since recovered and in 2020, the most recent publication year, publication output has increased by 19% from 2019 and 10% from 2018. This recovery was likely driven by new IMI 2 projects and other IMI 2 projects such as AIMS-2-Trials, RESCEU, and RHAPSODY which all published more than double the number of papers in 2020 than in 2019.

The majority of IMI research (67%) continues to be published in high impact journals, i.e., those journals in the highest quartile (Q1) when ranked by Journal Impact Factor, and the average Journal Impact Factor of all IMI project publications was 6.93. IMI research was wide-ranging from basic biological research to clinical practice. IMI project research has been published most frequently in the fields of Pharmacology & Pharmacy, Neurosciences and Biochemistry & Molecular Biology.

The impact of IMI project research (as indicated by citation impact) remains around twice (1.99) the world average (1.00), which indicates that the research was internationally influential. Between 2010 and 2020, the field-normalised citation impact of IMI papers was considerably higher (73%) than the European Union's (EU) average citation impact (1.15) in similar biomedical fields (journal subject categories). Around a quarter (25.7%) of IMI project papers were highly cited; that is, the papers were in the world's top 10% of papers (taking journal category and year of publication into account), when ranked by number of citations.

The output of individual IMI projects has also increased between 2010 and 2020. BTCure (Call 2) has remained the most prolific IMI project, with 703 publications as of this report. This is a 2% increase on the 689 publications attributed to BTCure in the previous report. However, this growth is slower than then last year's growth of 5.4%, supporting the fact that the BTCure project ended in early 2017. It's also worth noting that INNODIA is new to the Top 10 projects, ranking 9<sup>th</sup>, as its publication output has grown by 31% since the previous report. Although this project is not the fastest growing project as the publication output of the AIMS-2-TRIALS (ranked 20<sup>th</sup>) project grew by 110% (from 51 publications in 2019 to 107 in 2020.)

Projects funded by IMI are highly collaborative. Since the last report, an increasing percentage of IMI publications involve collaboration between researchers in different sectors. Nearly two-thirds (65.2%) of all IMI project papers were co-authored by researchers working in different sectors, more than three-quarters (84.8%) involved collaboration between institutions and more than half (63.3%) were internationally collaborative. Internationally collaborative IMI project research had an average citation impact (2.71) well over twice the world average (1.00) and higher than non-internationally collaborative IMI project research (1.85).

Research in both Europe and North America tends to be clustered in major cities with an existing strong academic research base. The citation impact of IMI papers within these clusters is higher than national averages and rates of international co-authorship are very high (70-100%) compared to the averages for EU-28 biomedical research (40%). The European and North American clusters with the highest proportion of open access publications are Oxford, UK (86.2%) and Seattle (90.4%) respectively.

IMI's field-normalised citation impact (1.99) fell by 3%, although this decrease is also seen with other well-established funding bodies such as the Commonwealth Scientific and Industrial Research Organisation (CSIRO), the Critical Path Institute and the Grand Challenges in Global Health who had a 6%, 5% and 3% decrease, respectively. The only exception is the Medical Research Council (MRC) which saw a 1% increase of its field-normalised citation impact (2.03). Even with this decrease IMI still exceeds many other funding bodies except for the MRC (2.03) and the Wellcome Trust (2.04). IMI's journal-normalised citation impact (1.21) is the highest among the comparators but only slightly outperforms CSIRO (1.20) and FNIH (1.19). IMI's percentage of highly cited papers (25.7%) outperforms all the comparators, except GCGH (26.4%).

A more detailed summary of the key findings of this report (with cross-references to the relevant sections) is provided below.

### Summary of key findings

Since its first call for proposals in 2008, IMI has funded 172 projects from a total of 34 funding calls. Of the calls, 11 were from IMI's first phase (IMI 1), which ran from 2008 to 2013, and the rest from its second phase (IMI 2), which was launched in 2014 and is ongoing.

It may take several months for a project to progress from inception to the point where it has generated sufficient data for a publication. It may take further months or years until it has produced its most valuable results. As some of the IMI projects analysed in this report are relatively young, the bibliometric indicators may not fully reflect their eventual impact.

- IMI projects have published a total of 7,177 unique Web of Science publications (Figure 4.1.1).
- IMI's publication growth has since recovered from its dip in 2019. (Figure 4.3.1).
- A quarter (25.7%) of IMI papers were in the world's top 10% of most highly cited papers in the relevant field and year of publication, suggesting very strong performance (Table 4.6.1).
- The field-normalised citation impact of IMI project papers was almost twice the world average (1.99) between 2010 and 2020, only slightly lower than last years (2.05). (Figure 4.6.1)
- More IMI project publications appeared in *Annals of the Rheumatic Diseases* (178 publications) and *PLOS One* (178 publications) than in other journals. Of the 20 journals in which IMI-funded projects published most frequently, nearly three-quarters (14 journals) rank in the top quartile by Journal Impact Factor (Table 4.7.1).
- The highest Impact Factor journal in which IMI research was published is *Nature Reviews Molecular Cell Biology* (1 publication), which has a Journal Impact Factor of 94.44. Of the Top 20 journals by Impact Factor, IMI published most frequently in *Nature* (49.96) with 22 publications, followed by *Lancet Neurology* (44.18) with 18 publications (Table 4.7.2).
- IMI project research was most frequently published in Pharmacology & Pharmacy journals (Figure 4.8.1). Of the 771 papers published in this field, 19.8% were highly cited, 50.2% were open access, and the average citation impact of these papers was 1.45 times the world average for the year and field of publication (Table 4.8.2 and Table 4.8.3).
- IMI 2 project research was most frequently published in Endocrinology & Metabolism journals (177 publications), suggesting that IMI 2 projects have had a slightly different focus to IMI 1 projects (Figure 4.8.2).
- IMI research in the Clinical Neurology category has the highest percentage of highly cited papers. (Table 4.8.3)
- IMI project research had a citation impact well above the European (EU-28) average in all of the 20 journal subject categories to which most IMI publications are assigned (

- Table 4.9.1 and Figure 4.9.1).
- Early IMI 1 calls (1-4) follow a similar pattern of initial growth in publication output for 3 to 6 years followed by a decline as projects end (Figure 5.1.1).
- The publication output of most of IMI 2 calls is currently growing. Especially Call 10 which published 100 papers in 2020, more than any other call. This growth was largely driven by the AIMS-2-Trials project which published 73 publications in 2020. (Figure 5.1.3)
- Papers assigned to IMI 2 call 7 had the highest average field-normalised citation impact (3.19); more than three times the world average. This is mainly driven by six highly cited papers mainly within the IMPRIND project, which were cited between 20 and 40 times the world average. (Table 5.1.1)
- The largest geographic clusters of research supported by IMI in Europe are London (1,454 publications), Amsterdam (1,221 publications) and Stockholm (685 publications). The largest clusters in North America are Toronto (310 publications), Boston (296 publications) and Bethesda (172 publications). (Table 6.1.1 and Table 6.1.3)
- IMI research in all the European and North American geographic clusters performs well above the national averages in terms of citation impact. The highest citation impact European clusters are Maastricht (3.69) and Cambridge (3.43), both more than twice their respective national averages of 1.70 and 1.52. (Table 6.1.2 and Table 6.1.4)
- Around 40% of all EU-28 biomedical research involves international co-authorship while in comparison rates of international collaboration for IMI project research are very high for most clusters, especially in North America where most clusters have around 90% international collaboration which is expected as IMI is European funding organisation that primarily funds researchers working in EU-28. The European cluster with the highest rate of internationally collaborative papers was Dresden, with 95.5% of its research involving international co-authorship. While the European cluster, Uppsala, remained the lowest at 70% international collaboration. (Table 6.1.1 and Table 6.1.3).
- IMI project research is collaborative across sectors, institutions, and countries. Nearly two-thirds (65%) of IMI project papers were co-authored by researchers from different sectors. More than three-quarters (85%) of IMI project papers involved collaboration between different institutions. And more than half (63%) of all IMI project papers were internationally collaborative (Table 7.1.1).
- IMI's collaborative research for sectors, institutions, and countries has an average field-normalised citation impact that is almost 50% higher than IMI's non-collaborative research. (sectors: 2.67 vs 1.84, institutions: 2.57 vs 1.63, and countries: 2.71 vs 1.84) (Figure 7.1.1)
- BTCURE, followed by EU-AIMS, had the highest number of papers with co-authors from more than one country, institution and sector. This may be due to these projects having the highest and second highest overall number of papers. (Table 7.1.1-Table 7.2.3)
- For those projects with at least 100 papers, AIMS-2-TRIALS has the highest percentage of its papers with co-authors from more than one country (76.2%) and institution (96%). While INNODIA has the highest percentage of its papers (82.5%) with co-authors from more than one sector. (Table 7.2.1-Table 7.2.3).
- King's College London is part of seven out of the ten most productive pairs of collaborating institutions, including the top pair where King's College London collaborated with Heidelberg University on 120 publications. (Figure 7.3.3.1)
- PROACTIVE has the highest collaboration index score of 2.62. (Table 7.4.1)
- IMI's research output grew faster between 2010 and 2020 than any of the seven selected comparators (Table 8.2.1.1).
- IMI's field-normalised citation impact (1.99) was only very slightly lower than the Wellcome Trust's (2.04) and the MRC's (2.03) and higher than all the other comparators (Figure 8.2.2.2).

- IMI's percentage of uncited research (44.6%) has remained the lowest of all the comparators since 2017. (Table 8.2.5.1 )
- IMI has a higher percentage of highly cited papers (25.7%) than all the comparators except GCGH (26.4%). (Figure 8.2.6.2 )

## 2 INTRODUCTION

### 2.1 OVERVIEW

The Innovative Medicines Initiative (IMI) Joint Undertaking has commissioned Clarivate to undertake a yearly evaluation of its research portfolio using bibliometric indicators.

The commissioned evaluation comprises a series of reports focusing on research publications produced by IMI funded researchers. This report is the twelfth evaluation in the series.

### 2.2 INNOVATIVE MEDICINES INITIATIVE (IMI) JOINT UNDERTAKING

IMI's purpose is to improve health by speeding up the development of, and patient access to, innovative medicines, particularly in areas where there is an unmet medical or social need. It does this by facilitating collaboration between the key players in healthcare research, including universities, pharmaceutical companies and other industries, small and medium-sized enterprises (SMEs), patient organisations, and medicines regulators.

IMI is a partnership between the EU and the European pharmaceutical industry, represented by the European Federation of Pharmaceutical Industries and Associations (EFPIA). IMI, as part of its second phase (IMI 2), has a budget of €3.3 billion for the period of 2014 to 2024. Half of this comes from the EU's research and innovation programme, Horizon 2020. The other half comes from large companies, mostly in the pharmaceutical sector; these organisations do not receive any EU funding, but contribute to the projects 'in kind', for example by donating their researchers' time or providing access to research facilities or resources. The first phase of IMI had a budget of €2 billion equally shared between EU and EFPIA.

To date, IMI has announced 11 calls for proposals under its first phase and a further 23 (ongoing) calls for proposals under its second phase. The first funding call was announced in 2008 and the final calls were launched in June 2020. In February 2021, the Innovative Health Initiative (IHI), a new public-private partnership in health was announced that will run under Horizon Europe, the new European framework programme for research and innovation. This new partnership will build upon the Innovative Medicines Initiative (IMI) but will have a greater focus on cross sectoral collaborations involving biopharmaceutical, medical technology, and biotechnology sectors. This report covers the research output (publications and papers) of a total of 61 projects from IMI phase one and 111 projects from IMI phase two.

### 2.3 CLARIVATE

Clarivate, provides reporting and consultancy services to enable customers to understand and interpret their research performance and to inform strategic decision-making. We have extensive experience with databases of research inputs, activity and outputs and have developed innovative analytical approaches for benchmarking, interpreting and visualising research impact.

Clarivate's Research Analytics is a suite of products, services and tools that provide comprehensive research analysis, evaluation and management. For over half a century we have pioneered the world of citation indexing and analysis, helping to connect scientific and scholarly thought around the world. Today, academic and research institutions, governments, not-for-profits, funding agencies, and all others with a stake in research, need reliable, objective methods for managing and measuring performance.



Our consultants have up to 20 years of experience in research performance analysis and interpretation. In addition, the Clarivate regional Sales team provide effective on-site support to maximise the value of our work.

Visit [Clarivate](#) or our [Professional Research Data Services](#) team online for more information.

## 2.4 SCOPE OF THIS REPORT

The analyses and indicators presented in this report have been selected to provide an analysis of IMI research published output for research management purposes:

- To identify excellence in IMI-supported research overall and at individual call or project level.
- To benchmark IMI project research performance against other funders research, the EU-28 biomedical research and world averages.
- To show that collaboration, at all levels (researcher, institutional and country), is being encouraged through the projects funded by IMI.
- 

Outline of this report:

- Section 3 describes the data sources and methodology used in this report along with definitions of the indicators and guidelines to interpretation.
- Bibliometrics
- Section 4 presents analyses of IMI project publications overall, including trends in publications, frequently used journals, and top research fields. Where possible IMI research is benchmarked to EU-28 biomedical research.<sup>1</sup>
- Section 5 presents citation analyses of IMI publications at the call level, examining the citation impact and outputs of individual project. Where possible the IMI projects are benchmarked to world output and overall IMI output.
- Section 6 presents geographic clusters where IMI research activity occurs, including bibliometric data, the constituent institutions and top five journal subject categories within the clusters.
- Collaboration
- Section 7 presents collaboration analyses for IMI publications overall and at the project level, examining collaboration between different sectors, institutions, and countries.
- Benchmarking
- Section 8 presents analysis of IMI publications, benchmarked to similar funding organisations. The organisations are: Commonwealth Scientific and Industrial Research Organisation (CSIRO), Critical Path Institute (C-Path), Foundation for the National Institutes of Health (FNIH), Grand Challenges in Global Health (GCGH), Indian Council of Medical Research (ICMR), Medical Research Council (MRC), and the Wellcome Trust (WT).

---

<sup>1</sup> At time of publication, September 2021, the United Kingdom has left the European Union, however as the EU and United Kingdom are a transitional period in their relationship and to date there has not been any large changes to the United Kingdom's participation in Horizon 2020 funded research the United Kingdom is still included in the EU-28.

## 3 DATA SOURCES, INDICATORS AND INTERPRETATION

### 3.1 BIBLIOMETRICS AND CITATION ANALYSIS

Research evaluation increasingly uses bibliometric data and analyses to assess performance. Bibliometrics is the analysis of data derived from publications and their citations. Publication of research outcomes is an integral part of the research process and is a universal activity. Consequently, bibliometric data have a currency across subjects, time and location that is found in few other sources of research-relevant data. The use of bibliometric analysis, allied to informed review by experts, increases the objectivity of, and confidence in, evaluation.

Research publications accumulate citation counts when they are referred to by more recent publications. Citations to prior work are a normal part of publication and reflect the value placed on a work by later researchers. Some papers get cited frequently and many remain uncited. Highly cited work is recognised as having a greater impact and Clarivate has shown that high citation rates are correlated with other qualitative evaluations of research performance, such as peer review.<sup>2</sup> This relationship holds across most science and technology areas and, to a limited extent, in social sciences and even in some humanities subjects.

Indicators derived from publication and citation data should always be used with caution. Some fields publish at faster rates than others and citation rates also vary. Citation counts must be carefully normalised to account for such variations by field. Because citation counts naturally grow over time, it is essential to account for growth by year. Normalisation is usually done by reference to the relevant global average for the field and for the year of publication.

Bibliometric indicators have been found to be more informative for core natural sciences, especially for basic science, than they are for applied and professional areas and for social sciences. In professional areas the range of publication modes used by leading researchers is likely to be diverse as they target a diverse, non-academic audience. In social sciences there is also a diversity of publication modes and citation rates are typically much lower than in natural sciences.

Bibliometrics work best with large data samples. As the data are disaggregated, so the relationship weakens. Average indicator values (e.g., of citation impact) for small numbers of publications can be skewed by single outlier values. At a finer scale, when analysing the specific outcome for individual departments, the statistical relationship is rarely a sufficient guide by itself. For this reason, bibliometrics are best used in support of, but not as a substitute for, expert decision processes. Well-founded analyses can enable conclusions to be reached more rapidly and with greater certainty and are therefore an aid to management and to increased confidence among stakeholders, but they cannot substitute for review by well-informed and experienced peers.

### 3.2 DATA SOURCE

For the bibliometric analysis, data will be sourced from the databases underlying the Clarivate **Web of Science**, which gives access to conference proceedings, patents, websites, and chemical structures, compounds and reactions in addition to journals. It has a unified structure that integrates all data and search terms together and therefore provides a level of comparability not found in other databases. It is widely acknowledged to be the world's leading source of citation and bibliometric data.

The **Web of Science Core Collection** is part of the Web of Science and focuses on research published in journals and conferences in science, medicine, arts, humanities, and social sciences. The authoritative, multidisciplinary content covers over 34,000 of the highest impact journals worldwide, including open access and over 205,000 conference proceedings. Coverage is both current and

---

<sup>2</sup> Evidence Ltd. (2002) Maintaining Research Excellence and Volume: A report by Evidence Ltd to the Higher Education Funding Councils for England, Scotland and Wales and to Universities United Kingdom (UK). (Adams J, et al.) 48pp.

retrospective in the sciences, social sciences, arts, and humanities, in some cases back to 1900. Within the research community, these data are often still referred to by the acronym 'ISI'.<sup>3</sup> Clarivate has extensive experience with databases on research inputs, activity and outputs and has developed innovative analytical approaches for benchmarking and interpreting international, national, and institutional research impact.

### 3.3 METHODOLOGY

**Publications:** Many different document types are indexed in the Web of Science, including editorials, meeting abstracts, book reviews as well as research journal articles and reviews. In this report all documents regardless of type are referred to as 'publications'.

**Article:** Reports of research on original works. Includes research papers, features, brief communications, case reports, technical notes, chronology, and full papers that were published in a journal and/or presented at a symposium or conference.

**Review:** A renewed study of material previously studied. Includes review articles and surveys of previously published literature. Usually will not present any new information on a subject.

**Papers:** The terms 'paper' and 'publication' are often used interchangeably to refer to printed and electronic outputs of many types. However, in this report the term 'paper' is used exclusively to refer to articles and reviews - a subset of 'publications' that excludes all other document types.

Articles and reviews are the main way researchers communicate their results to the wider community and standards in methodology and interpretation are ensured by pre-publication peer-review by experts in the same field. Therefore, citation data for papers is the most informative for bibliometric evaluations and only citations to papers are used in calculations of the citation impact indicators presented in this report.

**Citations:** Papers mention earlier papers to acknowledge their intellectual contribution to a field of research. A paper receives a citation when it is mentioned or cited by another, usually more recent paper.

**Citation count:** The number of citations received by a paper since it was published reflects the impact it has had on later research. Not all citations are necessarily recorded as not all the citing papers are indexed in the Web of Science. The material indexed by Clarivate, however, is estimated to attract about 95% of global citations.

**Citation impact:** Citations per paper is an index of academic or research impact (as compared with economic or social impact). For a single paper, raw citation impact is the same as its citation count. For a set of papers, it is calculated by dividing the sum of citations by the total number of papers in any given dataset. Impact can be calculated for papers within a specific research field such as Clinical Neurology, or for a specific institution or group of institutions, or a specific country.

Citation count declines in the most recent years of any time-period as papers have had less time to accumulate citations (papers published in 2007 will typically have more citations than papers published in 2010).

---

<sup>3</sup> The origins of citation analysis as a tool that could be applied to research performance can be traced to the mid-1950s, when Eugene Garfield proposed the concept of citation indexing and introduced the Science Citation Index, the Social Sciences Citation Index and the Arts & Humanities Citation Index, produced by the Institute of Scientific Information – ISI (now Clarivate).

**Field-normalised citation impact:** Broadly the field-normalised citation impact compares the citation impact of a paper or set of papers to the average citation impact of all similar papers published worldwide in the same field and year.

As citation rates vary between research fields and with time, analyses must take both field and year into account. In addition, the type of publication will influence the citation count. For this reason, only citation counts of papers (as defined above) are used in calculations of citation impact. The standard normalisation factor is the world average citations per paper for the year and journal category in which the paper was published.

As field-normalised citation impact is normalised to global averages the performance of papers in different fields can be directly compared as the world average always equals 1.00. Therefore, a field-normalised citation impact exceeding 1.00 indicates papers have received more citations than the world average, conversely a value below 1.00 suggests papers are underperforming. See page 113 for a worked example of how field-normalised citation impact is calculated.

**Highly Cited Papers:** Highly cited papers are papers that are recognized as having a greater impact than other papers published in a similar year and field. For a paper to be considered highly cited they must be in the Top 10% in terms of citation frequency, considering the field and year of publication. High citation rates have shown to be correlated with other qualitative research performance evaluations, such as peer reviews.

**Web of Science journal categories or Clarivate InCites: Essential Science Indicators<sup>SM</sup> fields:** Standard bibliometric methodology uses journal category or ESI fields as a proxy for research fields. ESI fields aggregate data at a higher level than the journal categories – there are only 22 ESI research fields compared to 254 journal categories.<sup>4</sup> Journals are assigned to one or more categories, and every article within that journal is subsequently assigned to that category. Papers from prestigious, ‘multidisciplinary’ and general medical journals such as *Nature*, *Science*, *The Lancet*, *The BMJ*, *The New England Journal of Medicine* and the *Proceedings of the National Academy of Sciences* (PNAS) are assigned to specific categories based on the journal categories of the references cited in the article. The selection procedures for the journals included in the citation databases are documented here <http://mjl.clarivate.com/>.

**Journal-normalised citation impact:** Broadly the journal-normalised citation impact compares a paper or set of papers citation impact to all the other papers published in the same journal in the same year.

It is another bibliometric indicator which can be very useful in small datasets. This indicator is calculated from the citation impact relative to the specific journal in which the paper is published. For example, a paper published in the journal *Acta Biomaterialia* in 2005 that has been cited 189 times, would have an expected citation rate of 49.57 (the average number of citations per paper for this journal and publication year) and hence a journal-normalised citation impact of 6.3. This paper, therefore, has been cited more than expected for the journal.

Like the field-normalised citation impact a value exceeding 1.00 indicates that a paper or set of papers is receiving more citations than other papers in the same journal, and a value less than 1.00 indicates that a paper or set of papers is underperforming, receiving fewer citations than papers in the same journal.

**Open access publication:** Open access publications are publications that are made available online, at no cost to the reader. The Web of Science open access data come from the Directory of Open Access

---

<sup>4</sup> Essential Science Indicators are defined by a unique grouping of journals with no journal being assigned to more than one field. These fields are focussed on the science, technology, engineering and medicine subjects and arts & humanities subjects are excluded. Customised analyses, however, can be designed to include these as an additional category.

Journals (DOAJ) and collaborations with Impact Story and Our Research's Unpaywall services. The Web of Science therefore provides unrivalled coverage of open access publications that are published through DOAJ Gold, Other Gold, Green Published, Green Accepted or Bronze routes.

It is also possible that some publishers make publications available without following a recognised open access route. In these cases publications will not be indexed as open access in the Web of Science. Additionally, the analysis presented in this report covers all document types and not just papers, and some of these are not indexed as open access in the Web of Science databases.

The Web of Science open access data coverage is summarised at: [clarivate.com/webofsciencelgroup/solutions/open-access/](https://clarivate.com/webofsciencelgroup/solutions/open-access/)

### 3.4 DATA COLLATION

This analysis used a dataset comprising publications arising from IMI-supported projects. These publications were identified using grant acknowledgments, title, and abstract text searches, as well as other parameters developed in conjunction with IMI staff. There are currently 172 IMI projects. IMI staff validated the publications identified by this process and the list of projects to be analysed was provided by IMI staff.

## 4 CITATION ANALYSIS – IMI SUPPORTED PUBLICATIONS OVERALL

This section analyses the volume and citation impact of publications arising from IMI-supported projects, and where possible, benchmarks this against similar European research funders.

The datasets analysed in this, the twelfth report, include IMI-supported publications identified in Clarivate Web of Science up to 31<sup>st</sup> December 2020. The census point for inclusion of publications into the eleventh report was 31<sup>st</sup> December 2019. Therefore, this report reflects changes in IMI activity between these points. Citations to these publications were counts up to 31<sup>st</sup> December 2020. Unless otherwise specified metrics are for all IMI-supported documents from all calls in IMI 1 and IMI 2, in aggregate.

When considering the analyses in this section, earlier caveats regarding paper numbers should be borne in mind (Section 3).

### 4.1 PUBLICATIONS FROM IMI-SUPPORTED PROJECTS

Publications from IMI-supported projects were identified using bibliographic data supplied by IMI, and through specific keyword searches using funding acknowledgment data in the Web of Science. The process of identifying publications from IMI-supported projects that have Clarivate citation data is outlined in Figure 4.1.1.

The IMI project dataset started with 5,943 publications which were previously identified as IMI publications and used as the IMI publication dataset in the previous report. Separately, 1,602 new publications were identified as IMI-associated through keyword searches of funding acknowledgement text in databases which underlie Clarivate Web of Science. The combination of these two datasets led to a total of 7,545 unique publication records associated with IMI-supported projects. Of these 7,545 publications, 368 were eliminated as they were either published in 2021 or could not be distinguished as IMI from a manual review of the dataset. Therefore, 7,177 Web of Science publications remained.

The citation counts for this report were sourced from the citation databases which underlie Clarivate Web of Science and were extracted in June 2020. Normalised bibliometric indicators were calculated using standard methodology and the Clarivate National Science Indicators (NSI) database for 2020.

FIGURE 4.1.1 PROCESS FOR IDENTIFYING PUBLICATIONS FROM IMI-SUPPORTED PROJECTS, 2010-2020




Table 4.1.1 NUMBER OF PUBLICATIONS FROM IMI PROJECTS, 2010-2020

	Number of publications	Number of papers
All IMI	7,177	6,566
IMI 1	5,912	5,512
IMI 2	1,325	1,125


Note that some publications belong to IMI 1 and IMI 2, therefore the total number of publications shown for All IMI is smaller than the sum of publications shown for IMI 1 and IMI 2.



## 4.2 PUBLICATIONS FROM IMI PROJECTS BY DOCUMENT TYPE

Figure 4.2.1 shows the percentage of Web of Science publications by document type and the same data is shown in Table 4.2.1.

FIGURE 4.2.1 PERCENTAGE OF IMI PROJECT PUBLICATIONS BY DOCUMENT TYPE, 2010-2020



Articles + Reviews = Papers, 91.5%


- IMI project research resulted in 7,177 unique Web of Science publications.
- Of these publications, 91.5% were articles (77.5%) and reviews (14%) which are collectively referred to as 'papers' in this report.
- A further 611 publications (8.5%) were not papers. These 'other' publications is composed of 140 editorials, 337 meeting abstracts, 59 proceeding papers, 57 letters, 11 corrections and three news items and four data papers.

TABLE 4.2.1 NUMBER AND PERCENTAGE OF IMI PROJECT PUBLICATIONS BY DOCUMENT TYPE, 2010-2020

	Document type	Number of publications	% of IMI publications
Papers	Article	5,563	77.51%
	Review	1,003	13.98%
Other document types	Meeting Abstract	337	4.70%
	Editorial Material	140	1.95%
	Proceedings Paper	59	0.82%
	Letter	57	0.79%
	Correction	11	0.15%
	News Item	3	0.04%
	Data Paper	4	0.06%

### 4.3 TRENDS IN PUBLICATION OUTPUT


FIGURE 4.3.1 NUMBER OF WEB OF SCIENCE PUBLICATIONS FOR IMI PROJECTS BY YEAR, 2010-2020



- During 2020, IMI project research output has since recovered from a decrease in 2019. It is now continuing its growth trajectory with an increase of 19% from 2019.
- The recovery of publication output in 2020 from the 2019 decrease is likely driven by projects such as AIMS-2-TRIALS, RESCEU, RHAPSODY, and SPRINTT who published more than double the number of papers in 2020 compared to 2019. For example, AIMS-2-TRIALS, which is the project with the second most papers published in 2020, published 30 publications in 2019 and then in 2020 published 73.

Figure 4.3.2 shows the proportion of papers (articles and reviews) relative to other document types for IMI project research between 2010 and 2020.

FIGURE 4.3.2 PERCENTAGE OF IMI PROJECT PUBLICATIONS EACH YEAR BY DOCUMENT TYPE, 2010-2020



- IMI project research continued to generate a high proportion of papers relative to other document types. Articles accounted for around 78.3% of all publications in 2020, consistent with recent years.

#### 4.4 PUBLICATION OUTPUT BY COUNTRY

Figure 4.4.1 shows a map highlighting all countries with one or more publication from IMI projects between 2010 and 2020. Figure 4.4.2 shows a map highlighting all countries with at least ten Web of Science publications from IMI projects between 2010 and 2020. Table 4.4.1 and Figure 4.4.3 shows the corresponding data; the total number of publications for the 20 and 10 countries respectively with the highest number publications from IMI projects between 2010 and 2020. A full list of all countries output of publications is included in Annex 3.

FIGURE 4.4.1 MAP OF COUNTRIES WHICH HAVE AT LEAST ONE WEB OF SCIENCE PUBLICATION FOR IMI PROJECTS, 2010-2020





FIGURE 4.4.2 MAP OF COUNTRIES WHICH HAVE AT LEAST TEN WEB OF SCIENCE PUBLICATION FOR IMI PROJECTS, 2010-2020



- In total 117 countries have at least one IMI publications and 52 countries have at least ten IMI publications.

FIGURE 4.4.3 TEN COUNTRIES WITH THE MOST IMI PROJECT PUBLICATIONS. ANNEX 3 LISTS ALL COUNTRIES WITH AT LEAST ONE IMI PROJECT PUBLICATION, 2010-2020




TABLE 4.4.1 TWENTY COUNTRIES WITH THE MOST IMI PROJECT PUBLICATIONS. ANNEX 3 LISTS ALL COUNTRIES WITH AT LEAST ONE IMI PROJECT PUBLICATION, 2010-2020


Country	Number of publications
UK	2,996
Germany	2,278
USA	1,690
Netherlands	1,681
Sweden	1,185
France	1,169
Italy	985
Switzerland	868
Spain	809
Belgium	681
Denmark	523
Canada	465
Austria	424
Finland	328
Australia	226
Greece	214
China	207
Ireland	171
Norway	161
Poland	146

- Researchers affiliated to the United Kingdom authored the most IMI project publications (2,996 publications).
- Other EU-28 countries where among the countries with the highest output. The most productive exceptions are the USA (1,690 publications) and Switzerland (868 publications).

## 4.5 PUBLICATION OUTPUT BY IMI PROJECT

Figure 4.5.1 shows the ten IMI projects with the highest output of publications between 2010 and 2020. Table 4.5.1 expands upon Figure 4.5.1, listing the 20 IMI projects with the most publications, including the number and percentage of open access publications and the number of papers between 2010 and 2020. A full list of projects and the number of associated publications is presented in Annex 4.

FIGURE 4.5.1 NUMBER OF WEB OF SCIENCE PUBLICATIONS FOR TEN IMI PROJECTS WITH THE HIGHEST OUTPUT OF PUBLICATIONS, 2010-2020



- BTCure remains the most productive IMI project in terms of number of publications (703 publications) and the second most productive project is still EU-AIMS (503 publications).
- INNODIA is new to the top 10 projects with highest output of publications (158 publications), displacing IMIDIA (149 publications)

TABLE 4.5.1 TWENTY IMI PROJECTS WITH THE MOST PUBLICATIONS, THE NUMBER OF PAPERS, NUMBER AND PERCENTAGE OF OPEN ACCESS PUBLICATIONS, 2010-2020.

Project	Number of publications	Number of papers	Number of open access publications	% of open access publications
BTCure	703	656	461	65.6%
EU-AIMS	503	488	378	75.1%
ULTRA-DD	379	371	295	77.8%
EMIF	300	279	229	76.3%
NEWMEDS	209	204	113	54.1%
CANCER-ID	193	167	136	70.5%
EUROPAIN	177	177	68	38.4%
ORBITO	168	165	47	28.0%
INNODIA	158	126	110	69.6%
TRANSLOCATION	152	152	90	59.2%
IMIDIA	149	139	120	80.5%
STEMBANCC	143	138	107	74.8%
U-BIOPRED	136	87	65	47.8%
SUMMIT	132	128	96	72.7%
CHEM21	130	127	61	46.9%
ELF	126	125	83	65.9%
PreDiCT-TB	118	112	101	85.6%
SPRINTT	113	106	63	55.8%
MIP-DILI	113	106	64	56.6%
AIMS-2-TRIALS	107	101	96	89.7%




## 4.6 IS IMI PROJECT RESEARCH WELL CITED?

The number of citations a paper receives (also known as its raw citation impact) is at least partly determined by the field to which it relates and the year in which it was published. Typically, papers published in disciplines such as biomedical research receive more citations than papers published in subjects such as engineering, and older papers tend to have higher citations counts on average than newer ones because they have had longer to accrue them. Therefore, citation impact is usually normalised to the relevant world average to allow comparison between years and fields; the resulting indicator is called the field-normalised citation impact.

Figure 4.6.1 shows the average field-normalised citation impact for all IMI papers compared to the average for EU-28 papers in relevant biomedical journal categories (see Annex 2) and all global papers published between 2010 and 2020. Table 4.6.1 and Table 4.6.2 present average citation impact indicators for all IMI papers.

FIGURE 4.6.1 FIELD-NORMALISED CITATION IMPACT FOR IMI SUPPORTED RESEARCH PAPERS COMPARED TO THE AVERAGE FOR EU-28 PAPERS AND WORLD PAPERS, 2010-2019



- IMI's field normalised citation impact is lower than last year's report but is still 73% higher than the EU-28 and almost double the World average.

TABLE 4.6.1 SUMMARY CITATION ANALYSIS FOR IMI SUPPORTED RESEARCH PAPERS, 2010-2020

	Number of papers	Citation impact			% highly cited papers
		Normalised at field level	Normalised at journal level	Average percentile	
IMI projects	6,566	1.99	1.21	35.0	25.7%
IMI 1	5,512	1.98	1.22	33.1	26.0%
IMI 2	1,125	1.94	1.11	45.6	23.0%

TABLE 4.6.2 SUMMARY OF IMI SUPPORTED RESEARCH PUBLICATIONS, 2010-2020

	Number of publications	% of open access publications <sup>†</sup>	Number of papers	Citations	Raw citation impact
IMI Projects	7,177	67.4%	6,566	179,823	27.39
IMI 1	5,912	65.8%	5,512	167,967	30.47
IMI 2	1,325	77.2%	1,125	10,791	9.59

#### SUMMARY OF KEY FINDINGS

- The field-normalised citation impact of IMI project papers was 1.99 for the eleven-year period, 2010-2020, 3% lower than last year's report but is still almost double the World average.
- The field-normalised citation impact of IMI project papers was 73% higher than the EU's average citation impact (1.15)<sup>5</sup> between 2010 and 2020, in similar biomedical journal categories.
- More than a quarter (25.7%) of IMI papers were highly cited, that is they were in the world's top 10% of most highly cited papers in the relevant journal category and year of publication.
- IMI 2 has a higher percentage of open access publications compared with IMI 1. This is likely due to the stipulation that IMI 2 funded researcher should publish open access articles.<sup>6</sup>

<sup>5</sup> EU-28 grouping of countries: Clarivate National Science Indicators 2020 database; similar research has been defined as biomedical journal categories listed in Annex 2.

<sup>6</sup> Note that IMI 2 funded researchers are contractually obliged to make their scientific articles open access through Green or Gold routes. However, for some of other document types, such as editorials, reviews or conference proceedings open access publication is strongly encouraged but not mandatory.

Nevertheless, it is obvious that fewer than all of IMI's publications are classified as open access in this analysis, and this is likely to be due to ancillary factors (such as challenges relating to definitions and coverage) as well as non-compliance. The Web of Science open access data come from the Directory of Open Access Journals (DOAJ) and collaborations with Impact Story and Our Research's Unpaywall services. The Web of Science therefore provides unrivalled coverage of open access publications that are published through DOAJ Gold, Other Gold, Green Published, Green Accepted or Bronze routes.

It is also possible that some publishers makes publications available without following a recognised open access route. In these cases publications will not be indexed as open access in the Web of Science or in this report. Additionally, the analysis presented in this report covers all document types and not just papers, and some of these are not indexed as open access in the Web of Science databases.

The Web of Science open access data coverage is summarised at: <https://clarivate.com/webofsciencegroup/solutions/open-access/>

## 4.7 IN WHICH JOURNALS DO IMI PROJECT PUBLICATIONS APPEAR MOST FREQUENTLY?

The 20 journals in which IMI project publications appeared most frequently (ranked by number of IMI publications) between 2010 and 2020, are listed in Table 4.7.1. Together, the 20 most frequently used journals account for 1,517 publications, 21.1% of IMI's publications

IMI project publications appeared most frequently in both *Annals of the Rheumatic Diseases* and *PLOS One* which IMI published 178 publications each. IMI published more papers in *PLOS One* (178 papers) than in *Annals of the Rheumatic Diseases* (119 papers). For most journals, papers (articles and reviews) were the most frequent publication type, however large collections of meeting abstracts were published in *Diabetologia* (60 meeting abstracts) and *European Respiratory Journal* (26 meeting abstracts).

IMI continued to have a strong focus on Rheumatology with three of the top ten most frequently used journals assigned to this journal subject category, as well as Pharmacology & Pharmacy with a quarter of the top 20 journals assigned to this journal subject category. Neurosciences was assigned to three journal titles, and multidisciplinary journals were assigned to four of the top 20 journals by publication count. A further two top-ten journals, *Diabetologia* and *Diabetes* are assigned to Endocrinology & Metabolism and the titles suggest a focus on diabetes.

Of the 20 most frequently used journals, just under three-quarters were in the top quartile (Q1) by Journal Impact Factor (JIF) while the rest were in the second quartile (Q2) ranked against other journals in the same category.

Overall IMI project publications were published in a total of 1,378 journals, of which 621 were ranked in the top quartile (by Journal Impact Factor) of journals in their relevant journal category. A total of 4,348 publications (60.6% of IMI project publications) were published in these well-regarded journals. The average Journal Impact Factor for all IMI project publications is 6.93, a slight increase of 0.55 compared to the previous year.

The 20 highest Journal Impact Factor journals in which IMI project research was published are listed in Table 4.7.2. The journal with the highest Impact Factor is *Nature Reviews Molecular Cell Biology*, with a Journal Impact Factor of 94.44 where IMI published 1 publication, followed by *Nature Reviews Drug Discovery* with an Impact Factor of 84.69 where IMI published 12 publications. Of the top 20 journals by Impact Factor, IMI published the most publications in *Nature* which has an Impact Factor of 49.96. IMI published a total of 131 publications in these top ranked journals by journal impact factor.

The 20 open access journals in which IMI projects publish most frequently (ranked by number of publications), are listed in Table 4.7.3. Of the top 20 open access journals *Annals of the Rheumatic Diseases* had the highest Journal Impact Factor (19.10) and *PLOS One* published the most IMI publications (177 publications). 16 of these journals are ranked in the top quartile in their relevant journal categories.

TABLE 4.7.1 JOURNALS IN WHICH IMI PROJECT PUBLICATIONS WERE PUBLISHED MOST FREQUENTLY, TOP 20 RANKED BY NUMBER OF IMI PUBLICATIONS, 2010-2020

Journal	Number of IMI publications	Number of IMI papers	Journal Impact Factor (2020)	Web of Science journal categories	Quartile
<i>Annals of the Rheumatic Diseases</i>	178	119	19.10	Rheumatology	Q1
<i>Plos One</i>	178	177	3.24	Multidisciplinary Sciences	Q2
<i>Scientific Reports</i>	171	171	4.38	Multidisciplinary Sciences	Q1
<i>Diabetologia</i>	133	70	10.12	Endocrinology & Metabolism	Q1
<i>Nature Communications</i>	95	94	14.92	Multidisciplinary Sciences	Q1
<i>Arthritis Research &amp; Therapy</i>	63	63	5.16	Rheumatology	Q2
<i>Diabetes</i>	62	44	9.46	Endocrinology & Metabolism	Q1
<i>Frontiers in Immunology</i>	62	61	7.56	Immunology	Q1
<i>Journal of Alzheimers Disease</i>	60	59	4.47	Neurosciences	Q2
<i>Arthritis &amp; Rheumatology</i>	58	49	10.99	Rheumatology	Q1
<i>Journal of Medicinal Chemistry</i>	57	57	7.45	Chemistry, Medicinal	Q1
<i>Pain</i>	51	51	6.96	Anesthesiology; Clinical Neurology; Neurosciences	Q1
<i>European Respiratory Journal</i>	50	17	16.67	Respiratory System	Q1
<i>European Journal of Pharmaceutics and Biopharmaceutics</i>	48	48	5.57	Pharmacology & Pharmacy	Q1
<i>European Journal of Pharmaceutical Sciences</i>	47	45	4.38	Pharmacology & Pharmacy	Q2
<i>Journal of Antimicrobial Chemotherapy</i>	44	43	5.79	Infectious Diseases; Microbiology; Pharmacology & Pharmacy	Q1
<i>Psychopharmacology</i>	42	42	4.53	Neurosciences; Pharmacology & Pharmacy; Psychiatry	Q2
<i>Proceedings of the National Academy of Sciences of the United States of America</i>	41	41	11.21	Multidisciplinary Sciences	Q1
<i>Translational Psychiatry</i>	39	39	6.22	Psychiatry	Q1
<i>Molecular Pharmaceutics</i>	38	38	4.93	Research & Experimental Medicine; Pharmacology & Pharmacy	Q2

TABLE 4.7.2 JOURNALS IN WHICH IMI PROJECT PUBLICATIONS WERE PUBLISHED MOST FREQUENTLY, TOP 20 RANKED BY JOURNAL IMPACT FACTOR, 2010-2020

Journal	Number of IMI publications	Number of IMI papers	Journal Impact Factor (2020)	Web of Science journal categories	Quartile
<i>Nature Reviews Molecular Cell Biology</i>	1	1	94.44	Cell Biology	Q1
<i>Nature Reviews Drug Discovery</i>	12	6	84.69	Biotechnology & Applied Microbiology; Pharmacology & Pharmacy	Q1
<i>Lancet</i>	5	3	79.32	General & Internal Medicine	Q1
<i>Nature Reviews Clinical Oncology</i>	8	7	66.67	Oncology	Q1
<i>Nature Reviews Cancer</i>	2	2	60.72	Oncology	Q1
<i>Nature Reviews Microbiology</i>	1	1	60.63	Microbiology	Q1
<i>Chemical Reviews</i>	2	2	60.62	Chemistry, Multidisciplinary	Q1
<i>Jama-Journal of the American Medical Association</i>	9	7	56.27	General & Internal Medicine	Q1
<i>Nature Biotechnology</i>	3	1	54.91	Biotechnology & Applied Microbiology	Q1
<i>Chemical Society Reviews</i>	1	1	54.56	Chemistry, Multidisciplinary	Q1
<i>Nature Medicine</i>	13	12	53.44	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	Q1
<i>Nature Reviews Genetics</i>	4	4	53.24	Genetics & Heredity	Q1
<i>Nature Reviews Immunology</i>	4	2	53.11	Immunology	Q1
<i>Nature Reviews Disease Primers</i>	3	3	52.33	General & Internal Medicine	Q1
<i>Nature</i>	22	22	49.96	Multidisciplinary Sciences	Q1
<i>Science</i>	16	15	47.73	Multidisciplinary Sciences	Q1
<i>Nature Reviews Gastroenterology &amp; Hepatology</i>	3	2	46.80	Gastroenterology & Hepatology	Q1
<i>Journal of Clinical Oncology</i>	1	0	44.54	Oncology	Q1
<i>Lancet Neurology</i>	18	16	44.18	Clinical Neurology	Q1
<i>Nature Reviews Endocrinology</i>	3	1	43.33	Endocrinology & Metabolism	Q1

TABLE 4.7.3 OPEN ACCESS JOURNALS IN WHICH IMI PROJECT PUBLICATIONS WERE PUBLISHED MOST FREQUENTLY, TOP 20 RANKED BY NUMBER OF OPEN ACCESS WEB OF SCIENCE PUBLICATIONS, 2010-2020


Journal	Number of IMI publications	Number of IMI papers	Journal Impact Factor (2020)	Web of Science journal categories	Quartile
<i>Plos One</i>	177	177	3.24	Multidisciplinary Sciences	Q2
<i>Scientific Reports</i>	171	171	4.38	Multidisciplinary Sciences	Q1
<i>Nature Communications</i>	95	94	14.92	Multidisciplinary Sciences	Q1
<i>Annals of the Rheumatic Diseases</i>	77	44	19.10	Rheumatology	Q1
<i>Diabetologia</i>	65	62	10.12	Endocrinology & Metabolism	Q1
<i>Arthritis Research &amp; Therapy</i>	63	63	5.16	Rheumatology	Q2
<i>Frontiers in Immunology</i>	62	61	7.56	Immunology	Q1
<i>Proceedings of the National Academy of Sciences of the United States of America</i>	41	41	11.21	Multidisciplinary Sciences	Q1
<i>Journal of Antimicrobial Chemotherapy</i>	40	39	5.79	Infectious Diseases; Microbiology; Pharmacology & Pharmacy	Q1
<i>Diabetes</i>	40	40	9.46	Endocrinology & Metabolism	Q1
<i>Translational Psychiatry</i>	39	39	6.22	Psychiatry	Q1
<i>Arthritis &amp; Rheumatology</i>	38	37	10.99	Rheumatology	Q1
<i>Journal of Alzheimers Disease</i>	36	35	4.47	Neurosciences	Q2
<i>International Journal of Molecular Sciences</i>	36	36	5.92	Biochemistry & Molecular Biology; Chemistry, Multidisciplinary	Q1
<i>Nucleic Acids Research</i>	36	36	16.97	Biochemistry & Molecular Biology	Q1
<i>Bioinformatics</i>	35	34	6.94	Biochemical Research Methods; Biotechnology & Applied Microbiology; Computer Science, Interdisciplinary Applications; Mathematical & Computational Biology; Statistics & Probability	Q1
<i>Antimicrobial Agents and Chemotherapy</i>	35	34	5.19	Microbiology; Pharmacology & Pharmacy	Q1
<i>Molecular Autism</i>	33	32	7.51	Genetics & Heredity; Neurosciences	Q1
<i>Cell Reports</i>	33	33	9.42	Cell Biology	Q1
<i>Journal of Biological Chemistry</i>	32	32	5.16	Biochemistry & Molecular Biology	Q2

## 4.8 WHICH RESEARCH FIELDS ACCOUNT FOR THE HIGHEST VOLUME OF IMI PROJECT PUBLICATIONS?

Figure 4.8.1 shows the twenty Web of Science journal categories<sup>7</sup> most frequently associated with IMI funded research between 2010 and 2020. IMI 1 calls 5-11 have a lower number of publications relative to calls 1-4 and for clarity of presentation these publications are shown as one group in Figure 4.8.1. Likewise, IMI 2 has far fewer publications compared to IMI 1 and so all IMI 2 publications are shown as one group in Figure 4.8.1. Publications that acknowledge IMI funding but do not specify a project, phase or call are classed as Unassigned. Note that some bars are longer than the total number of IMI publications in a journal category (indicated by the data labels) due to some papers being associated with multiple calls. Figure 4.8.2 shows the ten Web of Science journal categories most frequently associated with IMI 2 funded research.


Table 4.8.1 shows the same data as Figure 4.8.1 and Figure 4.8.2 for the top twenty journal categories. It provides the number of publications assigned to each of the top twenty Web of Science journal categories in which IMI project research is published by IMI 1 calls and IMI 2 in total.

FIGURE 4.8.1 TOP TWENTY WEB OF SCIENCE JOURNAL CATEGORIES IN WHICH IMI PROJECT RESEARCH WAS PUBLISHED MOST FREQUENTLY, 2010-2020. DATA LABELS SHOWS THE TOTAL NUMBER OF PUBLICATIONS PER JOURNAL CATEGORY



<sup>7</sup> Journals can be associated with more than one Web of Science category.

FIGURE 4.8.2 TOP TEN WEB OF SCIENCE JOURNAL CATEGORIES IN WHICH IMI 2 PROJECT RESEARCH (ALL CALLS) WAS PUBLISHED MOST FREQUENTLY, 2010-2020. DATA LABELS SHOWS THE TOTAL NUMBER OF PUBLICATIONS PER JOURNAL CATEGORY



- IMI projects produced more publications in Pharmacology & Pharmacy (819 publications) than in other journal categories, followed by Neurosciences (782 publications) and Biochemistry & Molecular Biology (598 publications).
- Most publications in IMI 1 calls 5 to 11 belong to call 11.
- IMI 2 publications most frequently appeared in Endocrinology & Metabolism journals (177 publications), followed by Neurosciences (156 publications) and Immunology (120 publications).



TABLE 4.8.1 NUMBER OF PUBLICATIONS BY IMI 1 CALL AND IMI 2 FOR TWENTY WEB OF SCIENCE JOURNAL CATEGORIES IN WHICH IMI PROJECT RESEARCH WAS PUBLISHED MOST FREQUENTLY, 2010-2020. ORDERED BY TOTAL NUMBER OF PUBLICATIONS.

Journal Category	Number of publications by IMI 1 Call											IMI 2	Not assigned
	1	2	3	4	5	6	7	8	9	10	11		
Pharmacology & Pharmacy	192	70	106	235	12	35	8	15	45	0	57	62	11
Neurosciences	277	3	231	96	0	0	0	29	3	0	20	156	8
Biochemistry & Molecular Biology	85	59	61	70	28	40	0	33	16	0	142	77	5
Immunology	33	142	79	10	0	8	17	15	8	30	25	120	2
Rheumatology	2	339	11	0	0	0	1	33	0	0	28	38	2
Endocrinology & Metabolism	118	19	63	62	0	0	0	1	2	0	6	177	5
Clinical Neurology	148	1	63	57	0	0	0	10	0	0	18	83	8
Cell Biology	28	59	29	56	2	6	0	19	11	0	87	72	5
Psychiatry	125	0	167	12	0	0	1	1	1	0	4	59	5
Research & Experimental Medicine	37	44	28	60	0	3	19	3	1	14	30	73	2
Multidisciplinary Chemistry	30	24	15	102	35	13	0	5	5	0	33	22	1
Microbiology	2	12	49	5	1	73	1	10	48	6	55	34	14
Medicinal Chemistry	23	18	14	40	46	9	0	11	1	0	89	13	4
Oncology	9	85	0	8	1	0	2	1	0	0	124	22	2
Genetics & Heredity	43	46	60	34	0	2	0	10	1	0	28	40	2
Infectious Diseases	4	8	22	2	1	47	2	5	56	8	65	43	6
Biochemical Research Methods	45	43	20	36	2	7	0	13	1	1	28	23	0
Biotechnology & Applied Microbiology	32	34	13	52	2	3	0	20	2	6	21	29	3
Toxicology	69	1	63	4	0	1	1	0	13	0	9	13	1
Public, Environmental & Occupational Health	53	7	2	4	0	10	18	0	27	1	21	31	3

Table 4.8.2 and Table 4.8.3 show the citation impact, percentage of highly cited papers and percentage of open access publications for IMI project research in the top twenty journal categories.

TABLE 4.8.2 FIELD-NORMALISED, JOURNAL-NORMALISED AND RAW CITATION IMPACT OF PAPERS FOR THE TWENTY WEB OF SCIENCE JOURNAL CATEGORIES IN WHICH IMI PROJECT RESEARCH WAS PUBLISHED MOST FREQUENTLY, 2010-2020. ORDERED BY TOTAL NUMBER OF PAPERS.

Journal category	Number of papers	Citation impact		Raw citation impact
		Normalised at field level	Normalised at journal level	
Pharmacology & Pharmacy	771	1.45	1.12	18.57
Neurosciences	733	1.95	1.36	28.65
Biochemistry & Molecular Biology	584	2.44	1.54	31.78
Immunology	443	1.83	1.36	21.34
Rheumatology	366	1.77	0.86	25.48
Endocrinology & Metabolism	341	1.64	1.06	17.11
Clinical Neurology	337	2.53	1.56	35.82
Cell Biology	345	2.25	1.38	29.15
Psychiatry	324	2.04	1.10	27.25
Research & Experimental Medicine	295	1.97	1.17	23.47
Chemistry, Multidisciplinary	279	1.45	1.15	30.86
Microbiology	262	1.48	1.02	18.07
Chemistry, Medicinal	257	1.44	1.16	13.86
Oncology	227	2.49	1.42	40.21
Genetics & Heredity	224	2.24	1.22	35.60
Infectious Diseases	206	2.20	1.39	16.54
Biochemical Research Methods	201	1.44	1.08	21.99
Biotechnology & Applied Microbiology	185	1.63	1.20	22.91
Toxicology	162	1.41	1.23	18.10
Public, Environmental & Occupational Health	142	1.50	1.07	12.91

TABLE 4.8.3 NUMBER OF PUBLICATIONS, NUMBER OF PAPERS, PERCENTAGE OPEN ACCESS AND PERCENTAGE HIGHLY CITED PAPERS FOR THE TOP TWENTY WEB OF SCIENCE JOURNAL CATEGORIES IN WHICH IMI PROJECT RESEARCH WAS PUBLISHED MOST FREQUENTLY 2010-2020. ORDERED BY TOTAL NUMBER OF PUBLICATIONS.

Journal category	Number of publications	% of open access publications	Number of papers	% of highly cited papers
Pharmacology & Pharmacy	819	50.2%	771	19.8%
Neurosciences	782	61.9%	733	28.1%
Biochemistry & Molecular Biology	598	70.6%	584	27.7%
Immunology	468	74.4%	443	22.3%
Rheumatology	448	58.0%	366	27.3%
Endocrinology & Metabolism	435	64.1%	341	20.5%
Clinical Neurology	378	48.7%	337	38.0%
Cell Biology	360	79.4%	345	36.2%
Psychiatry	351	64.1%	324	28.1%
Research & Experimental Medicine	303	68.6%	295	27.1%
Multidisciplinary Chemistry	284	61.3%	279	21.9%
Microbiology	270	84.8%	262	25.6%
Medicinal Chemistry	260	54.2%	257	19.1%
Oncology	253	70.8%	227	35.2%
Genetics & Heredity	240	80.0%	224	26.3%
Infectious Diseases	223	81.2%	206	27.2%
Biochemical Research Methods	204	63.7%	201	22.4%
Biotechnology & Applied Microbiology	203	77.3%	185	25.9%
Toxicology	173	43.4%	162	20.4%
Public, Environmental & Occupational Health	161	57.8%	142	19.0%

- IMI project research was most frequently published in Pharmacology & Pharmacy journals. Of the 771 papers published in this category, around one fifth were highly cited.
- Clinical Neurology (337 papers) remains the category with the highest percentage of highly cited papers (38%), followed by Cell Biology with 345 papers of which 36.2% are highly cited.
- The percentage of open access publications is highest in Microbiology (84.8%), followed by Infectious Diseases (81.2%), it is worth noting that these categories share more than 50% (136 papers) of their papers which likely contributes to their similarity.

#### 4.9 IMI RESEARCH FIELDS WITH THE HIGHEST VOLUME OF PUBLICATIONS BENCHMARKED AGAINST EU-28 PUBLICATIONS OF THE SAME FIELD

Figure 4.9.1 shows the field-normalised citation impact of IMI funded research in the twenty Web of Science journal categories in which IMI project research was published most frequently between 2010 and 2020. These data are benchmarked against the average citation impact of all EU-28 research papers in the same journal categories.

Table 4.9.1, expands on the data presented in Figure 4.9.1, showing the percentage of IMI and EU-28 papers in each journal category.

FIGURE 4.9.1 THE FIELD-NORMALISED CITATION IMPACT OF IMI PROJECT RESEARCH IN THE TOP 20 WEB OF SCIENCE JOURNAL CATEGORIES IN WHICH IMI PROJECT RESEARCH WAS MOST FREQUENTLY PUBLISHED, BENCHMARKED AGAINST EU-28 PAPERS IN THE SAME JOURNAL CATEGORIES, 2010-2020. ORDERED BY THE FIELD-NORMALISED CITATION IMPACT OF IMI RESEARCH.




TABLE 4.9.1 CITATION IMPACT AND PERCENTAGE OF PAPERS IN TOP TWENTY WEB OF SCIENCE JOURNAL CATEGORIES IN WHICH IMI PROJECT RESEARCH WAS MOST FREQUENTLY PUBLISHED, BENCHMARKED AGAINST EU-28 PAPERS IN THE SAME JOURNAL CATEGORIES, 2010-2020

Journal category	% of IMI papers	% of EU-28 papers	Citation impact normalised at field level	
			IMI papers	EU-28
Clinical Neurology	5.76%	1.94%	2.53	1.21
Oncology	3.85%	2.36%	2.49	1.25
Biochemistry & Molecular Biology	9.11%	3.56%	2.44	1.14
Cell Biology	5.48%	1.74%	2.25	1.13
Genetics & Heredity	3.66%	1.34%	2.24	1.23
Infectious Diseases	3.40%	1.01%	2.20	1.16
Psychiatry	5.35%	1.46%	2.04	1.09
Research & Experimental Medicine	4.61%	1.13%	1.97	1.25
Neurosciences	11.91%	2.74%	1.95	1.09
Immunology	7.13%	1.52%	1.83	1.09
Rheumatology	6.82%	0.45%	1.77	1.24
Endocrinology & Metabolism	6.63%	1.36%	1.64	1.12
Biotechnology & Applied Microbiology	3.09%	1.35%	1.63	1.13
Public, Environmental & Occupational Health	2.45%	1.85%	1.50	1.13
Microbiology	4.11%	1.53%	1.48	1.13
Chemistry, Multidisciplinary	4.33%	3.02%	1.45	1.00
Pharmacology & Pharmacy	12.47%	2.20%	1.45	1.12
Biochemical Research Methods	3.11%	1.04%	1.44	1.10
Chemistry, Medicinal	3.96%	0.67%	1.44	1.16
Toxicology	2.63%	0.58%	1.41	1.09

- In all twenty journal categories listed, IMI project research had a higher field-normalised citation impact than EU-28 papers in the same field.
- Clinical Neurology (2.53) and Oncology (2.49) remained the top two journal categories in which IMI-supported research had the highest field-normalised citation impact. Although the field normalised citation impacts are 14% and 9% lower than that reported in the 2020 report, respectively.
- The average field-normalised citation impact of EU-28 papers was highest in Oncology (1.25) and Research & Experimental Medicine (1.25).

## 5 CITATION ANALYSIS – AT IMI PROJECT LEVEL


This section analyses the volume and citation impact of publications arising from different IMI-phases and calls.

### 5.1 TRENDS IN PUBLICATION OUTPUT BY IMI FUNDING CALL

Figure 5.1.1 and Figure 5.1.2 show the number of Web of Science publications between 2010 and 2020 for IMI project research disaggregated by call. IMI 1 calls 1-4 (Figure 5.1.1) are shown separately from the more recent IMI 1 calls 5-11 (Figure 5.1.2) which tend to have fewer publications. Likewise, IMI 2 calls are shown separately in Figure 5.1.3 as individual IMI 2 calls has far fewer publication compared to most IMI 1 calls as the longest running IMI 2 projects only started publishing in 2015.


Table 5.1.1 presents summary bibliometric data for all IMI 1 and IMI 2 calls that have at least one publication, including the number of publications, numbers of papers, and citation impact indicators.

FIGURE 5.1.1 NUMBER OF WEB OF SCIENCE PUBLICATIONS BY YEAR AND FUNDING CALL, 2010-2020



- Over the five years 2010 to 2014, IMI 1 call 1 had the highest output of publications, reaching a peak output of 178 publications in 2013.
- In 2015 and 2016, IMI 1 call 2 had the highest number of publications (180 and 208, respectively). In 2017 call 2's output fell (162 publications) and call 4 had the highest output of publications (185 publications).
- In 2020 all IMI 1 calls 1-4 are on a downward trend. Which is likely to continue since all the calls are now closed.
- Call 3 remains the call with the highest number of publications and appears to have a steeper decline than the other calls.


FIGURE 5.1.2 NUMBER OF WEB OF SCIENCE PUBLICATIONS BY YEAR AND FUNDING CALL, 2010-2020



- Overall IMI 1 calls 5-10 have not grown as rapidly as IMI 1 calls 1-4, most calls produce fewer than 50 publications a year. Call 11 is the exception, with growth in output akin to IMI 1 calls 1-4. This growth declined slightly (5%) in 2020.
- Many of the call 11 projects are due to close in 2021 so it is quite possible that we will start to see a plateau for call 11 publications.



FIGURE 5.1.3 NUMBER OF WEB OF SCIENCE PUBLICATIONS BY YEAR AND FUNDING CALL, 2010-2020. ONLY SHOWING IMI 2 CALLS WITH AT LEAST 50 PUBLICATIONS IN TOTAL.



- The output of publications from IMI 2 calls is growing. IMI 2 call 2 was the first to start publishing in 2015 and after plateauing between 2017-2019 it now has begun declining.
- IMI 2 Calls 10 and 13 are newly included to this analysis as the number of publications within these calls has increased rapidly. Especially, Call 10 which published 100 papers in 2020, more than any other call and more than double the number of publications published in 2019.
- Call 10's rapid increase is largely driven by the AIMS-2-Trials which published 73 publications in 2020.
- Calls 3,6,7, and 9 have sustained their growth in the number of publications. While Calls 1 and 5 have begun to plateau.

TABLE 5.1.1 SUMMARY BIBLIOMETRIC ANALYSES OF IMI PROJECTS AGGREGATED BY FUNDING CALL, 2010-2020

Phase	Call	Number of Publications <sup>8</sup>	% Open Access Publications	Number of Papers	Citation Impact		
					Raw citation impact	Normalised at field level	Normalised at journal level
1	1	1,213	56.0%	1,122	39.29	1.83	1.12
1	2	1,138	68.0%	1,071	40.35	2.14	1.19
1	3	1,012	71.0%	933	26.46	1.87	1.06
1	4	944	61.0%	900	28.81	2.12	1.35
1	5	126	66.0%	125	14.75	1.15	0.99

<sup>8</sup> Publications can be associated with more than one call.


Phase	Call	Number of Publications <sup>8</sup>	% Open Access Publications	Number of Papers	Citation Impact		
					Raw citation impact	Normalised at field level	Normalised at journal level
1	6	239	66.0%	232	16.86	1.26	1.01
1	7	67	81.0%	60	14.35	1.84	1.74
1	8	211	74.0%	187	24.26	2.46	1.47
1	9	238	69.0%	220	20.62	1.90	1.75
1	10	37	78.0%	36	13.25	1.09	1.15
1	11	881	74.0%	805	20.49	2.18	1.28
2	1	158	70.0%	126	9.88	1.63	1.09
2	2	90	87.0%	85	13.59	1.73	1.26
2	3	215	70.0%	169	9.21	1.88	1.22
2	4	4	50.0%	4	6.25	0.61	0.33
2	5	180	84.0%	158	10.70	1.85	0.93
2	6	114	79.0%	92	7.11	1.96	1.25
2	7	149	84.0%	134	17.50	3.19	1.31
2	8	18	83.0%	16	6.56	0.68	0.72
2	9	165	80.0%	141	9.76	2.81	1.52
2	10	146	80.0%	126	4.14	1.69	0.85
2	12	28	64.0%	22	2.45	1.54	0.69
2	13	61	70.0%	53	3.72	1.87	1.42
2	14	15	60.0%	14	0.43	0.32	0.18
2	15	12	83.0%	9	1.67	1.46	2.02
2	17	24	71.0%	24	0.83	0.63	0.25
2	19	14	79.0%	11	1.27	0.93	0.82
2	21	12	100.0%	10	4.50	3.06	1.15

- IMI 1 call 1 remains the funding call that produced the highest number of publications (1,213), and papers (1,122). Although papers from IMI 1 call 2 had the highest raw citation impact (40.35), slightly higher than IMI 1 Call 1 (39.28).
- Papers assigned to IMI 2 call 7 had the highest average field-normalised citation impact (3.19), which is three times the world average. This is driven by six highly cited papers, mainly within the IMPRIND project, which were cited between 20 and 40 times the world average.
- IMI 2 call 21 which mainly consists of Coronavirus related topics is perhaps unsurprisingly the second highest average field-normalised citation impact (3.05). Although, due to the low paper counts (10) within this call it is difficult to make any firm conclusions.
- The highest percentage of open access publications belongs to IMI 2 call 21 where all the publications are open access.
- Generally, IMI 2 calls have a higher proportion of open access publications compared to IMI 1 calls.
- IMI 2 call 3 with 215 publications is IMI 2's highest output call while IMI 2 call 7 which has the highest field-normalised citation impact (3.19) overall, ranks 5<sup>th</sup> in terms of output (149) for IMI 2 calls.

## 5.2 SUMMARY BIBLIOMETRIC ANALYSES FOR IMI 1 PROJECTS – CALL 1

Figure 5.2.1 compares the number of papers, average field-normalised citation impact and share of highly cited papers for IMI 1 call 1 projects. Only projects with at least 10 papers and one highly cited paper over the time period (2010-2020) are shown. The area of the 'bubble' is proportional to the share of highly cited papers. The dotted horizontal line indicates the average field-normalised citation impact for all IMI project papers.

FIGURE 5.2.1 PAPER NUMBERS, AVERAGE FIELD-NORMALISED CITATION IMPACT AND SHARE OF HIGHLY CITED RESEARCH FOR SELECTED IMI 1 PROJECTS – CALL 1, 2010-2020



The data in Figure 5.2.1 shows that:

- The average field-normalised citation impact of all IMI 1 call 1 projects with at least 10 papers was above the world average (1.00). Furthermore, the percentage of highly cited research was also above or in line with the world average (10%) for all projects. This indicates excellent research performance.
- Research associated with NEWMEDS, EUROPAIN, PROACTIVE and U-BIOPRED was cited more than twice the world average. These four projects have an average citation impact greater than the average citation impact of all IMI project papers (1.99).

Table 5.2.1 shows raw citation impact and the percentage of open access publication by project for IMI 1 call 1 publications. Table 5.2.2 shows the normalised citation impact (normalised against world average values) of IMI 1 call 1 projects and is an expansion of the data shown in Figure 5.2.1.

TABLE 5.2.1 BIBLIOMETRIC INDICATORS FOR IMI 1 PROJECTS IN CALL 1, 2010-2020

Project	Number of publications	Number of papers	% open access publications	Citations	Raw citation impact
NEWMEDS	209	204	54.1%	10,613	52.02
EUROPAIN	177	177	38.4%	9,629	54.40
IMIDIA	149	139	80.5%	5,627	40.48
SUMMIT	132	128	72.7%	3,249	25.38
PROTECT	101	99	41.6%	2,070	20.91
eTOX	97	92	66.0%	3,536	38.43
U-BIOPRED	136	87	47.8%	3,563	40.95
Pharma-Cog	89	83	39.3%	2,656	32.00
MARCAR	58	57	75.9%	1,319	23.14
PROACTIVE	32	27	78.1%	1,241	45.96
SAFE-T	22	20	27.3%	503	25.15

TABLE 5.2.2 SUMMARY CITATION INDICATORS FOR IMI 1 PROJECTS IN CALL 1, 2010-2020

Project	Citation impact				
	Number of papers	Normalised at field level	Normalised at journal level	Average percentile	% highly cited papers
NEWMEDS	204	2.16	1.15	30.80	26.0%
EUROPAIN	177	2.48	1.34	25.30	37.3%
IMIDIA	139	1.63	1.03	31.01	21.6%
SUMMIT	128	1.53	0.95	35.43	18.0%
PROTECT	99	1.08	0.93	39.37	10.1%
eTOX	92	1.71	1.28	30.20	21.7%
U-BIOPRED	87	2.57	1.30	22.78	37.9%
Pharma-Cog	83	1.19	0.90	42.31	14.5%
MARCAR	57	1.08	0.77	41.04	10.5%
PROACTIVE	27	2.17	1.60	27.65	29.6%
SAFE-T	20	1.88	1.16	30.18	10.0%
<b>Overall (IMI projects)</b>	<b>6,566</b>	<b>1.99</b>	<b>1.21</b>	<b>35.00</b>	<b>25.7%</b>

- Of the projects in call 1, NEWMEDS had the highest number of publications (209) and IMIDIA had the highest percentage of open access publications (78.6%).

### 5.3 SUMMARY BIBLIOMETRIC ANALYSES FOR IMI 1 PROJECTS – CALL 2

Figure 5.3.1 compares the number of papers, average field-normalised citation impact and share of highly cited papers for IMI 1 call 2 projects. Only projects with at least 10 papers and one highly cited paper over the time period (2010-2020) are shown. The area of the 'bubble' is proportional to the share of highly cited papers. The dotted horizontal line indicates the average field-normalised citation impact for all IMI project papers. The same data is shown in Figure 5.3.1 and Figure 5.3.2, however Figure 5.3.1 has a smaller x-axis range that excludes BTCure so that the other projects are less clustered.

FIGURE 5.3.1 PAPER NUMBERS, AVERAGE FIELD-NORMALISED CITATION IMPACT AND SHARE OF HIGHLY CITED RESEARCH FOR SELECTED IMI 1 PROJECTS – CALL 2, 2010-2020





FIGURE 5.3.2 PAPER NUMBERS, AVERAGE FIELD-NORMALISED CITATION IMPACT AND SHARE OF HIGHLY CITED RESEARCH FOR SELECTED IMI 1 PROJECTS – CALL 2, 2010-2020 SAME GRAPH AS FIGURE 5.3.1 BUT WITH A SMALLER X-AXIS RANGE



The data in Figure 5.3.1 and Figure 5.3.2 shows that:

- The average field-normalised citation impact of most IMI 1 call 2 projects was above world average apart from RAPP-ID which had the lowest citation impact (0.88).

- BTCURE remains the most prolific IMI 1 call 2 project with 656 papers and a citation impact of 1.85, which is 7.5% lower than the 2020 report and lower than the citation impact of all IMI project papers (1.99).
- QUIC-CONCEPT is the most highly cited project with a citation impact more than four times the world average (4.34).
- Open Phacts and Predect are also well cited with a citation impact of 3.47 and 2.52, respectively.
- Four of the eight projects in this call had an average citation impact greater than the average citation impact of all IMI project papers (1.99).

Table 5.3.1 shows raw citation impact and the percentage of open access publication by project for IMI 1 call 2 publications. Table 5.3.2 shows the normalised citation impact (normalised against world average values) of IMI 1 call 2 projects and is an expansion of the data shown in Figure 5.3.1 and Figure 5.3.2.

TABLE 5.3.1 BIBLIOMETRIC INDICATORS FOR IMI 1 PROJECTS IN CALL 2, 2010-2020

Project	Number of publications	Number of papers	% open access publications	Citations	Raw citation impact
BTCure	703	656	65.6%	23,302	35.52
Quic-Concept	102	101	80.4%	7,620	75.45
DDMoRe	81	76	64.2%	1,196	15.74
Open PHACTS	73	70	86.3%	4,561	65.16
Onco Track	65	61	67.7%	3,649	59.82
RAPP-ID	46	45	52.2%	864	19.20
Predect	47	43	76.6%	2,122	49.35
EHR4CR	21	19	61.9%	353	18.58

TABLE 5.3.2 SUMMARY CITATION INDICATORS FOR IMI 1 PROJECTS IN CALL 2, 2010-2020


Project	Citation impact				
	Number of papers	Normalised at field level	Normalised at journal level	Average percentile	% highly cited papers
BTCure	656	1.85	1.01	30.55	25.3%
Quic-Concept	101	4.34	2.17	29.96	35.6%
DDMoRe	76	1.08	0.90	47.65	13.2%
Open PHACTS	70	3.47	1.83	36.29	24.3%
Onco Track	61	2.30	1.19	25.92	36.1%
RAPP-ID	45	0.88	0.79	41.62	11.1%
Predect	43	2.52	1.47	32.16	37.2%
EHR4CR	19	1.17	0.97	43.80	15.8%
<b>Overall (IMI projects)</b>	<b>6,566</b>	<b>1.99</b>	<b>1.21</b>	<b>35.00</b>	<b>25.7%</b>

- Among IMI 1 call 2 projects Open PHACTS has the highest percentage of open access publications (86.3%).
- Predect has the highest percentage of highly cited papers (37.2%)

## 5.4 SUMMARY BIBLIOMETRIC ANALYSES FOR IMI 1 PROJECTS – CALL 3

Figure 5.4.1 compares the number of papers, average field-normalised citation impact and share of highly cited papers for IMI 1 call 3 projects. Only projects with at least 10 papers and one highly cited paper over the time period (2010-2020) are shown. The area of the 'bubble' is proportional to the share of highly cited papers. The dotted horizontal line indicates the average field-normalised citation impact for all IMI project papers.

FIGURE 5.4.1 PAPER NUMBERS, AVERAGE FIELD-NORMALISED CITATION IMPACT AND SHARE OF HIGHLY CITED RESEARCH FOR SELECTED IMI 1 PROJECTS – CALL 3, 2010-2020



The data in Figure 5.4.1 shows that:

- The average citation impact and percentage of highly cited papers for all projects in this call was above the world average.
- EU-AIMS was by far the most prolific IMI 1, call 3 project with 488 papers. The field-normalised citation impact of this research was twice the world average (2.03) and above average for all IMI research (1.99).
- EU-AIMS also has the highest percentage of highly cited papers 28.5%
- Research associated with DIRECT was very well-cited with a field-normalised citation impact of almost three times (2.98) the world average.

Table 5.4.1 shows raw citation impact and the percentage of open access publications by project for IMI 1 call 3 publications. Table 5.4.2 shows the normalised citation impact (normalised against world average values) of IMI 1 call 3 projects and is an expansion of the data shown in Figure 5.4.1.

TABLE 5.4.1 SUMMARY BIBLIOMETRIC INDICATORS FOR IMI 1 PROJECTS IN CALL 3, 2010-2020

Project	Number of publications	Number of papers	% open access publications	Citations	Raw citation impact
EU-AIMS	503	488	75.1%	14,458	29.63
PreDiCT-TB	118	112	85.6%	1,989	17.76
MIP-DILI	113	106	56.6%	2,544	24.00
DIRECT	105	79	62.9%	2,311	29.25
ABIRISK	97	76	49.5%	1,680	22.11
BioVacSafe	69	66	73.9%	1,777	26.92

TABLE 5.4.2 SUMMARY CITATION INDICATORS FOR IMI 1 PROJECTS IN CALL 3, 2010-2020

Project	Citation impact				
	Number of papers	Normalised at field level	Normalised at journal level	Average percentile	% highly cited papers
EU-AIMS	488	2.03	1.11	31.15	28.5%
PreDiCT-TB	112	1.22	0.82	42.90	14.3%
MIP-DILI	106	1.82	1.33	34.12	26.4%
DIRECT	79	2.98	0.90	38.15	27.8%
ABIRISK	76	1.32	0.93	44.48	17.1%
BioVacSafe	66	1.27	0.99	32.27	19.7%
<b>Overall (IMI projects)</b>	<b>6,566</b>	<b>1.99</b>	<b>1.21</b>	<b>35.00</b>	<b>25.7%</b>


- PreDiCT-TB had the highest percentage of open access publications (85.6%).



## 5.5 SUMMARY BIBLIOMETRIC ANALYSES FOR IMI 1 PROJECTS – CALL 4

Figure 5.5.1 compares the number of papers, average field-normalised citation impact and share of highly cited papers for IMI 1 call 4 projects. Only projects with at least 10 papers and one highly cited paper over the time period (2010-2020) are shown. The area of the 'bubble' is proportional to the share of highly cited papers. The dotted horizontal line indicates the average field-normalised citation impact for all IMI project papers.

FIGURE 5.5.1 PAPER NUMBERS, AVERAGE FIELD-NORMALISED CITATION IMPACT AND SHARE OF HIGHLY CITED RESEARCH FOR SELECTED IMI 1 PROJECTS – CALL 4, 2010-2020



The data in Figure 5.5.1 shows that:

- The average field-normalised citation impact of all projects in this call is above world average.
- EMIF produced the highest number of papers in call 4, with 279 papers published by the end of 2020 and has a field-normalised citation impact more than two and half times the world average (2.66).
- eTRICKS has the highest percentage of highly cited papers (39.0%)
- Two-of-the- seven projects in this call had an average field-normalised citation impact greater than the average citation impact for all IMI project research (1.99), which is two less than last years (2020) report.

Table 5.5.1 shows raw citation impact and the percentage of open access publications by project for IMI 1 call 4 publications. Table 5.5.2 shows the normalised citation impact (normalised against world average values) of IMI 1 call 4 projects and is an expansion of the data shown in Figure 5.5.1.

TABLE 5.5.1 BIBLIOMETRIC INDICATORS FOR IMI 1 PROJECTS IN CALL 4, 2010-2020

Project	Number of publications	Number of papers	% open access publications	Citations	Raw citation impact
EMIF	300	279	76.3%	9,136	32.75
ORBITO	168	165	28.0%	3,468	21.02
STEMBANCC	143	138	74.8%	3,489	25.28
CHEM21	130	127	46.9%	4,305	33.90
COMPACT	87	87	48.3%	3,038	34.92
K4DD	65	63	67.7%	1,382	21.94
eTRIKS	51	41	82.4%	1,279	31.20

TABLE 5.5.2 SUMMARY CITATION INDICATORS FOR IMI 1 PROJECTS IN CALL 4, 2010-2020


Project	Citation impact				
	Number of papers	Normalised at field level	Normalised at journal level	Average percentile	% highly cited papers
EMIF	279	2.66	1.36	28.56	34.1%
ORBITO	165	1.84	1.40	30.26	23.0%
STEMBANCC	138	1.95	1.30	34.47	30.4%
CHEM21	127	1.75	1.29	37.29	22.0%
COMPACT	87	1.86	1.39	29.73	26.4%
K4DD	63	1.74	1.36	29.02	27.0%
eTRIKS	41	2.44	1.48	22.27	39.0%
<b>Overall (IMI projects)</b>	<b>6,566</b>	<b>1.99</b>	<b>1.21</b>	<b>35.00</b>	<b>25.7%</b>

- eTRIKS has the highest percentage of open access publications (82.4%).

## 5.6 SUMMARY BIBLIOMETRIC ANALYSES FOR IMI 1 PROJECTS – CALLS 5-10

Figure 5.6.1 compares the number of papers, average field-normalised citation impact and share of highly cited papers for IMI 1 calls 5-10 projects. Only projects with at least 10 papers and one highly cited paper over the time period (2010-2020) are shown. The area of the 'bubble' is proportional to the share of highly cited papers. The dotted horizontal line indicates the average field-normalised citation impact for all IMI project papers.

FIGURE 5.6.1 PAPER NUMBERS, AVERAGE FIELD-NORMALISED CITATION IMPACT AND SHARE OF HIGHLY CITED RESEARCH FOR SELECTED IMI 1 PROJECTS – CALLS 5-10, 2010-2020



The data in Figure 5.6.1 shows that:

- Research associated with EBiSC was very well cited with an astounding field-normalised citation impact of more than seven times the world average (7.64). However, the total number of EBiSC papers is relatively low (28 papers) so citation indicators are easily inflated by one or a few very highly cited papers.
- SPRINTT has the highest percentage of highly cited papers (42.5%).
- TRANSLOCATION produced the most papers (152) likely due to it being one of the longest running projects from IMI 1 calls 5-10.
- All of the projects in calls 5-10 have a field-normalised citation impact greater than the world average but below average for all IMI project research (1.99), with the exception of EBiSC and SPRINTT.

Table 5.6.1 shows raw citation impact and the percentage of open access publications by project for IMI 1 call 5-10 publications. Table 5.6.2 shows the normalised citation impact (normalised against world average values) of IMI 1 calls 5-10 projects and is an expansion of the data shown in Figure 5.6.1.

TABLE 5.6.1 BIBLIOMETRIC INDICATORS FOR IMI 1 PROJECTS IN CALLS 5-10, 2010-2020

Project	Number of publications	Number of papers	% open access publications	Citations	Raw citation impact
TRANSLOCATION	152	152	59.2%	3,018	19.86
ELF	126	125	65.9%	1,845	14.76
SPRINTT	113	106	55.8%	2,515	23.73
COMBACTE-NET	87	80	78.2%	915	11.44
AETIONOMY	69	68	78.3%	1,206	17.74
DRIVE-AB	57	51	80.7%	908	17.80
COMBACTE-CARE	52	48	84.6%	971	20.23
ENABLE	47	47	85.1%	735	15.64
PRECISESADS	64	44	56.3%	742	16.86
FLUCOP	37	36	78.4%	486	13.50
GETREAL	41	35	75.6%	633	18.09
EBiSC	31	28	87.1%	1,884	67.29
ADVANCE	26	25	88.5%	270	10.80
WEB-RADR	16	15	75.0%	231	15.40

TABLE 5.6.2 SUMMARY CITATION INDICATORS FOR IMI 1 PROJECTS IN CALLS 5-10, 2010-2020


Project	Citation impact				
	Number of papers	Normalised at field level	Normalised at journal level	Average percentile	% highly cited papers
TRANSLOCATION	152	1.39	1.04	36.94	20.4%
ELF	125	1.15	0.99	41.68	16.0%
SPRINTT	106	2.22	2.29	26.98	42.5%
COMBACTE-NET	80	1.01	0.96	39.99	16.3%
AETIONOMY	68	1.71	1.20	40.16	22.1%
DRIVE-AB	51	1.37	1.13	31.23	29.4%
COMBACTE-CARE	48	1.78	1.21	37.88	31.3%
ENABLE	47	1.61	1.14	33.87	25.5%
PRECISESADS	44	1.23	0.89	40.91	13.6%
FLUCOP	36	1.09	1.15	39.24	22.2%
GETREAL	35	1.82	1.23	32.93	22.9%
EBiSC	28	7.64	3.59	29.52	32.1%
ADVANCE	25	1.87	2.45	24.57	40.0%
WEB-RADR	15	1.80	1.65	28.59	33.3%
<b>Overall (IMI projects)</b>	<b>6,566</b>	<b>1.99</b>	<b>1.21</b>	<b>35.00</b>	<b>25.7%</b>

- ADVANCE has the highest percentage (88.5%) of open access publications.

## 5.7 SUMMARY BIBLIOMETRIC ANALYSES FOR IMI 1 PROJECTS – CALL 11

Figure 5.7.1 compares the number of papers, average field-normalised citation impact and share of highly cited papers for IMI 1 call 11 projects. Only projects with at least 10 papers and one highly cited paper over the time period (2010-2020) are shown. The area of the 'bubble' is proportional to the share of highly cited papers. The dotted horizontal line indicates the average field-normalised citation impact for all IMI project papers.

FIGURE 5.7.1 PAPER NUMBERS, AVERAGE FIELD-NORMALISED CITATION IMPACT AND SHARE OF HIGHLY CITED RESEARCH FOR SELECTED IMI 1 PROJECTS – CALL 11, 2010-2020



The data in Figure 5.7.1 shows that:

- ULTRA-DD produced by far the most papers (371).
- All of the projects (except for iABC) perform above world average for percentage of highly cited papers and field-normalised citation impact.
- Research papers associated with CANCER-ID and ZAPI were very well-cited with a field-normalised citation impact nearly three (3.27) and (5.61) five times the world average, respectively. They are also the only two projects in this call that are higher than the average for all IMI projects (1.99).
- Over half of CANCER-ID papers are highly cited (50.3%).

Table 5.7.1 shows raw citation impact and the percentage of open access publications by project for IMI 1 call 11 publications. Table 5.7.2 shows the normalised citation impact (normalised against world average values) of IMI 1 call 11 projects and is an expansion of the data shown in Figure 5.7.1.

TABLE 5.7.1 BIBLIOMETRIC INDICATORS FOR IMI 1 PROJECTS IN CALL 11, 2010-2020

Project	Number of publications	Number of papers	% open access publications	Citations	Raw citation impact
ULTRA-DD	379	371	77.8%	5,690	15.34
CANCER-ID	193	167	70.5%	6,429	38.50
COMBACTE-MAGNET	91	81	74.7%	928	11.46
ZAPI	53	50	98.1%	1,494	29.88
APPROACH	52	42	69.2%	1,179	28.07
iPiE	38	37	63.2%	487	13.16
EPAD	39	35	64.1%	463	13.23
iABC	36	22	50.0%	224	10.18

TABLE 5.7.2 SUMMARY CITATION INDICATORS FOR IMI 1 PROJECTS IN CALL 11, 2010-2020


Project	Number of papers	Citation impact			% highly cited papers
		Normalised at field level	Normalised at journal level	Average percentile	
ULTRA-DD	371	1.74	1.01	35.76	24.5%
CANCER-ID	167	3.27	1.63	17.83	50.3%
COMBACTE-MAGNET	81	1.18	1.00	42.49	24.7%
ZAPI	50	5.61	3.05	27.23	42.0%
APPROACH	42	1.95	1.65	27.55	40.5%
iPiE	37	1.32	1.08	35.83	27.0%
EPAD	35	1.01	0.74	48.53	11.4%
iABC	22	0.87	0.90	60.99	9.1%
<b>Overall (IMI projects)</b>	<b>6,566</b>	<b>1.99</b>	<b>1.21</b>	<b>35.00</b>	<b>25.7%</b>

- ZAPI has the highest percentage (98.1%) of open access publications.

## 5.8 SUMMARY BIBLIOMETRIC ANALYSES FOR IMI 2 CALLS 1-4 PROJECTS

Figure 5.8.1 compares the number of papers, average field-normalised citation impact and share of highly cited papers from IMI 2 projects from calls 1-4. Only projects with at least 10 papers and one highly cited paper over the time period (2015-2020) are shown. The area of the 'bubble' is proportional to the share of highly cited papers. The dotted horizontal line indicates the average field-normalised citation impact for all IMI project papers.

FIGURE 5.8.1 PAPER NUMBERS, AVERAGE FIELD-NORMALISED CITATION IMPACT AND SHARE OF HIGHLY CITED RESEARCH FOR SELECTED IMI 2 PROJECTS – CALLS 1-4, 2015-2020



The data in Figure 5.8.1 shows that:

- INNODIA was the most productive project, publishing 126 papers.
- With the exception of EbolaMoDRAD, all of the projects meet or exceed the world average for highly cited papers.
- RHAPSODY and PRISM are the most impactful projects with a field-normalized citation impact of more than two times the world average, 2.10 and 2.14 respectively.
- Besides RHAPSODY and PRISM, the other projects fall short of the average field-normalized citation impact for all IMI projects (1.99)

Table 5.8.1 shows raw citation impact and percentage of open access publications by project for IMI 2 calls 1-4 publications and Table 5.8.2 shows indicators for IMI 2 calls 1-4 project research where citation impact has been normalised against world average values.

TABLE 5.8.1 BIBLIOMETRIC INDICATORS FOR IMI 2 CALLS 1-4 PROJECTS, 2015-2020

Project	Number of publications	Number of papers	% open access publications <sup>9</sup>	Citations	Raw citation impact
INNODIA	158	126	69.6%	1,306	10.37
RHAPSODY	75	60	78.7%	754	12.57
PRISM	58	49	75.9%	513	10.47
RADAR-CNS	64	42	48.4%	393	9.36
EBOVAC1	31	29	100.0%	529	18.24
EbolaMoDRAD	26	25	69.2%	227	9.08
EBOVAC2	15	15	100.0%	192	12.80
VSV-EBOVAC	11	10	63.6%	149	14.90

- All the EBOVAC1 & EBOVAC2 project papers are open access.  
RADAR-CNS has less than 50% of its publications as open access.<sup>9</sup>

TABLE 5.8.2 SUMMARY CITATION INDICATORS FOR IMI 2 CALLS 1-4 PROJECTS, 2015-2020

Project	Citation impact				
	Number of papers	Normalised at field level	Normalised at journal level	Average percentile	% highly cited papers
INNODIA	126	1.63	1.09	40.38	20.6%
RHAPSODY	60	2.10	1.01	41.44	26.7%
PRISM	49	2.14	1.05	43.16	26.5%
RADAR-CNS	42	1.64	1.76	42.66	28.6%
EBOVAC1	29	1.93	1.29	38.90	31.0%
EbolaMoDRAD	25	1.45	1.09	40.15	8.0%
EBOVAC2	15	1.46	1.27	42.24	26.7%
VSV-EBOVAC	10	1.00	0.69	26.23	10.0%
<b>Overall (IMI projects)</b>	<b>6,566</b>	<b>1.99</b>	<b>1.21</b>	<b>35.00</b>	<b>25.7%</b>

<sup>9</sup> Note that IMI 2 funded researchers are contractually obliged to make their scientific articles open access through Green or Gold routes. However, for some of other document types, such as editorials, reviews or conference proceedings open access publication is strongly encouraged but not mandatory.

Nevertheless, it is obvious that fewer than all of IMI's publications are classified as open access in this analysis, and this is likely to be due to ancillary factors (such as challenges relating to definitions and coverage) as well as non-compliance. The Web of Science open access data come from the Directory of Open Access Journals (DOAJ) and collaborations with Impact Story and Our Research's Unpaywall services. The Web of Science therefore provides unrivalled coverage of open access publications that are published through DOAJ Gold, Other Gold, Green Published, Green Accepted or Bronze routes.

It is also possible that some publishers makes publications available without following a recognised open access route. In these cases publications will not be indexed as open access in the Web of Science or in this report. Additionally, the analysis presented in this report covers all document types and not just papers, and some of these are not indexed as open access in the Web of Science databases.

The Web of Science open access data coverage is summarised at: <https://clarivate.com/webofsciencegroup/solutions/open-access/>



## 5.9 SUMMARY BIBLIOMETRIC ANALYSES FOR IMI 2 CALLS 5-10 PROJECTS

Figure 5.9.1 compares the number of papers, average field-normalised citation impact and share of highly cited papers from IMI 2 projects from calls 5-10. Only projects with at least 10 papers and one highly cited paper over the time period (2017-2020) are shown. The area of the 'bubble' is proportional to the share of highly cited papers. The dotted horizontal line indicates the average field-normalised citation impact for all IMI project papers. The same data is shown in Figure 5.9.1 and Figure 5.9.2, however Figure 5.9.2 has a smaller x-axis range in order to get a better view of the clustered projects in the bottom left corner of Figure 5.9.1.

FIGURE 5.9.1 PAPER NUMBERS, AVERAGE FIELD-NORMALISED CITATION IMPACT AND SHARE OF HIGHLY CITED RESEARCH FOR SELECTED IMI 2 PROJECTS – CALLS 5-10, 2017-2020





FIGURE 5.9.2 PAPER NUMBERS, AVERAGE FIELD-NORMALISED CITATION IMPACT AND SHARE OF HIGHLY CITED RESEARCH FOR SELECTED IMI 2 PROJECTS – CALLS 5-10, 2017-2020. SMALLER AXIS RANGE.



The data in Figure 5.9.1 and Figure 5.9.2 shows that:

- The AIMS-2-Trials publishes the most papers, 101 papers. Although, the field-normalized citation impact remains low compared to many of the other projects. This is likely because 69 out of 101 papers were published in 2020 and therefore have not had much time to accumulate citations.
- IMPRIND project is very well cited and has exceeded the world average field-normalized citation impact by more than six times (6.47). It has more than half (56.5%) of its papers that are highly cited.

Table 5.9.1 shows raw citation impact and percentage of open access publications by project for IMI 2 calls 5-10 publications and Table 5.9.2 shows indicators for IMI 2 calls 5-10 project research where citation impact has been normalised against world average values.

TABLE 5.9.1 BIBLIOMETRIC INDICATORS FOR IMI 2 CALLS 5-10 PROJECTS, 2017-2020

Project	Number of publications	Number of papers	% open access publications <sup>10</sup>	Citations	Raw citation impact
AIMS-2-TRIALS	107	101	89.7%	522	5.17
RTCure	94	87	84.0%	1,142	13.13
BEAT-DKD	78	73	83.3%	659	9.03
BigData@Heart	69	60	78.3%	363	6.05
IMPRIND	48	46	85.4%	1,798	39.09
RESCEU	31	29	87.1%	204	7.03
PHAGO	29	29	96.6%	474	16.34
TransQST	30	28	83.3%	273	9.75
LITMUS	26	21	65.4%	178	8.48
ROADMAP	26	20	80.8%	102	5.10
AMYPAD	26	20	69.2%	211	10.55
ADAPTED	20	18	90.0%	274	15.22
TRISTAN	15	15	93.3%	142	9.47
eTRANSafe	20	15	75.0%	104	6.93
HARMONY	27	15	63.0%	161	10.73
PREFER	23	14	78.3%	115	8.21
DRIVE	12	11	83.3%	50	4.55
VSV-EBOPUS	12	11	75.0%	97	8.82

<sup>10</sup> Note that IMI 2 funded researchers are contractually obliged to make their scientific articles open access through Green or Gold routes. However, for some of other document types, such as editorials, reviews or conference proceedings open access publication is strongly encouraged but not mandatory.

Nevertheless, it is obvious that fewer than all of IMI's publications are classified as open access in this analysis, and this is likely to be due to ancillary factors (such as challenges relating to definitions and coverage) as well as non-compliance. The Web of Science open access data come from the Directory of Open Access Journals (DOAJ) and collaborations with Impact Story and Our Research's Unpaywall services. The Web of Science therefore provides unrivalled coverage of open access publications that are published through DOAJ Gold, Other Gold, Green Published, Green Accepted or Bronze routes.

It is also possible that some publishers makes publications available without following a recognised open access route. In these cases publications will not be indexed as open access in the Web of Science or in this report. Additionally, the analysis presented in this report covers all document types and not just papers, and some of these are not indexed as open access in the Web of Science databases.

The Web of Science open access data coverage is summarised at: <https://clarivate.com/webofsciencegroup/solutions/open-access/>

- 96.6% of PHAGO project papers are open access.


TABLE 5.9.2 SUMMARY CITATION INDICATORS FOR IMI 2 CALLS 5-10 PROJECTS, 2017-2020

Project	Citation impact				
	Number of papers	Normalised at field level	Normalised at journal level	Average percentile	% highly cited papers
AIMS-2-TRIALS	101	1.88	0.89	57.06	16.8%
RTCure	87	2.68	1.49	37.33	27.6%
BEAT-DKD	73	1.46	0.81	40.90	20.5%
BigData@Heart	60	1.53	0.85	51.39	15.0%
IMPRIND	46	6.47	2.18	15.90	56.5%
RESCEU	29	2.00	1.26	34.56	27.6%
PHAGO	29	3.34	1.53	31.59	37.9%
TransQST	28	3.25	2.09	38.36	28.6%
LITMUS	21	4.14	1.40	37.46	47.6%
ROADMAP	20	0.90	0.61	52.97	5.0%
AMYPAD	20	1.45	0.84	40.78	20.0%
ADAPTED	18	2.34	0.78	45.77	38.9%
HARMONY	15	0.87	0.52	52.90	6.7%
TRISTAN	15	1.17	0.91	51.77	26.7%
eTRANSFAE	15	3.25	1.83	44.09	13.3%
PREFER	14	0.99	0.86	54.30	21.4%
DRIVE	11	1.23	1.79	53.91	27.3%
VSV-EBOPUS	11	0.81	0.94	32.51	9.1%
<b>Overall (IMI projects)</b>	<b>6,566</b>	<b>1.99</b>	<b>1.21</b>	<b>35.00</b>	<b>25.7%</b>

## 5.10 SUMMARY BIBLIOMETRIC ANALYSES FOR IMI 2 CALLS 11-21 PROJECTS

Figure 5.10.1 compares the number of papers, average field-normalised citation impact and share of highly cited papers from IMI 2 projects from calls 11-21. Only projects with at least 10 papers and one highly cited paper over the time period (2019-2020) are shown. The area of the 'bubble' is proportional to the share of highly cited papers. The dotted horizontal line indicates the average field-normalised citation impact for all IMI project papers.

FIGURE 5.10.1 PAPER NUMBERS, AVERAGE FIELD-NORMALISED CITATION IMPACT AND SHARE OF HIGHLY CITED RESEARCH FOR SELECTED IMI 2 PROJECTS – CALLS 11-21, 2019-2020



The data in Figure 5.10.1 and Figure shows that:

- Publication rates in these calls are still quite low, with EUbOPEN being the most prolific with 20 papers. This is because these projects are quite new, and the oldest publication was published in 2019.
- As these publications are so new their percentage of highly cited papers and field-normalized citation impact is also low. Except for MOBILISE-D.
- MOBILISE-D is the most well-cited in this group with an average field-normalised citation impact (2.61) of more than two times the world average.
- Almost a third (31.3%) of MOBILISE-D project papers are highly cited.

Table 5.10.1 shows raw citation impact and percentage of open access publications by project for IMI 2 calls 11-21 publications and Table 5.9.2 shows indicators for IMI 2 calls 11-21 project research where citation impact has been normalised against world average values.

TABLE 5.10.1 BIBLIOMETRIC INDICATORS FOR IMI 2 CALLS 11-21 PROJECTS, 2019-2020

Project	Number of publications	Number of papers	% open access publications <sup>11</sup>	Citations	Raw citation impact
EUbOPEN	20	20	65.0%	13	0.65
MOBILISE-D	18	16	55.6%	40	2.50
INNODIA HARVEST	14	11	78.6%	16	1.45
CARDIATEAM	13	11	69.2%	19	1.73

- INNODIA HARVEST has the highest percentage of open access publications, 78.6%.

TABLE 5.10.2 SUMMARY CITATION INDICATORS FOR IMI 2 CALLS 11-21 PROJECTS, 2019-2020

Project	Number of papers	Citation impact		Average percentile	% highly cited papers
		Normalised at field level	Normalised at journal level		
EUbOPEN	20	0.45	0.19	81.85	5.0%
MOBILISE-D	16	2.61	1.61	51.37	31.3%
INNODIA HARVEST	11	0.93	0.82	53.00	9.1%
CARDIATEAM	11	0.89	1.00	57.38	9.1%
<b>Overall (IMI projects)</b>	<b>6,566</b>	<b>1.99</b>	<b>1.21</b>	<b>35.00</b>	<b>25.7%</b>

<sup>10</sup> Note that IMI 2 funded researchers are contractually obliged to make their scientific articles open access through Green or Gold routes. However, for some of other document types, such as editorials, reviews or conference proceedings open access publication is strongly encouraged but not mandatory.

Nevertheless, it is obvious that fewer than all of IMI's publications are classified as open access in this analysis, and this is likely to be due to ancillary factors (such as challenges relating to definitions and coverage) as well as non-compliance. The Web of Science open access data come from the Directory of Open Access Journals (DOAJ) and collaborations with Impact Story and Our Research's Unpaywall services. The Web of Science therefore provides unrivalled coverage of open access publications that are published through DOAJ Gold, Other Gold, Green Published, Green Accepted or Bronze routes.

It is also possible that some publishers makes publications available without following a recognised open access route. In these cases publications will not be indexed as open access in the Web of Science or in this report. Additionally, the analysis presented in this report covers all document types and not just papers, and some of these are not indexed as open access in the Web of Science databases.

The Web of Science open access data coverage is summarised at: <https://clarivate.com/webofsciencegroup/solutions/open-access/>

## 6 GEOGRAPHIC CLUSTERING ANALYSIS

### 6.1 LOCATIONS WHERE IMI-FUNDED RESEARCH TAKES PLACE

This section of the report analyses geographic clusters where IMI research occurs, the citation impact of research published by these clusters and the clusters' constituent institutions.

Substantial clusters of research activity were identified in Europe and North America. While IMI project research also involves institutions in other parts of the world, publication rates for other geographies were low. This analysis, therefore, focuses on Europe and North America and we have identified the 36 and 16 geographic clusters respectively with the highest output.

Clusters have a 20km radius and the clusters in Europe and North America tend to focus on major cities with an existing strong academic research base. The largest European clusters are London (1,454 publications), Amsterdam (1,221 publications), Stockholm (685 publications), Paris (630 publications) and Oxford (587) which replaced Copenhagen (502) since last year's report. The largest clusters in North America are Toronto (310 publications), Boston (296 publications), Bethesda (172 publications), New York (131 publications), and Montreal (119 publications).

IMI research performs well above the national averages for citation impact for all the European and North American clusters. The highest European clusters for citation impact are Maastricht (3.69) and Cambridge (3.43) both more than two times their national averages of 1.70 and 1.52, respectively.

A relatively high percentage of IMI research is open access, with the Seattle cluster being among the highest with 90.4% of its IMI project research as open access publications and Rome being the lowest with over half (57.7%) of its publications being open access. The European cluster with the highest percentage of IMI research was Oxford with 86.2 % of its publication being open access.

Around 40% of all EU-28 biomedical research involves international co-authorship while in comparison rates of international collaboration for IMI project research are very high for most clusters, especially in North America where most clusters have around 90% international collaboration which is expected as IMI is European funding organisation that primarily funds researchers working in EU-28. The European cluster with the highest rate of internationally collaborative papers was Dresden with 95.5% of its research involving international co-authorship. While the European cluster, Uppsala, remained the lowest at 70% international collaboration.

The clusters are visualised on maps in

Figure 6.1.1 and Figure 6.1.2. Both maps are scaled separately so that the most intensive areas of output are shaded red and the areas of lowest output are blue. This means that the same colour shading is not comparable between maps. Table 6.1.1 to Table 6.1.4 show the research publication outputs of the individual clusters along with bibliometric indicators of their research performance. The citation metrics in Table 6.1.2 and Table 6.1.4 are shaded green when the performance of a cluster of IMI-supported research outperforms the national average performance for biomedical research.<sup>12</sup> The institutions that constitute the top five clusters within the European and North American regions are shown in Table 6.1.5 and Table 6.1.6 respectively. The five journal subject categories in which the top five clusters published most frequently within the European and North American regions are shown in Table 6.1.7 and Table 6.1.8 Respectively.

---

<sup>12</sup> Web of Science journal categories which capture biomedically related publications used to calculate the national baselines are listed in [Annex 2](#).

Figure 6.1.1 MAP SHOWING EUROPEAN GEOGRAPHIC CLUSTERS OF IMI PROJECT RESEARCH, 2010-2020






FIGURE 6.1.2 MAP SHOWING NORTH AMERICAN GEOGRAPHIC CLUSTERS OF IMI PROJECT RESEARCH, 2010-2020




TABLE 6.1.1 OUTPUT AND RESEARCH PERFORMANCE OF EUROPEAN GEOGRAPHIC CLUSTERS OF IMI PROJECT RESEARCH, 2010-2020

Cluster	Number of publications	Number of papers	% open access publications	Raw citation impact	% internationally collaborative publications
London (UK)	1,454	1,322	75.2%	30.77	83.1%
Amsterdam (Netherlands)	1,221	1,102	69.3%	32.57	80.9%
Stockholm (Sweden)	685	636	70.4%	33.71	77.8%
Paris (France)	630	590	70.6%	32.75	84.1%
Oxford (UK)	587	561	86.2%	27.82	82.2%
Cambridge (UK)	516	477	81.0%	40.57	82.4%
Copenhagen (Denmark)	502	464	63.9%	26.22	81.5%
Barcelona (Spain)	406	366	70.2%	28.43	77.9%
Berlin (Germany)	355	330	74.1%	31.04	80.9%
Mannheim (Germany)	353	342	70.8%	38.10	85.7%
Basel (Switzerland)	312	283	67.3%	27.25	94.0%
Uppsala (Sweden)	269	253	72.5%	23.20	70.0%
Rome (Italy)	260	235	57.7%	32.58	74.9%
Madrid (Spain)	257	238	75.5%	25.23	76.5%
Groningen (Netherlands)	255	240	80.8%	28.58	82.1%
Milan (Italy)	249	212	63.1%	33.90	83.5%
Vienna (Austria)	246	227	72.8%	20.45	81.5%
Frankfurt (Germany)	245	227	60.8%	20.52	87.2%
Nijmegen (Netherlands)	243	230	74.9%	34.51	83.5%
Gothenburg (Sweden)	243	227	68.7%	33.44	89.0%
Geneva (Switzerland)	236	213	78.0%	37.48	85.4%
Hamburg (Germany)	232	218	77.2%	29.03	80.3%
Munich (Germany)	214	191	64.5%	31.73	82.7%
Manchester (UK)	213	188	71.4%	41.28	86.2%
Erlangen (Germany)	212	201	64.2%	40.63	72.1%
Maastricht (Netherlands)	201	193	80.1%	61.05	92.2%
Leuven (Belgium)	199	172	68.3%	32.38	85.5%
Nottingham (UK)	190	176	77.9%	26.15	88.6%
Helsinki (Finland)	161	155	84.5%	36.14	86.5%
Dresden (Germany)	146	132	76.7%	24.27	95.5%
Bonn (Germany)	143	137	83.9%	28.58	78.1%
Tubingen (Germany)	137	129	72.3%	19.20	75.2%
Beerse (Belgium)	125	118	62.4%	23.14	89.8%
Marseille (France)	117	105	64.1%	30.30	82.9%
Zurich (Switzerland)	99	89	83.8%	40.56	84.3%
Lille (France)	75	70	64.0%	25.74	90.0%

TABLE 6.1.2 RESEARCH PERFORMANCE OF EUROPEAN GEOGRAPHIC CLUSTERS OF IMI PROJECT RESEARCH COMPARED TO NATIONAL BENCHMARKS, 2010-2020

Cluster	Field-normalised citation impact		Journal-normalised citation impact		% highly cited papers	
	Cluster	National	Cluster	National	Cluster	National
London (UK)	2.39	1.52	1.30	1.08	31.4%	17.2%
Amsterdam (Netherlands)	2.50	1.70	1.36	1.13	30.1%	19.5%
Stockholm (Sweden)	2.33	1.61	1.28	1.12	29.2%	17.9%
Paris (France)	2.87	1.45	1.40	1.05	32.4%	15.5%
Oxford (UK)	2.44	1.52	1.31	1.08	32.6%	17.2%
Cambridge (UK)	3.43	1.52	1.47	1.08	34.2%	17.2%
Copenhagen (Denmark)	2.27	1.70	1.25	1.15	26.7%	18.6%
Barcelona (Spain)	2.74	1.35	1.43	1.06	31.7%	14.2%
Mannheim (Germany)	2.73	1.33	1.27	1.06	30.1%	14.9%
Berlin (Germany)	2.81	1.33	1.45	1.06	27.9%	14.9%
Basel (Switzerland)	2.10	1.71	1.49	1.16	30.7%	19.2%
Uppsala (Sweden)	2.04	1.61	1.11	1.12	23.3%	17.9%
Groningen (Netherlands)	2.58	1.70	1.17	1.13	27.1%	19.5%
Madrid (Spain)	2.55	1.35	1.46	1.06	29.0%	14.2%
Rome (Italy)	2.38	1.40	1.81	1.16	37.4%	15.1%
Nijmegen (Netherlands)	2.57	1.70	1.29	1.13	34.3%	19.5%
Gothenburg (Sweden)	3.01	1.61	1.68	1.12	36.6%	17.9%
Vienna (Austria)	1.77	1.57	1.17	1.13	20.3%	17.3%
Frankfurt (Germany)	1.90	1.33	1.23	1.06	27.3%	14.9%
Hamburg (Germany)	2.56	1.33	1.23	1.06	31.2%	14.9%
Geneva (Switzerland)	2.32	1.71	1.01	1.16	29.6%	19.2%
Milan (Italy)	2.73	1.40	1.48	1.16	36.8%	15.1%
Erlangen (Germany)	2.71	1.33	1.45	1.06	32.8%	14.9%
Maastricht (Netherlands)	3.69	1.70	1.93	1.13	37.3%	19.5%
Munich (Germany)	2.81	1.33	1.42	1.06	31.4%	14.9%
Manchester (UK)	2.75	1.52	1.52	1.08	38.8%	17.2%
Nottingham (UK)	2.28	1.52	1.25	1.08	32.4%	17.2%
Leuven (Belgium)	2.57	1.77	1.54	1.20	33.7%	19.8%
Helsinki (Finland)	3.08	1.62	1.48	1.09	39.4%	17.0%
Bonn (Germany)	2.22	1.33	1.35	1.06	24.1%	14.9%
Dresden (Germany)	2.45	1.33	0.86	1.06	21.2%	14.9%
Tubingen (Germany)	1.96	1.33	1.15	1.06	30.2%	14.9%
Beerse (Belgium)	2.03	1.77	1.41	1.20	24.6%	19.8%
Marseille (France)	2.74	1.45	1.52	1.05	31.4%	15.5%
Zurich (Switzerland)	3.28	1.71	1.71	1.16	36.0%	19.2%
Lille (France)	1.79	1.45	0.94	1.05	28.6%	15.5%
London (UK)	2.39	1.52	1.30	1.08	31.4%	17.2%
Amsterdam (Netherlands)	2.50	1.70	1.36	1.13	30.1%	19.5%
Stockholm (Sweden)	2.33	1.61	1.28	1.12	29.2%	17.9%

TABLE 6.1.3 OUTPUT AND RESEARCH PERFORMANCE OF NORTH AMERICAN GEOGRAPHIC CLUSTERS OF IMI PROJECT RESEARCH, 2010-2020

Cluster	Number of publications	Number of papers	% open access publications	Raw citation impact	% internationally collaborative publications
Toronto (Canada)	310	302	81.0%	36.61	91.4%
Boston (USA)	296	286	86.1%	58.51	98.6%
Bethesda (USA)	172	164	80.2%	45.16	98.2%
New York (USA)	131	129	72.5%	46.97	99.2%
Montreal (Canada)	119	118	80.7%	40.28	98.3%
Chapel Hill (USA)	111	108	87.4%	30.59	88.9%
Indianapolis (USA)	100	95	69.0%	39.82	97.9%
Burlington (USA)	87	85	78.2%	23.01	100.0%
San Francisco (USA)	83	80	85.5%	81.89	100.0%
New York (USA)	79	78	84.8%	45.44	100.0%
Baltimore (USA)	68	66	88.2%	66.47	100.0%
Ann Arbor (USA)	56	54	85.7%	51.69	98.1%
Seattle (USA)	52	51	90.4%	65.20	98.0%
Gainesville (USA)	42	40	66.7%	31.00	97.5%
Los Angeles (USA)	34	34	76.5%	88.15	97.1%
Houston (USA)	31	30	90.3%	54.23	100.0%

TABLE 6.1.4 RESEARCH PERFORMANCE OF NORTH AMERICAN GEOGRAPHIC CLUSTERS OF IMI PROJECT RESEARCH COMPARED TO NATIONAL BENCHMARKS, 2010-2020

Cluster	Field-normalised citation impact		Journal-normalised citation impact		% highly cited papers	
	Cluster	National	Cluster	National	Cluster	National
Toronto (Canada)	2.81	1.49	1.34	1.07	33.4%	16.2%
Boston (USA)	3.92	1.33	1.51	1.01	39.2%	15.5%
New York (USA)	4.29	1.33	1.63	1.01	35.3%	15.5%
Bethesda (USA)	3.50	1.33	1.57	1.01	48.2%	15.5%
Montreal (Canada)	3.24	1.49	1.09	1.07	28.8%	16.2%
Chapel Hill (USA)	3.21	1.33	1.44	1.01	34.3%	15.5%
Indianapolis (USA)	3.82	1.33	1.34	1.01	32.6%	15.5%
Burlington (USA)	1.79	1.33	0.79	1.01	18.8%	15.5%
San Francisco (USA)	6.14	1.33	2.17	1.01	53.7%	15.5%
Baltimore (USA)	6.50	1.33	1.67	1.01	60.6%	15.5%
Ann Arbor (USA)	5.12	1.33	2.20	1.01	55.6%	15.5%
Seattle (USA)	5.68	1.33	2.29	1.01	52.9%	15.5%
Gainesville (USA)	2.33	1.33	1.74	1.01	50.0%	15.5%
Los Angeles (USA)	5.76	1.33	1.53	1.01	52.9%	15.5%
Houston (USA)	4.93	1.33	2.46	1.01	53.3%	15.5%
Toronto (Canada)	2.81	1.49	1.34	1.07	33.4%	16.2%
Boston (USA)	3.92	1.33	1.51	1.01	39.2%	15.5%
New York (USA)	4.29	1.33	1.63	1.01	35.3%	15.5%

Table 6.1.5 Institutions constituting top-five, by number of publications, European geographic clusters of IMI PROJECT RESEARCH, 2010-2020

Cluster	Country	Institutions	Number of publications
London	UK	Kings College London	590
		Imperial College London	391
		University College London	354
		GlaxoSmithKline	108
		London School of Hygiene & Tropical Medicine	67
		South London & Maudsley NHS Trust	61
		Birkbeck University London	61
		Guy's & St Thomas' NHS Foundation Trust	58
		Queen Mary University London	46
		St Georges University London	35
		Royal Brompton Harefield NHS Foundation Trust	34
		Royal Brompton Hosp	33
		University of London	31
		University College London Hospitals NHS Foundation Trust	26
		Med & Healthcare Prod Regulatory Agency	26
		Francis Crick Institute	22
		European Med Agency	18
		UCB Pharma SA	18
		Institute Cancer Research UK	17
		Medical Research Council	16
		London School Economics & Political Science	14
		Natl Inst Health Care Excellence	13
		South London & Maudsley NHS Foundation	13
		University of Westminster	11
		Royal Marsden NHS Foundation Trust	11
		EMA	10
		Public Health England	9
		Kings College Hospital	9
		Royal Coll Gen Practitioners	8
		MRC Social Genet & Dev Psychiat SGDP Ctr	8
		Alan Turing Inst	7
		Amgen	7
		AMGEN LTD	7
		Health Data Res UK	7
		Natl Inst Biol Stand Control	7
		Royal Brompton NIHR Biomed Res Unit	7
		Kings Coll Hosp NHS Foundation Trust	6
		South London & Maudsley Foundation NHS Trust	6
		UCL Medical School	6
		UK Dementia Res Inst	6
South London & Maudsley NHS Foundation Trust SLaM	6		
Moorfields Eye Hospital NHS Foundation Trust	6		
Genet Alliance UK	5		
Heptares Therapeut	5		
UKRI	4		

Cluster	Country	Institutions	Number of publications
<b>Amsterdam</b>	<b>Netherlands</b>	Utrecht University	349
		Vrije Universiteit Amsterdam	342
		Leiden University	339
		University of Amsterdam	325
		Leiden University Med Center	269
		Erasmus University Rotterdam	234
		Acad Med Center University Amsterdam	224
		Erasmus MC	213
		VU UNIV MED CTR	85
		Utrecht University Med Center	40
		Netherlands National Institute for Public Health & the Environment	39
		Netherlands Cancer Inst	12
		Delft University of Technology	12
		Med Evaluation Board	8
		ICIN Netherlands Heart Inst	8
		Netherlands Inst Health Serv Res	8
		ReSViNET Foundation	7
		Lygature	6
		Jan van Breemen Res Inst Reade	6
		Janssen Vaccines & Prevent BV	6
Netherlands Heart Inst	6		
Amsterdam University Med Center	5		
Weibel Consulting	5		
Emma Childrens Hospital	4		
<b>Stockholm</b>	<b>Sweden</b>	Karolinska Institutet	622
		Karolinska University Hosp	247
		Royal Institute of Technology	56
		Stockholm City Council	53
		Stockholm University	48
		Danderyds Hosp	10
		AstraZeneca	8
		Sci Life Lab	6
<b>Paris</b>	<b>France</b>	Institut National de la Sante et de la Recherche Medicale (Inserm)	350
		University Paris	285
		Universite Paris Saclay (ComUE)	220
		University Paris Saclay	186
		Centre National de la Recherche Scientifique (CNRS)	165
		Sorbonne University	159
		CEA	132
		CNRS INSB	85
		Hopital Universitaire Pitie-Salpetriere - APHP	83
		Hopital Universitaire Cochin - APHP	70
		Le Reseau International des Instituts Pasteur (RIIP)	59
		Inst Pasteur Paris	52
Sanofi-Aventis	46		

Cluster	Country	Institutions	Number of publications
		Sanofi France	44
		Assistance Publique Hopitaux Paris (APHP)	35
		Institut de Recherches Internationales Servier	33
		Hopital Universitaire Bichat-Claude Bernard - APHP	24
		UNICANCER	22
		Inst Curie	21
		Orsay Hosp	20
		Hopital Universitaire Saint-Louis - APHP	16
		Hopital Universitaire Europeen Georges-Pompidou - APHP	16
		Hopital Universitaire Necker-Enfants Malades - APHP	16
		PSL Res Univ Paris ComUE	15
		Universite Grenoble Alpes (UGA)	14
		Communaute University Grenoble Alpes	14
		Gustave Roussy	13
		CNRS Inst Chem	12
		Hopital Universitaire Paul-Brousse - APHP	11
		Hopital Universitaire Saint-Antoine - APHP	9
		Hopital Universitaire Robert-Debre - APHP	9
		Hopital Universitaire Bicetre - APHP	9
		Inst Ecol Environment	9
		Hopital Universitaire Beaujon - APHP	7
		Servier	7
		Hop Univ Ambroise-Pare APHP	6
		SOLEIL Synchrotron	6
		Museum Natl Histoire Nat	3
		University Paris XIII	1
<b>Oxford</b>	<b>UK</b>	University of Oxford	580
		Wellcome Center Human Genetics	82
		Oxford University Hosp NHS Foundation Trust	22
		Diamond Light Source	14
		Ludwig Institute for Cancer Research	12
		P1vital Ltd	5

TABLE 6.1.6 INSTITUTIONS CONSTITUTING TOP-FIVE, BY NUMBER OF PUBLICATIONS, NORTH AMERICAN GEOGRAPHIC CLUSTERS OF IMI PROJECT RESEARCH, 2010-2020

Cluster	Country	Institutions	Number of publications		
<b>Toronto</b>	<b>Canada</b>	University of Toronto	309		
		Struct Genom Consortium	129		
		Hospital for Sick Children (SickKids)	71		
		Princess Margaret Cancer Center	61		
		Baycrest	54		
		University Toronto Affiliates	38		
		Centre for Addiction & Mental Health - Canada	25		
		Ontario Institute for Cancer Research	21		
		University Health Network Toronto	21		
		Holland Bloorview Kids Rehab Hosp	14		
		Lunenfeld Tanenbaum Res Inst	12		
		Toronto General Hosp	6		
		Mt Sinai Hosp Toronto	2		
		<b>Boston</b>	<b>USA</b>	Harvard University	219
Harvard University Medical Affiliates	73				
Harvard Med School	66				
Brigham & Womens Hospital	58				
Harvard T.H. Chan School Public Health	57				
Broad Institute	53				
Pfizer	37				
Boston Child Hosp	27				
Boston University	25				
Dana-Farber Cancer Institute	17				
Massachusetts Gen Hosp	15				
Beth Israel Deaconess Medical Center	14				
Biogen	13				
Massachusetts Institute of Technology (MIT)	12				
Framingham Heart Study	11				
NIH National Heart Lung & Blood Institute (NHLBI)	8				
Merck & Company	6				
Tufts University	6				
CARB X	5				
Natl Inst Health USA	2				
US Dept Health Human Services	2				
<b>Bethesda</b>	<b>USA</b>			Natl Inst Health USA	108
				NIH National Heart Lung & Blood Institute (NHLBI)	21
		AstraZeneca	20		
		US Dept Health Human Services	19		
		NIH National Institute of Mental Health (NIMH)	16		
		NIH National Human Genome Research Institute (NHGRI)	10		
		NIH National Institute on Aging (NIA)	10		
		Medimmune	9		
		US Food & Drug Administration (FDA)	9		
NIH Natl Cancer Inst	8				



Cluster	Country	Institutions	Number of publications
		Natl Inst Allergy Infectious Dis (NIAID)	8
		NIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)	7
		NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)	7
		George Washington University	6
		GlaxoSmithKline	5
		Naval Research Laboratory	5
		Natl Inst Neuro Disorders Stroke	2
<b>New York</b>	<b>USA</b>	Columbia University	47
		Pfizer	39
		New York University	27
		Albert Einstein College of Medicine	14
		Memorial Sloan Kettering Cancer Center	12
		NewYork–Presbyterian Hosp	7
<b>Montreal</b>	<b>Canada</b>	University of Montreal	82
		McGill University	70

TABLE 6.1.7 FIVE JOURNAL SUBJECT CATEGORIES IN WHICH TOP-FIVE, BY NUMBER OF PUBLICATIONS, EUROPEAN GEOGRAPHIC CLUSTERS OF IMI PROJECT RESEARCH PUBLISHED MOST FREQUENTLY, 2010-2020

Cluster	Country	Journal subject category	Number of publications
<b>London</b>	<b>UK</b>	Neurosciences	301
		Psychiatry	179
		Clinical Neurology	151
		Pharmacology & Pharmacy	139
		Immunology	118
<b>Amsterdam</b>	<b>Netherlands</b>	Rheumatology	159
		Pharmacology & Pharmacy	156
		Neurosciences	142
		Immunology	135
		Clinical Neurology	89
<b>Stockholm</b>	<b>Sweden</b>	Rheumatology	121
		Immunology	91
		Neurosciences	75
		Clinical Neurology	64
		Biochemistry & Molecular Biology	55
<b>Paris</b>	<b>France</b>	Neurosciences	130
		Psychiatry	65
		Pharmacology & Pharmacy	56
		Endocrinology & Metabolism	50
		Biochemistry & Molecular Biology	46
<b>Oxford</b>	<b>UK</b>	Biochemistry & Molecular Biology	109
		Neurosciences	81
		Cell Biology	55
		Endocrinology & Metabolism	55
		Medicinal Chemistry	53

Table 6.1.8 FIVE JOURNAL SUBJECT CATEGORIES IN WHICH TOP-FIVE, BY NUMBER OF PUBLICATIONS, NORTH AMERICAN GEOGRAPHIC CLUSTERS OF IMI PROJECT RESEARCH PUBLISHED MOST FREQUENTLY, 2010-2020

Cluster	Country	Journal subject category	Number of publications
<b>Toronto</b>	<b>Canada</b>	Biochemistry & Molecular Biology	82
		Neurosciences	66
		Psychiatry	59
		Cell Biology	34
		Medicinal Chemistry	32
<b>Boston</b>	<b>USA</b>	Neurosciences	45
		Genetics & Heredity	39
		Endocrinology & Metabolism	34
		Clinical Neurology	27
		Pharmacology & Pharmacy	25
<b>Bethesda</b>	<b>USA</b>	Pharmacology & Pharmacy	29
		Immunology	24
		Neurosciences	23

		Psychiatry	21
		Public, Environmental & Occupational Health	21
<b>New York</b>	<b>USA</b>	Pharmacology & Pharmacy	35
		Neurosciences	23
		Psychiatry	20
		Public, Environmental & Occupational Health	17
		Clinical Neurology	14
<b>Montreal</b>	<b>Canada</b>	Neurosciences	45
		Psychiatry	40
		Biochemistry & Molecular Biology	15
		Psychology, Developmental	12
		Genetics & Heredity	11

## 7 COLLABORATION ANALYSIS FOR IMI RESEARCH

### 7.1 COLLABORATION ANALYSIS FOR IMI RESEARCH

International research collaboration is increasing<sup>13</sup> and although the reasons for this have not been fully clarified they are likely to include increasing access to facilities, resources, knowledge, people and expertise. In addition, international collaboration has been shown to be associated with an increase in the number of citations received by research papers, although this does depend upon the partner countries involved.<sup>14</sup> Co-authorship is likely to be a good indicator of collaboration, although there will be research collaborations that do not result in co-authored papers, and co-authored papers which may have required limited collaboration. Alternative data-based approaches, for example using information about co-funding or international exchanges, have limitations in terms of both comprehensiveness and validity.

In this report, co-authorship of papers<sup>15</sup> is used as an indicator of collaboration between different sectors, institutions and countries.

In this analysis, different institutions/organisation are assigned to sectors with the following definitions:

- **Medical:** Organisations with the primary function of providing patient care. Typical these are public, private and university hospitals, though we have included in this sector Chinese medicine hospitals and umbrella organisations such as hospital systems (e.g., Mt Sinai) or UK National Health Services Healthcare Trusts.
- **Corporate:** Private or public companies or enterprises that operate for-profit. For IMI projects most corporate organisations are pharmaceuticals, others manufacture medical devices or provide information technology services. Included in this sector are any organisation with a suffix indicating limited liability (e.g., AB, LTD, GmbH, SA, LLC, INC and AG). Other organisations were identified as corporate from their website. It can be challenging to assign smaller organisations, potential small and medium sized enterprises (SMEs) to this category as they may have a limited online presence and if a SME has spun out from a university it can be difficult to ascertain the current relationship between the spin out and academic institution.
- **Academic:** Public and private universities and university departments. This includes research institutes, that may not have a teaching remit but have a clear affiliation to one or more universities and programs of research spanning multiple academic institutions.
- **Government:** Includes state, regional or federally funded research institutions, laboratories and facilities such as NIH or the World Health Organization (WHO); country or regional funders that disperse public money to research (e.g., BBSRC in the UK); government departments and agencies.
- **Other:** Organisation that do not fit in any other sector but have a role in the healthcare or research infrastructure. For example, research institutions not attached to a government, university or hospital; non-governmental organisations like patient groups, advocacy groups, not-for profits and charities; professional associations for healthcare professionals; non-governmental funders; regulators and tissue sample banks.
- **Unknown:** If an organisation cannot be identified as belonging to any of the other sectors, then it is assigned as unknown.

A paper is defined as cross-sector if the co-authors are affiliated to organisations that are assigned to different sectors. For example, if a paper has author addresses corresponding to the University of Copenhagen (academic) and the company Novartis (corporate), it would be classified as cross-sector. If a paper only has author addresses corresponding to the University of Cambridge (academic) and Utrecht University (academic), it would be classified as single-sector since both addresses are academic institutions, but it would be defined as cross-institution as more than one institution is listed

---

<sup>13</sup> Adams J (2013) Collaborations: the fourth age of research. *Nature*, **497**, 557-560.

<sup>14</sup> Adams, J., Gurney, K., & Marshall, S. (2007). Patterns of international collaboration for the UK and leading partners. A report by *Evidence Ltd* to the UK Office of Science and Innovation. 27pp.

<sup>15</sup> In the collaboration analysis papers rather than publications are analysed as some publications, such as editorials do not communicate novel research finding so cannot be considered a product of research collaboration.


in the addresses. A paper is defined as international if more than one country is listed in the addresses, or domestic if only a single country is listed.

The data in Table 7.1.1 compares the output and field-normalised citation impact of collaborative IMI project research with its non-collaborative research. Figure 7.1.1 presents the same data visually.

TABLE 7.1.1 CROSS-SECTOR, CROSS-INSTITUTION AND INTERNATIONAL OUTPUT AND FIELD-NORMALISED CITATION IMPACT OF IMI PROJECT RESEARCH, 2010-2020

	Number of papers	% of papers	Citation impact (normalised at field level)
Cross-sector	4,286	65%	2.67
Single-sector	2,276	35%	1.84
Cross-institution	5,576	85%	2.57
Single-institution	986	15%	1.63
International	4,161	63%	2.71
Domestic	2,401	37%	1.84

FIGURE 7.1.1 FIELD-NORMALISED CITATION IMPACT OF AND PERCENTAGE OF CROSS-SECTOR, CROSS-INSTITUTION AND INTERNATIONALLY COLLABORATIVE PAPERS FROM IMI PROJECT RESEARCH, 2010-2020



- Nearly two-thirds of (65.3%) of all IMI project papers were published by co-authors working in different sectors.
- The majority (84.9%) of IMI project papers involved collaboration between different institutions.
- More than half (63.4%) of all IMI project papers involved international collaboration.
- Collaborative IMI project research was internationally influential with field-normalised citation impacts over 2.5-times the world average (1.00), regardless of the type of collaborations.
- IMI's collaborative research has an average field-normalised citation impact that is almost 50% higher than IMI's non-collaborative research and the non-collaborative research field-normalised citation impact was below average for IMI project research (1.99).

## 7.2 COLLABORATION ANALYSIS BY IMI PROJECT

This section analyses the collaboration of IMI research at the individual project level.

Table 7.2.1 shows the number, percentage, and field-normalised citation impact of IMI research papers with co-authors from more than one country. Table 7.2.2 shows number, percentage, and field-normalised citation impact of IMI research papers with co-authors from more than one institution. Table 7.2.3 shows number, percentage, and field-normalised citation impact of IMI research papers with co-authors from more than one sector.

Figure 7.2.1 to Figure 7.2.5 are maps showing international collaboration for the five IMI projects with the highest number of papers: BTCURE, EU-AIMS, ULTRA-DD, EMIF, and NEWMEDS. The countries with the most frequent collaboration are the darkest shade of blue and gradually gets lighter the less collaboration there is.

It should be noted that the last column in Table 7.2.1 to Table 7.2.3 shows the field-normalised citation impact of those papers involving collaboration of the type being analysed, rather than for all papers belonging to a project. Therefore, in Table 7.2.1, the last column contains the field-normalised citation impact of only the internationally collaborative papers for each project. Similarly, the last column in Table 7.2.2 contains only the field-normalised citation impact of the papers with co-authors from more than one institution, and in Table 7.2.3, the last column contains only the field-normalised citation impact of cross-sector papers.

The key findings of Section 7.2 are:

- BTCURE had the highest number of papers with co-authors from more than one country, institution and sector (Table 7.1.1-Table 7.2.3). This may be due to BTCURE having the highest overall number of papers.
- EU-AIMS had the second highest number of papers with authors from more than one country, institution and sector (Table 7.1.1-Table 7.2.3). Again, this also may be due to EU-AIMS having the second highest overall number of papers
- For those projects with at least 100 papers, AIMS-2-TRIALS has the highest percentage of its papers that are co-authors from more than one country (76.2%) and institution (96%). While INNODIA has the highest percentage of its papers (82.5%) that are co-authors from more than one sector.
- The majority of collaborative papers from the top five projects were co-authored with researchers from the United States (USA), Germany and the UK (Figure 7.2.1 to Figure 7.2.5).
- In general, there is a high level of collaboration within Europe for all of the top five projects. The most frequently collaborating European countries were the UK, Sweden, Netherlands, France and Germany.
- EU-AIMS, NEWMEDS and ULTRA-DD had substantial input from Canadian researchers and ULTRA-DD had a noteworthy amount of collaboration from Chinese researchers (Figure 7.2.2- Figure 7.2.5).

TABLE 7.2.1 NUMBER, PERCENTAGE AND CITATION IMPACT<sup>16</sup> OF IMI-SUPPORTED RESEARCH PAPERS WITH AUTHORS FROM MORE THAN ONE COUNTRY, 2010-2020

Project	Number of papers	Number of internationally collaborative papers	% internationally collaborative papers	Citation impact (normalised at field level)
BTCure	656	387	59.0%	2.19
EU-AIMS	488	348	71.3%	2.47
ULTRA-DD	371	279	75.2%	2.20
EMIF	279	206	73.8%	3.18
NEWMEDS	204	129	63.2%	2.56
EUROPAIN	177	74	41.8%	3.19
CANCER-ID	167	84	50.3%	4.36
ORBITO	165	91	55.2%	1.94
TRANSLOCATION	152	87	57.2%	1.72
IMIDIA	139	80	57.6%	1.92
STEMBANCC	138	75	54.3%	2.37
SUMMIT	128	86	67.2%	1.80
CHEM21	127	46	36.2%	2.44
INNODIA	126	95	75.4%	2.22
ELF	125	72	57.6%	1.20
PreDiCT-TB	112	63	56.3%	1.58
MIP-DILI	106	56	52.8%	2.32
SPRINTT	106	67	63.2%	2.41
Quic-Concept	101	68	67.3%	5.94
AIMS-2-TRIALS	101	77	76.2%	3.86
PROTECT	99	71	71.7%	1.24
eTOX	92	38	41.3%	1.70
COMPACT	87	47	54.0%	2.42
U-BIOPRED	87	64	73.6%	3.25
RTCure	87	52	59.8%	4.32
Pharma-Cog	83	67	80.7%	1.42
COMBACTE-MAGNET	81	53	65.4%	1.30
COMBACTE-NET	80	45	56.3%	1.06
DIRECT	79	61	77.2%	3.73
ABIRISK	76	39	51.3%	1.51
DDMoRe	76	50	65.8%	1.18
BEAT-DKD	73	58	79.5%	1.48
Open PHACTS	70	43	61.4%	3.49
AETIONOMY	68	34	50.0%	2.54
BioVacSafe	66	36	54.5%	1.45
K4DD	63	37	58.7%	2.24
Onco Track	61	30	49.2%	3.10
BigData@Heart	60	45	75.0%	1.88
RHAPSODY	60	43	71.7%	3.23

<sup>16</sup> The last column is the citation impact of only the internationally collaborative papers.



Project	Number of papers	Number of internationally collaborative papers	% internationally collaborative papers	Citation impact (normalised at field level)
MARCAR	57	28	49.1%	1.25
DRIVE-AB	51	35	68.6%	1.51
ZAPI	50	37	74.0%	7.33
None	50	40	80.0%	4.71
PRISM	49	35	71.4%	3.10
COMBACTE-CARE	48	33	68.8%	2.04
ENABLE	47	21	44.7%	1.50
IMPRiND	46	28	60.9%	8.85
RAPP-ID	45	24	53.3%	0.97
PRECISESADS	44	38	86.4%	1.54
Prelect	43	31	72.1%	1.93
APPROACH	42	34	81.0%	2.31
RADAR-CNS	42	36	85.7%	2.16
eTRIKS	41	38	92.7%	2.65
iPiE	37	12	32.4%	1.54
FLUCOP	36	22	61.1%	1.13
EPAD	35	23	65.7%	1.49
GETREAL	35	29	82.9%	1.74
RESCEU	29	24	82.8%	2.78
EBOVAC1	29	19	65.5%	2.57
PHAGO	29	20	69.0%	4.35
TransQST	28	21	75.0%	2.63
EBiSC	28	21	75.0%	2.13
PROACTIVE	27	23	85.2%	2.47
EbolaMoDRAD	25	15	60.0%	1.63
ADVANCE	25	22	88.0%	1.79
iABC	22	16	72.7%	1.61
LITMUS	21	15	71.4%	4.89
AMYPAD	20	17	85.0%	1.56
EUbOPEN	20	12	60.0%	1.49
SAFE-T	20	11	55.0%	2.48
ROADMAP	20	15	75.0%	0.65
EHR4CR	19	13	68.4%	1.47
ADAPTED	18	13	72.2%	3.75
MOBILISE-D	16	12	75.0%	4.17
eTRANSafe	15	6	40.0%	0.64
TRISTAN	15	10	66.7%	1.53
HARMONY	15	7	46.7%	1.29
WEB-RADR	15	12	80.0%	2.05
EBOVAC2	15	7	46.7%	2.61
COMBACTE	14	2	14.3%	9.77
PREFER	14	12	85.7%	1.51
INNODIA HARVEST	11	11	100.0%	1.26

<b>Project</b>	<b>Number of papers</b>	<b>Number of internationally collaborative papers</b>	<b>% internationally collaborative papers</b>	<b>Citation impact (normalised at field level)</b>
VSV-EBOPLUS	11	9	81.8%	0.89
DRIVE	11	3	27.3%	1.84
CARDIATEAM	11	11	100.0%	1.38
3TR	11	5	45.5%	0.75
VSV-EBOVAC	10	7	70.0%	1.15
PERISCOPE	9	4	44.4%	1.78
IMI-PainCare	9	4	44.4%	0.63
VAC2VAC	9	6	66.7%	0.71
Hypo-RESOLVE	8	7	87.5%	1.64
EHDEN	8	7	87.5%	3.01
PD-MitoQUANT	8	4	50.0%	2.16
ITCC-P4	6	5	83.3%	2.12
BIOMAP	6	6	100.0%	3.62
EUPATI	6	6	100.0%	0.97
RADAR-AD	5	2	40.0%	0.50
DRAGON	5	5	100.0%	3.49
ERA4TB	5	3	60.0%	1.35
EQIPD	5	4	80.0%	3.40
ADAPT-SMART	4	2	50.0%	1.17
MOPEAD	4	3	75.0%	0.17
EBODAC	4	3	75.0%	3.81
ReSOLUTE	4	1	25.0%	0.00
SafeSciMET	4	4	100.0%	0.97
SOPHIA	4	3	75.0%	2.05
TransBioLine	4	1	25.0%	0.00
FAIRplus	3	1	33.3%	13.59
DO->IT	3	3	100.0%	1.32
VITAL	3	2	66.7%	0.20
MACUSTAR	3	2	66.7%	2.28
Eu2P	3	2	66.7%	0.11
MAD-CoV 2	2	2	100.0%	0.29
c4c	2	2	100.0%	0.00
NECESSITY	2	2	100.0%	1.40
ND4BB	2	2	100.0%	1.85
VHFMoDRAD	2	1	50.0%	0.00
PEVIA	2	2	100.0%	0.92
EBOMAN	2	2	100.0%	5.40
IMMUCAN	2	1	50.0%	0.65
ConcePTION	2	1	50.0%	0.00
EU-PEARL	2	1	50.0%	8.33
COMBACTE-CDI	2	2	100.0%	0.25
Immune-Image	2	2	100.0%	0.97
EBiSC2	2	2	100.0%	1.60

<b>Project</b>	<b>Number of papers</b>	<b>Number of internationally collaborative papers</b>	<b>% internationally collaborative papers</b>	<b>Citation impact (normalised at field level)</b>
PIONEER	1	1	100.0%	4.49
EMTRAIN	1	1	100.0%	0.12
NGN-PET	1	0	0.0%	0.00
EBOVAC3	1	1	100.0%	0.20
EBOVAC	1	1	100.0%	3.53
NeuroDeRisk	1	1	100.0%	0.00
IM2PACT	1	0	0.0%	0.00
COVID-RED	1	1	100.0%	0.00
COMBINE	1	0	0.0%	0.00
MELLODDY	1	0	0.0%	0.00
CARE	1	0	0.0%	0.00
IDEA-FAST	1	1	100.0%	0.79
KRONO	1	1	100.0%	0.00
VALUE-Dx	1	1	100.0%	0.67
PARADIGM	1	1	100.0%	0.40
Pharmatrain	1	1	100.0%	0.09
FILODIAG	0	0	0.0%	0.00
imSAVAR	0	0	0.0%	0.00

TABLE 7.2.2 NUMBER, PERCENTAGE AND CITATION IMPACT<sup>17</sup> OF IMI-SUPPORTED RESEARCH PAPERS WITH AUTHORS FROM MORE THAN ONE INSTITUTION, 2010-2020

Project	Number of papers	Number of papers from more than one institution	% of papers from more than one institution	Citation impact (normalised at field level)
BTCure	656	537	81.9%	2.07
EU-AIMS	488	454	93.0%	2.32
ULTRA-DD	371	331	89.2%	2.15
EMIF	279	261	93.5%	2.99
NEWMEDS	204	168	82.4%	2.39
EUROPAIN	177	121	68.4%	2.88
CANCER-ID	167	143	85.6%	3.70
ORBITO	165	129	78.2%	2.09
TRANSLOCATION	152	109	71.7%	1.67
IMIDIA	139	116	83.5%	1.74
STEMBANCC	138	109	79.0%	2.35
SUMMIT	128	113	88.3%	1.63
CHEM21	127	68	53.5%	2.16
INNODIA	126	120	95.2%	2.03
ELF	125	92	73.6%	1.27
PreDiCT-TB	112	93	83.0%	1.35
MIP-DILI	106	79	74.5%	2.08
SPRINTT	106	90	84.9%	2.50
Quic-Concept	101	96	95.0%	4.76
AIMS-2-TRIALS	101	97	96.0%	3.65
PROTECT	99	97	98.0%	1.10
eTOX	92	52	56.5%	1.59
COMPACT	87	67	77.0%	2.04
U-BIOPRED	87	77	88.5%	2.85
RTCure	87	81	93.1%	3.59
Pharma-Cog	83	77	92.8%	1.33
COMBACTE-MAGNET	81	68	84.0%	1.45
COMBACTE-NET	80	70	87.5%	1.10
DIRECT	79	76	96.2%	3.41
ABIRISK	76	65	85.5%	1.55
DDMoRe	76	63	82.9%	1.12
BEAT-DKD	73	67	91.8%	1.60
Open PHACTS	70	57	81.4%	3.52
AETIONOMY	68	68	100.0%	1.90
BioVacSafe	66	40	60.6%	1.39
K4DD	63	51	81.0%	2.03
Onco Track	61	50	82.0%	2.45
BigData@Heart	60	59	98.3%	2.39
RHAPSODY	60	53	88.3%	2.94

<sup>17</sup> The last column in is only the citation impact of the papers from more than one institution.

<b>Project</b>	<b>Number of papers</b>	<b>Number of papers from more than one institution</b>	<b>% of papers from more than one institution</b>	<b>Citation impact (normalised at field level)</b>
MARCAR	57	41	71.9%	1.22
DRIVE-AB	51	45	88.2%	1.54
ZAPI	50	42	84.0%	6.59
None	50	47	94.0%	4.43
PRISM	49	44	89.8%	2.96
COMBACTE-CARE	48	47	97.9%	2.08
ENABLE	47	42	89.4%	1.74
IMPRIND	46	40	87.0%	6.98
RAPP-ID	45	36	80.0%	0.95
PRECISESADS	44	42	95.5%	1.46
Predect	43	34	79.1%	1.89
APPROACH	42	38	90.5%	2.21
RADAR-CNS	42	39	92.9%	2.27
eTRIKS	41	40	97.6%	2.56
iPiE	37	32	86.5%	1.43
FLUCOP	36	34	94.4%	1.19
EPAD	35	28	80.0%	1.50
GETREAL	35	34	97.1%	1.88
RESCEU	29	28	96.6%	2.68
EBOVAC1	29	22	75.9%	2.48
PHAGO	29	24	82.8%	4.26
TransQST	28	24	85.7%	2.47
EBiSC	28	25	89.3%	7.14
PROACTIVE	27	27	100.0%	2.17
EbolaMoDRAD	25	23	92.0%	1.53
ADVANCE	25	24	96.0%	1.93
iABC	22	19	86.4%	1.51
LITMUS	21	18	85.7%	5.69
AMYPAD	20	19	95.0%	1.68
EUbOPEN	20	19	95.0%	1.49
SAFE-T	20	19	95.0%	1.95
ROADMAP	20	18	90.0%	1.10
EHR4CR	19	18	94.7%	1.19
ADAPTED	18	18	100.0%	3.24
MOBILISE-D	16	16	100.0%	4.18
eTRANSafe	15	8	53.3%	0.66
TRISTAN	15	14	93.3%	1.75
HARMONY	15	12	80.0%	1.23
WEB-RADR	15	13	86.7%	1.96
EBOVAC2	15	14	93.3%	1.69
COMBACTE	14	12	85.7%	2.70
PREFER	14	13	92.9%	1.54
INNODIA HARVEST	11	11	100.0%	1.26

<b>Project</b>	<b>Number of papers</b>	<b>Number of papers from more than one institution</b>	<b>% of papers from more than one institution</b>	<b>Citation impact (normalised at field level)</b>
VSV-EBOPLUS	11	10	90.9%	0.83
DRIVE	11	10	90.9%	1.69
CARDIATEAM	11	11	100.0%	1.38
3TR	11	11	100.0%	0.85
VSV-EBOVAC	10	8	80.0%	1.04
PERISCOPE	9	6	66.7%	1.23
IMI-PainCare	9	7	77.8%	0.65
VAC2VAC	9	8	88.9%	0.97
Hypo-RESOLVE	8	7	87.5%	1.64
EHDEN	8	7	87.5%	3.01
PD-MitoQUANT	8	7	87.5%	2.53
ITCC-P4	6	6	100.0%	2.08
BIOMAP	6	6	100.0%	3.62
EUPATI	6	6	100.0%	0.97
RADAR-AD	5	4	80.0%	0.33
DRAGON	5	5	100.0%	3.49
ERA4TB	5	4	80.0%	1.35
EQIPD	5	4	80.0%	3.40
ADAPT-SMART	4	3	75.0%	0.81
MOPEAD	4	4	100.0%	1.19
EBODAC	4	4	100.0%	3.04
ReSOLUTE	4	2	50.0%	0.95
SafeSciMET	4	4	100.0%	0.97
SOPHIA	4	4	100.0%	2.05
TransBioLine	4	4	100.0%	0.35
FAIRplus	3	1	33.3%	13.59
DO->IT	3	3	100.0%	1.32
VITAL	3	3	100.0%	0.76
MACUSTAR	3	2	66.7%	2.28
Eu2P	3	3	100.0%	1.95
MAD-CoV 2	2	2	100.0%	0.29
c4c	2	2	100.0%	0.00
NECESSITY	2	2	100.0%	1.40
ND4BB	2	2	100.0%	1.85
VHFMoDRAD	2	2	100.0%	0.00
PEVIA	2	2	100.0%	0.92
EBOMAN	2	2	100.0%	5.40
IMMUCAN	2	2	100.0%	1.24
ConcePTION	2	2	100.0%	0.00
EU-PEARL	2	2	100.0%	4.17
COMBACTE-CDI	2	2	100.0%	0.25

<b>Project</b>	<b>Number of papers</b>	<b>Number of papers from more than one institution</b>	<b>% of papers from more than one institution</b>	<b>Citation impact (normalised at field level)</b>
Immune-Image	2	2	100.0%	0.97
EBiSC2	2	2	100.0%	1.60
PIONEER	1	1	100.0%	4.49
EMTRAIN	1	1	100.0%	0.12
NGN-PET	1	0	0.0%	0.00
EBOVAC3	1	1	100.0%	0.20
EBOVAC	1	1	100.0%	3.53
NeuroDeRisk	1	1	100.0%	0.00
IM2PACT	1	0	0.0%	0.00
COVID-RED	1	1	100.0%	0.00
COMBINE	1	1	100.0%	0.00
MELLODDY	1	0	0.0%	0.00
CARE	1	1	100.0%	23.03
IDEA-FAST	1	1	100.0%	0.79
KRONO	1	1	100.0%	0.00
VALUE-Dx	1	1	100.0%	0.67
PARADIGM	1	1	100.0%	0.40
Pharmatrain	1	1	100.0%	0.09
FILODIAG	0	0	0.0%	0.00
imSAVAR	0	0	0.0%	0.00

TABLE 7.2.3 NUMBER, PERCENTAGE AND CITATION IMPACT<sup>18</sup> OF IMI-SUPPORTED RESEARCH PAPERS WITH AUTHORS FROM MORE THAN ONE SECTOR, 2010-2020

Project	Number of papers	Number of cross sector papers	% of cross sector papers	Citation impact (normalised at field level)
BTCure	656	422	64.3%	2.17
EU-AIMS	488	354	72.5%	2.44
ULTRA-DD	371	226	60.9%	2.37
EMIF	279	225	80.6%	2.85
NEWMEDS	204	128	62.7%	2.48
EUROPAIN	177	96	54.2%	3.02
CANCER-ID	167	124	74.3%	3.90
ORBITO	165	103	62.4%	2.24
TRANSLOCATION	152	56	36.8%	1.82
IMIDIA	139	73	52.5%	1.96
STEMBANCC	138	68	49.3%	2.31
SUMMIT	128	97	75.8%	1.61
CHEM21	127	30	23.6%	2.18
INNODIA	126	104	82.5%	2.14
ELF	125	41	32.8%	1.18
PreDiCT-TB	112	61	54.5%	1.34
MIP-DILI	106	71	67.0%	2.04
SPRINTT	106	76	71.7%	2.62
Quic-Concept	101	72	71.3%	3.61
AIMS-2-TRIALS	101	76	75.2%	3.93
PROTECT	99	96	97.0%	1.10
eTOX	92	28	30.4%	1.85
COMPACT	87	19	21.8%	3.49
U-BIOPRED	87	71	81.6%	3.00
RTCure	87	67	77.0%	4.13
Pharma-Cog	83	70	84.3%	1.36
COMBACTE-MAGNET	81	54	66.7%	1.41
COMBACTE-NET	80	60	75.0%	1.18
DIRECT	79	59	74.7%	3.85
ABIRISK	76	58	76.3%	1.60
DDMoRe	76	49	64.5%	1.19
BEAT-DKD	73	52	71.2%	1.73
Open PHACTS	70	42	60.0%	4.40
AETIONOMY	68	44	64.7%	2.37
BioVacSafe	66	29	43.9%	1.41
K4DD	63	34	54.0%	1.94
Onco Track	61	39	63.9%	2.52
BigData@Heart	60	55	91.7%	2.50
RHAPSODY	60	32	53.3%	2.19

<sup>18</sup> The last column is only field-normalised citation impact for cross sector papers only.



Project	Number of papers	Number of cross sector papers	% of cross sector papers	Citation impact (normalised at field level)
MARCAR	57	25	43.9%	1.30
DRIVE-AB	51	38	74.5%	1.55
ZAPI	50	34	68.0%	7.37
None	50	38	76.0%	4.62
PRISM	49	36	73.5%	3.29
COMBACTE-CARE	48	44	91.7%	2.14
ENABLE	47	28	59.6%	1.70
IMPRiND	46	29	63.0%	4.77
RAPP-ID	45	15	33.3%	1.08
PRECISESADS	44	34	77.3%	1.61
Prelect	43	29	67.4%	1.79
APPROACH	42	32	76.2%	1.81
RADAR-CNS	42	25	59.5%	2.82
eTRIKS	41	35	85.4%	2.76
iPiE	37	20	54.1%	1.12
FLUCOP	36	32	88.9%	1.21
EPAD	35	25	71.4%	1.55
GETREAL	35	31	88.6%	2.01
RESCEU	29	26	89.7%	2.80
EBOVAC1	29	20	69.0%	2.48
PHAGO	29	19	65.5%	4.80
TransQST	28	16	57.1%	2.89
EBiSC	28	20	71.4%	8.14
PROACTIVE	27	27	100.0%	2.17
EbolaMoDRAD	25	17	68.0%	1.69
ADVANCE	25	22	88.0%	1.99
iABC	22	18	81.8%	1.58
LITMUS	21	17	81.0%	5.69
AMYPAD	20	18	90.0%	1.72
EUbOPEN	20	13	65.0%	1.64
SAFE-T	20	19	95.0%	1.95
ROADMAP	20	18	90.0%	1.10
EHR4CR	19	17	89.5%	1.26
ADAPTED	18	17	94.4%	3.47
MOBILISE-D	16	14	87.5%	4.18
eTRANSAFE	15	5	33.3%	0.56
TRISTAN	15	12	80.0%	1.61
HARMONY	15	12	80.0%	1.23
WEB-RADR	15	11	73.3%	1.86
EBOVAC2	15	6	40.0%	2.51
COMBACTE	14	7	50.0%	3.62
PREFER	14	12	85.7%	1.54
INNODIA HARVEST	11	10	90.9%	1.28

Project	Number of papers	Number of cross sector papers	% of cross sector papers	Citation impact (normalised at field level)
VSV-EBOPLUS	11	7	63.6%	0.82
DRIVE	11	9	81.8%	1.69
CARDIATEAM	11	11	100.0%	1.38
3TR	11	11	100.0%	0.85
VSV-EBOVAC	10	5	50.0%	0.99
PERISCOPE	9	4	44.4%	1.78
IMI-PainCare	9	5	55.6%	0.57
VAC2VAC	9	5	55.6%	0.90
Hypo-RESOLVE	8	4	50.0%	2.02
EHDEN	8	6	75.0%	3.01
PD-MitoQUANT	8	7	87.5%	2.53
ITCC-P4	6	6	100.0%	2.08
BIOMAP	6	6	100.0%	3.62
EUPATI	6	6	100.0%	0.97
RADAR-AD	5	4	80.0%	0.33
DRAGON	5	5	100.0%	3.49
ERA4TB	5	3	60.0%	1.35
EQIPD	5	3	60.0%	4.18
ADAPT-SMART	4	3	75.0%	0.81
MOPEAD	4	4	100.0%	1.19
EBODAC	4	3	75.0%	3.85
ReSOLUTE	4	1	25.0%	0.00
SafeSciMET	4	4	100.0%	0.97
SOPHIA	4	3	75.0%	2.05
TransBioLine	4	3	75.0%	0.00
FAIRplus	3	1	33.3%	13.59
DO->IT	3	3	100.0%	1.32
VITAL	3	1	33.3%	0.40
MACUSTAR	3	2	66.7%	2.28
Eu2P	3	1	33.3%	0.00
MAD-CoV 2	2	1	50.0%	0.00
c4c	2	2	100.0%	0.00
NECESSITY	2	2	100.0%	1.40
ND4BB	2	1	50.0%	2.07
VHFMoDRAD	2	2	100.0%	0.00
PEVIA	2	2	100.0%	0.92
EBOMAN	2	2	100.0%	5.40
IMMUCAN	2	1	50.0%	0.65
ConcePTION	2	2	100.0%	0.00
EU-PEARL	2	2	100.0%	4.17
COMBACTE-CDI	2	2	100.0%	0.25

<b>Project</b>	<b>Number of papers</b>	<b>Number of cross sector papers</b>	<b>% of cross sector papers</b>	<b>Citation impact (normalised at field level)</b>
Immune-Image	2	2	100.0%	0.97
EBiSC2	2	2	100.0%	1.60
PIONEER	1	1	100.0%	4.49
EMTRAIN	1	1	100.0%	0.12
NGN-PET	1	0	0.0%	0.00
EBOVAC3	1	0	0.0%	0.00
EBOVAC	1	1	100.0%	3.53
NeuroDeRisk	1	1	100.0%	0.00
IM2PACT	1	0	0.0%	0.00
COVID-RED	1	1	100.0%	0.00
COMBINE	1	1	100.0%	0.00
MELLODDY	1	0	0.0%	0.00
CARE	1	1	100.0%	23.03
IDEA-FAST	1	0	0.0%	0.00
KRONO	1	1	100.0%	0.00
VALUE-Dx	1	1	100.0%	0.67
PARADIGM	1	1	100.0%	0.40
Pharmatrain	1	1	100.0%	0.09
FILODIAG	0	0	0.0%	0.00
imSAVAR	0	0	0.0%	0.00

FIGURE 7.2.1 INTERNATIONAL COLLABORATION BY COUNTRY, FOR IMI PROJECT: BTCURE, 2010-2020




FIGURE 7.2.2 INTERNATIONAL COLLABORATION BY COUNTRY, FOR IMI PROJECT: EMIF, 2010-2020




FIGURE 7.2.3 INTERNATIONAL COLLABORATION BY COUNTRY, FOR IMI PROJECT: EU-AIMS, 2010-2020




FIGURE 7.2.4 INTERNATIONAL COLLABORATION BY COUNTRY, FOR IMI PROJECT: NEWMEDS, 2010-2020





FIGURE 7.2.5 INTERNATIONAL COLLABORATION BY COUNTRY, FOR IMI PROJECT: ULTRA-DD, 2010-2020



### 7.3 COLLABORATION METRICS FOR IMI RESEARCH

This section of the report analyses the types of collaboration that occurred within each IMI project and examines the stability of institutional collaborations within each project.

In common with other metrics based on papers and citations, the indicators we present here work best with larger sample sizes. Indicators based on small numbers of papers will be less informative than those calculated for larger bodies of work. Therefore, the analysis presented in this section is for projects with at least 20 papers published between 2010 and 2020.

In the ninth (2018) and earlier versions of this report metric 3 indicated the intensity of international collaboration, in the tenth report (2019) it was updated to measure the stability of institutional collaborations which is what it shows in this report.

The results for all projects are shown in Annex 5.

Three metrics were used to evaluate the collaborative nature of IMI projects:

- Metric 1 (Cross-sector Score) – Fraction of “cross-sector” papers with co-authors affiliated to institutions in different sectors (Figure 7.3.1.1). The institutions affiliated with each author on an IMI project paper were manually assigned by Clarivate to the relevant sector. Author affiliations were obtained through the Web of Science.
- Metric 2 (International Score) – Percentage of internationally collaborative papers. In calculating the international score for each project, greater weighting is given to papers with multilateral collaboration (co-authors from more than two countries), compared to bilateral collaboration (co-authors from two countries) (Figure 7.3.2.1). The country location of each author was determined using author addresses extracted in the Web of Science.
- Metric 3 (Stability Score) – Stability of institutional collaboration over the lifetime of the project. The collaboration stability for pairs of collaborating institutions was calculated following the method proposed by Y. Bu et al.<sup>19</sup> A stable institutional collaboration has a stable output, i.e. pairs of institutions co-publish a similar volume of papers in consecutive years for the duration of a project. The stability score for each project is the mean average stability of all the collaborating institutional pairs that have contributed to that IMI project research.

Each metric is calculated for an IMI project and can take a value between 0 and 1, with 1 indicating more collaborative activity. The collaboration index is a sum of all three metrics and the maximum possible value for a project is 3.

---

<sup>19</sup> Bu, Y., Murray, D.S., Ding, Y. et al. (2018) Measuring the stability of scientific collaboration. *Scientometrics*, **114**, 463.

### 7.3.1 METRIC 1 (CROSS-SECTOR SCORE): FRACTION OF CROSS SECTOR COLLABORATIVE PAPERS


Authors institutional affiliations, as they appear on IMI project research were assigned to sectors. Sector assignments were then used to classify each paper as “within one sector”, when all co-authors work within the same sector or “cross-sector” when co-authors work in two or more different sectors. The number and percentage of cross-sector papers for projects are presented in Table 7.2.3.

Figure 7.3.1.1 shows the total number of “within one sector” and “cross-sector” papers for each project. Projects are ordered by the number of cross-sector collaborative papers. The dark blue bars represent the number or fraction of “cross-sector” papers. The fraction of cross-sector papers in each project is referred to in the figure as “Cross-Sector Score”. Only projects with more than 20 associated papers are shown.

- BTCURE had the greatest number of cross-sector collaborative papers, 422 out of a total of 656. PRO-active, PROTECT and SAFE-T had the highest percentage of cross-sector collaborative papers (100%, 96.9% and 95.0% respectively).



FIGURE 7.3.1.1 NUMBER AND FRACTION OF CROSS-SECTOR COLLABORATIVE PAPERS BY PROJECT, 2010-2020. ORDERED BY NUMBER OF CROSS-SECTOR PAPERS



### 7.3.2 METRIC 2 (INTERNATIONAL SCORE): FRACTION OF INTERNATIONALLY COLLABORATIVE PAPERS


Author names and affiliations were extracted for all IMI project papers. The number of countries in the author affiliations for each paper was counted and used to classify the papers as “more than two countries”, “two countries” or “within one country” (same as domestic in the Section 7.1).

Figure 7.3.2.1 below shows the total number of papers for each project. Projects are ordered by the number of papers with author affiliations from more than one country. The bar colours reflect the fraction of papers that include international collaboration between “two countries” (bilateral) and “more than two countries” (multilateral). Only projects with more than 20 associated papers are shown.

The International Score was calculated by weighting each paper that involved only two countries by 0.75 and each paper that involved more than two countries by 1.00. The sum of the weighted papers was then divided by the total number of project papers. Total number of internationally collaborative papers for each project is shown in Table 7.2.1.

- BTCURE had the most internationally collaborative papers involving two or more countries (387 out of 656), with an International Score of 0.51.
- EU-AIMS had the most internationally collaborative papers involving more than two countries. (226 out of 488), with an international Score of 0.65.
- eTRICKS, ADVANCE, and PROACTIVE had the highest International Scores (0.87, 0.85 and 0.80 respectively).

FIGURE 7.3.2.1 NUMBER AND FRACTION OF INTERNATIONALLY COLLABORATIVE PAPERS BY PROJECT, 2010-2020




### 7.3.3 METRIC 3 (STABILITY SCORE): STABILITY OF INSTITUTIONAL COLLABORATION

This section looks in depth at institutional collaboration activities in IMI funded research. Figure 7.3.3.1 shows the ten most productive, collaborating institution pairs, by total number of collaborative papers. Figure 7.3.3.2 shows the ten institutions that collaborate with the highest number of other institutions. Figure 7.3.3.3 shows the distribution of Metric 3 scores for IMI projects. Table 7.3.3.1 is an expansion of the data in Figure 7.3.3.3, showing the Metric 3 score for all projects with at least 20 papers and the number of collaborating institution pairs. The number and proportion of papers with authors from more than one institution for each project is shown in Table 7.2.2.


A project's Metric 3 is the mean average stability of collaborations between pairs of institutions that have co-authored papers that belong to that project. Pairs of institutions must have published two or more papers together as part of the same IMI project to be considered. A second requirement is that the IMI projects must have started in, or before, 2018. If a project started after 2018, too little time has elapsed for most pairs of institutions to have published more than one paper.

FIGURE 7.3.3.1 THE TEN MOST PRODUCTIVE PAIRS OF COLLABORATING INSTITUTIONS, 2010-2020




- The institutions that collaborated most frequently on IMI project papers were Kings College London and Heidelberg University, researchers at these institutions together, co-authored 120 publications.
- Kings College London is part of seven out of ten pairs of the most productive pairs of collaborating institutions.

FIGURE 7.3.3.2 THE TEN INSTITUTIONS THAT HAVE COLLABORATED WITH THE GREATEST NUMBER OF OTHER INSTITUTIONS, 2010-2020



- The University of Oxford has collaborated with 1,813 other institutions on IMI project papers, the most of any of the other institutions.
- Half of the ten most collaborative institutions are located in the United Kingdom.

FIGURE 7.3.3.3 METRIC 3: STABILITY SCORE DISTRIBUTION, 2010-2020



- Most IMI projects have a stability score of between 0.70 and 0.90.

TABLE 7.3.1 STABILITY SCORE FOR IMI PROJECTS, NUMBER OF COLLABORATING INSTITUTION PAIRS, TOTAL NUMBER OF PAPERS AND PROJECT START YEAR FOR ALL PROJECTS WITH AT LEAST 20 PAPERS THAT STARTED IN OR BEFORE 2018, 2010-2020

Project	Stability score (Metric 3)	Number of collaborating institution pairs	Number of papers	Project start year
BTCure	0.83	1,074	656	2011
EU-AIMS	0.80	3,196	488	2012
ULTRA-DD	0.75	332	371	2015
EMIF	0.84	2,438	279	2012
NEWMEDS	0.81	644	204	2010
EUROPAIN	0.84	326	177	2010
CANCER-ID	0.75	177	167	2015
ORBITO	0.76	350	165	2013
TRANSLOCATION	0.80	75	152	2013
IMIDIA	0.83	156	139	2010
STEMBANCC	0.80	54	138	2013
SUMMIT	0.82	6,978	128	2011
CHEM21	0.79	22	127	2013
INNODIA	0.88	385	126	2010
ELF	0.73	43	125	2014
PreDiCT-TB	0.79	62	112	2013
MIP-DILI	0.81	144	106	2012
SPRINTT	0.80	234	106	2014
AIMS-2-TRIALS	0.68	563	101	2018
Quic-Concept	0.80	131	101	2012
PROTECT	0.86	300	99	2010
eTOX	0.86	126	92	2010
COMPACT	0.71	26	87	2014
RTCure	0.71	129	87	2017
U-BIOPRED	0.86	917	87	2010
Pharma-Cog	0.85	1,007	83	2010
COMBACTE-MAGNET	0.73	106	81	2015
COMBACTE-NET	0.78	102	80	2013
DIRECT	0.88	1,218	79	2012
ABIRISK	0.86	489	76	2012
DDMoRe	0.81	56	76	2012
BEAT-DKD	0.61	284	73	2017
Open PHACTS	0.76	63	70	2011
AETIONOMY	0.78	79	68	2014
BioVacSafe	0.81	21	66	2012
K4DD	0.79	31	63	2013
Onco Track	0.83	79	61	2011
BigData@Heart	0.56	3,099	60	2017
RHAPSODY	0.83	223	60	2016
MARCAR	0.82	38	57	2011

Project	Stability score (Metric 3)	Number of collaborating institution pairs	Number of papers	Project start year
DRIVE-AB	0.71	60	51	2015
ZAPI	0.71	44	50	2015
PRISM	0.66	64	49	2017
COMBACTE-CARE	0.73	552	48	2015
ENABLE	0.80	25	47	2015
IMPRiND	0.76	26	46	2017
RAPP-ID	0.89	13	45	2011
PRECISESADS	0.69	158	44	2015
Prelect	0.74	25	43	2012
APPROACH	0.73	61	42	2015
RADAR-CNS	0.76	68	42	2016
eTRIKS	0.72	708	41	2014
iPiE	0.71	21	37	2016
FLUCOP	0.69	28	36	2015
EPAD	0.73	86	35	2015
GETREAL	0.74	36	35	2015
EBOVAC1	0.72	23	29	2015
PHAGO	0.71	36	29	2017
RESCEU	0.71	219	29	2018
EBiSC	0.75	14	28	2015
TransQST	0.74	6	28	2017
PROACTIVE	0.82	164	27	2011
ADVANCE	0.85	290	25	2015
EbolaMoDRAD	0.65	33	25	2016
iABC	0.81	31	22	2015
LITMUS	0.69	78	21	2018
AMYPAD	0.77	78	20	2017
ROADMAP	0.68	62	20	2017
SAFE-T	0.85	21	20	2011

- RAPP-ID has the highest stability score (0.89) while BigData@Heart has the lowest (0.56).
- There is considerable variation in the number collaborating institution pairs that does not appear to be proportional to the number of project papers or dependent on the project start year. For example, BTCure started in 2011 and has the highest output of papers (656), only has 1,074 institution pairs compared with SUMMIT that started in the same year, has only produced 128 papers but has 6,978 institution pairs. This suggests that SUMMIT publishes papers with many authors from multiple institutions. In fact, one of SUMMIT's papers has 267 affiliations.



## 7.4 COLLABORATION INDEX

The cross-sector score (Metric 1) and international score (Metric 2) (described above) measure different types of collaboration. The first measures the fraction of papers that involve cross-sector collaborations, and the second reflects the fraction of papers that involve multilateral and bilateral international collaborations. Metric 3 or stability score is based on the collaboration stability of pairs of institutional collaborators that contribute to IMI project research. We compute a “collaboration index” across IMI projects as the sum of all three of the metrics. These data are shown in Table 7.4.1 for all IMI projects with 20 or more papers.

This year’s collaboration index is not comparable with the collaboration index in the ninth (2018) and earlier versions of this report as Metric 3 was updated in the tenth report (2019) to indicate the stability of institutional collaboration rather than intensity.

- PROACTIVE had the highest overall collaboration index score (2.62) followed by ADVANCE (2.58).

TABLE 7.4.1 SUMMARY SCORE FOR COLLABORATION METRICS, TOTAL NUMBER OF PAPERS AND FIELD-NORMALISED CITATION IMPACT FOR IMI PROJECTS WITH AT LEAST 20 PAPERS, 2010-2020

Project	Cross-sector Score (Metric 1)	International Score (Metric 2)	Stability score (Metric 3)	Collaboration index	Number of papers	Citation impact (field-normalised)
BTCure	0.64	0.51	0.83	1.98	656	1.85
EU-AIMS	0.73	0.65	0.80	2.18	488	2.03
ULTRA-DD	0.61	0.66	0.75	2.02	371	1.74
EMIF	0.81	0.66	0.84	2.31	279	2.66
NEWMEDS	0.63	0.57	0.81	2.01	204	2.16
EUROPAIN	0.54	0.37	0.84	1.75	177	2.48
CANCER-ID	0.74	0.43	0.75	1.92	167	3.27
ORBITO	0.62	0.47	0.76	1.85	165	1.84
TRANSLOCATION	0.37	0.49	0.80	1.66	152	1.39
IMIDIA	0.53	0.50	0.83	1.85	139	1.63
STEMBANCC	0.49	0.46	0.80	1.75	138	1.95
SUMMIT	0.76	0.63	0.82	2.21	128	1.53
CHEM21	0.24	0.29	0.79	1.31	127	1.75
INNODIA	0.83	0.67	0.88	2.38	126	1.63
ELF	0.33	0.52	0.73	1.58	125	1.15
PreDiCT-TB	0.54	0.48	0.79	1.81	112	1.22
SPRINTT	0.72	0.54	0.80	2.05	106	2.22
MIP-DILI	0.67	0.45	0.81	1.94	106	1.82
AIMS-2-TRIALS	0.75	0.70	0.68	2.13	101	1.88
Quic-Concept	0.71	0.58	0.80	2.09	101	4.34
PROTECT	0.97	0.63	0.86	2.46	99	1.08
eTOX	0.30	0.36	0.86	1.53	92	1.71
U-BIOPRED	0.82	0.70	0.86	2.38	87	2.57
RTCure	0.77	0.52	0.71	2.00	87	2.68

<b>Project</b>	<b>Cross-sector Score (Metric 1)</b>	<b>International Score (Metric 2)</b>	<b>Stability score (Metric 3)</b>	<b>Collaboration index</b>	<b>Number of papers</b>	<b>Citation impact (field-normalised)</b>
COMPACT	0.22	0.45	0.71	1.39	87	1.86
Pharma-Cog	0.84	0.74	0.85	2.44	83	1.19
COMBACTE-MAGNET	0.67	0.60	0.73	1.99	81	1.18
COMBACTE-NET	0.75	0.52	0.78	2.05	80	1.01
DIRECT	0.75	0.72	0.88	2.35	79	2.98
ABIRISK	0.76	0.48	0.86	2.10	76	1.32
DDMoRe	0.64	0.56	0.81	2.01	76	1.08
BEAT-DKD	0.71	0.74	0.61	2.05	73	1.46
Open PHACTS	0.60	0.55	0.76	1.92	70	3.47
AETIONOMY	0.65	0.44	0.78	1.87	68	1.71
BioVacSafe	0.44	0.47	0.81	1.72	66	1.27
K4DD	0.54	0.51	0.79	1.84	63	1.74
Onco Track	0.64	0.43	0.83	1.90	61	2.30
BigData@Heart	0.92	0.68	0.56	2.16	60	1.53
RHAPSODY	0.53	0.64	0.83	2.00	60	2.10
MARCAR	0.44	0.42	0.82	1.68	57	1.08
DRIVE-AB	0.75	0.62	0.71	2.08	51	1.37
None	0.76	0.72	0.92	2.40	50	3.41
ZAPI	0.68	0.65	0.71	2.03	50	5.61
PRISM	0.73	0.66	0.66	2.05	49	2.14
COMBACTE-CARE	0.92	0.64	0.73	2.29	48	1.78
ENABLE	0.60	0.41	0.80	1.80	47	1.61
IMPRiND	0.63	0.54	0.76	1.93	46	6.47
RAPP-ID	0.33	0.43	0.89	1.65	45	0.88
PRECISESADS	0.77	0.77	0.69	2.23	44	1.23
Predect	0.67	0.62	0.74	2.04	43	2.52
RADAR-CNS	0.60	0.76	0.76	2.11	42	1.64
APPROACH	0.76	0.76	0.73	2.24	42	1.95
eTRIKS	0.85	0.87	0.72	2.45	41	2.44
iPIE	0.54	0.25	0.71	1.50	37	1.32
FLUCOP	0.89	0.51	0.69	2.08	36	1.09
EPAD	0.71	0.64	0.73	2.08	35	1.01
GETREAL	0.89	0.77	0.74	2.39	35	1.82
RESCEU	0.90	0.77	0.71	2.38	29	2.00
PHAGO	0.66	0.60	0.71	1.97	29	3.34
EBOVAC1	0.69	0.64	0.72	2.04	29	1.93
EbiSC	0.71	0.64	0.75	2.11	28	7.64
TransQST	0.57	0.70	0.74	2.01	28	3.25
PROACTIVE	1.00	0.80	0.82	2.62	27	2.17
ADVANCE	0.88	0.85	0.85	2.58	25	1.87
EbolaMoDRAD	0.68	0.52	0.65	1.85	25	1.45
iABC	0.82	0.65	0.81	2.27	22	0.87
LITMUS	0.81	0.68	0.69	2.18	21	4.14

<b>Project</b>	<b>Cross-sector Score (Metric 1)</b>	<b>International Score (Metric 2)</b>	<b>Stability score (Metric 3)</b>	<b>Collaboration index</b>	<b>Number of papers</b>	<b>Citation impact (field-normalised)</b>
AMYPAD	0.90	0.79	0.77	2.46	20	1.45
ROADMAP	0.90	0.72	0.68	2.30	20	0.90
SAFE-T	0.95	0.53	0.85	2.32	20	1.88

## 8 BENCHMARKING ANALYSIS – IMI PROJECT RESEARCH AGAINST RESEARCH FROM SELECTED COMPARATORS

This section of the report analyses the output and citation impact of IMI project research benchmarked against research supported by other Public-Private Partnerships, and funders of biomedical research across Europe, Asia, Australia, and North America.

The publications funded by each comparator were identified using specific searches of the funding acknowledgment data provided by authors and extracted in Web of Science. This is the same process by which IMI project publications have been identified. Authors may not always acknowledge their sources of funding and may not always do so correctly. Therefore, the coverage of the datasets used in these analyses may not be complete and may not be entirely accurate; however, the sample represented by these datasets is sufficient to allow a comparison to be made.

### 8.1 IDENTIFYING COMPARATORS

The seven funders listed in Table 8.1.1 are used as comparators for IMI in this report. They are the same comparators as in the previous eleventh report produced in 2020. Each comparator had sufficient publications to allow a meaningful analysis.

TABLE 8.1.1 SUMMARY OF INFORMATION OF IMI-SELECTED COMPARATORS, 2010-2020

Comparator	Number of publications (2010-2020)	Number of papers (2010-2020)	Country	Region
Critical Path (C-Path)	526	490	USA	North America
Commonwealth Scientific and Industrial Research Organisation (CSIRO) <sup>20</sup>	920	889	Australia	Australia
Foundation for the National Institutes of Health (FNIH)	4,329	4,102	USA	North America
Grand Challenges in Global Health (GCGH)	882	881	USA	North America
Indian Council of Medical Research (ICMR)	15,158	14,743	India	Asia
Medical Research Council (MRC)	119,662	107,203	UK	Europe
Wellcome Trust (WT)	84,927	78,962	UK	Europe

<sup>20</sup> The dataset containing all publications attributed to CSIRO between 2010 and 2018 has been reduced to include only medically related publications for these analyses. A list of Web of Science journal categories which capture medically related publications is given in [Annex 2](#).


## 8.2 TRENDS IN OUTPUT: IMI PROJECT RESEARCH COMPARED WITH SELECTED COMPARATORS

This section of the report analyses trends in the performance of IMI project research and the selected comparators.

### 8.2.1 TRENDS IN OUTPUT: IMI PROJECT RESEARCH COMPARED WITH SELECTED COMPARATORS


The output of IMI and the comparators varies widely (some produced many papers and some relatively few), therefore a visual comparison of absolute paper counts would not provide an understanding of their growth relative to one another. To provide a more easily interpretable comparison, Figure 8.2.1.1 shows the percentage of each organisation's total paper count between 2010 and 2020 published in each year. Table 8.2.1.1 shows the same data as in Figure 8.2.1.1 and Table 8.2.1.2 show the number of papers per year for IMI and the selected comparators.

FIGURE 8.2.1.1 TRENDS IN OUTPUT – IMI PROJECT RESEARCH COMPARED WITH SELECTED COMPARATORS, 2010-2020



- Most of IMI's research output was published in the last four years 2017-2020, accounting for more than half of its paper output.
- IMI has experienced the most rapid increase in percentage of output, only in 2019 seeing a slight decrease.
- GCGH has sustained a decreasing percentage of output since 2011, with a brief recovery in 2014.
- After peaking 2015, CSIRO was on a steady decrease in percentage of output but in 2020, has increased by 2.3% since 2019.

FIGURE 8.2.1.2 COMPARING PERCENTAGE OUTPUT IN THE FIRST FIVE YEARS (2010–2014) TO MOST RECENT FIVE YEARS (2016-2020) – IMI PROJECT RESEARCH COMPARED WITH SELECTED COMPARATORS, 2010-2020<sup>21</sup>



<sup>21</sup> note 2015 is excluded

TABLE 8.2.1.1 Share of output – IMI PROJECT RESEARCH COMPARED WITH SELECTED COMPARATORS, 2010-2020

Year	IMI	CSIRO	C-Path	FNIH	GCGH	ICMR	MRC	WT
2010	0.4%	6.4%	4.1%	4.4%	15.8%	5.7%	7.8%	7.1%
2011	1.5%	8.8%	6.5%	4.6%	16.6%	6.7%	8.2%	7.3%
2012	3.6%	9.0%	8.0%	5.9%	14.2%	7.5%	8.9%	8.0%
2013	5.7%	9.3%	7.1%	6.7%	12.0%	8.7%	9.7%	8.6%
2014	7.1%	10.6%	8.2%	7.8%	12.9%	9.7%	9.7%	8.5%
2015	10.8%	11.7%	13.3%	9.1%	9.1%	9.4%	10.1%	9.2%
2016	12.4%	10.0%	8.6%	8.4%	5.9%	10.1%	10.2%	9.4%
2017	13.4%	8.3%	13.7%	11.0%	4.9%	10.3%	10.2%	9.6%
2018	14.5%	8.5%	11.4%	12.0%	3.7%	9.5%	8.7%	10.1%
2019	13.8%	7.5%	10.4%	14.0%	3.4%	10.0%	7.9%	10.6%
2020	16.9%	9.8%	8.8%	16.1%	1.5%	12.4%	8.6%	11.6%

TABLE 8.2.1.2 NUMBER OF PAPERS – IMI PROJECT RESEARCH COMPARED WITH SELECTED COMPARATORS, 2010-2020


Year	IMI	CSIRO	C-Path	FNIH	GCGH	ICMR	MRC	WT
2010	26	57	20	181	139	841	8,393	5,606
2011	97	78	32	188	146	990	8,829	5,788
2012	235	80	39	240	125	1,099	9,522	6,317
2013	371	83	35	274	106	1,278	10,368	6,783
2014	469	94	40	321	114	1,432	10,419	6,740
2015	707	104	65	373	80	1,393	10,809	7,251
2016	814	89	42	345	52	1,493	10,897	7,413
2017	883	74	67	450	43	1,519	10,967	7,546
2018	953	76	56	492	33	1,397	9,314	8,006
2019	903	67	51	576	30	1,472	8,518	8,379
2020	1,108	87	43	662	13	1,829	9,167	9,133
<b>Total</b>	<b>6,566</b>	<b>889</b>	<b>490</b>	<b>4,102</b>	<b>881</b>	<b>14,743</b>	<b>107,203</b>	<b>78,962</b>

## 8.2.2 TRENDS IN FIELD-NORMALISED CITATION IMPACT: IMI PROJECT RESEARCH COMPARED WITH SELECTED COMPARATORS

As discussed in Section 3, citations accumulate over time at a rate that is dependent upon the field of research. Therefore, it is standard bibliometric practice to normalise citation counts for these two factors. In this report, field-normalised citation impact has been calculated by dividing the citations received by each publication by the world average citations per publication for the relevant year and field.

Figure 8.2.2.1 shows the annual trends in field-normalised citation impact of IMI and the comparators between 2010 and 2020 and Figure 8.2.2.2 shows the average field-normalised citation impact of IMI and the comparators between 2010 and 2020. Table 8.2.2.1 has the same data as in Figure 8.2.2.1 and Figure 8.2.2.2.


FIGURE 8.2.2.1 TRENDS IN FIELD-NORMALISED CITATION IMPACT – IMI PROJECT RESEARCH COMPARED WITH SELECTED COMPARATORS, 2010-2020



- The field-normalised citation impact of IMI, MRC and the WT were stable at close to twice the world average between 2010 and 2019, indicating highly cited, internationally significant research.
- The exceptionally high field-normalised citation impact of IMI, CSIRO, and C-Path project research in 2010 was driven by a small number of highly cited papers.
- ICMR has consistently underperformed in comparison to the world average between 2010-2020.
- CSIRO's field normalized citation impact dropped significantly in 2020, but it is too early to make any definitive conclusions as the low citation impact could be due to many or most of the publications being published late in the year so has not had time to accumulate citations. This is supported by CSIRO's high percentage of uncited papers (60.9%) for the most recent year 2020 (see Figure 8.2.5.1 and Table 8.2.5.1), which was higher than last years of 48.5%.



FIGURE 8.2.2.2 AVERAGE FIELD-NORMALISED CITATION IMPACT – IMI PROJECT RESEARCH COMPARED WITH SELECTED COMPARATORS, 2010-2020



- The average field-normalised citation impact of IMI project research (1.99) between 2010 and 2020 was just shy of two times the world average and ahead of five out of the seven comparators.
- Only ICMR's average field-normalised citation impact (0.82) was below world average impact (1.00).

TABLE 8.2.2.1 FIELD-NORMALISED CITATION IMPACT – IMI PROJECT RESEARCH COMPARED WITH SELECTED COMPARATORS, 2010-2020

Year	IMI	CSIRO	C-Path	FNIH	GCGH	ICMR	MRC	WT
2010	3.31	3.66	2.98	2.29	1.98	0.86	2.07	2.05
2011	1.85	1.80	1.17	3.00	2.28	0.87	2.10	1.98
2012	2.27	1.52	1.44	1.85	1.54	0.84	2.02	2.06
2013	1.71	2.09	1.42	2.06	1.86	0.85	2.02	1.93
2014	2.23	1.48	1.35	2.03	1.61	0.81	2.03	2.10
2015	1.93	1.42	1.12	2.12	1.72	0.83	2.09	2.15
2016	1.91	1.27	0.95	1.95	2.57	0.79	2.19	2.19
2017	2.11	1.62	1.77	2.03	1.96	0.82	2.15	2.06
2018	1.91	1.44	1.16	1.41	1.63	0.78	1.91	2.00
2019	2.20	1.44	1.60	1.71	2.40	0.85	1.88	2.03
2020	1.82	0.77	1.03	1.31	0.53	0.66	1.78	1.94
<b>Average</b>	<b>1.99</b>	<b>1.61</b>	<b>1.39</b>	<b>1.84</b>	<b>1.90</b>	<b>0.81</b>	<b>2.03</b>	<b>2.04</b>


- In 2012 and 2014 IMI had the highest field-normalised citation impact (2.27 and 2.23 respectively) of the funding organisations analysed.

### 8.2.3 TRENDS IN JOURNAL-NORMALISED CITATION IMPACT: IMI PROJECT RESEARCH COMPARED WITH SELECTED COMPARATORS

As discussed in Section 3, an alternative indicator to field-normalised citation impact is citation impact normalised at the journal level. The journal-normalised citation impact is calculated by dividing the number of citations a paper received by the average number of citations for the year and the journal in which the paper is published. As for the field-normalised citation impact, the world average for journal-normalised citation impact is 1.00.


Figure 8.2.3.1 shows the annual trends in journal-normalised citation impact of IMI and the comparators between 2010 and 2020. Figure 8.2.2.2 shows the average field-normalised citation impact of IMI and the comparators between 2010 and 2020. Table 8.2.3.1 shows the same data as in Figure 8.2.3.1 and Figure 8.2.3.2.

FIGURE 8.2.3.1 TRENDS IN JOURNAL-NORMALISED CITATION IMPACT – IMI PROJECT RESEARCH COMPARED WITH SELECTED COMPARATORS, 2010-2020



- IMI project research has a journal-normalised citation impact that has remained above the world average between 2010 and 2020 and since 2014 has been relatively stable.
- IMI projects had the highest journal normalised citation impact for 2012, 2014, 2019 and the most recent year 2020.
- The journal-normalised citation impact of ICMR, MRC and WT remained relatively stable between 2010 and 2020, while that of the other comparators such as CSIRO and GCGH showed greater variability. This is to be expected given the smaller number of papers funded by CSIRO and GCGH relative to the output of research institutions like the MRC and WT.
- Since 2015 ICMR's journal normalised citation impact has been below the world average, apart from 2019 where it performed around the world average (1.02).

FIGURE 8.2.3.2 AVERAGE JOURNAL-NORMALISED CITATION IMPACT – IMI PROJECT RESEARCH COMPARED WITH SELECTED COMPARATORS, 2010-2020



- IMI had the highest average journal-normalised citation impact (1.21) between 2010 and 2020.

TABLE 8.2.3.1 JOURNAL-NORMALISED CITATION IMPACT – IMI PROJECT RESEARCH COMPARED WITH SELECTED COMPARATORS, 2010-2020


Year	IMI	CSIRO	C-Path	FNIH	GCGH	ICMR	MRC	WT
2010	1.65	2.26	0.99	1.27	1.21	1.05	1.14	1.13
2011	1.05	1.28	0.96	1.46	1.23	1.03	1.17	1.13
2012	1.35	1.14	1.12	1.25	1.15	1.07	1.18	1.13
2013	1.03	1.25	1.11	1.28	1.17	1.00	1.18	1.12
2014	1.28	1.19	1.01	1.27	1.15	1.06	1.16	1.16
2015	1.19	1.14	1.00	1.22	1.02	1.01	1.16	1.17
2016	1.20	0.99	0.89	1.18	1.47	0.93	1.20	1.17
2017	1.23	1.21	1.37	1.26	1.06	0.94	1.19	1.16
2018	1.15	1.19	1.01	1.08	0.80	0.93	1.17	1.14
2019	1.32	1.04	1.06	1.20	1.12	1.02	1.14	1.14
2020	1.17	0.90	0.87	1.02	0.44	0.96	1.09	1.10
<b>Average</b>	<b>1.21</b>	<b>1.20</b>	<b>1.05</b>	<b>1.19</b>	<b>1.15</b>	<b>0.99</b>	<b>1.16</b>	<b>1.14</b>

## 8.2.4 TRENDS IN RAW CITATION IMPACT: IMI PROJECT RESEARCH COMPARED WITH SELECTED COMPARATORS

The raw (un-normalised) citation impact of a group of papers is calculated by dividing the sum of citations by the total number of papers published. As such it is the mean average number of citations to a paper. This indicator must be used with caution as it is not normalised to field or year.


Figure 8.2.4.1 shows the annual trends in average raw citation impact of IMI and the comparators for papers published each year between 2010 and 2020. Figure 8.2.4.2 shows the average raw citation impact of IMI and the comparators for papers published between 2010 and 2020. Table 8.2.4.1 has the same data as in Figure 8.2.4.1 and Figure 8.2.4.2.

FIGURE 8.2.4.1 TRENDS IN RAW CITATION IMPACT – IMI PROJECT RESEARCH COMPARED WITH SELECTED COMPARATORS, 2010-2020



- The raw citation impact of all organisations decreased from 2010 to 2020. This is expected as more recent publications have had less time to accumulate citations, and the raw citation impact is not normalised.
- IMI's 2020 raw citation impact (2.57) is higher than all comparators raw citation impacts except for WT.

FIGURE 8.2.4.2 AVERAGE RAW CITATION IMPACT – IMI PROJECT RESEARCH COMPARED WITH SELECTED COMPARATORS, 2010-2020



- IMI’s average raw citation impact between 2010 and 2020 (27.39) is higher than three out of the seven comparators (C-Path (24.01) ICMR (12.88) and newly FNIH (27.09)).
- GCGH had the highest raw citation impact (46.16).


TABLE 8.2.4.1 RAW CITATION IMPACT – IMI PROJECT RESEARCH COMPARED WITH SELECTED COMPARATORS, 2010-2020

Year	IMI	CSIRO	C-Path	FNIH	GCGH	ICMR	MRC	WT
2010	115.70	133.23	148.71	84.60	69.46	26.36	73.73	73.84
2011	64.95	53.76	34.19	91.59	69.28	24.96	64.10	65.15
2012	71.74	38.52	32.83	50.75	48.00	22.85	57.00	61.51
2013	46.29	48.11	53.03	48.86	47.52	20.55	49.69	51.29
2014	50.25	31.40	24.78	42.31	34.68	18.26	42.71	47.08
2015	39.37	25.63	19.50	36.86	30.25	15.02	36.87	40.10
2016	29.91	16.29	11.50	26.73	34.06	11.78	30.73	33.22
2017	25.86	16.35	20.07	21.68	21.77	9.15	23.55	23.38
2018	15.24	10.22	8.17	9.92	15.88	6.00	14.87	16.31
2019	9.32	5.23	6.13	6.32	8.50	3.73	7.53	8.37
2020	2.57	0.98	0.74	1.37	0.92	0.92	2.47	3.01
<b>Average</b>	<b>27.39</b>	<b>31.46</b>	<b>24.01</b>	<b>27.09</b>	<b>46.16</b>	<b>12.88</b>	<b>36.13</b>	<b>35.00</b>

## 8.2.5 TRENDS IN UNCITED RESEARCH: IMI PROJECT RESEARCH COMPARED WITH SELECTED COMPARATORS


Most publication datasets will include papers which have no citations. Figure 8.2.5.1 shows the percentage of uncited papers between 2010 and 2020 for IMI and the selected comparators. Figure 8.2.5.1 shows the trend in average percentage of uncited papers between 2010 and 2020 for IMI and the selected comparators. Figure 8.2.5.2 shows the average percentage of uncited papers between 2010 and 2020 for IMI and the selected comparators. Table 8.2.5.1 has the same data as in Figure 8.2.5.1 and Figure 8.2.5.2.

FIGURE 8.2.5.1 TRENDS IN UNCITED PAPERS – IMI PROJECT RESEARCH COMPARED WITH SELECTED COMPARATORS, 2010-2020



- The similar trends in uncited papers indicate the similar citation life-cycle for biomedical research funded across all the benchmarking organisations. More recent publications are less likely to be cited than older publications. Therefore, the higher percentage of uncited papers in most recent years should not be taken as evidence that these articles are more likely to remain uncited.
- Since 2017 IMI has had the lowest percentage of uncited papers compared to the comparators. While ICMR has consistently had the highest percentage, apart from 2020. This helps explain ICMR's lower than average citation impact.

FIGURE 8.2.5.1 AVERAGE PERCENTAGE OF UNCITED PAPERS – IMI PROJECT RESEARCH COMPARED WITH SELECTED COMPARATORS, 2010-2020



- Around 9% of IMI project papers remained uncited between 2010 and 2020
- GCGH has the lowest percentage of uncited papers, around 2% of its papers uncited

TABLE 8.2.5.1 PERCENTAGE OF UNCITED PAPERS – IMI PROJECT RESEARCH COMPARED WITH SELECTED COMPARATORS, 2010-2020

Year	IMI	CSIRO	C-Path	FNIH	GCGH	ICMR	MRC	WT
2010	0.0%	0.0%	0.0%	0.0%	0.0%	2.4%	0.4%	0.4%
2011	0.0%	0.0%	0.0%	0.5%	0.0%	1.6%	0.5%	0.5%
2012	0.0%	1.3%	2.6%	0.0%	0.0%	2.5%	0.4%	0.5%
2013	0.5%	0.0%	2.9%	0.4%	0.0%	2.5%	0.6%	0.6%
2014	0.0%	1.1%	2.5%	0.9%	0.0%	2.9%	0.7%	0.5%
2015	0.7%	1.0%	1.5%	0.5%	2.5%	4.7%	0.8%	1.0%
2016	0.9%	1.1%	2.4%	0.6%	1.9%	5.0%	1.4%	1.2%
2017	1.4%	2.7%	1.5%	3.6%	2.3%	7.1%	1.6%	1.9%
2018	2.4%	3.9%	7.1%	4.5%	9.1%	11.9%	3.1%	3.3%
2019	6.9%	7.5%	19.6%	10.6%	10.0%	20.4%	9.2%	9.5%
2020	44.6%	60.9%	67.4%	55.1%	69.2%	62.4%	48.2%	46.5%
<b>Total</b>	<b>9.2%</b>	<b>7.5%</b>	<b>10.0%</b>	<b>11.5%</b>	<b>2.2%</b>	<b>13.5%</b>	<b>5.7%</b>	<b>7.3%</b>


- No IMI project papers published between 2010 and 2012 are uncited. IMI's share of uncited research since 2017 has been the lowest of all the comparators.

## 8.2.6 TRENDS IN HIGHLY CITED RESEARCH: IMI PROJECT RESEARCH COMPARED WITH SELECTED COMPARATORS

As discussed in Section 3, highly cited work is recognised as having a greater impact, and citation counts have been correlated with other qualitative evaluations of research performance, such as peer review. For institutional research evaluation, we have found that the world's top 10% of most highly cited papers is often a suitable definition of highly cited work. Therefore, if more than 10% of an entity's publications are in the top 10% of the world's most highly cited papers, then it has performed better than expected.

Figure 8.2.6.1 shows the annual trends in percentage of highly cited papers between 2010 and 2020 for IMI and the selected comparators. Figure 8.2.6.2 shows the total percentage of highly cited papers between 2010 and 2020 for IMI and the selected comparators. Table 8.2.6.1 has the same data as in Figure 8.2.6.1 and Figure 8.2.6.2.

FIGURE 8.2.6.1 TRENDS IN HIGHLY CITED PAPERS – IMI PROJECT RESEARCH COMPARED WITH SELECTED COMPARATORS, 2010-2020




- Between 2010 and 2020, IMI and most of the comparators had an above average (10%) percentage of highly cited papers the exceptions being ICMR, which was consistently below the world average, and C-Path, which was below average in 2016 and 2020.
- In most years, IMI is among the organisations with the highest percentage of highly cited papers. IMI had the highest percentage of highly cited papers among the comparators in 2014, 2016, 2019 and 2020.



FIGURE 8.2.6.2 PERCENTAGE OF HIGHLY CITED PAPERS – IMI PROJECT RESEARCH COMPARED WITH SELECTED COMPARATORS, 2010-2020

Percentage of highly cited papers



- IMI ranks second in comparison to the comparators for percentage of highly-cited papers, with only GCGH outperforming IMI.
- Around a quarter of papers published by IMI and the comparators between 2010 and 2020 were highly cited. C-Path had a comparatively lower proportions of highly cited papers (14.8%) while ICMR was well below world average performance (6.4%).


TABLE 8.2.6.1 PERCENTAGE OF HIGHLY CITED PAPERS – IMI PROJECT RESEARCH COMPARED WITH SELECTED COMPARATORS, 2010-2020

Year	IMI	CSIRO	C-Path	FNIH	GCGH	ICMR	MRC	WT
2010	34.6%	19.3%	20.0%	41.4%	30.2%	6.4%	25.6%	25.2%
2011	25.8%	26.9%	12.5%	42.6%	34.2%	6.8%	25.8%	25.2%
2012	29.8%	26.3%	15.4%	30.4%	23.2%	7.6%	26.1%	26.6%
2013	24.8%	22.9%	11.4%	28.1%	27.4%	7.4%	25.9%	25.5%
2014	29.2%	22.3%	15.0%	29.0%	21.1%	7.3%	25.9%	27.7%
2015	26.9%	18.3%	16.9%	25.7%	21.2%	5.9%	25.1%	27.7%
2016	28.4%	16.9%	4.8%	22.3%	26.9%	6.4%	26.2%	27.6%
2017	28.9%	21.6%	22.4%	26.2%	30.2%	5.3%	26.6%	26.5%
2018	24.2%	21.1%	14.3%	17.5%	21.2%	6.0%	25.5%	25.7%
2019	28.0%	16.4%	11.8%	19.6%	23.3%	7.7%	23.0%	23.3%
2020	17.4%	9.2%	7.0%	12.2%	7.7%	6.6%	16.4%	16.8%
<b>Total</b>	<b>25.7%</b>	<b>20.0%</b>	<b>14.1%</b>	<b>23.6%</b>	<b>26.4%</b>	<b>6.4%</b>	<b>24.8%</b>	<b>25.0%</b>

## 8.2.7 TRENDS IN OPEN ACCESS RESEARCH: IMI PROJECT RESEARCH COMPARED WITH SELECTED COMPARATORS

Figure 8.2.7.1 shows annual trends in the percentage of open access publications between 2010 and 2020 for IMI and the selected comparators. Figure 8.2.7.2 shows the total percentage of open access publications between 2010 and 2020 for IMI and the selected comparators. Table 8.2.7.1 shows the same data as in Figure 8.2.7.1 and Figure 8.2.7.2.<sup>22</sup>


FIGURE 8.2.7.1 TRENDS IN OPEN ACCESS PUBLICATIONS – IMI PROJECT RESEARCH COMPARED WITH SELECTED COMPARATORS, 2010-2020



- IMI and most of the comparators have increased their output of open access publications between 2010 and 2020, except for FNIH which is trending slightly downward.
- IMI increased its percentage of open access publications at a faster rate than any of the comparators.

<sup>22</sup> The Web of Science open access data come from the Directory of Open Access Journals (DOAJ) and collaborations with Impact Story and Our Research's Unpaywall services. The Web of Science therefore provides unrivalled coverage of open access publications that are published through DOAJ Gold, Other Gold, Green Published, Green Accepted or Bronze routes. It is also possible that some publishers make publications available without following a recognised open access route. In these cases publications will not be indexed as open access in the Web of Science or in this report.

FIGURE 8.2.7.2 TOTAL PERCENTAGE OF OPEN ACCESS PUBLICATIONS – IMI PROJECT RESEARCH COMPARED WITH SELECTED COMPARATORS, 2010-2020



- The majority of organisations, including IMI, have published more than half of their publications as open access. IMI had a lower share of open access publications compared to FNIH, GCGH, MRC, and WT.
- WT has the highest percentage of open access publications in all years between 2010 and 2020, with an average of 86.7% of all publications. While ICMR, had the lowest with an average of 38.8%.

TABLE 8.2.7.1 PERCENTAGE OF OPEN ACCESS PAPERS – IMI PROJECT RESEARCH COMPARED WITH SELECTED COMPARATORS, 2010-2020

Year	IMI	CSIRO	C-Path	FNIH	GCGH	ICMR	MRC	WT
2010	38.5%	40.4%	35.0%	86.7%	73.4%	32.2%	59.8%	77.7%
2011	56.7%	32.1%	43.8%	83.0%	77.4%	33.6%	61.6%	78.0%
2012	57.4%	53.7%	30.8%	82.1%	72.0%	34.0%	66.0%	80.4%
2013	54.2%	43.4%	37.1%	78.8%	75.5%	38.6%	69.9%	84.3%
2014	52.9%	53.2%	45.0%	86.3%	77.2%	40.4%	74.2%	86.7%
2015	65.2%	46.2%	56.9%	85.0%	82.5%	38.3%	78.2%	88.3%
2016	69.4%	49.4%	57.1%	78.0%	84.6%	41.0%	84.7%	90.6%
2017	71.0%	56.8%	56.7%	82.4%	90.7%	42.0%	86.9%	91.4%
2018	78.1%	53.9%	55.4%	85.6%	97.0%	41.1%	86.2%	91.0%
2019	80.6%	56.7%	64.7%	80.4%	86.7%	41.4%	85.8%	91.2%
2020	77.6%	58.6%	53.5%	66.2%	92.3%	38.2%	82.9%	87.6%
<b>Total</b>	<b>70.6%</b>	<b>49.6%</b>	<b>51.0%</b>	<b>80.0%</b>	<b>78.5%</b>	<b>38.8%</b>	<b>76.4%</b>	<b>86.7%</b>

### 8.3 SUMMARY OF BIBLIOMETRIC INDICATORS: IMI PROJECT RESEARCH COMPARED WITH SELECTED COMPARATORS

Although IMI has only been funding research for just over a decade, its performance is on par with well-established funding bodies that have been operating for much longer, like the MRC and the Wellcome Trust, as indicated by comparable citation impacts, and percentages of highly cited papers (Table 8.3.1).

TABLE 8.3.1 SUMMARY OF BIBLIOMETRIC INDICATORS – IMI PROJECT RESEARCH COMPARED WITH SELECTED COMPARATORS, 2010-2020

<b>Project</b>	<b>Number of papers</b>	<b>Citation impact (normalised at field level)</b>	<b>Percentage of uncited papers</b>	<b>Percentage of highly cited papers</b>
IMI	6,566	1.99	9.2%	25.7%
C-Path	490	1.39	10.0%	14.1%
CSIRO	889	1.61	7.5%	20.0%
FNIH	4,102	1.84	11.5%	23.6%
GCGH	881	1.90	2.2%	26.4%
ICMR	14,743	0.81	13.5%	6.6%
MRC	107,203	2.03	5.7%	24.8%
WT	78,962	2.04	7.3%	25.0%

## ANNEX 1: BIBLIOMETRICS AND CITATION ANALYSIS

Bibliometrics are about publications and their citations. The academic field emerged from 'information science' and now usually refers to the methods used to study and index texts and information.

Publications cite other publications. These citation links grow into networks, and their numbers are likely to be related to the significance or impact of the publication. The meaning of the publication is determined from keywords and content. Citation analysis and content analysis have therefore become a common part of bibliometric methodology. Historically, bibliometric methods were used to trace relationships amongst academic journal citations. Now, bibliometrics are important in indexing research performance.

Bibliometric data have particular characteristics of which the user should be aware, and these are considered here.

Journal papers (publications, sources) report research work. Papers refer to or 'cite' earlier work relevant to the material being reported. New papers are cited in their turn. Papers that accumulate more citations are thought of as having greater 'impact', which is interpreted as significance or influence on their field. Citation counts are therefore recognised as a measure of impact, which can be used to index the excellence of the research from a particular group, institution or country.

The origins of citation analysis as a tool that could be applied to research performance can be traced to the mid-1950s, when Eugene Garfield proposed the concept of citation indexing and introduced the Science Citation Index, the Social Sciences Citation Index and the Arts & Humanities Citation Index, produced by the Institute of Scientific Information (now Clarivate).<sup>23</sup>

We can count citations, but they are only 'indicators' of impact or quality – not metrics. Most impact indicators use average citation counts from groups of papers, because some individual papers may have unusual or misleading citation profiles. These outliers are diluted in larger samples.

### **Data source**

The data we use come from the Clarivate Web of Science databases which give access not only to journals but also to conference proceedings, books, patents, websites, and chemical structures, compounds and reactions. It has a unified structure that integrates all data and search terms together and therefore provides a level of comparability not found in other databases. It is widely acknowledged to be the world's leading source of citation and bibliometric data. The Clarivate Web of Science Core Collection is part of the Web of Science, and focuses on research published in journals and conferences in science, medicine, arts, humanities and social sciences.

The Web of Science was originally created as an awareness and information retrieval tool but it has acquired an important primary use as a tool for research evaluation, using citation analysis and bibliometrics. Data coverage is both current and retrospective in the sciences, social sciences, arts and humanities, in some cases back to 1900. Within the research community this data source was previously referred to by the acronym 'ISI'.

Unlike other databases, the Web of Science and underlying databases are selective, that is: the journals abstracted are selected using rigorous editorial and quality criteria. The authoritative, multidisciplinary content covers over 12,000 of the highest impact journals worldwide, including open access journals, and over 150,000 conference proceedings. The abstracted journals encompass the majority of significant, frequently cited scientific reports and, more importantly, an even greater proportion of the scientific research output which is cited. This selective process ensures that the citation counts remain

---

<sup>23</sup> Garfield, E (1955) Citation Indexes for Science – New dimension in documentation through association of ideas. *Science*: **122**, 108-111.

relatively stable in given research fields and do not fluctuate unduly from year to year, which increases the usability of such data for performance evaluation.

Clarivate has extensive experience with databases on research inputs, activity and outputs and has developed innovative analytical approaches for benchmarking and interpreting international, national and institutional research impact.

### **Database categories**

The source data can be grouped in various classification systems. Most of these are based on groups of journals that have a relatively high cross-citation linkage and naturally cluster together. Custom classifications use subject maps in third-party data such as the OECD categories set out in the Frascati manual.

Clarivate frequently uses the broader field categories in the InCites: Essential Science Indicators™ and the finer journal categories in the Web of Science. There are 22 fields in Essential Science Indicators and 254 fields in Web of Science. In either case, our bibliometric analyses draw on the full range of data available in the underlying database, so analyses in our reports will differ slightly from anything created 'on the fly' from data in the web interface.

The lists of journal categories in these systems are attached at the end of this document.

Most analyses start with an overall view across the data, then move to a view across broad categories and only then focus in at a finer level in the areas of greatest interest to policy, programme or organisational purpose.

### **Assigning papers to addresses**

A paper is assigned to each country and each organisation whose address appears at least once for any author on that paper. One paper counts once and only once for each assignment, however many address variants occur for the country or organisation. No weighting is applied.

For example, a paper has five authors, thus:

Author	Organisation	Country		
Gurney, KA	Univ Leeds	UK	<b>Counts for Univ Leeds</b>	<b>Counts for UK</b>
Adams, J	Univ Leeds	UK	No gain for Univ Leeds	No gain for UK
Kochalko, D	Univ C San Diego	USA	<b>Counts for UCSD</b>	<b>Counts for USA</b>
Munshi, S	Gujarat Univ	India	<b>Counts for Gujarat Univ</b>	<b>Counts for India</b>
Pendlebury, D	Univ Oregon	USA	<b>Counts for Univ Oregon</b>	No gain for USA

So this one paper with five authors would be included once in the tallies for each of four universities and once in the tallies for each of three countries.

Work carried out within Clarivate, and research published elsewhere, indicates that fractional weighting based on the balance of authors by organisation and country makes little difference to the conclusions of an analysis at an aggregate level. Such fractional analysis can introduce unforeseen errors in the attempt to create a detailed but uncertain assignment. Partitioning credit would make a greater difference at a detailed, group level but the analysis can then be manually validated.

### **Citation counts**


A publication accumulates citation counts when it is referred to by more recent publications. Some papers get cited frequently and many get cited rarely or never, so the distribution of citations is highly skewed.

Why are many papers never cited? Certainly some papers remain uncited because their content is of little or no impact, but that is not the only reason. It might be because they have been published in a

journal not read by researchers to whom the paper might be interesting. It might be that they represent important but 'negative' work reporting a blind alley to be avoided by others. The publication may be a commentary in an editorial, rather than a normal journal article and thus of general rather than research interest. Or it might be that the work is a 'sleeping beauty' that has yet to be recognised for its significance.

Other papers can be very highly cited: hundreds, even thousands of times. Again, there are multiple reasons for this. Most frequently cited work is being recognised for its innovative significance and impact on the research field of which it speaks. Impact here is a good reflection of quality: it is an indicator of excellence. But there are other papers which are frequently cited because their significance is slightly different: they describe key methodology; they are a thoughtful and wide-ranging review of a field; or they represent contentious views which others seek to refute.

Citation analysis cannot make value judgments about why an article is uncited nor about why it is highly cited. The analysis can only report the citation impact that the publication has achieved. We normally assume, based on many other studies linking bibliometric and peer judgments, that high citation counts correlate on average with the quality of the research.



The figure shows the skewed distribution of more or less frequently cited papers from a sample of UK authored publications in cell biology. The skew in the distribution varies from field to field. It is to compensate for such factors that actual citation counts must be normalised, or rebased, against a world baseline.


We do not seek to account separately for the effect of self-citation. If the citation count is significantly affected by self-citation then the paper is likely to have been infrequently cited. This is therefore only of consequence for low impact activity. Studies show that for large samples at national and organisational level the effect of self-citation has little or no effect on the analytical outcomes and would not alter interpretation of the results.

### **Time factors**

Citations accumulate over time. Older papers therefore have, on average, more citations than more recent work. The graph below shows the pattern of citation accumulation for a set of 33 journals in the journal category **Materials Science, Biomaterials**. Papers less than eight years old are, on average, still accumulating additional citations. The citation count goes on to reach a plateau for older sources.

The graph shows that the percentage of papers that have never been cited drops over about five years. Beyond five years, between 5% and 10% or more of papers remain uncited.

Account must be taken of these time factors in comparing current research with historical patterns. For these reasons, it is sometimes more appropriate to use a fixed five-year window of papers and citations to compare two periods than to look at the longer term profile of citations and of uncitedness for a recent year and an historical year.



### Discipline factors

Citation rates vary between disciplines and fields. For the UK science base as a whole, ten years produces a general plateau beyond which few additional citations would be expected. On the whole, citations accumulate more rapidly and plateau at a higher level in biological sciences than physical sciences, and natural sciences generally cite at a higher rate than social sciences.

Papers are assigned to disciplines (journal categories or research fields) by Clarivate, bringing cognate research areas together. The journal category classification scheme has been recently revised and updated. Before 2007, journals were assigned to the older, well established Current Contents categories which were informed by extensive work by Thomson and with the research community since the early 1960s. This scheme has been superseded by the 252 Web of Science journal categories which allow for greater disaggregation for the growing volume of research which is published and abstracted.

Papers are allocated according to the journal in which the paper is published. Some journals may be considered to be part of the publication record for more than one research field. As the example below illustrates, the journal *Acta Biomaterialia* is assigned to two journal categories: **Materials Science, Biomaterials** and **Engineering, Biomedical**.

Very few papers are not assigned to any research field and as such will not be included in specific analyses using normalised citation impact data. The journals included in the Clarivate databases and how they are selected are detailed here <http://www.clarivate.com/>.

Some journals with a very diverse content, including the prestigious journals *Nature* and *Science* were classified as **Multidisciplinary** in databases created prior to 2007. The papers from these **Multidisciplinary** journals are now re-assigned to more specific research fields using an algorithm based on the research area(s) of the references cited by the article.




### Normalised citation impact

Because citations accumulate over time at a rate that is dependent upon the field of research, all analyses must take both field and year into account. In other words, because the absolute citation count for a specific article is influenced by its field and by the year it was published, we can only make comparisons of indexed data after normalising with reference to these two variables.

We only use citation counts for reviews and articles in calculations of impact, because document type influences the citation count. For example, a review will often be cited more frequently than an article in the same field, but editorials and meeting abstracts are rarely cited and citation rates for conference proceedings are extremely variable. The most common normalisation factors are the average citations per paper for (1) the year and (2) either the field or the journal in which the paper was published. This normalisation is also referred to as 'rebasing' the citation count.

Impact is therefore most commonly analysed in terms of 'normalised impact', or NCI. The following schematic illustrates how the normalised citation impact is calculated at paper level and journal category level.



This article in the journal *Acta Biomaterialia* is assigned to two journal categories: **Materials Science, Biomaterials** and **Engineering, Biomedical**. The world average baselines for, as an example, **Materials science, Biomaterials** are calculated by summing the citations to all the articles and reviews published worldwide in the journal *Acta Biomaterialia* and the other 32 journals assigned to this category for each year, and dividing this by the total number of articles and reviews published in the journal category. This gives the category-specific normalised citation impact (in the above example the category-specific field-normalised citation impact for **Materials Science, Biomaterials** is 5.8 and the category-specific field-normalised citation impact for **Engineering, Biomedical** is higher at 6.7). Most papers (nearly two-thirds) are assigned to a single journal category whilst a minority are assigned to more than 5.

Citation data provided by Clarivate are assigned on an annual census date referred to as the Article Time Period. For the majority of publications the Article Time Period is the same as the year of publication, but for a few publications (especially those published at the end of the calendar year in less main-stream journals) the Article Time Period may vary from the actual year of publication.

World average impact data are sourced from the Clarivate National Science Indicators baseline data for 2016.

### ***Mean normalised citation impact***

Research performance has historically been indexed by using average citation impact, usually compared to a world average that accounts for time and discipline. As noted, however, the distribution of citations amongst papers is highly skewed because many papers are never cited while a few papers accumulate very large citation counts. That means that an average may be misleading if assumptions are made about the distribution of the underlying data.

In fact, almost all research activity metrics are skewed: for research income, PhD numbers and publications there are many low activity values and a few exceptionally high values. In reality, therefore, the skewed distribution means that average impact tends to be greater than and often significantly different from either the median or mode in the distribution. This should be borne in mind when reviewing analytical outcomes.

The average (normalised) citation impact can be calculated at an individual paper level where it can be associated with more than one journal category. It can also be calculated for a set of papers at any level from a single country to an individual researcher's output. In the example above, the average citation impact of the *Acta Biomaterialia* paper can be expressed as  $((5.8 + 6.7)/2) = 6.3$ .

### ***What are uncited papers?***

It may be a surprise that some journal papers are never subsequently cited after publication, even by their authors. This accounts for about half the total global output for a typical, recent 10-year period. We cannot tell why papers are not cited. It is likely that a significant proportion of papers remain uncited because they are reporting negative results which are an essential matter of record in their field but make the content less likely to be referenced in other papers. Inevitably, other papers are uncited because their content is trivial or marginal to the mainstream. However, it should not be assumed that this is the case for all such papers.

There is variation in non-citation between countries and between fields. For example, relatively more engineering papers tend to remain uncited than papers in other sciences, indicative of a disciplinary factor but not a quality factor. While there is also an obvious increase in the likelihood of citation over time, most papers that are going to be cited will be cited within a few years of publication.

## ***Journal category systems used in our analyses***

### WEB OF SCIENCE

Acoustics	Classics	Engineering, multidisciplinary
Agricultural economics & policy	Clinical neurology	Engineering, ocean
Agricultural engineering	Communication	Engineering, petroleum
Agriculture, dairy & animal science	Computer science, artificial intelligence	Entomology
Agriculture, multidisciplinary	Computer science, cybernetics	Environmental sciences
Agriculture, soil science	Computer science, hardware & architecture	Environmental studies
Agronomy	Computer science, information systems	Ergonomics
Allergy	Computer science, interdisciplinary applications	Ethics
Anatomy & morphology	Computer science, software engineering	Ethnic studies
Andrology	Computer science, theory & methods	Evolutionary biology
Anesthesiology	Construction & building technology	Family studies
Anthropology	Criminology & penology	Film, radio, television
Applied linguistics	Critical care medicine	Fisheries
Archaeology	Crystallography	Folklore
Architecture	Dance	Food science & technology
Area studies	Demography	Forestry
Art	Dentistry, oral surgery & medicine	Gastroenterology & hepatology
Asian studies	Dermatology	Genetics & heredity
Astronomy & astrophysics	Developmental biology	Geochemistry & geophysics
Automation & control systems	Ecology	Geography
Behavioral sciences	Economics	Geography, physical
Biochemical research methods	Education & educational research	Geology
Biochemistry & molecular biology	Education, scientific disciplines	Geosciences, multidisciplinary
Biodiversity conservation	Education, special	Geriatrics & gerontology
Biology	Electrochemistry	Health care sciences & services
Biology, miscellaneous	Emergency medicine	Health policy & services
Biophysics	Endocrinology & metabolism	Hematology
Biotechnology & applied microbiology	Energy & fuels	History
Business	Engineering, aerospace	History & philosophy of science
Business, finance	Engineering, biomedical	History of social sciences
Cardiac & cardiovascular systems	Engineering, chemical	Horticulture
Cell biology	Engineering, civil	Humanities, multidisciplinary
Chemistry, analytical	Engineering, electrical & electronic	Imaging science & photographic technology
Chemistry, applied	Engineering, environmental	Immunology
Chemistry, inorganic & nuclear	Engineering, geological	Industrial relations & labor
Chemistry, medicinal	Engineering, industrial	Infectious diseases

Chemistry, multidisciplinary	Engineering, manufacturing	Information & library science
Chemistry, organic	Engineering, marine	Instruments & instrumentation
Chemistry, physical	Engineering, mechanical	Integrative & complementary medicine
International relations	Mining & mineral processing	Psychology
Language & linguistics	Multidisciplinary sciences	Psychology, applied
Language & linguistics theory	Music	Psychology, biological
Law	Mycology	Psychology, clinical
Limnology	Nanoscience & nanotechnology	Psychology, developmental
Linguistics	Neuroimaging	Psychology, educational
Literary reviews	Neurosciences	Psychology, experimental
Literary theory & criticism		Psychology, mathematical
Literature	Nuclear science & technology	Psychology, multidisciplinary
Literature, African, Australian, Canadian	Nursing	Psychology, psychoanalysis
Literature, American	Nutrition & dietetics	Psychology, social
Literature, British Isles	Obstetrics & gynecology	Public administration
Literature, German, Dutch, Scandinavian	Oceanography	Public, environmental & occupational health
Literature, romance	Oncology	Radiology, nuclear medicine & medical imaging
Literature, Slavic	Operations research & management science	Rehabilitation
Management	Ophthalmology	Religion
Marine & freshwater biology	Optics	Remote sensing
Materials science, biomaterials	Ornithology	Reproductive biology
Materials science, ceramics	Orthopedics	Respiratory system
Materials science, characterization & testing	Otorhinolaryngology	Rheumatology
Materials science, coatings & films	Paleontology	Robotics
Materials science, composites	Parasitology	Social issues
Materials science, multidisciplinary	Pathology	Social sciences, biomedical
Materials science, paper & wood	Pediatrics	Social sci, interdisciplinary
Materials science, textiles	Peripheral vascular disease	Social sci, mathematical methods
Math & computational biology	Pharmacology & pharmacy	Social work
Mathematics	Philosophy	Sociology
Mathematics, applied	Physics, applied	Soil science
Mathematics, interdisciplinary applications	Physics, atomic, molecular & chemical	Spectroscopy
Mechanics	Physics, condensed matter	Sport sciences
Medical ethics	Physics, fluids & plasmas	Statistics & probability
Medical informatics	Physics, mathematical	Substance abuse
Medical laboratory technology	Physics, multidisciplinary	Surgery
Medicine, general & internal	Physics, nuclear	Telecommunications
Medicine, legal	Physics, particles & fields	Theater
Medicine, research & experimental	Physiology	Thermodynamics
Medieval & renaissance studies	Planning & development	Toxicology

Metallurgy & metallurgical engineering	Plant sciences	Transplantation
Meteorology & atmospheric sci	Poetry	Transportation
Microbiology	Political science	Transportation science & technology
Microscopy	Polymer science	Tropical medicine
Mineralogy	Psychiatry	
Urban studies		
Urology & nephrology		
Veterinary		
Veterinary sciences		
Virology		
Water resources		
Women's studies		
Zoology		

#### ESSENTIAL SCIENCE INDICATORS

Agricultural Sciences	Geosciences	Pharmacology
Biology & Biochemistry	Immunology	Physics
Chemistry	Law	Plant & Animal Science
Clinical Medicine	Materials Science	Psychology/Psychiatry
Computer Science	Mathematics	Social Sciences, general
Ecology/Environment	Microbiology	Space Science
Economics & Business	Molecular Biology & Genetics	
Education	Multidisciplinary	
Engineering	Neurosciences & Behaviour	

## ANNEX 2: BIOMEDICALLY RELATED JOURNAL CATEGORIES

This Annex lists the Web of Science journal categories which capture biomedically related publications.

Allergy	Physiology
Anaesthesiology	Primary Health Care
Anatomy & Morphology	Psychiatry
Andrology	Psychology
Audiology & Speech-Language Pathology	Psychology, Applied
Behavioural Sciences	Psychology, Biological
Cardiac & Cardiovascular Systems	Psychology, Clinical
Cell & Tissue Engineering	Psychology, Developmental
Clinical Neurology	Psychology, Educational
Critical Care Medicine	Psychology, Experimental
Dentistry, Oral Surgery & Medicine	Psychology, Mathematical
Dermatology	Psychology, Psychoanalysis
Emergency Medicine	Psychology, Social
Endocrinology & Metabolism	Public, Environmental & Occupational Health
Ergonomics	Radiology, Nuclear Medicine & Medical Imaging
Gastroenterology & Hepatology	Rehabilitation
Geriatrics & Gerontology	Reproductive Biology
Gerontology	Respiratory System
Haematology	Rheumatology
Health Care Sciences & Services	Substance Abuse
Health Policy & Services	Surgery
Immunology	Transplantation
Infectious Diseases	Tropical Medicine
Integrative & Complementary Medicine	Urology & Nephrology
Medical Ethics	Virology
Medical Informatics	
Medical Laboratory Technology	
Medicine, General & Internal	
Medicine, Legal	
Medicine, Research & Experimental	
Neuroimaging	
Neurosciences	
Nursing	
Nutrition & Dietetics	
Obstetrics & Gynaecology	
Oncology	
Ophthalmology	
Orthopaedics	
Otorhinolaryngology	
Paediatrics	
Pathology	
Peripheral Vascular Disease	
Pharmacology & Pharmacy	

ANNEX 3: TOTAL NUMBER OF WEB OF SCIENCE  
PUBLICATIONS FROM IMI PROJECTS BETWEEN 2010 AND 2020  
BY COUNTRY

Country	Number of publications
UK	2,996
Germany	2,278
USA	1,690
Netherlands	1,681
Sweden	1,185
France	1,169
Italy	985
Switzerland	868
Spain	809
Belgium	681
Denmark	523
Canada	465
Austria	424
Finland	328
Australia	226
Greece	214
Peoples R China	207
Ireland	171
Norway	161
Poland	146
Japan	127
Brazil	113
Portugal	112
Israel	97
Singapore	71
Hungary	70
South Africa	63
Estonia	61
Czech Republic	55
Luxembourg	47
India	46
Iceland	40
Saudi Arabia	39
Taiwan	38
South Korea	37
Turkey	35
New Zealand	31
Cyprus	31
Slovenia	29

<b>Country</b>	<b>Number of publications</b>
Croatia	29
Lithuania	27
Egypt	25
Argentina	24
Russia	19
Romania	19
Thailand	18
Qatar	17
Serbia	17
Kenya	13
Iran	12
Chile	11
Lebanon	10
Bulgaria	9
Latvia	8
Mexico	8
Ukraine	7
Tanzania	7
Malta	6
Pakistan	6
Uruguay	6
Colombia	6
Vietnam	5
Tunisia	5
Uganda	5
Nigeria	5
Peru	5
Gambia	4
Kuwait	4
Liechtenstein	4
Gabon	4
Jordan	4
Philippines	4
Guinea	3
BELARUS	3
Georgia	3
Palestine	3
Slovakia	3
Mozambique	3
Sierra Leone	3
U Arab Emirates	3
Iraq	3
Malaysia	2
Monaco	2



<b>Country</b>	<b>Number of publications</b>
Bangladesh	2
Bosnia & Herceg	2
Guatemala	2
Oman	2
Ghana	2
Ethiopia	2
Sri Lanka	2
Malawi	2
Macedonia	2
Morocco	1
Algeria	1
Bolivia	1
Botswana	1
Burkina Faso	1
Burundi	1
Cambodia	1
Cameroon	1
Cook Islands	1
Cote Ivoire	1
DEM REP CONGO	1
Ecuador	1
Indonesia	1
Kazakhstan	1
Kosovo	1
Liberia	1
Libya	1
Mali	1
Moldova	1
Mongolia	1
Albania	1
Senegal	1
Uzbekistan	1
Zambia	1
Zimbabwe	1

**ANNEX 4: TOTAL NUMBER OF WEB OF SCIENCE  
PUBLICATIONS, PAPERS AND OPEN ACCESS PUBLICATIONS  
BETWEEN 2010 AND 2020 BY PROJECT**

<b>Project</b>	<b>Number of publications</b>	<b>Number of papers</b>	<b>Number of open access publications</b>	<b>% of open access publications</b>
BTCure	703	656	461	65.6%
EU-AIMS	503	488	378	75.1%
ULTRA-DD	379	371	295	77.8%
EMIF	300	279	229	76.3%
NEWMEDS	209	204	113	54.1%
CANCER-ID	193	167	136	70.5%
EUROPAIN	177	177	68	38.4%
ORBITO	168	165	47	28.0%
INNODIA	158	126	110	69.6%
TRANSLOCATION	152	152	90	59.2%
IMIDIA	149	139	120	80.5%
STEMBANCC	143	138	107	74.8%
U-BIOPRED	136	87	65	47.8%
SUMMIT	132	128	96	72.7%
CHEM21	130	127	61	46.9%
ELF	126	125	83	65.9%
PreDiCT-TB	118	112	101	85.6%
SPRINTT	113	106	63	55.8%
MIP-DILI	113	106	64	56.6%
AIMS-2-TRIALS	107	101	96	89.7%
DIRECT	105	79	66	62.9%
Quic-Concept	102	101	82	80.4%
PROTECT	101	99	42	41.6%
ABIRISK	97	76	48	49.5%
eTOX	97	92	64	66.0%
RTCure	94	87	79	84.0%
COMBACTE-MAGNET	91	81	68	74.7%
Pharma-Cog	89	83	35	39.3%
COMBACTE-NET	87	80	68	78.2%
COMPACT	87	87	42	48.3%
DDMoRe	81	76	52	64.2%
BEAT-DKD	78	73	65	83.3%
RHAPSODY	75	60	59	78.7%
Open PHACTS	73	70	63	86.3%
BigData@Heart	69	60	54	78.3%
BioVacSafe	69	66	51	73.9%
AETIONOMY	69	68	54	78.3%
None	68	50	37	54.4%
Onco Track	65	61	44	67.7%

Project	Number of publications	Number of papers	Number of open access publications	% of open access publications
K4DD	65	63	44	67.7%
PRECISESADS	64	44	36	56.3%
RADAR-CNS	64	42	31	48.4%
PRISM	58	49	44	75.9%
MARCAR	58	57	44	75.9%
DRIVE-AB	57	51	46	80.7%
ZAPI	53	50	52	98.1%
COMBACTE-CARE	52	48	44	84.6%
APPROACH	52	42	36	69.2%
eTRIKS	51	41	42	82.4%
IMPRiND	48	46	41	85.4%
Prelect	47	43	36	76.6%
ENABLE	47	47	40	85.1%
RAPP-ID	46	45	24	52.2%
GETREAL	41	35	31	75.6%
EPAD	39	35	25	64.1%
iPiE	38	37	24	63.2%
FLUCOP	37	36	29	78.4%
iABC	36	22	18	50.0%
PROACTIVE	32	27	25	78.1%
EBiSC	31	28	27	87.1%
RESCEU	31	29	27	87.1%
EBOVAC1	31	29	31	100.0%
TransQST	30	28	25	83.3%
PHAGO	29	29	28	96.6%
HARMONY	27	15	17	63.0%
AMYPAD	26	20	18	69.2%
ADVANCE	26	25	23	88.5%
EbolaMoDRAD	26	25	18	69.2%
ROADMAP	26	20	21	80.8%
LITMUS	26	21	17	65.4%
PREFER	23	14	18	78.3%
SAFE-T	22	20	6	27.3%
EHR4CR	21	19	13	61.9%
eTRANSafe	20	15	15	75.0%
EUBOPEN	20	20	13	65.0%
ADAPTED	20	18	18	90.0%
MOBILISE-D	18	16	10	55.6%
WEB-RADR	16	15	12	75.0%
COMBACTE	15	14	10	66.7%
EBOVAC2	15	15	15	100.0%
TRISTAN	15	15	14	93.3%
INNODIA HARVEST	14	11	11	78.6%
IMI-PainCare	14	9	4	28.6%

<b>Project</b>	<b>Number of publications</b>	<b>Number of papers</b>	<b>Number of open access publications</b>	<b>% of open access publications</b>
Hypo-RESOLVE	13	8	7	53.8%
CARDIATEAM	13	11	9	69.2%
DRIVE	12	11	10	83.3%
VSV-EBOPLUS	12	11	9	75.0%
EHDEN	11	8	7	63.6%
3TR	11	11	8	72.7%
VSV-EBOVAC	11	10	7	63.6%
EQUIPD	10	5	9	90.0%
BIOMAP	9	6	7	77.8%
VAC2VAC	9	9	8	88.9%
PERISCOPE	9	9	9	100.0%
RADAR-AD	8	5	5	62.5%
PD-MitoQUANT	8	8	7	87.5%
MACUSTAR	7	3	7	100.0%
EUPATI	7	6	7	100.0%
ITCC-P4	6	6	6	100.0%
DRAGON	5	5	5	100.0%
ReSOLUTE	5	4	5	100.0%
ERA4TB	5	5	5	100.0%
SafeSciMET	5	4	2	40.0%
EU-PEARL	4	2	3	75.0%
MOPEAD	4	4	4	100.0%
ADAPT-SMART	4	4	2	50.0%
TransBioLine	4	4	3	75.0%
SOPHIA	4	4	4	100.0%
c4c	4	2	2	50.0%
EBODAC	4	4	4	100.0%
FAIRplus	3	3	2	66.7%
ConcePTION	3	2	1	33.3%
PEVIA	3	2	3	100.0%
Eu2P	3	3	2	66.7%
DO->IT	3	3	3	100.0%
MAD-CoV 2	3	2	3	100.0%
COMBACTE-CDI	3	2	2	66.7%
VITAL	3	3	3	100.0%
CARE	2	1	2	100.0%
NECESSITY	2	2	1	50.0%
PIONEER	2	1	2	100.0%
EMTRAIN	2	1	0	0.0%
MELLODDY	2	1	0	0.0%
EBOMAN	2	2	2	100.0%
EBiSC2	2	2	2	100.0%
IMMUCAN	2	2	2	100.0%
ND4BB	2	2	2	100.0%

<b>Project</b>	<b>Number of publications</b>	<b>Number of papers</b>	<b>Number of open access publications</b>	<b>% of open access publications</b>
Immune-Image	2	2	1	50.0%
VHFMoDRAD	2	2	2	100.0%
EBOVAC3	1	1	1	100.0%
IDEA-FAST	1	1	1	100.0%
KRONO	1	1	1	100.0%
imSAVAR	1	0	0	0.0%
Pharmatrain	1	1	1	100.0%
PARADIGM	1	1	1	100.0%
FILODIAG	1	0	1	100.0%
VALUE-Dx	1	1	1	100.0%
NeuroDeRisk	1	1	1	100.0%
IM2PACT	1	1	0	0.0%
COVID-RED	1	1	1	100.0%
COMBINE	1	1	1	100.0%
EBOVAC	1	1	1	100.0%
NGN-PET	1	1	0	0.0%

## ANNEX 5: COLLABORATION INDEX FOR ALL IMI SUPPORTED RESEARCH PROJECTS

This Annex provides the calculation of the collaboration indicators for all IMI supported research projects with at least one paper. Collaboration index only calculated for projects with a Stability score and at least 20 papers.

Project	Cross-sector score	International score	Stability score	Collaboration Index	Total papers	Citation impact (field-normalised)
BTCure	0.64	0.51	0.83	1.98	656	1.85
EU-AIMS	0.73	0.65	0.80	2.18	488	2.03
ULTRA-DD	0.61	0.66	0.75	2.02	371	1.74
EMIF	0.81	0.66	0.84	2.31	279	2.66
NEWMEDS	0.63	0.57	0.81	2.01	204	2.16
EUROPAIN	0.54	0.37	0.84	1.75	177	2.48
CANCER-ID	0.74	0.43	0.75	1.92	167	3.27
ORBITO	0.62	0.47	0.76	1.85	165	1.84
TRANSLOCATION	0.37	0.49	0.80	1.66	152	1.39
IMIDIA	0.53	0.50	0.83	1.85	139	1.63
STEMBANCC	0.49	0.46	0.80	1.75	138	1.95
SUMMIT	0.76	0.63	0.82	2.21	128	1.53
CHEM21	0.24	0.29	0.79	1.31	127	1.75
INNODIA	0.83	0.67	0.88	2.38	126	1.63
ELF	0.33	0.52	0.73	1.58	125	1.15
PreDiCT-TB	0.54	0.48	0.79	1.81	112	1.22
SPRINTT	0.72	0.54	0.80	2.05	106	2.22
MIP-DILI	0.67	0.45	0.81	1.94	106	1.82
Quic-Concept	0.71	0.58	0.80	2.09	101	4.34
AIMS-2-TRIALS	0.75	0.70	0.68	2.13	101	1.88
PROTECT	0.97	0.63	0.86	2.46	99	1.08
eTOX	0.30	0.36	0.86	1.53	92	1.71
U-BIOPRED	0.82	0.70	0.86	2.38	87	2.57
COMPACT	0.22	0.45	0.71	1.39	87	1.86
RTCure	0.77	0.52	0.71	2.00	87	2.68
Pharma-Cog	0.84	0.74	0.85	2.44	83	1.19
COMBACTE-MAGNET	0.67	0.60	0.73	1.99	81	1.18
COMBACTE-NET	0.75	0.52	0.78	2.05	80	1.01
DIRECT	0.75	0.72	0.88	2.35	79	2.98
ABIRISK	0.76	0.48	0.86	2.10	76	1.32
DDMoRe	0.64	0.56	0.81	2.01	76	1.08
BEAT-DKD	0.71	0.74	0.61	2.05	73	1.46
Open PHACTS	0.60	0.55	0.76	1.92	70	3.47
AETIONOMY	0.65	0.44	0.78	1.87	68	1.71
BioVacSafe	0.44	0.47	0.81	1.72	66	1.27
K4DD	0.54	0.51	0.79	1.84	63	1.74

Project	Cross-sector score	International score	Stability score	Collaboration Index	Total papers	Citation impact (field-normalised)
Onco Track	0.64	0.43	0.83	1.90	61	2.30
BigData@Heart	0.92	0.68	0.56	2.16	60	1.53
RHAPSODY	0.53	0.64	0.83	2.00	60	2.10
MARCAR	0.44	0.42	0.82	1.68	57	1.08
DRIVE-AB	0.75	0.62	0.71	2.08	51	1.37
None	0.76	0.72	0.92	2.40	50	3.41
ZAPI	0.68	0.65	0.71	2.03	50	5.61
PRISM	0.73	0.66	0.66	2.05	49	2.14
COMBACTE-CARE	0.92	0.64	0.73	2.29	48	1.78
ENABLE	0.60	0.41	0.80	1.80	47	1.61
IMPRiND	0.63	0.54	0.76	1.93	46	6.47
RAPP-ID	0.33	0.43	0.89	1.65	45	0.88
PRECISESADS	0.77	0.77	0.69	2.23	44	1.23
Prelect	0.67	0.62	0.74	2.04	43	2.52
APPROACH	0.76	0.76	0.73	2.24	42	1.95
RADAR-CNS	0.60	0.76	0.76	2.11	42	1.64
eTRIKS	0.85	0.87	0.72	2.45	41	2.44
iPiE	0.54	0.25	0.71	1.50	37	1.32
FLUCOP	0.89	0.51	0.69	2.08	36	1.09
EPAD	0.71	0.64	0.73	2.08	35	1.01
GETREAL	0.89	0.77	0.74	2.39	35	1.82
PHAGO	0.66	0.60	0.71	1.97	29	3.34
RESCEU	0.90	0.77	0.71	2.38	29	2.00
EBOVAC1	0.69	0.64	0.72	2.04	29	1.93
EBiSC	0.71	0.64	0.75	2.11	28	7.64
TransQST	0.57	0.70	0.74	2.01	28	3.25
PROACTIVE	1.00	0.80	0.82	2.62	27	2.17
EbolaMoDRAD	0.68	0.52	0.65	1.85	25	1.45
ADVANCE	0.88	0.85	0.85	2.58	25	1.87
iABC	0.82	0.65	0.81	2.27	22	0.87
LITMUS	0.81	0.68	0.69	2.18	21	4.14
ROADMAP	0.90	0.72	0.68	2.30	20	0.90
EUbOPEN	0.65	0.53	#N/A	#N/A	20	0.45
AMYPAD	0.90	0.79	0.77	2.46	20	1.45
SAFE-T	0.95	0.53	0.85	2.32	20	1.88
EHR4CR	0.89	0.63	#N/A	#N/A	19	1.17
ADAPTED	0.94	0.67	#N/A	#N/A	18	2.34
MOBILISE-D	0.88	0.59	#N/A	#N/A	16	2.61
HARMONY	0.80	0.42	#N/A	#N/A	15	0.87
eTRANSafe	0.33	0.38	#N/A	#N/A	15	3.25
EBOVAC2	0.40	0.38	#N/A	#N/A	15	1.46
TRISTAN	0.80	0.58	#N/A	#N/A	15	1.17
WEB-RADR	0.73	0.73	#N/A	#N/A	15	1.80

Project	Cross-sector score	International score	Stability score	Collaboration Index	Total papers	Citation impact (field-normalised)
COMBACTE	0.50	0.13	#N/A	#N/A	14	2.78
PREFER	0.86	0.80	#N/A	#N/A	14	0.99
3TR	1.00	0.39	#N/A	#N/A	11	0.23
CARDIATEAM	1.00	0.95	#N/A	#N/A	11	0.89
DRIVE	0.82	0.23	#N/A	#N/A	11	1.23
INNODIA HARVEST	0.91	0.93	#N/A	#N/A	11	0.93
VSV-EBOPLUS	0.64	0.73	#N/A	#N/A	11	0.81
VSV-EBOVAC	0.50	0.60	#N/A	#N/A	10	1.00
IMI-PainCare	0.56	0.33	#N/A	#N/A	9	1.05
VAC2VAC	0.56	0.56	#N/A	#N/A	9	0.68
PERISCOPE	0.44	0.42	#N/A	#N/A	9	1.28
Hypo-RESOLVE	0.50	0.75	#N/A	#N/A	8	0.72
PD-MitoQUANT	0.88	0.38	#N/A	#N/A	8	2.33
EHDEN	0.75	0.81	#N/A	#N/A	8	1.13
BIOMAP	1.00	0.96	#N/A	#N/A	6	3.62
ITCC-P4	1.00	0.79	#N/A	#N/A	6	1.73
EUPATI	1.00	1.00	#N/A	#N/A	6	0.97
ERA4TB	0.60	0.50	#N/A	#N/A	5	0.81
RADAR-AD	0.80	0.40	#N/A	#N/A	5	0.77
DRAGON	1.00	0.90	#N/A	#N/A	5	1.40
EQIPD	0.60	0.70	#N/A	#N/A	5	2.72
MOPEAD	1.00	0.69	#N/A	#N/A	4	0.89
ADAPT-SMART	0.75	0.50	#N/A	#N/A	4	0.61
EBODAC	0.75	0.69	#N/A	#N/A	4	3.04
TransBioLine	0.75	0.25	#N/A	#N/A	4	0.18
ReSOLUTE	0.25	0.19	#N/A	#N/A	4	0.63
SafeSciMET	1.00	1.00	#N/A	#N/A	4	0.97
SOPHIA	0.75	0.69	#N/A	#N/A	4	1.54
FAIRplus	0.33	0.33	#N/A	#N/A	3	4.72
VITAL	0.33	0.58	#N/A	#N/A	3	0.76
DO->IT	1.00	0.83	#N/A	#N/A	3	1.32
Eu2P	0.33	0.67	#N/A	#N/A	3	1.95
MACUSTAR	0.67	0.67	#N/A	#N/A	3	1.67
MAD-CoV 2	0.50	0.88	#N/A	#N/A	2	0.29
ND4BB	0.50	0.88	#N/A	#N/A	2	1.85
NECESSITY	1.00	1.00	#N/A	#N/A	2	1.40
Immune-Image	1.00	0.75	#N/A	#N/A	2	0.97
IMMUCAN	0.50	0.50	#N/A	#N/A	2	1.24
PEVIA	1.00	0.88	#N/A	#N/A	2	0.92
EU-PEARL	1.00	0.50	#N/A	#N/A	2	4.17
EBOMAN	1.00	0.88	#N/A	#N/A	2	5.40
EBiSC2	1.00	0.88	#N/A	#N/A	2	1.60
ConcePTION	1.00	0.50	#N/A	#N/A	2	0.00



Project	Cross-sector score	International score	Stability score	Collaboration Index	Total papers	Citation impact (field-normalised)
COMBACTE-CDI	1.00	0.75	#N/A	#N/A	2	0.25
c4c	1.00	0.88	#N/A	#N/A	2	0.00
VHFMoDRAD	1.00	0.38	#N/A	#N/A	2	0.00
PIONEER	1.00	1.00	#N/A	#N/A	1	4.49
COVID-RED	1.00	1.00	#N/A	#N/A	1	0.00
Pharmatrain	1.00	1.00	#N/A	#N/A	1	0.09
KRONO	1.00	1.00	#N/A	#N/A	1	0.00
COMBINE	1.00	0.00	#N/A	#N/A	1	0.00
NGN-PET	0.00	0.00	#N/A	#N/A	1	1.02
CARE	1.00	0.00	#N/A	#N/A	1	23.03
NeuroDeRisk	1.00	1.00	#N/A	#N/A	1	0.00
IM2PACT	0.00	0.00	#N/A	#N/A	1	1.68
VALUE-Dx	1.00	1.00	#N/A	#N/A	1	0.67
MELLODDY	0.00	0.00	#N/A	#N/A	1	0.00
EBOVAC	1.00	1.00	#N/A	#N/A	1	3.53
EBOVAC3	0.00	1.00	#N/A	#N/A	1	0.20
PARADIGM	1.00	1.00	#N/A	#N/A	1	0.40
EMTRAIN	1.00	1.00	#N/A	#N/A	1	0.12
IDEA-FAST	0.00	0.75	#N/A	#N/A	1	0.79

## ANNEX 6: BIBLIOGRAPHY OF HOT PAPERS AND HIGHLY CITED PAPERS

This Annex provides bibliographic data for hot and highly cited papers. Hot papers are papers that receive citations soon after publication, relative to other papers of the same field and age. For the purpose of this report, highly cited papers have been defined as those articles and reviews which belong to the world's top decile of papers in that journal category and year of publication, when ranked by number of citations received. A percentage that is above 10 indicates above-average performance.

Papers are listed in ascending alphabetical order (project, first author) and unassigned papers, are listed at the end of each section.

This section lists papers that have been identified as current hot papers or that have been identified as highly cited in the IMI project publication dataset.

### HOT PAPERS ASSOCIATED WITH IMI PROJECTS

AIMS-2-TRIALS: Moreno, Carmen et al. How mental health care should change as a consequence of the COVID-19 pandemic, *LANCET PSYCHIAT* (2020) 7: 813-824

CANCER-ID: Pantel, Klaus et al. Liquid biopsy and minimal residual disease - latest advances and implications for cure, *NAT REV CLIN ONCOL* (2019) 16: 409-424

eTRANSafe: Pinero, Janet et al. The DisGeNET knowledge platform for disease genomics: 2019 update, *NUCLEIC ACIDS RES* (2020) 48: D845-D855

IMPRiND: Zhang, Wenjuan et al. Novel tau filament fold in corticobasal degeneration, *NATURE* (2020) 580: 283-+

PHAGO: Meinhardt, Jenny et al. Olfactory transmucosal SARS-CoV-2 invasion as a port of central nervous system entry in individuals with COVID-19, *NAT NEUROSCI* (2020) 24: 168-+

PRISM: Moreno, Carmen et al. How mental health care should change as a consequence of the COVID-19 pandemic, *LANCET PSYCHIAT* (2020) 7: 813-824

RTCure: Cossarizza, Andrea et al. Guidelines for the use of flow cytometry and cell sorting in immunological studies (second edition), *EUR J IMMUNOL* (2019) 49: 1457-1973

RTCure: Nemeth, Tamas et al. Neutrophils as emerging therapeutic targets, *NAT REV DRUG DISCOV* (2020) 19: 253-275

TransQST: Pinero, Janet et al. The DisGeNET knowledge platform for disease genomics: 2019 update, *NUCLEIC ACIDS RES* (2020) 48: D845-D855

ULTRA-DD: Douangamath, Alice et al. Crystallographic and electrophilic fragment screening of the SARS-CoV-2 main protease, *NAT COMMUN* (2020) 11:

ULTRA-DD: Schapira, Matthieu et al. Targeted protein degradation: expanding the toolbox, *NAT REV DRUG DISCOV* (2019) 18: 949-963

ZAPI: Okba, Nisreen M. A. et al. Severe Acute Respiratory Syndrome Coronavirus 2-Specific Antibody Responses in Coronavirus Disease Patients, *EMERG INFECT DIS* (2020) 26: 1478-1488

## HIGHLY CITED PAPERS ASSOCIATED WITH IMI PROJECTS

This section lists papers that perform above average as defined by citation counts in the 10<sup>th</sup> percentile. There are 1788 papers in total.

ABIRISK: Cassotta, Antonino et al. A single T cell epitope drives the neutralizing anti-drug antibody response to natalizumab in multiple sclerosis patients, *NAT MED* (2019) 25: 1402-+

ABIRISK: Diebold, Martin et al. Dimethyl fumarate influences innate and adaptive immunity in multiple sclerosis, *J AUTOIMMUN* (2018) 86: 39-50

ABIRISK: Hemmer, Bernhard et al. Role of the innate and adaptive immune responses in the course of multiple sclerosis, *LANCET NEUROL* (2015) 14: 406-419

ABIRISK: Kieseier, Bernd C. et al. Disease Amelioration With Tocilizumab in a Treatment-Resistant Patient With Neuromyelitis Optica Implication for Cellular Immune Responses, *JAMA NEUROL* (2013) 70: 390-393

ABIRISK: Quistrebert, Jocelyn et al. Incidence and risk factors for adalimumab and infliximab anti-drug antibodies in rheumatoid arthritis: A European retrospective multicohort analysis, *SEMIN ARTHRITIS RHEU* (2019) 48: 967-975

ABIRISK: Ringelstein, Marius et al. Long-term Therapy With Interleukin 6 Receptor Blockade in Highly Active Neuromyelitis Optica Spectrum Disorder, *JAMA NEUROL* (2015) 72: 756-763

ABIRISK: Rup, B. et al. Standardizing terms, definitions and concepts for describing and interpreting unwanted immunogenicity of biopharmaceuticals: recommendations of the Innovative Medicines Initiative ABIRISK consortium, *CLIN EXP IMMUNOL* (2015) 181: 385-400

ABIRISK: Shankar, G. et al. Assessment and Reporting of the Clinical Immunogenicity of Therapeutic Proteins and Peptides-Harmonized Terminology and Tactical Recommendations, *AAPS J* (2014) 16: 658-673

ABIRISK: Ungar, Bella et al. The temporal evolution of antidrug antibodies in patients with inflammatory bowel disease treated with infliximab, *GUT* (2014) 63: 1258-1264

ABIRISK: Warnke, Clemens et al. Cerebrospinal Fluid JC Virus Antibody Index for Diagnosis of Natalizumab-Associated Progressive Multifocal Leukoencephalopathy, *ANN NEUROL* (2014) 76: 792-801

ABIRISK: Warnke, Clemens et al. Changes to anti-JCV antibody levels in a Swedish national MS cohort, *J NEUROL NEUROSUR PS* (2013) 84: 1199-1205

ABIRISK: Warnke, Clemens et al. Natalizumab exerts a suppressive effect on surrogates of B cell function in blood and CSF, *MULT SCLER J* (2015) 21: 1036-1044

ABIRISK: Wenniger, Lucas J. Maillette de Buy et al. Immunoglobulin G4+clones identified by next-generation sequencing dominate the B cell receptor repertoire in immunoglobulin G4 associated cholangitis, *HEPATOLOGY* (2013) 57: 2390-2398

ADAPTED: Ahmad, Shahzad et al. Disentangling the biological pathways involved in early features of Alzheimers disease in the Rotterdam Study, *ALZHEIMERS DEMENT* (2018) 14: 848-857

ADAPTED: Moreno-Grau, Sonia et al. Genome-wide association analysis of dementia and its clinical endophenotypes reveal novel loci associated with Alzheimers disease and three causality networks: The GR@ACE project, *ALZHEIMERS DEMENT* (2019) 15: 1333-1347

ADAPTED: Tynkkynen, Juho et al. Association of branched-chain amino acids and other circulating metabolites with risk of incident dementia and Alzheimers disease: A prospective study in eight cohorts, *ALZHEIMERS DEMENT* (2018) 14: 723-733

ADAPTED: van der Lee, Sven J. et al. A nonsynonymous mutation in PLCG2 reduces the risk of Alzheimers disease, dementia with Lewy bodies and frontotemporal dementia, and increases the likelihood of longevity, ACTA NEUROPATHOL (2019) 138: 237-250

ADAPTED: van der Lee, Sven J. et al. Circulating metabolites and general cognitive ability and dementia: Evidence from 11 cohort studies, ALZHEIMERS DEMENT (2018) 14: 707-722

ADAPTED: van der Lee, Sven J. et al. The effect of &ITAPOE&IT and other common genetic variants on the onset of Alzheimers disease and dementia: a community-based cohort study, LANCET NEUROL (2018) 17: 434-444

ADAPTED: Wevers, Nienke R. et al. A perfused human blood-brain barrier on-a-chip for high-throughput assessment of barrier function and antibody transport, FLUIDS BARRIERS CNS (2018) 15:

ADVANCE: Bollaerts, Kaatje et al. ADVANCE system testing: Benefit-risk analysis of a marketed vaccine using multi-criteria decision analysis and individual-level state transition modelling, VACCINE (2020) 38: B65-B75

ADVANCE: Bollaerts, Kaatje et al. Disease misclassification in electronic healthcare database studies: Deriving validity indices-A contribution from the ADVANCE project, PLOS ONE (2020) 15:

ADVANCE: Emborg, Hanne-Dorthe et al. ADVANCE system testing: Can coverage of pertussis vaccination be estimated in European countries using electronic healthcare databases: An example, VACCINE (2020) 38: B22-B30

ADVANCE: Gini, Rosa et al. Quantifying outcome misclassification in multi-database studies: The case study of pertussis in the ADVANCE project, VACCINE (2020) 38: B56-B64

ADVANCE: Karafillakis, Emilie et al. The benefit of the doubt or doubts over benefits? A systematic literature review of perceived risks of vaccines in European populations, VACCINE (2017) 35: 4840-4850

ADVANCE: Lehtinen, Matti et al. Impact of gender-neutral or girls-only vaccination against human papillomavirus-Results of a community-randomized clinical trial (I), INT J CANCER (2018) 142: 949-958

ADVANCE: Pebody, R. et al. Effectiveness of seasonal influenza vaccine for adults and children in preventing laboratory-confirmed influenza in primary care in the United Kingdom: 2015/16 end-of-season results, EUROSURVEILLANCE (2016) 21: 41-51

ADVANCE: Sturkenboom, Miriam et al. ADVANCE database characterisation and fit for purpose assessment for multi-country studies on the coverage, benefits and risks of pertussis vaccinations, VACCINE (2020) 38: B8-B21

ADVANCE: Sturkenboom, Miriam et al. Why we need more collaboration in Europe to enhance post-marketing surveillance of vaccines, VACCINE (2020) 38: B1-B7

ADVANCE: Weibel, Daniel et al. ADVANCE system testing: Can safety studies be conducted using electronic healthcare data? An example using pertussis vaccination, VACCINE (2020) 38: B38-B46

AETIONOMY: Aarestrup, F. M. et al. Towards a European health research and innovation cloud (HRIC), GENOME MED (2020) 12:

AETIONOMY: Antonell, Anna et al. Synaptic, axonal damage and inflammatory cerebrospinal fluid biomarkers in neurodegenerative dementias, ALZHEIMERS DEMENT (2020) 16: 262-272

AETIONOMY: Auffray, Charles et al. Making sense of big data in health research: Towards an EU action plan, GENOME MED (2016) 8:

AETIONOMY: Bedarf, J. R. et al. Functional implications of microbial and viral gut metagenome changes in early stage L-DOPA-naive Parkinsons disease patients, GENOME MED (2017) 9:

AETIONOMY: Bonello, Fiona et al. LRRK2 impairs PINK1/Parkin-dependent mitophagy via its kinase activity: pathologic insights into Parkinsons disease, *HUM MOL GENET* (2019) 28: 1645-1660

AETIONOMY: Brosseron, Frederic et al. Characterization and clinical use of inflammatory cerebrospinal fluid protein markers in Alzheimers disease, *ALZHEIMERS RES THER* (2018) 10:

AETIONOMY: Brosseron, Frederic et al. Multicenter Alzheimers and Parkinsons disease immune biomarker verification study, *ALZHEIMERS DEMENT* (2020) 16: 292-304

AETIONOMY: Corti, Olga et al. Autophagy in neurodegeneration: New insights underpinning therapy for neurological diseases, *J NEUROCHEM* (2020) 154: 354-371

AETIONOMY: Crous-Bou, Marta et al. Alzheimers disease prevention: from risk factors to early intervention, *ALZHEIMERS RES THER* (2017) 9:

AETIONOMY: Domingo Gispert, Juan et al. Cerebrospinal fluid sTREM2 levels are associated with gray matter volume increases and reduced diffusivity in early Alzheimers disease, *ALZHEIMERS DEMENT* (2016) 12: 1259-1272

AETIONOMY: Froehlich, Holger et al. From hype to reality: data science enabling personalized medicine, *BMC MED* (2018) 16:

AETIONOMY: Gautier, Clement A. et al. The endoplasmic reticulum-mitochondria interface is perturbed in PARK2 knockout mice and patients with PARK2 mutations, *HUM MOL GENET* (2016) 25: 2972-2984

AETIONOMY: McWilliams, Thomas G. et al. Phosphorylation of Parkin at serine 65 is essential for its activation in vivo, *OPEN BIOL* (2018) 8:

AETIONOMY: Mouton-Liger, Francois et al. Parkin deficiency modulates NLRP3 inflammasome activation by attenuating an A20-dependent negative feedback loop, *GLIA* (2018) 66: 1736-1751

AETIONOMY: Mouton-Ligeri, Francois et al. PINK1/Parkin-Dependent Mitochondrial Surveillance: From Pleiotropy to Parkinsons Disease, *FRONT MOL NEUROSCI* (2017) 10:

AIMS-2-TRIALS: Bolte, Sven et al. The contribution of environmental exposure to the etiology of autism spectrum disorder, *CELL MOL LIFE SCI* (2019) 76: 1275-1297

AIMS-2-TRIALS: Ching, Christopher R. K. et al. Mapping Subcortical Brain Alterations in 22q11.2 Deletion Syndrome: Effects of Deletion Size and Convergence With Idiopathic Neuropsychiatric Illness, *AM J PSYCHIAT* (2020) 177: 589-600

AIMS-2-TRIALS: Cursano, Silvia et al. A CRHR1 antagonist prevents synaptic loss and memory deficits in a trauma-induced delirium-like syndrome, *MOL PSYCHIATR* (2020) :

AIMS-2-TRIALS: de Pablo, Gonzalo Salazar et al. Impact of coronavirus syndromes on physical and mental health of health care workers: Systematic review and meta-analysis, *J AFFECT DISORDERS* (2020) 275: 48-57

AIMS-2-TRIALS: Greenberg, David M. et al. Testing the Empathizing-Systemizing theory of sex differences and the Extreme Male Brain theory of autism in half a million people, *P NATL ACAD SCI USA* (2018) 115: 12152-12157

AIMS-2-TRIALS: Greven, Corina U. et al. Sensory Processing Sensitivity in the context of Environmental Sensitivity: A critical review and development of research agenda, *NEUROSCI BIOBEHAV R* (2019) 98: 287-305

AIMS-2-TRIALS: Holiga, Stefan et al. Patients with autism spectrum disorders display reproducible functional connectivity alterations, *SCI TRANSL MED* (2019) 11:

AIMS-2-TRIALS: Lombardo, Michael, V et al. Big data approaches to decomposing heterogeneity across the autism spectrum, *MOL PSYCHIATR* (2019) 24: 1435-1450

AIMS-2-TRIALS: Lord, Catherine et al. Autism spectrum disorder, *NAT REV DIS PRIMERS* (2020) 6:

AIMS-2-TRIALS: Martinez, Kenia et al. Sensory-to-Cognitive Systems Integration Is Associated With Clinical Severity in Autism Spectrum Disorder, *J AM ACAD CHILD PSY* (2020) 59: 422-433

AIMS-2-TRIALS: Moessnang, Carolin et al. Social brain activation during mentalizing in a large autism cohort: the Longitudinal European Autism Project, *MOL AUTISM* (2020) 11:

AIMS-2-TRIALS: Moreno, Carmen et al. How mental health care should change as a consequence of the COVID-19 pandemic, *LANCET PSYCHIAT* (2020) 7: 813-824

AIMS-2-TRIALS: Nystrom, Par et al. Joint Attention in Infancy and the Emergence of Autism, *BIOL PSYCHIAT* (2019) 86: 631-638

AIMS-2-TRIALS: Oldehinkel, Marianne et al. Altered Connectivity Between Cerebellum, Visual, and Sensory-Motor Networks in Autism Spectrum Disorder: Results from the EU-AIMS Longitudinal European Autism Project, *BIOL PSYCHIAT-COGN N* (2019) 4: 260-270

AIMS-2-TRIALS: Postema, Merel C. et al. Altered structural brain asymmetry in autism spectrum disorder in a study of 54 datasets, *NAT COMMUN* (2019) 10:

AIMS-2-TRIALS: Pretzsch, Charlotte Marie et al. Effects of cannabidiol on brain excitation and inhibition systems, a randomised placebo-controlled single dose trial during magnetic resonance spectroscopy in adults with and without autism spectrum disorder, *NEUROPSYCHOPHARMACOL* (2019) 44: 1398-1405

AIMS-2-TRIALS: van Kessel, Robin et al. Autism and education-Teacher policy in Europe: Policy mapping of Austria, Hungary, Slovakia and Czech Republic, *RES DEV DISABIL* (2020) 105:

AMYPAD: Collij, Lyduine E. et al. Assessing Amyloid Pathology in Cognitively Normal Subjects Using F-18-Flutemetamol PET: Comparing Visual Reads and Quantitative Methods, *J NUCL MED* (2019) 60: 541-547

AMYPAD: Crous-Bou, Marta et al. Alzheimers disease prevention: from risk factors to early intervention, *ALZHEIMERS RES THER* (2017) 9:

AMYPAD: Fantoni, Enrico et al. The Spatial-Temporal Ordering of Amyloid Pathology and Opportunities for PET Imaging, *J NUCL MED* (2020) 61: 166-171

AMYPAD: Tur, Carmen et al. Assessing treatment outcomes in multiple sclerosis trials and in the clinical setting, *NAT REV NEUROL* (2018) 14: 75-93

APPROACH: Fellows, Christopher R. et al. Adipose, Bone Marrow and Synovial Joint-Derived Mesenchymal Stem Cells for Cartilage Repair, *FRONT GENET* (2016) 7:

APPROACH: Francisco, Vera et al. Adipokines and inflammation: is it a question of weight?, *BRIT J PHARMACOL* (2018) 175: 1569-1579

APPROACH: Guan, Vivienne X. et al. A systematic review of osteoarthritis prevention and management with dietary phytochemicals from foods, *MATURITAS* (2019) 122: 35-43

APPROACH: Henrotin, Y. et al. Osteoarthritis biomarkers derived from cartilage extracellular matrix: Current status and future perspectives, *ANN PHYS REHABIL MED* (2016) 59: 145-148

APPROACH: Lewis, Rebecca et al. Strategies for optimising musculoskeletal health in the 21st century, *BMC MUSCULOSKEL DIS* (2019) 20:

APPROACH: Mobasheri, A. et al. Osteoarthritis Year in Review 2016: biomarkers (biochemical markers), *OSTEOARTHR CARTILAGE* (2017) 25: 199-208

APPROACH: Mobasheri, Ali et al. An update on the pathophysiology of osteoarthritis, *ANN PHYS REHABIL MED* (2016) 59: 333-339

APPROACH: Mobasheri, Ali et al. Molecular taxonomy of osteoarthritis for patient stratification, disease management and drug development: biochemical markers associated with emerging clinical phenotypes and molecular endotypes, *CURR OPIN RHEUMATOL* (2019) 31: 80-89

APPROACH: Mobasheri, Ali et al. The role of metabolism in the pathogenesis of osteoarthritis, *NAT REV RHEUMATOL* (2017) 13: 302-311

APPROACH: Musumeci, Giuseppe et al. Biomarkers of Chondrocyte Apoptosis and Autophagy in Osteoarthritis, *INT J MOL SCI* (2015) 16: 20560-20575

APPROACH: Rahmati, Maryam et al. Aging and osteoarthritis: Central role of the extracellular matrix, *AGEING RES REV* (2017) 40: 20-30

APPROACH: Rahmati, Maryam et al. Inflammatory mediators in osteoarthritis: A critical review of the state-of-the-art, current prospects, and future challenges, *BONE* (2016) 85: 81-90

APPROACH: Richardson, Stephen M. et al. Mesenchymal stem cells in regenerative medicine: Focus on articular cartilage and intervertebral disc regeneration, *METHODS* (2016) 99: 69-80

APPROACH: Sanchez, C. et al. Chondrocyte secretome: a source of novel insights and exploratory biomarkers of osteoarthritis, *OSTEOARTHR CARTILAGE* (2017) 25: 1199-1209

APPROACH: Szychlinska, M. A. et al. Altered joint tribology in osteoarthritis: Reduced lubricin synthesis due to the inflammatory process. New horizons for therapeutic approaches, *ANN PHYS REHABIL MED* (2016) 59: 149-156

APPROACH: Thomas, Sally et al. What is the evidence for a role for diet and nutrition in osteoarthritis?, *RHEUMATOLOGY* (2018) 57: 61-74

APPROACH: Van Spil, Willem Evert et al. Osteoarthritis phenotypes and novel therapeutic targets, *BIOCHEM PHARMACOL* (2019) 165: 41-48

BEAT-DKD: Anders, Hans-Joachim et al. CKD in diabetes: diabetic kidney disease versus nondiabetic kidney disease, *NAT REV NEPHROL* (2018) 14: 361-377

BEAT-DKD: Brinkkoetter, Paul T. et al. Anaerobic Glycolysis Maintains the Glomerular Filtration Barrier Independent of Mitochondrial Metabolism and Dynamics, *CELL REP* (2019) 27: 1551-+

BEAT-DKD: Conserva, Francesca et al. Urinary miRNA-27b-3p and miRNA-1228-3p correlate with the progression of Kidney Fibrosis in Diabetic Nephropathy, *SCI REP-UK* (2019) 9:

BEAT-DKD: Henique, Carole et al. Genetic and pharmacological inhibition of microRNA-92a maintains podocyte cell cycle quiescence and limits crescentic glomerulonephritis, *NAT COMMUN* (2017) 8:

BEAT-DKD: Hoehne, Martin et al. Single-nephron proteomes connect morphology and function in proteinuric kidney disease, *KIDNEY INT* (2018) 93: 1308-1319

BEAT-DKD: Ljimini, Alexandra et al. Consensus-based technical recommendations for clinical translation of renal diffusion-weighted MRI, *MAGN RESON MATER PHY* (2019) 33: 177-195

BEAT-DKD: Mendichovszky, Iosif et al. Technical recommendations for clinical translation of renal MRI: a consensus project of the Cooperation in Science and Technology Action PARENCHIMA, *MAGN RESON MATER PHY* (2019) 33: 131-140

BEAT-DKD: Meyer-Schwesinger, Catherine et al. A novel mouse model of phospholipase A2 receptor 1-associated membranous nephropathy mimics podocyte injury in patients, *KIDNEY INT* (2020) 97: 913-919

BEAT-DKD: Ramnath, Raina D. et al. Blocking matrix metalloproteinase-mediated syndecan-4 shedding restores the endothelial glycocalyx and glomerular filtration barrier function in early diabetic kidney disease, *KIDNEY INT* (2020) 97: 951-965

BEAT-DKD: Rinschen, Markus M. et al. YAP-mediated mechanotransduction determines the podocytes response to damage, *SCI SIGNAL* (2017) 10:

BEAT-DKD: Schell, Christoph et al. The Evolving Complexity of the Podocyte Cytoskeleton, *J AM SOC NEPHROL* (2017) 28: 3166-3174

BEAT-DKD: Viau, Amandine et al. Cilia-localized LKB1 regulates chemokine signaling, macrophage recruitment, and tissue homeostasis in the kidney, *EMBO J* (2018) 37:

BEAT-DKD: Wanner, Nicola et al. DNA Methyltransferase 1 Controls Nephron Progenitor Cell Renewal and Differentiation, *J AM SOC NEPHROL* (2019) 30: 63-78

BEAT-DKD: Wolf, Marcos et al. Magnetic resonance imaging T-1- and T-2-mapping to assess renal structure and function: a systematic review and statement paper, *NEPHROL DIAL TRANSPL* (2018) 33: II41-II50

BEAT-DKD: Zschiedrich, Stefan et al. Targeting mTOR Signaling Can Prevent the Progression of FSGS, *J AM SOC NEPHROL* (2017) 28: 2144-2157

BigData@Heart: Bean, Daniel M. et al. Angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers are not associated with severe COVID-19 infection in a multi-site UK acute hospital trust, *EUR J HEART FAIL* (2020) 22: 967-974

BigData@Heart: Denaxas, Spiros et al. UK phenomics platform for developing and validating electronic health record phenotypes: CALIBER, *J AM MED INFORM ASSN* (2019) 26: 1545-1559

BigData@Heart: DeSalvo, Daniel J. et al. Continuous glucose monitoring and glycemic control among youth with type 1 diabetes: International comparison from the T1D Exchange and DPV Initiative, *PEDIATR DIABETES* (2018) 19: 1271-1275

BigData@Heart: Hemingway, Harry et al. Big data from electronic health records for early and late translational cardiovascular research: challenges and potential, *EUR HEART J* (2018) 39: 1481-+

BigData@Heart: Schrage, Benedikt et al. Association Between Use of Primary-Prevention Implantable Cardioverter-Defibrillators and Mortality in Patients With Heart Failure A Prospective Propensity Score-Matched Analysis From the Swedish Heart Failure Registry, *CIRCULATION* (2019) 140: 1530-1539

BigData@Heart: Seligman, William H. et al. Development of an international standard set of outcome measures for patients with atrial fibrillation: a report of the International Consortium for Health Outcomes Measurement (ICHOM) atrial fibrillation working group, *EUR HEART J* (2020) 41: 1132-1140

BigData@Heart: van Ouwkerk, Antoinette F. et al. Epigenetic and Transcriptional Networks Underlying Atrial Fibrillation, *CIRC RES* (2020) 127: 34-50

BigData@Heart: Vollmer, Sebastian et al. Machine learning and artificial intelligence research for patient benefit: 20 critical questions on transparency, replicability, ethics, and effectiveness, *BMJ-BRIT MED J* (2020) 368:

BigData@Heart: Willems, Stephan et al. Cabins, castles, and constant hearts: rhythm control therapy in patients with atrial fibrillation, *EUR HEART J* (2019) 40: 3793-+

BIOMAP: Fyhrquist, Nanna et al. Microbe-host interplay in atopic dermatitis and psoriasis, *NAT COMMUN* (2019) 10:

BIOMAP: Langan, Sinead M. et al. Atopic dermatitis, *LANCET* (2020) 396: 345-360

BIOMAP: Tsoi, Lam C. et al. Progression of acute-to-chronic atopic dermatitis is associated with quantitative rather than qualitative changes in cytokine responses, *J ALLERGY CLIN IMMUN* (2020) 145: 1406-1415

BioVacSafe: Andersen, Peter et al. Novel Vaccination Strategies against Tuberculosis, *CSH PERSPECT MED* (2014) 4:



BioVacSafe: Andersen, Peter et al. Tuberculosis vaccines - rethinking the current paradigm, *TRENDS IMMUNOL* (2014) 35: 387-395

BioVacSafe: Cliff, Jacqueline M. et al. The human immune response to tuberculosis and its treatment: a view from the blood, *IMMUNOL REV* (2015) 264: 88-102

BioVacSafe: Gao, Yong et al. Advances in HIV-1 Vaccine Development, *VIRUSES-BASEL* (2018) 10:

BioVacSafe: Kaufmann, Stefan H. E. et al. Host-directed therapies for bacterial and viral infections, *NAT REV DRUG DISCOV* (2018) 17: 35-56

BioVacSafe: Kaufmann, Stefan H. E. et al. Molecular Determinants in Phagocyte-Bacteria Interactions, *IMMUNITY* (2016) 44: 476-491

BioVacSafe: Kaufmann, Stefan H. E. et al. Progress in tuberculosis vaccine development and host-directed therapies-a state of the art review, *LANCET RESP MED* (2014) 2: 301-320

BioVacSafe: Kaufmann, Stefan H. E. et al. Tuberculosis vaccines: Time to think about the next generation, *SEMIN IMMUNOL* (2013) 25: 172-181

BioVacSafe: Olafsdottir, Thorunn et al. Molecular signatures of vaccine adjuvants, *VACCINE* (2015) 33: 5302-5307

BioVacSafe: Rappuoli, Rino et al. Vaccines, new opportunities for a new society, *P NATL ACAD SCI USA* (2014) 111: 12288-12293

BioVacSafe: Tricot, Sabine et al. Evaluating the Efficiency of Isotope Transmission for Improved Panel Design and a Comparison of the Detection Sensitivities of Mass Cytometer Instruments, *CYTOM PART A* (2015) 87A: 357-368

BioVacSafe: Weiner, J., III et al. Recent advances towards tuberculosis control: vaccines and biomarkers, *J INTERN MED* (2014) 275: 467-480

BioVacSafe: Zyla, Joanna et al. Gene set enrichment for reproducible science: comparison of CERNO and eight other algorithms, *BIOINFORMATICS* (2019) 35: 5146-5154

BTCure: Ajeganova, S. et al. The association between anti-carbamylated protein (anti-CarP) antibodies and radiographic progression in early rheumatoid arthritis: a study exploring replication and the added value to ACPA and rheumatoid factor, *ANN RHEUM DIS* (2017) 76: 112-118

BTCure: Akhmetshina, Alfiya et al. Activation of canonical Wnt signalling is required for TGF-beta-mediated fibrosis, *NAT COMMUN* (2012) 3:

BTCure: Alissafi, Themis et al. Tregs restrain dendritic cell autophagy to ameliorate autoimmunity, *J CLIN INVEST* (2017) 127: 2789-2804

BTCure: Amara, Khaled et al. Monoclonal IgG antibodies generated from joint-derived B cells of RA patients have a strong bias toward citrullinated autoantigen recognition, *J EXP MED* (2013) 210: 445-455

BTCure: Araujo, Elizabeth G. et al. Tophus resolution with pegloticase: a prospective dual-energy CT study, *RMD OPEN* (2015) 1:

BTCure: Arbore, Giuseppina et al. A novel complement-metabolism-inflammasome axis as a key regulator of immune cell effector function, *EUR J IMMUNOL* (2016) 46: 1563-1573

BTCure: Arbore, Giuseppina et al. Intracellular complement - the complosome - in immune cell regulation, *MOL IMMUNOL* (2017) 89: 2-9

BTCure: Arntz, Onno J. et al. Oral administration of bovine milk derived extracellular vesicles attenuates arthritis in two mouse models, *MOL NUTR FOOD RES* (2015) 59: 1701-1712

BTCure: Bozec, Aline et al. T Cell Costimulation Molecules CD80/86 Inhibit Osteoclast Differentiation by Inducing the IDO/Tryptophan Pathway, *SCI TRANSL MED* (2014) 6:

BTCure: Brink, Mikael et al. Multiplex Analyses of Antibodies Against Citrullinated Peptides in Individuals Prior to Development of Rheumatoid Arthritis, *ARTHRITIS RHEUM-US* (2013) 65: 899-910

BTCure: Budin-Ljosne, Isabelle et al. Dynamic Consent: a potential solution to some of the challenges of modern biomedical research, *BMC MED ETHICS* (2017) 18:

BTCure: Burja, Blaz et al. Olive Leaf Extract Attenuates Inflammatory Activation and DNA Damage in Human Arterial Endothelial Cells, *FRONT CARDIOVASC MED* (2019) 6:

BTCure: Burska, Agata et al. Cytokines as Biomarkers in Rheumatoid Arthritis, *MEDIAT INFLAMM* (2014) 2014:

BTCure: Campbell, T. Mark et al. Mesenchymal Stem Cell Alterations in Bone Marrow Lesions in Patients With Hip Osteoarthritis, *ARTHRITIS RHEUMATOL* (2016) 68: 1648-1659

BTCure: Catrina, Anca I. et al. Lungs, joints and immunity against citrullinated proteins in rheumatoid arthritis, *NAT REV RHEUMATOL* (2014) 10: 645-653

BTCure: Catrina, Anca I. et al. Mechanisms involved in triggering rheumatoid arthritis, *IMMUNOL REV* (2016) 269: 162-174

BTCure: Catrina, Anca I. et al. Mechanisms leading from systemic autoimmunity to joint-specific disease in rheumatoid arthritis, *NAT REV RHEUMATOL* (2017) 13: 79-86

BTCure: Chen, Zhu et al. Th2 and eosinophil responses suppress inflammatory arthritis, *NAT COMMUN* (2016) 7:

BTCure: Choi, Ivy Y. et al. MRP8/14 serum levels as a strong predictor of response to biological treatments in patients with rheumatoid arthritis, *ANN RHEUM DIS* (2015) 74: 499-505

BTCure: Cope, Andrew et al. The Th1 life cycle: molecular control of IFN-gamma to IL-10 switching, *TRENDS IMMUNOL* (2011) 32: 278-286

BTCure: Cui, Jing et al. Genome-Wide Association Study and Gene Expression Analysis Identifies CD84 as a Predictor of Response to Etanercept Therapy in Rheumatoid Arthritis, *PLOS GENET* (2013) 9:

BTCure: DAlessio, Silvia et al. VEGF-C-dependent stimulation of lymphatic function ameliorates experimental inflammatory bowel disease, *J CLIN INVEST* (2014) 124: 3863-3878

BTCure: Danks, Lynett et al. RANKL expressed on synovial fibroblasts is primarily responsible for bone erosions during joint inflammation, *ANN RHEUM DIS* (2016) 75: 1187-1195

BTCure: de Aquino, Sabrina G. et al. Periodontal Pathogens Directly Promote Autoimmune Experimental Arthritis by Inducing a TLR2-and IL-1-Driven Th17 Response, *J IMMUNOL* (2014) 192: 4103-4111

BTCure: de Hair, M. J. H. et al. Features of the Synovium of Individuals at Risk of Developing Rheumatoid Arthritis, *ARTHRITIS RHEUMATOL* (2014) 66: 513-522

BTCure: de Hair, Maria J. H. et al. Smoking and overweight determine the likelihood of developing rheumatoid arthritis, *ANN RHEUM DIS* (2013) 72: 1654-1658

BTCure: de Lange-Brokaar, B. J. E. et al. Characterization of synovial mast cells in knee osteoarthritis: association with clinical parameters, *OSTEOARTHR CARTILAGE* (2016) 24: 664-671

BTCure: Doorenspleet, M. E. et al. Rheumatoid arthritis synovial tissue harbours dominant B-cell and plasma-cell clones associated with autoreactivity, *ANN RHEUM DIS* (2014) 73: 756-762

BTCure: Evans, Hayley G. et al. TNF-alpha blockade induces IL-10 expression in human CD4+T cells, NAT COMMUN (2014) 5:

BTCure: Faustini, Francesca et al. Subclinical joint inflammation in patients with psoriasis without concomitant psoriatic arthritis: a cross-sectional and longitudinal analysis, ANN RHEUM DIS (2016) 75: 2068-2074

BTCure: Finzel, Stephanie et al. Interleukin-6 receptor blockade induces limited repair of bone erosions in rheumatoid arthritis: a micro CT study, ANN RHEUM DIS (2013) 72: 396-400

BTCure: Finzel, Stephanie et al. Repair of bone erosions in rheumatoid arthritis treated with tumour necrosis factor inhibitors is based on bone apposition at the base of the erosion, ANN RHEUM DIS (2011) 70: 1587-1593

BTCure: Frangou, Eleni et al. REDD1/autophagy pathway promotes thromboinflammation and fibrosis in human systemic lupus erythematosus (SLE) through NETs decorated with tissue factor (TF) and interleukin-17A (IL-17A), ANN RHEUM DIS (2019) 78: 238-248

BTCure: Frank-Bertoncelj, Mojca et al. Epigenetically-driven anatomical diversity of synovial fibroblasts guides joint-specific fibroblast functions, NAT COMMUN (2017) 8:

BTCure: Freeley, Simon et al. The ins and outs of complement-driven immune responses, IMMUNOL REV (2016) 274: 16-32

BTCure: Frey, Silke et al. The novel cytokine interleukin-36 alpha is expressed in psoriatic and rheumatoid arthritis synovium, ANN RHEUM DIS (2013) 72: 1569-1574

BTCure: Frisell, Thomas et al. Comparative effectiveness of abatacept, rituximab, tocilizumab and TNFi biologics in RA: results from the nationwide Swedish register, RHEUMATOLOGY (2019) 58: 1367-1377

BTCure: Frisell, Thomas et al. Familial Risks and Heritability of Rheumatoid Arthritis Role of Rheumatoid Factor/Anti-Citrullinated Protein Antibody Status, Number and Type of Affected Relatives, Sex, and Age, ARTHRITIS RHEUM-US (2013) 65: 2773-2782

BTCure: Gan, Ryan W. et al. Anti-carbamylated Protein Antibodies Are Present Prior to Rheumatoid Arthritis and Are Associated with Its Future Diagnosis, J RHEUMATOL (2015) 42: 572-579

BTCure: Ganguly, Payal et al. Age-related Changes in Bone Marrow Mesenchymal Stromal Cells: A Potential Impact on Osteoporosis and Osteoarthritis Development, CELL TRANSPLANT (2017) 26: 1520-1529

BTCure: Gao, W. et al. Tofacitinib regulates synovial inflammation in psoriatic arthritis, inhibiting STAT activation and induction of negative feedback inhibitors, ANN RHEUM DIS (2016) 75: 311-315

BTCure: Gao, Wei et al. Hypoxia and STAT3 signalling interactions regulate pro-inflammatory pathways in rheumatoid arthritis, ANN RHEUM DIS (2015) 74: 1275-1283

BTCure: Ge, Changrong et al. Structural Basis of Cross-Reactivity of Anti-Citrullinated Protein Antibodies, ARTHRITIS RHEUMATOL (2019) 71: 210-221

BTCure: Ge, Changrong et al. The structure, specificity and function of anti-citrullinated protein antibodies, NAT REV RHEUMATOL (2019) 15: 503-508

BTCure: Gerlag, Danielle M. et al. Effects of B-cell directed therapy on the preclinical stage of rheumatoid arthritis: the PRAIRI study, ANN RHEUM DIS (2019) 78: 179-185

BTCure: Gerlag, Danielle M. et al. EULAR recommendations for terminology and research in individuals at risk of rheumatoid arthritis: report from the Study Group for Risk Factors for Rheumatoid Arthritis, ANN RHEUM DIS (2012) 71: 638-641

BTCure: Gerlag, Danielle M. et al. Towards prevention of autoantibody-positive rheumatoid arthritis: from lifestyle modification to preventive treatment, RHEUMATOLOGY (2016) 55: 607-614

BTCure: Giera, Martin et al. Lipid and lipid mediator profiling of human synovial fluid in rheumatoid arthritis patients by means of LC-MS/MS, *BBA-MOL CELL BIOL L* (2012) 1821: 1415-1424

BTCure: Guenther, Claudia et al. Apoptosis, necrosis and necroptosis: cell death regulation in the intestinal epithelium, *GUT* (2013) 62: 1062-1071

BTCure: Guenther, Claudia et al. Caspase-8 controls the gut response to microbial challenges by Tnf-alpha-dependent and independent pathways, *GUT* (2015) 64: 601-U1111

BTCure: Hafkenscheid, Lise et al. N-Linked Glycans in the Variable Domain of IgG Anti-Citrullinated Protein Antibodies Predict the Development of Rheumatoid Arthritis, *ARTHRITIS RHEUMATOL* (2019) 71: 1626-1633

BTCure: Hafkenscheid, Lise et al. Structural Analysis of Variable Domain Glycosylation of Anti-Citrullinated Protein Antibodies in Rheumatoid Arthritis Reveals the Presence of Highly Sialylated Glycans, *MOL CELL PROTEOMICS* (2017) 16: 278-287

BTCure: Han, Buhm et al. Fine Mapping Seronegative and Seropositive Rheumatoid Arthritis to Shared and Distinct HLA Alleles by Adjusting for the Effects of Heterogeneity, *AM J HUM GENET* (2014) 94: 522-532

BTCure: Harre, Ulrike et al. Cellular and molecular pathways of structural damage in rheumatoid arthritis, *SEMIN IMMUNOPATHOL* (2017) 39: 355-363

BTCure: Harre, Ulrike et al. Glycosylation of immunoglobulin G determines osteoclast differentiation and bone loss, *NAT COMMUN* (2015) 6:

BTCure: Harre, Ulrike et al. Induction of osteoclastogenesis and bone loss by human autoantibodies against citrullinated vimentin, *J CLIN INVEST* (2012) 122: 1791-1802

BTCure: Haschka, Judith et al. Relapse rates in patients with rheumatoid arthritis in stable remission tapering or stopping antirheumatic therapy: interim results from the prospective randomised controlled RETRO study, *ANN RHEUM DIS* (2016) 75: 45-51

BTCure: He, Gui-Wei et al. PGAM5-mediated programmed necrosis of hepatocytes drives acute liver injury, *GUT* (2017) 66: 716-723

BTCure: Hecht, Carolin et al. Additive effect of anti-citrullinated protein antibodies and rheumatoid factor on bone erosions in patients with RA, *ANN RHEUM DIS* (2015) 74: 2151-2156

BTCure: Hedstrom, Anna Karin et al. Complex Relationships of Smoking, HLA-DRB1 Genes, and Serologic Profiles in Patients With Early Rheumatoid Arthritis: Update From a Swedish Population-Based Case-Control Study, *ARTHRITIS RHEUMATOL* (2019) 71: 1504-1511

BTCure: Hedstrom, Anna Karin et al. Smoking and susceptibility to rheumatoid arthritis in a Swedish population-based case-control study, *EUR J EPIDEMIOL* (2018) 33: 415-423

BTCure: Heiland, Gisela Ruiz et al. High level of functional dickkopf-1 predicts protection from syndesmophyte formation in patients with ankylosing spondylitis, *ANN RHEUM DIS* (2012) 71: 572-574

BTCure: Hellgren, K. et al. Rheumatoid Arthritis and Risk of Malignant Lymphoma, *ARTHRITIS RHEUMATOL* (2017) 69: 700-708

BTCure: Hensvold, Aase Haj et al. Environmental and genetic factors in the development of anticitrullinated protein antibodies (ACPAs) and ACPA-positive rheumatoid arthritis: an epidemiological investigation in twins, *ANN RHEUM DIS* (2015) 74: 375-380

BTCure: Hensvold, Aase Haj et al. How well do ACPA discriminate and predict RA in the general population: a study based on 12 590 population-representative Swedish twins, *ANN RHEUM DIS* (2017) 76: 119-125

BTCure: Hess, Christoph et al. Complement-Mediated Regulation of Metabolism and Basic Cellular Processes, *IMMUNITY* (2016) 45: 240-254

BTCure: Holmdahl, Rikard et al. Ncf1 polymorphism reveals oxidative regulation of autoimmune chronic inflammation, *IMMUNOL REV* (2016) 269: 228-247

BTCure: James, Eddie A. et al. Citrulline-Specific Th1 Cells Are Increased in Rheumatoid Arthritis and Their Frequency Is Influenced by Disease Duration and Therapy, *ARTHRITIS RHEUMATOL* (2014) 66: 1712-1722

BTCure: Jonasdottir, H. S. et al. Targeted lipidomics reveals activation of resolution pathways in knee osteoarthritis in humans, *OSTEOARTHR CARTILAGE* (2017) 25: 1150-1160

BTCure: Karouzakis, Emmanuel et al. Analysis of early changes in DNA methylation in synovial fibroblasts of RA patients before diagnosis, *SCI REP-UK* (2018) 8:

BTCure: Kato, Masaru et al. Dual Role of Autophagy in Stress-Induced Cell Death in Rheumatoid Arthritis Synovial Fibroblasts, *ARTHRITIS RHEUMATOL* (2014) 66: 40-48

BTCure: Kelkka, Tiina et al. Reactive Oxygen Species Deficiency Induces Autoimmunity with Type 1 Interferon Signature, *ANTIOXID REDOX SIGN* (2014) 21: 2231-2245

BTCure: Kerkman, Priscilla F. et al. Identification and characterisation of citrullinated antigen-specific B cells in peripheral blood of patients with rheumatoid arthritis, *ANN RHEUM DIS* (2016) 75: 1170-1176

BTCure: Khmaladze, Ia et al. Mannan induces ROS-regulated, IL-17A-dependent psoriasis arthritis-like disease in mice, *P NATL ACAD SCI USA* (2014) 111: E3669-E3678

BTCure: Kiechl, Stefan et al. Blockade of receptor activator of nuclear factor-kappa B (RANKL) signaling improves hepatic insulin resistance and prevents development of diabetes mellitus, *NAT MED* (2013) 19: 358-363

BTCure: Klarenbeek, P. L. et al. Inflamed target tissue provides a specific niche for highly expanded T-cell clones in early human autoimmune disease, *ANN RHEUM DIS* (2012) 71: 1088-1093

BTCure: Klareskog, L. et al. The importance of differences, On environment and its interactions with genes and immunity in the causation of rheumatoid arthritis, *J INTERN MED* (2020) 287: 514-533

BTCure: Klein, Kerstin et al. Epigenetics in rheumatoid arthritis, *CURR OPIN RHEUMATOL* (2015) 27: 76-82

BTCure: Klein, Kerstin et al. The bromodomain protein inhibitor I-BET151 suppresses expression of inflammatory genes and matrix degrading enzymes in rheumatoid arthritis synovial fibroblasts, *ANN RHEUM DIS* (2016) 75: 422-429

BTCure: Kleyer, Arnd et al. Bone loss before the clinical onset of rheumatoid arthritis in subjects with anticitrullinated protein antibodies, *ANN RHEUM DIS* (2014) 73: 854-860

BTCure: Klocke, Katrin et al. Induction of autoimmune disease by deletion of CTLA-4 in mice in adulthood, *P NATL ACAD SCI USA* (2016) 113: E2383-E2392

BTCure: Koenders, Marije I. et al. Novel therapeutic targets in rheumatoid arthritis, *TRENDS PHARMACOL SCI* (2015) 36: 189-195

BTCure: Kolev, Martin et al. Complement Regulates Nutrient Influx and Metabolic Reprogramming during Th1 Cell Responses, *IMMUNITY* (2015) 42: 1033-1047

BTCure: Kolev, Martin et al. Keeping it All Going - Complement Meets Metabolism, *FRONT IMMUNOL* (2017) 8:

BTCure: Koliaraki, Vasiliki et al. IKK beta in intestinal mesenchymal cells promotes initiation of colitis-associated cancer, *J EXP MED* (2015) 212: 2235-2251

BTCure: Koliaraki, Vasiliki et al. Mesenchymal Cells in Colon Cancer, *GASTROENTEROLOGY* (2017) 152: 964-979

BTCure: Koppejan, Hester et al. Altered composition and phenotype of mucosal-associated invariant T cells in early untreated rheumatoid arthritis, *ARTHRITIS RES THER* (2019) 21:

BTCure: Krishnamurthy, Akilan et al. Identification of a novel chemokine-dependent molecular mechanism underlying rheumatoid arthritis-associated autoantibody-mediated bone loss, *ANN RHEUM DIS* (2016) 75: 721-729

BTCure: Kumari, Snehlata et al. Tumor Necrosis Factor Receptor Signaling in Keratinocytes Triggers Interleukin-24-Dependent Psoriasis-like Skin Inflammation in Mice, *IMMUNITY* (2013) 39: 899-911

BTCure: Le Fric, Gaëlle et al. The CD46-Jagged1 interaction is critical for human T(H)1 immunity, *NAT IMMUNOL* (2012) 13: 1213-+

BTCure: Lenz, Tobias L. et al. Widespread non-additive and interaction effects within HLA loci modulate the risk of autoimmune diseases, *NAT GENET* (2015) 47: 1085-+

BTCure: Leppkes, Moritz et al. Pleiotropic functions of TNF-alpha in the regulation of the intestinal epithelial response to inflammation, *INT IMMUNOL* (2014) 26: 509-515

BTCure: Lie, Elisabeth et al. Tumour necrosis factor inhibitor treatment and occurrence of anterior uveitis in ankylosing spondylitis: results from the Swedish biologics register, *ANN RHEUM DIS* (2017) 76: 1515-1521

BTCure: Lin, Neng-Yu et al. Autophagy regulates TNF alpha-mediated joint destruction in experimental arthritis, *ANN RHEUM DIS* (2013) 72: 761-768

BTCure: Liszewski, M. Kathryn et al. Intracellular Complement Activation Sustains T Cell Homeostasis and Mediates Effector Differentiation, *IMMUNITY* (2013) 39: 1143-1157

BTCure: Liu, Bi-Sheng et al. TLR-mediated STAT3 and ERK activation controls IL-10 secretion by human B cells, *EUR J IMMUNOL* (2014) 44: 2121-2129

BTCure: Lloyd, Katy A. et al. Differential ACPA Binding to Nuclear Antigens Reveals a PAD-Independent Pathway and a Distinct Subset of Acetylation Cross-Reactive Autoantibodies in Rheumatoid Arthritis, *FRONT IMMUNOL* (2019) 9:

BTCure: Lopez-Mejias, Raquel et al. Cardiovascular risk assessment in patients with rheumatoid arthritis: The relevance of clinical, genetic and serological markers, *AUTOIMMUN REV* (2016) 15: 1013-1030

BTCure: Lopez-Mejias, Raquel et al. Identification of a 3'-Untranslated Genetic Variant of RARB Associated With Carotid Intima-Media Thickness in Rheumatoid Arthritis: A Genome-Wide Association Study, *ARTHRITIS RHEUMATOL* (2019) 71: 351-360

BTCure: Lubbers, R. et al. Complement component C1q is produced by isolated articular chondrocytes, *OSTEOARTHR CARTILAGE* (2020) 28: 675-684

BTCure: Lubbers, R. et al. Production of complement components by cells of the immune system, *CLIN EXP IMMUNOL* (2017) 188: 183-194

BTCure: Lundberg, Karin et al. Genetic and environmental determinants for disease risk in subsets of rheumatoid arthritis defined by the anticitrullinated protein/peptide antibody fine specificity profile, *ANN RHEUM DIS* (2013) 72: 652-658

BTCure: Luo, Yubin et al. Microbiota from Obese Mice Regulate Hematopoietic Stem Cell Differentiation by Altering the Bone Niche, *CELL METAB* (2015) 22: 886-894

BTCure: Malmstrom, Vivianne et al. The immunopathogenesis of seropositive rheumatoid arthritis: from triggering to targeting, *NAT REV IMMUNOL* (2017) 17: 60-75

BTCure: Maresz, Katarzyna J. et al. Porphyromonas gingivalis Facilitates the Development and Progression of Destructive Arthritis through Its Unique Bacterial Peptidylarginine Deiminase (PAD), PLOS PATHOG (2013) 9:

BTCure: Marquez, Ana et al. A combined large-scale meta-analysis identifies COG6 as a novel shared risk locus for rheumatoid arthritis and systemic lupus erythematosus, ANN RHEUM DIS (2017) 76: 286-294

BTCure: Martin, Paul et al. Capture Hi-C reveals novel candidate genes and complex long-range interactions with related autoimmune risk loci, NAT COMMUN (2015) 6:

BTCure: Mascalzoni, Deborah et al. International Charter of principles for sharing bio-specimens and data, EUR J HUM GENET (2015) 23: 721-728

BTCure: Melagraki, Georgia et al. Cheminformatics-aided discovery of small-molecule Protein-Protein Interaction (PPI) dual inhibitors of Tumor Necrosis Factor (TNF) and Receptor Activator of NF-kappa B Ligand (RANKL), PLOS COMPUT BIOL (2017) 13:

BTCure: Menon, Bina et al. Interleukin-17+CD8+T Cells Are Enriched in the Joints of Patients With Psoriatic Arthritis and Correlate With Disease Activity and Joint Damage Progression, ARTHRITIS RHEUMATOL (2014) 66: 1272-1281

BTCure: Montgomery, Anna B. et al. Crystal structure of Porphyromonas gingivalis peptidylarginine deiminase: implications for autoimmunity in rheumatoid arthritis, ANN RHEUM DIS (2016) 75: 1255-1261

BTCure: Munoz, Luis E. et al. Nanoparticles size-dependently initiate self-limiting NETosis-driven inflammation, P NATL ACAD SCI USA (2016) 113: E5856-E5865

BTCure: Nikitopoulou, Ioanna et al. Autotaxin expression from synovial fibroblasts is essential for the pathogenesis of modeled arthritis, J EXP MED (2012) 209: 923-931

BTCure: Okada, Yukinori et al. Genetics of rheumatoid arthritis contributes to biology and drug discovery, NATURE (2014) 506: 376+

BTCure: Olsson, Lina M. et al. A single nucleotide polymorphism in the NCF1 gene leading to reduced oxidative burst is associated with systemic lupus erythematosus, ANN RHEUM DIS (2017) 76: 1607-1613

BTCure: Ospelt, Caroline et al. Carbamylation of vimentin is inducible by smoking and represents an independent autoantigen in rheumatoid arthritis, ANN RHEUM DIS (2017) 76: 1176-1183

BTCure: Palumbo-Zerr, Katrin et al. Orphan nuclear receptor NR4A1 regulates transforming growth factor-beta signaling and fibrosis, NAT MED (2015) 21: 150-158

BTCure: Pandis, Ioannis et al. Identification of microRNA-221/222 and microRNA-323-3p association with rheumatoid arthritis via predictions using the human tumour necrosis factor transgenic mouse model, ANN RHEUM DIS (2012) 71: 1716-1723

BTCure: Perucha, Esperanza et al. The cholesterol biosynthesis pathway regulates IL-10 expression in human Th1 cells, NAT COMMUN (2019) 10:

BTCure: Pfeifle, Rene et al. Regulation of autoantibody activity by the IL-23-T(H)17 axis determines the onset of autoimmune disease, NAT IMMUNOL (2017) 18: 104-113

BTCure: Pieters, Bartijn C. H. et al. Commercial Cow Milk Contains Physically Stable Extracellular Vesicles Expressing Immunoregulatory TGF-beta, PLOS ONE (2015) 10:

BTCure: Preglej, Teresa et al. Histone deacetylases 1 and 2 restrain CD4(+) cytotoxic T lymphocyte differentiation, JCI INSIGHT (2020) 5:

BTCure: Puchner, Antonia et al. Non-classical monocytes as mediators of tissue destruction in arthritis, ANN RHEUM DIS (2018) 77: 1490-1497

BTCure: Quirke, Anne-Marie et al. Heightened immune response to autocitrullinated Porphyromonas gingivalis peptidylarginine deiminase: a potential mechanism for breaching immunologic tolerance in rheumatoid arthritis, ANN RHEUM DIS (2014) 73: 263-269

BTCure: Raaschou, Pauline et al. Rheumatoid arthritis, anti-tumour necrosis factor treatment, and risk of squamous cell and basal cell skin cancer: cohort study based on nationwide prospectively recorded data from Sweden, BMJ-BRIT MED J (2016) 352:

BTCure: Raaschou, Pauline et al. TNF inhibitor therapy and risk of breast cancer recurrence in patients with rheumatoid arthritis: a nationwide cohort study, ANN RHEUM DIS (2015) 74: 2137-2143

BTCure: Ramwadhoebe, Tamara H. et al. Effect of rituximab treatment on T and B cell subsets in lymph node biopsies of patients with rheumatoid arthritis, RHEUMATOLOGY (2019) 58: 1075-1085

BTCure: Rech, Juergen et al. Prediction of disease relapses by multibiomarker disease activity and autoantibody status in patients with rheumatoid arthritis on tapering DMARD treatment, ANN RHEUM DIS (2016) 75: 1637-1644

BTCure: Reynisdottir, Gudrun et al. Signs of immune activation and local inflammation are present in the bronchial tissue of patients with untreated early rheumatoid arthritis, ANN RHEUM DIS (2016) 75: 1722-1727

BTCure: Reynisdottir, Gudrun et al. Structural Changes and Antibody Enrichment in the Lungs Are Early Features of Anti-Citrullinated Protein Antibody-Positive Rheumatoid Arthritis, ARTHRITIS RHEUMATOL (2014) 66: 31-39

BTCure: Rodriguez-Carrio, Javier et al. Altered Innate Lymphoid Cell Subsets in Human Lymph Node Biopsy Specimens Obtained During the At-Risk and Earliest Phases of Rheumatoid Arthritis, ARTHRITIS RHEUMATOL (2017) 69: 70-76

BTCure: Rogier, Rebecca et al. Alteration of the intestinal microbiome characterizes preclinical inflammatory arthritis in mice and its modulation attenuates established arthritis, SCI REP-UK (2017) 7:

BTCure: Rombouts, Yoann et al. Anti-citrullinated protein antibodies acquire a pro-inflammatory Fc glycosylation phenotype prior to the onset of rheumatoid arthritis, ANN RHEUM DIS (2015) 74: 234-241

BTCure: Rombouts, Yoann et al. Extensive glycosylation of ACPA-IgG variable domains modulates binding to citrullinated antigens in rheumatoid arthritis, ANN RHEUM DIS (2016) 75: 578-585

BTCure: Rose, Thomas et al. IFN and its response proteins, IP-10 and SIGLEC-1, are biomarkers of disease activity in systemic lupus erythematosus, ANN RHEUM DIS (2013) 72: 1639-1645

BTCure: Scher, Jose U. et al. The lung microbiota in early rheumatoid arthritis and autoimmunity, MICROBIOME (2016) 4:

BTCure: Scherer, Hans Ulrich et al. The B cell response to citrullinated antigens in the development of rheumatoid arthritis, NAT REV RHEUMATOL (2018) 14: 157-169

BTCure: Scherer, Hans Ulrich et al. The etiology of rheumatoid arthritis, J AUTOIMMUN (2020) 110:

BTCure: Schett, Georg et al. Bone erosion in rheumatoid arthritis: mechanisms, diagnosis and treatment, NAT REV RHEUMATOL (2012) 8: 656-664

BTCure: Schett, Georg et al. Diabetes Is an Independent Predictor for Severe Osteoarthritis Results from a longitudinal cohort study, DIABETES CARE (2013) 36: 403-409



BTCure: Schoenau, Verena et al. The value of F-18-FDG-PET/CT in identifying the cause of fever of unknown origin (FUO) and inflammation of unknown origin (IUO): data from a prospective study, *ANN RHEUM DIS* (2018) 77: 70-77

BTCure: Shi, Jing et al. Anti-carbamylated protein (anti-CarP) antibodies precede the onset of rheumatoid arthritis, *ANN RHEUM DIS* (2014) 73: 780-783

BTCure: Shi, Jing et al. Autoantibodies recognizing carbamylated proteins are present in sera of patients with rheumatoid arthritis and predict joint damage, *P NATL ACAD SCI USA* (2011) 108: 17372-17377

BTCure: Shi, Jing et al. Brief Report: AntiCarbamylated Protein Antibodies Are Present in Arthralgia Patients and Predict the Development of Rheumatoid Arthritis, *ARTHRITIS RHEUM-US* (2013) 65: 911-915

BTCure: Shi, Jing et al. Carbamylation and antibodies against carbamylated proteins in autoimmunity and other pathologies, *AUTOIMMUN REV* (2014) 13: 225-230

BTCure: Steen, Johanna et al. Recognition of Amino Acid Motifs, Rather Than Specific Proteins, by Human Plasma Cell-Derived Monoclonal Antibodies to Posttranslationally Modified Proteins in Rheumatoid Arthritis, *ARTHRITIS RHEUMATOL* (2019) 71: 196-209

BTCure: Suwannalai, P. et al. Avidity maturation of anti-citrullinated protein antibodies in rheumatoid arthritis, *ARTHRITIS RHEUM-US* (2012) 64: 1323-1328

BTCure: Tacconi, Carlotta et al. Vascular Endothelial Growth Factor C Disrupts the Endothelial Lymphatic Barrier to Promote Colorectal Cancer Invasion, *GASTROENTEROLOGY* (2015) 148: 1438-+

BTCure: Trenkmann, Michelle et al. Tumor Necrosis Factor alpha-Induced MicroRNA-18a Activates Rheumatoid Arthritis Synovial Fibroblasts Through a Feedback Loop in NF-kappa B Signaling, *ARTHRITIS RHEUM-US* (2013) 65: 916-927

BTCure: Trouw, Leendert A. et al. Beyond citrullination: other post-translational protein modifications in rheumatoid arthritis, *NAT REV RHEUMATOL* (2017) 13: 331-339

BTCure: Trouw, Leendert A. et al. Closing the serological gap: promising novel biomarkers for the early diagnosis of rheumatoid arthritis, *AUTOIMMUN REV* (2012) 12: 318-322

BTCure: Udalova, Irina A. et al. Macrophage heterogeneity in the context of rheumatoid arthritis, *NAT REV RHEUMATOL* (2016) 12: 472-485

BTCure: Uderhardt, Stefan et al. 12/15-Lipoxygenase Orchestrates the Clearance of Apoptotic Cells and Maintains Immunologic Tolerance, *IMMUNITY* (2012) 36: 834-846

BTCure: Uluckan, Oezge et al. Chronic skin inflammation leads to bone loss by IL-17-mediated inhibition of Wnt signaling in osteoblasts, *SCI TRANSL MED* (2016) 8:

BTCure: van Baarsen, Lisa G. M. et al. Heterogeneous expression pattern of interleukin 17A (IL-17A), IL-17F and their receptors in synovium of rheumatoid arthritis, psoriatic arthritis and osteoarthritis: possible explanation for nonresponse to anti-IL-17 therapy?, *ARTHRITIS RES THER* (2014) 16:

BTCure: van de Bovenkamp, Fleur S. et al. The Emerging Importance of IgG Fab Glycosylation in Immunity, *J IMMUNOL* (2016) 196: 1435-1441

BTCure: van Nies, J. A. B. et al. What is the evidence for the presence of a therapeutic window of opportunity in rheumatoid arthritis? A systematic literature review, *ANN RHEUM DIS* (2014) 73: 861-870

BTCure: van Steenberg, Hanna W. et al. Characterising arthralgia in the preclinical phase of rheumatoid arthritis using MRI, *ANN RHEUM DIS* (2015) 74: 1225-1232

BTCure: Viatte, Sebastien et al. Association of HLA-DRB1 Haplotypes With Rheumatoid Arthritis Severity, Mortality, and Treatment Response, *JAMA-J AM MED ASSOC* (2015) 313: 1645-1656

BTCure: Vicente, Rita et al. Cellular senescence impact on immune cell fate and function, *AGING CELL* (2016) 15: 400-406

BTCure: Vicente, Rita et al. Deregulation and therapeutic potential of microRNAs in arthritic diseases, *NAT REV RHEUMATOL* (2016) 12: 211-220

BTCure: Webster, Amy P. et al. Increased DNA methylation variability in rheumatoid arthritis-discordant monozygotic twins, *GENOME MED* (2018) 10:

BTCure: Wenniger, Lucas J. Maillette de Buy et al. Immunoglobulin G4+clones identified by next-generation sequencing dominate the B cell receptor repertoire in immunoglobulin G4 associated cholangitis, *HEPATOLOGY* (2013) 57: 2390-2398

BTCure: Wesley, Annmarie et al. Association between body mass index and anti-citrullinated protein antibody-positive and anti-citrullinated protein antibody-negative rheumatoid arthritis: Results from a population-based case-control study, *ARTHRIT CARE RES* (2013) 65: 107-112

BTCure: Wigerblad, Gustaf et al. Autoantibodies to citrullinated proteins induce joint pain independent of inflammation via a chemokine-dependent mechanism, *ANN RHEUM DIS* (2016) 75: 730-738

BTCure: Ytterberg, A. Jimmy et al. Shared immunological targets in the lungs and joints of patients with rheumatoid arthritis: identification and validation, *ANN RHEUM DIS* (2015) 74: 1772-1777

CANCER-ID: Alix-Panabieres, Catherine et al. Characterization of single circulating tumor cells, *FEBS LETT* (2017) 591: 2241-2250

CANCER-ID: Alix-Panabieres, Catherine et al. Clinical Applications of Circulating Tumor Cells and Circulating Tumor DNA as Liquid Biopsy, *CANCER DISCOV* (2016) 6: 479-491

CANCER-ID: Alix-Panabieres, Catherine et al. Epithelial-mesenchymal plasticity in circulating tumor cells, *J MOL MED* (2017) 95: 133-142

CANCER-ID: Alix-Panabieres, Catherine et al. Functional studies on circulating and disseminated-tumor cells in carcinoma patients, *MOL ONCOL* (2016) 10: 443-449

CANCER-ID: Amirouchene-Angelozzi, Nabil et al. Tumor Evolution as a Therapeutic Target, *CANCER DISCOV* (2017) 7: 805-817

CANCER-ID: Andree, Kiki C. et al. Challenges in circulating tumor cell detection by the CellSearch system, *MOL ONCOL* (2016) 10: 395-407

CANCER-ID: Andree, Kiki C. et al. Toward a real liquid biopsy in metastatic breast and prostate cancer: Diagnostic LeukApheresis increases CTC yields in a European prospective multicenter study (CTCTrap), *INT J CANCER* (2018) 143: 2584-2591

CANCER-ID: Anfossi, Simone et al. Clinical utility of circulating non-coding RNAs - an update, *NAT REV CLIN ONCOL* (2018) 15: 541-563

CANCER-ID: Arena, Sabrina et al. A Subset of Colorectal Cancers with Cross-Sensitivity to Olaparib and Oxaliplatin, *CLIN CANCER RES* (2020) 26: 1372-1384

CANCER-ID: Arena, Sabrina et al. MM-151 overcomes acquired resistance to cetuximab and panitumumab in colorectal cancers harboring EGFR extracellular domain mutations, *SCI TRANSL MED* (2016) 8:

CANCER-ID: Auffray, Charles et al. Making sense of big data in health research: Towards an EU action plan, *GENOME MED* (2016) 8:

CANCER-ID: Barault, L. et al. Digital PCR quantification of MGMT methylation refines prediction of clinical benefit from alkylating agents in glioblastoma and metastatic colorectal cancer, *ANN ONCOL* (2015) 26: 1994-1999

CANCER-ID: Barault, Ludovic et al. Discovery of methylated circulating DNA biomarkers for comprehensive non-invasive monitoring of treatment response in metastatic colorectal cancer, *GUT* (2018) 67: 1995-2005

CANCER-ID: Bardelli, Alberto et al. Liquid Biopsies, What We Do Not Know (Yet), *CANCER CELL* (2017) 31: 172-179

CANCER-ID: Belic, Jelena et al. Genomic alterations in plasma DNA from patients with metastasized prostate cancer receiving abiraterone or enzalutamide, *INT J CANCER* (2018) 143: 1236-1248

CANCER-ID: Bidard, Francois-Clement et al. Circulating Tumor Cells in Breast Cancer Patients Treated by Neoadjuvant Chemotherapy: A Meta-analysis, *JNCI-J NATL CANCER I* (2018) 110: 560-567

CANCER-ID: Bidard, Francois-Clement et al. Circulating tumor cells in breast cancer, *MOL ONCOL* (2016) 10: 418-430

CANCER-ID: Cabel, L. et al. Circulating tumor cells and circulating tumor DNA: What surgical oncologists need to know?, *EJSO-EUR J SURG ONC* (2017) 43: 949-962

CANCER-ID: Cabel, Luc et al. Circulating tumor cells: clinical validity and utility, *INT J CLIN ONCOL* (2017) 22: 421-430

CANCER-ID: Chudziak, Jakub et al. Clinical evaluation of a novel microfluidic device for epitope-independent enrichment of circulating tumour cells in patients with small cell lung cancer, *ANALYST* (2016) 141: 669-678

CANCER-ID: Cieslikowski, Wojciech A. et al. Circulating Tumor Cells as a Marker of Disseminated Disease in Patients with Newly Diagnosed High-Risk Prostate Cancer, *CANCERS* (2020) 12:

CANCER-ID: Cortes-Hernandez, Luis Enrique et al. Circulating tumor cell as the functional aspect of liquid biopsy to understand the metastatic cascade in solid cancer, *MOL ASPECTS MED* (2020) 72:

CANCER-ID: de Wit, Sanne et al. Single tube liquid biopsy for advanced non-small cell lung cancer, *INT J CANCER* (2019) 144: 3127-3137

CANCER-ID: Germano, Giovanni et al. Parallel Evaluation of Circulating Tumor DNA and Circulating Tumor Cells in Metastatic Colorectal Cancer, *CLIN COLORECTAL CANC* (2018) 17: 80-83

CANCER-ID: Germano, Giovanni et al. The Clinical Impact of the Genomic Landscape of Mismatch Repair-Deficient Cancers, *CANCER DISCOV* (2018) 8: 1518-1528

CANCER-ID: Gorges, Tobias M. et al. Accession of Tumor Heterogeneity by Multiplex Transcriptome Profiling of Single Circulating Tumor Cells, *CLIN CHEM* (2016) 62: 1504-1515

CANCER-ID: Gorges, Tobias M. et al. Enumeration and Molecular Characterization of Tumor Cells in Lung Cancer Patients Using a Novel In Vivo Device for Capturing Circulating Tumor Cells, *CLIN CANCER RES* (2016) 22: 2197-2206

CANCER-ID: Hanssen, Annkathrin et al. Characterization of different CTC subpopulations in non-small cell lung cancer, *SCI REP-UK* (2016) 6:

CANCER-ID: Heitzer, Ellen et al. Cell-Free DNA and Apoptosis: How Dead Cells Inform About the Living, *TRENDS MOL MED* (2020) 26: 519-528

CANCER-ID: Heitzer, Ellen et al. Current and future perspectives of liquid biopsies in genomics-driven oncology, *NAT REV GENET* (2019) 20: 71-88

CANCER-ID: Heitzer, Ellen et al. Non-invasive detection of genome-wide somatic copy number alterations by liquid biopsies, *MOL ONCOL* (2016) 10: 494-502

CANCER-ID: Hofman, P. et al. Liquid biopsy in the era of immuno-oncology: is it ready for prime-time use for cancer patients?, *ANN ONCOL* (2019) 30: 1448-1459

CANCER-ID: Huggett, Jim F. et al. The Digital MIQE Guidelines Update: Minimum Information for Publication of Quantitative Digital PCR Experiments for 2020, *CLIN CHEM* (2020) 66: 1012-1029

CANCER-ID: Hvichia, G. E. et al. A novel microfluidic platform for size and deformability based separation and the subsequent molecular characterization of viable circulating tumor cells, *INT J CANCER* (2016) 138: 2894-2904

CANCER-ID: Janning, Melanie et al. Determination of PD-L1 Expression in Circulating Tumor Cells of NSCLC Patients and Correlation with Response to PD-1/PD-L1 Inhibitors, *CANCERS* (2019) 11:

CANCER-ID: Keller, Laura et al. Biology and clinical relevance of EpCAM, *CELL STRESS* (2019) 3: 165-180

CANCER-ID: Keller, Laura et al. Clinical relevance of blood-based ctDNA analysis: mutation detection and beyond, *BRIT J CANCER* (2020) 124: 345-358

CANCER-ID: Keller, Laura et al. Unravelling tumour heterogeneity by single-cell profiling of circulating tumour cells, *NAT REV CANCER* (2019) 19: 553-567

CANCER-ID: Klotten, Vera et al. Multicenter Evaluation of Circulating Plasma MicroRNA Extraction Technologies for the Development of Clinically Feasible Reverse Transcription Quantitative PCR and Next-Generation Sequencing Analytical Work Flows, *CLIN CHEM* (2019) 65: 1132-1140

CANCER-ID: Koch, Claudia et al. Characterization of circulating breast cancer cells with tumorigenic and metastatic capacity, *EMBO MOL MED* (2020) 12:

CANCER-ID: Kuskel, Andra et al. Improved detection of circulating tumor cells in non-metastatic high-risk prostate cancer patients, *SCI REP-UK* (2016) 6:

CANCER-ID: Lazzari, Luca et al. Patient-Derived Xenografts and Matched Cell Lines Identify Pharmacogenomic Vulnerabilities in Colorectal Cancer, *CLIN CANCER RES* (2019) 25: 6243-6259

CANCER-ID: Lianidou, Evi et al. Liquid biopsies, *GENE CHROMOSOME CANC* (2019) 58: 219-232

CANCER-ID: Lindsay, C. R. et al. A prospective examination of circulating tumor cell profiles in non-small-cell lung cancer molecular subgroups, *ANN ONCOL* (2017) 28: 1523-1531

CANCER-ID: Lindsay, C. R. et al. EPAC-lung: pooled analysis of circulating tumour cells in advanced non-small cell lung cancer, *EUR J CANCER* (2019) 117: 60-68

CANCER-ID: Magri, Alessandro et al. High-dose vitamin C enhances cancer immunotherapy, *SCI TRANSL MED* (2020) 12:

CANCER-ID: Mainardi, Sara et al. SHP2 is required for growth of KRAS-mutant non-small-cell lung cancer in vivo, *NAT MED* (2018) 24: 961-+

CANCER-ID: Mastoraki, Sophia et al. ESR1 Methylation: A Liquid Biopsy-Based Epigenetic Assay for the Follow-up of Patients with Metastatic Breast Cancer Receiving Endocrine Treatment, *CLIN CANCER RES* (2018) 24: 1500-1510

CANCER-ID: Misale, Sandra et al. Vertical suppression of the EGFR pathway prevents onset of resistance in colorectal cancers, *NAT COMMUN* (2015) 6:

CANCER-ID: Nanou, Afroditi et al. Tumour-derived extracellular vesicles in blood of metastatic cancer patients associate with overall survival, *BRIT J CANCER* (2020) 122: 801-811

CANCER-ID: Neumann, Martin H. D. et al. ctDNA and CTCs in Liquid Biopsy - Current Status and Where We Need to Progress, *COMPUT STRUCT BIOTEC* (2018) 16: 190-195

CANCER-ID: Pailler, Emma et al. Acquired Resistance Mutations to ALK Inhibitors Identified by Single Circulating Tumor Cell Sequencing in ALK-Rearranged Non-Small-Cell Lung Cancer, CLIN CANCER RES (2019) 25: 6671-6682

CANCER-ID: Pailler, Emma et al. Circulating Tumor Cells with Aberrant ALK Copy Number Predict Progression-Free Survival during Crizotinib Treatment in ALK-Rearranged Non-Small Cell Lung Cancer Patients, CANCER RES (2017) 77: 2222-2230

CANCER-ID: Pantel, K. et al. The biology of circulating tumor cells, ONCOGENE (2016) 35: 1216-1224

CANCER-ID: Pantel, Klaus et al. Circulating Tumor Cells in Prostate Cancer: From Discovery to Clinical Utility, CLIN CHEM (2019) 65: 87-99

CANCER-ID: Pantel, Klaus et al. Liquid biopsy and minimal residual disease - latest advances and implications for cure, NAT REV CLIN ONCOL (2019) 16: 409-424

CANCER-ID: Parikh, Aparna R. et al. Liquid versus tissue biopsy for detecting acquired resistance and tumor heterogeneity in gastrointestinal cancers, NAT MED (2019) 25: 1415-+

CANCER-ID: Perakis, Samantha et al. Emerging concepts in liquid biopsies, BMC MED (2017) 15:

CANCER-ID: Pietrantonio, Filippo et al. Heterogeneity of Acquired Resistance to Anti-EGFR Monoclonal Antibodies in Patients with Metastatic Colorectal Cancer, CLIN CANCER RES (2017) 23: 2414-2422

CANCER-ID: Poudineh, Mahla et al. Profiling circulating tumour cells and other biomarkers of invasive cancers, NAT BIOMED ENG (2018) 2: 72-84

CANCER-ID: Reimers, Natalie et al. Liquid biopsy: novel technologies and clinical applications, CLIN CHEM LAB MED (2019) 57: 312-316

CANCER-ID: Riethdorf, Sabine et al. Clinical applications of the CellSearch platform in cancer patients, ADV DRUG DELIVER REV (2018) 125: 102-121

CANCER-ID: Rothwell, Dominic G. et al. Utility of ctDNA to support patient selection for early phase clinical trials: the TARGET study, NAT MED (2019) 25: 738-+

CANCER-ID: Russo, Mariangela et al. Acquired Resistance to the TRK Inhibitor Entrectinib in Colorectal Cancer, CANCER DISCOV (2016) 6: 36-44

CANCER-ID: Russo, Mariangela et al. Tumor Heterogeneity and Lesion-Specific Response to Targeted Therapy in Colorectal Cancer, CANCER DISCOV (2016) 6: 147-153

CANCER-ID: Siena, S. et al. Dynamic molecular analysis and clinical correlates of tumor evolution within a phase II trial of panitumumab-based therapy in metastatic colorectal cancer, ANN ONCOL (2018) 29: 119-126

CANCER-ID: Siravegna, G. et al. How liquid biopsies can change clinical practice in oncology, ANN ONCOL (2019) 30: 1580-1590

CANCER-ID: Siravegna, Giulia et al. Integrating liquid biopsies into the management of cancer, NAT REV CLIN ONCOL (2017) 14: 531-548

CANCER-ID: Siravegna, Giulia et al. Plasma HER2 (ERBB2) Copy Number Predicts Response to HER2-targeted Therapy in Metastatic Colorectal Cancer, CLIN CANCER RES (2019) 25: 3046-3053

CANCER-ID: Siravegna, Giulia et al. Radiologic and Genomic Evolution of Individual Metastases during HER2 Blockade in Colorectal Cancer, CANCER CELL (2018) 34: 148-+

CANCER-ID: Soler, Alexandra et al. Autologous cell lines from circulating colon cancer cells captured from sequential liquid biopsies as model to study therapy-driven tumor changes, SCI REP-UK (2018) 8:

CANCER-ID: Stoecklein, Nikolas H. et al. Challenges for CTC-based liquid biopsies: low CTC frequency and diagnostic leukapheresis as a potential solution, *EXPERT REV MOL DIAGN* (2016) 16: 147-164

CANCER-ID: Swennenhuis, J. F. et al. Improving the CellSearch (R) system, *EXPERT REV MOL DIAGN* (2016) 16: 1291-1305

CANCER-ID: Tamminga, Menno et al. Circulating tumor cells in advanced non-small cell lung cancer patients are associated with worse tumor response to checkpoint inhibitors, *J IMMUNOTHER CANCER* (2019) 7:

CANCER-ID: Tayoun, Tala et al. CTC-Derived Models: A Window into the Seeding Capacity of Circulating Tumor Cells (CTCs), *CELLS-BASEL* (2019) 8:

CANCER-ID: Tzanikou, Eleni et al. PIK3CA hotspot mutations in circulating tumor cells and paired circulating tumor DNA in breast cancer: a direct comparison study, *MOL ONCOL* (2019) 13: 2515-2530

CANCER-ID: Ulz, Peter et al. Inference of transcription factor binding from cell-free DNA enables tumor subtype prediction and early detection, *NAT COMMUN* (2019) 10:

CANCER-ID: Ulz, Peter et al. Inferring expressed genes by whole-genome sequencing of plasma DNA, *NAT GENET* (2016) 48: 1273-1278

CANCER-ID: Valihrach, Lukas et al. Circulating miRNA analysis for cancer diagnostics and therapy, *MOL ASPECTS MED* (2020) 72:

CANCER-ID: van Emburgh, Beth O. et al. Acquired RAS or EGFR mutations and duration of response to EGFR blockade in colorectal cancer, *NAT COMMUN* (2016) 7:

CANCER-ID: Weber, Sabrina et al. Technical Evaluation of Commercial Mutation Analysis Platforms and Reference Materials for Liquid Biopsy Profiling, *CANCERS* (2020) 12:

CANCER-ID: Werner, Stefan et al. Epithelial keratins: Biology and implications as diagnostic markers for liquid biopsies, *MOL ASPECTS MED* (2020) 72:

CANCER-ID: Zeune, Leonie et al. Multiscale Segmentation via Bregman Distances and Nonlinear Spectral Analysis, *SIAM J IMAGING SCI* (2017) 10: 111-146

CANCER-ID: Zhou, Qing et al. Cell-free DNA analysis reveals POLR1D-mediated resistance to bevacizumab in colorectal cancer, *GENOME MED* (2020) 12:

CARDIATEAM: Simmonds, Steven J. et al. Cellular and Molecular Differences between HFpEF and HFrEF: A Step Ahead in an Improved Pathological Understanding, *CELLS-BASEL* (2020) 9:

CARE: Maisonnasse, Pauline et al. Hydroxychloroquine use against SARS-CoV-2 infection in non-human primates, *NATURE* (2020) 585: 584-+

CHEM21: Adams, Joseph P. et al. Biocatalysis: A Pharma Perspective, *ADV SYNTH CATAL* (2019) 361: 2421-2432

CHEM21: Aleku, Godwin A. et al. A reductive aminase from *Aspergillus oryzae*, *NAT CHEM* (2017) 9: 961-969

CHEM21: Ashcroft, Christopher P. et al. Survey of Solvent Usage in Papers Published in Organic Process Research & Development 1997-2012, *ORG PROCESS RES DEV* (2015) 19: 740-747

CHEM21: Both, Peter et al. Whole-Cell Biocatalysts for Stereoselective C-H Amination Reactions, *ANGEW CHEM INT EDIT* (2016) 55: 1511-1513

CHEM21: Chapman, Michael R. et al. Simple and Versatile Laboratory Scale CSTR for Multiphasic Continuous-Flow Chemistry and Long Residence Times, *ORG PROCESS RES DEV* (2017) 21: 1294-1301

CHEM21: Cioc, Razvan C. et al. Multicomponent reactions: advanced tools for sustainable organic synthesis, GREEN CHEM (2014) 16: 2958-2975

CHEM21: Collet, Jurrien W. et al. Synthesis of Densely Functionalized Pyrimidouracils by Nickel(II)-Catalyzed Isocyanide Insertion, ORG LETT (2020) 22: 914-919

CHEM21: Grundtvig, Ines P. Rosinha et al. Screening of organic solvents for bioprocesses using aqueous-organic two-phase systems, BIOTECHNOL ADV (2018) 36: 1801-1814

CHEM21: Harsanyi, Antal et al. One-Step Continuous Flow Synthesis of Antifungal WHO Essential Medicine Flucytosine Using Fluorine, ORG PROCESS RES DEV (2017) 21: 273-276

CHEM21: Harsanyi, Antal et al. Organofluorine chemistry: applications, sources and sustainability, GREEN CHEM (2015) 17: 2081-2086

CHEM21: Herter, Susanne et al. Mapping the substrate scope of monoamine oxidase (MAO-N) as a synthetic tool for the enantioselective synthesis of chiral amines, BIOORGAN MED CHEM (2018) 26: 1338-1346

CHEM21: Hussain, Shahed et al. An (R)-Imine Reductase Biocatalyst for the Asymmetric Reduction of Cyclic Imines, CHEMCATCHEM (2015) 7: 579-583

CHEM21: Lenz, Maike et al. Asymmetric Ketone Reduction by Imine Reductases, CHEMBIOCHEM (2017) 18: 253-256

CHEM21: Mampuys, Pieter et al. Iodide-Catalyzed Synthesis of Secondary Thiocarbamates from Isocyanides and Thiosulfonates, ORG LETT (2016) 18: 2808-2811

CHEM21: McElroy, C. Robert et al. Towards a holistic approach to metrics for the 21st century pharmaceutical industry, GREEN CHEM (2015) 17: 3111-3121

CHEM21: McKenna, Shane M. et al. Enzyme cascade reactions: synthesis of furandicarboxylic acid (FDCA) and carboxylic acids using oxidases in tandem, GREEN CHEM (2015) 17: 3271-3275

CHEM21: Monteith, Edward R. et al. Why we might be misusing process mass intensity (PMI) and a methodology to apply it effectively as a discovery level metric, GREEN CHEM (2020) 22: 123-135

CHEM21: Prat, Denis et al. A survey of solvent selection guides, GREEN CHEM (2014) 16: 4546-4551

CHEM21: Prat, Denis et al. CHEM21 selection guide of classical- and less classical-solvents, GREEN CHEM (2016) 18: 288-296

CHEM21: Reay, Alan J. et al. Catalytic C-H bond functionalisation chemistry: the case for quasi-heterogeneous catalysis, CHEM COMMUN (2015) 51: 16289-16307

CHEM21: Reay, Alan J. et al. Mild and Regioselective Pd(OAc)<sub>2</sub>-Catalyzed C-H Arylation of Tryptophans by [ArN<sub>2</sub>]X, Promoted by Tosic Acid, ACS CATAL (2017) 7: 5174-5179

CHEM21: Reay, Alan J. et al. Unified mild reaction conditions for C2-selective Pd-catalysed tryptophan arylation, including tryptophan-containing peptides, ORG BIOMOL CHEM (2015) 13: 8298-8309

CHEM21: Scheller, Philipp N. et al. Enzyme Toolbox: Novel Enantiocomplementary Imine Reductases, CHEMBIOCHEM (2014) 15: 2201-2204

CHEM21: Sturmberger, Lukas et al. Refined Pichia pastoris reference genome sequence, J BIOTECHNOL (2016) 235: 121-131

CHEM21: Vogl, Thomas et al. A Toolbox of Diverse Promoters Related to Methanol Utilization: Functionally Verified Parts for Heterologous Pathway Expression in Pichia pastoris, ACS SYNTH BIOL (2016) 5: 172-186

CHEM21: Weninger, Astrid et al. Combinatorial optimization of CRISPR/Cas9 expression enables precision genome engineering in the methylotrophic yeast *Pichia pastoris*, *J BIOTECHNOL* (2016) 235: 139-149

CHEM21: Wiltschi, Birgit et al. Enzymes revolutionize the bioproduction of value-added compounds: From enzyme discovery to special applications, *BIOTECHNOL ADV* (2020) 40:

CHEM21: Windle, Claire L. et al. Engineering aldolases as biocatalysts, *CURR OPIN CHEM BIOL* (2014) 19: 25-33

COMBACTE: Deng, Zhi-Luo et al. Dysbiosis in chronic periodontitis: Key microbial players and interactions with the human host, *SCI REP-UK* (2017) 7:

COMBACTE: Gottschick, Cornelia et al. The urinary microbiota of men and women and its changes in women during bacterial vaginosis and antibiotic treatment, *MICROBIOME* (2017) 5:

COMBACTE: Lee, Andie S. et al. Methicillin-resistant *Staphylococcus aureus*, *NAT REV DIS PRIMERS* (2018) 4:

COMBACTE: Schechner, Vered et al. Epidemiological Interpretation of Studies Examining the Effect of Antibiotic Usage on Resistance, *CLIN MICROBIOL REV* (2013) 26: 289-307

COMBACTE: Sztajer, Helena et al. Cross-feeding and interkingdom communication in dual-species biofilms of *Streptococcus mutans* and *Candida albicans*, *ISME J* (2014) 8: 2256-2271

COMBACTE-CARE: Bassetti, M. et al. Management of KPC-producing *Klebsiella pneumoniae* infections, *CLIN MICROBIOL INFECTION* (2018) 24: 133-144

COMBACTE-CARE: Bluhmki, Tobias et al. A wild bootstrap approach for the Aalen-Johansen estimator, *BIOMETRICS* (2018) 74: 977-985

COMBACTE-CARE: Cornely, Oliver A. et al. Pharmacokinetics and safety of aztreonam/avibactam for the treatment of complicated intra-abdominal infections in hospitalized adults: results from the REJUVENATE study, *J ANTIMICROB CHEMOTH* (2020) 75: 618-627

COMBACTE-CARE: de Kraker, M. E. A. et al. Good epidemiological practice: a narrative review of appropriate scientific methods to evaluate the impact of antimicrobial stewardship interventions, *CLIN MICROBIOL INFECTION* (2017) 23: 819-825

COMBACTE-CARE: Docobo-Perez, F. et al. Pharmacodynamics of Fosfomycin: Insights into Clinical Use for Antimicrobial Resistance, *ANTIMICROB AGENTS CH* (2015) 59: 5602-5610

COMBACTE-CARE: Eliakim-Raz, Noa et al. Risk Factors for Treatment Failure and Mortality Among Hospitalized Patients With Complicated Urinary Tract Infection: A Multicenter Retrospective Cohort Study (RESCUING Study Group), *CLIN INFECT DIS* (2019) 68: 29-36

COMBACTE-CARE: Grabein, B. et al. Intravenous fosfomycin-back to the future. Systematic review and meta-analysis of the clinical literature, *CLIN MICROBIOL INFECTION* (2017) 23: 363-372

COMBACTE-CARE: Gudiol, Carlota et al. Efficacy of beta-Lactam/beta-Lactamase Inhibitor Combinations for the Treatment of Bloodstream Infection Due to Extended-Spectrum-beta-Lactamase-Producing Enterobacteriaceae in Hematological Patients with Neutropenia, *ANTIMICROB AGENTS CH* (2017) 61:

COMBACTE-CARE: Gutierrez-Gutierrez, Belen et al. A Predictive Model of Mortality in Patients With Bloodstream Infections due to Carbapenemase-Producing Enterobacteriaceae, *MAYO CLIN PROC* (2016) 91: 1362-1371

COMBACTE-CARE: Gutierrez-Gutierrez, Belen et al. Effect of appropriate combination therapy on mortality of patients with bloodstream infections due to carbapenemase-producing Enterobacteriaceae (INCREMENT): a retrospective cohort study, *LANCET INFECT DIS* (2017) 17: 726-734



COMBACTE-CARE: Harris, P. N. A. et al. Proposed primary endpoints for use in clinical trials that compare treatment options for bloodstream infection in adults: a consensus definition, *CLIN MICROBIOL INFECTION* (2017) 23: 533-541

COMBACTE-CARE: Kaier, Klaus et al. Mechanical ventilation and the daily cost of ICU care, *BMC HEALTH SERV RES* (2020) 20:

COMBACTE-CARE: Raquel Palacios-Baena, Zaira et al. Development and validation of the INCREMENT-ESBL predictive score for mortality in patients with bloodstream infections due to extended-spectrum- beta-lactamase-producing Enterobacteriaceae, *J ANTIMICROB CHEMOTH* (2017) 72: 906-913

COMBACTE-CARE: Rodriguez-Bano, Jesus et al. Treatment of Infections Caused by Extended-Spectrum-Beta-Lactamase-, AmpC-, and Carbapenemase-Producing Enterobacteriaceae, *CLIN MICROBIOL REV* (2018) 31:

COMBACTE-CARE: Troeman, D. P. R. et al. Antimicrobial approaches in the prevention of *Staphylococcus aureus* infections: a review, *J ANTIMICROB CHEMOTH* (2019) 74: 281-294

COMBACTE-MAGNET: Bluhmki, Tobias et al. A wild bootstrap approach for the Aalen-Johansen estimator, *BIOMETRICS* (2018) 74: 977-985

COMBACTE-MAGNET: de Kraker, M. E. A. et al. Good epidemiological practice: a narrative review of appropriate scientific methods to evaluate the impact of antimicrobial stewardship interventions, *CLIN MICROBIOL INFECTION* (2017) 23: 819-825

COMBACTE-MAGNET: Docobo-Perez, F. et al. Pharmacodynamics of Fosfomycin: Insights into Clinical Use for Antimicrobial Resistance, *ANTIMICROB AGENTS CH* (2015) 59: 5602-5610

COMBACTE-MAGNET: Eliakim-Raz, Noa et al. Risk Factors for Treatment Failure and Mortality Among Hospitalized Patients With Complicated Urinary Tract Infection: A Multicenter Retrospective Cohort Study (RESCUING Study Group), *CLIN INFECT DIS* (2019) 68: 29-36

COMBACTE-MAGNET: Grabein, B. et al. Intravenous fosfomycin-back to the future. Systematic review and meta-analysis of the clinical literature, *CLIN MICROBIOL INFECTION* (2017) 23: 363-372

COMBACTE-MAGNET: Gudiol, Carlota et al. Efficacy of beta-Lactam/beta-Lactamase Inhibitor Combinations for the Treatment of Bloodstream Infection Due to Extended-Spectrum-beta-Lactamase-Producing Enterobacteriaceae in Hematological Patients with Neutropenia, *ANTIMICROB AGENTS CH* (2017) 61:

COMBACTE-MAGNET: Horcajada, Juan P. et al. Epidemiology and Treatment of Multidrug-Resistant and Extensively Drug-Resistant *Pseudomonas aeruginosa* Infections, *CLIN MICROBIOL REV* (2019) 32:

COMBACTE-MAGNET: Hotterbeekx, An et al. In vivo and In vitro Interactions between *Pseudomonas aeruginosa* and *Staphylococcus* spp., *FRONT CELL INFECT MI* (2017) 7:

COMBACTE-MAGNET: Juan, Carlos et al. Host and Pathogen Biomarkers for Severe *Pseudomonas aeruginosa* Infections, *J INFECT DIS* (2017) 215: S44-S51

COMBACTE-MAGNET: Kaier, Klaus et al. Mechanical ventilation and the daily cost of ICU care, *BMC HEALTH SERV RES* (2020) 20:

COMBACTE-MAGNET: Lopez-Causape, Carla et al. The Versatile Mutational Resistome of *Pseudomonas aeruginosa*, *FRONT MICROBIOL* (2018) 9:

COMBACTE-MAGNET: Nunez-Nunez, M. et al. The methodology of surveillance for antimicrobial resistance and healthcare-associated infections in Europe (SUSPIRE): a systematic review of publicly available information, *CLIN MICROBIOL INFECTION* (2018) 24: 105-109

COMBACTE-MAGNET: Perner, Anders et al. Sepsis: frontiers in diagnosis, resuscitation and antibiotic therapy, *INTENS CARE MED* (2016) 42: 1958-1969

COMBACTE-MAGNET: Perner, Anders et al. The intensive care medicine research agenda on septic shock, *INTENS CARE MED* (2017) 43: 1294-1305

COMBACTE-MAGNET: Poguntke, Inga et al. Simulation shows undesirable results for competing risks analysis with time-dependent covariates for clinical outcomes, *BMC MED RES METHODOL* (2018) 18:

COMBACTE-MAGNET: Rajendran, N. Babu et al. Mandatory surveillance and outbreaks reporting of the WHO priority pathogens for research & discovery of new antibiotics in European countries, *CLIN MICROBIOL INFEC* (2020) 26:

COMBACTE-MAGNET: Schrijver, R. et al. Review of antimicrobial resistance surveillance programmes in livestock and meat in EU with focus on humans, *CLIN MICROBIOL INFEC* (2018) 24: 577-590

COMBACTE-MAGNET: Tacconelli, Evelina et al. Surveillance for control of antimicrobial resistance, *LANCET INFECT DIS* (2018) 18: E99-E106

COMBACTE-MAGNET: Troeman, D. P. R. et al. Antimicrobial approaches in the prevention of *Staphylococcus aureus* infections: a review, *J ANTIMICROB CHEMOTH* (2019) 74: 281-294

COMBACTE-MAGNET: Tschudin-Sutter, Sarah et al. Contact Precautions for Preventing Nosocomial Transmission of Extended-Spectrum beta Lactamase-Producing *Escherichia coli*: A Point/Counterpoint Review, *CLIN INFECT DIS* (2017) 65: 342-347

COMBACTE-NET: Barbier, Francois et al. Colonization and infection with extended-spectrum beta-lactamase-producing Enterobacteriaceae in ICU patients: what impact on outcomes and carbapenem exposure?, *J ANTIMICROB CHEMOTH* (2016) 71: 1088-1097

COMBACTE-NET: Bluhmki, Tobias et al. A wild bootstrap approach for the Aalen-Johansen estimator, *BIOMETRICS* (2018) 74: 977-985

COMBACTE-NET: de Kraker, M. E. A. et al. Good epidemiological practice: a narrative review of appropriate scientific methods to evaluate the impact of antimicrobial stewardship interventions, *CLIN MICROBIOL INFEC* (2017) 23: 819-825

COMBACTE-NET: Eliakim-Raz, Noa et al. Risk Factors for Treatment Failure and Mortality Among Hospitalized Patients With Complicated Urinary Tract Infection: A Multicenter Retrospective Cohort Study (RESCUING Study Group), *CLIN INFECT DIS* (2019) 68: 29-36

COMBACTE-NET: Grabein, B. et al. Intravenous fosfomycin-back to the future. Systematic review and meta-analysis of the clinical literature, *CLIN MICROBIOL INFEC* (2017) 23: 363-372

COMBACTE-NET: Gravestock, Isaac et al. Adaptive power priors with empirical Bayes for clinical trials, *PHARM STAT* (2017) 16: 349-360

COMBACTE-NET: Gudiol, Carlota et al. Efficacy of beta-Lactam/beta-Lactamase Inhibitor Combinations for the Treatment of Bloodstream Infection Due to Extended-Spectrum-beta-Lactamase-Producing Enterobacteriaceae in Hematological Patients with Neutropenia, *ANTIMICROB AGENTS CH* (2017) 61:

COMBACTE-NET: Israel, Laura et al. Human Adaptive Immunity Rescues an Inborn Error of Innate Immunity, *CELL* (2017) 168: 789-+

COMBACTE-NET: Kaier, Klaus et al. Mechanical ventilation and the daily cost of ICU care, *BMC HEALTH SERV RES* (2020) 20:

COMBACTE-NET: Passaro, Leonor et al. Prevention of hospital-acquired pneumonia in non-ventilated adult patients: a narrative review, *ANTIMICROB RESIST IN* (2016) 5:

COMBACTE-NET: Tacke, Daniela et al. Primary prophylaxis of invasive fungal infections in patients with haematologic malignancies. 2014 update of the recommendations of the Infectious Diseases Working Party of the German Society for Haematology and Oncology, *ANN HEMATOL* (2014) 93: 1449-1456

COMBACTE-NET: Troeman, D. P. R. et al. Antimicrobial approaches in the prevention of *Staphylococcus aureus* infections: a review, *J ANTIMICROB CHEMOTH* (2019) 74: 281-294

COMBACTE-NET: Xavier, Basil B. et al. BacPipe: A Rapid, User-Friendly Whole-Genome Sequencing Pipeline for Clinical Diagnostic Bacteriology, *ISCIENCE* (2020) 23:

COMPACT: Abdelhamid, Hani Nasser et al. Gene delivery using cell penetrating peptides-zeolitic imidazolate frameworks, *MICROPOR MESOPOR MAT* (2020) 300:

COMPACT: Birch, Ditlev et al. Fluorophore labeling of a cell-penetrating peptide induces differential effects on its cellular distribution and affects cell viability, *BBA-BIOMEMBRANES* (2017) 1859: 2483-2494

COMPACT: Carvalho, Cristiane de Souza et al. Carrier interactions with the biological barriers of the lung: Advanced in vitro models and challenges for pulmonary drug delivery, *ADV DRUG DELIVER REV* (2014) 75: 129-140

COMPACT: Colombo, Stefano et al. Mechanistic profiling of the siRNA delivery dynamics of lipid-polymer hybrid nanoparticles, *J CONTROL RELEASE* (2015) 201: 22-31

COMPACT: de Groot, Anne Marit et al. Hollow microneedle-mediated intradermal delivery of model vaccine antigen-loaded PLGA nanoparticles elicits protective T cell-mediated immunity to an intracellular bacterium, *J CONTROL RELEASE* (2017) 266: 27-35

COMPACT: Dowaidar, Moataz et al. Graphene oxide nanosheets in complex with cell penetrating peptides for oligonucleotides delivery, *BBA-GEN SUBJECTS* (2017) 1861: 2334-2341

COMPACT: Du, Guangsheng et al. Intradermal vaccination with hollow microneedles: A comparative study of various protein antigen and adjuvant encapsulated nanoparticles, *J CONTROL RELEASE* (2017) 266: 109-118

COMPACT: Heldring, Nina et al. Therapeutic Potential of Multipotent Mesenchymal Stromal Cells and Their Extracellular Vesicles, *HUM GENE THER* (2015) 26: 506-517

COMPACT: Kristensen, Mie et al. Applications and Challenges for Use of Cell-Penetrating Peptides as Delivery Vectors for Peptide and Protein Cargos, *INT J MOL SCI* (2016) 17:

COMPACT: Kuehn, Anna et al. Human Alveolar Epithelial Cells Expressing Tight Junctions to Model the Air-Blood Barrier, *ALTEX-ALTERN ANIM EX* (2016) 33: 251-260

COMPACT: Laechelt, Ulrich et al. Nucleic Acid Therapeutics Using Polyplexes: A Journey of 50 Years (and Beyond), *CHEM REV* (2015) 115: 11043-11078

COMPACT: Lorenzer, Cornelia et al. Going beyond the liver: Progress and challenges of targeted delivery of siRNA therapeutics, *J CONTROL RELEASE* (2015) 203: 1-15

COMPACT: Mager, Imre et al. Targeting blood-brain-barrier transcytosis - perspectives for drug delivery, *NEUROPHARMACOLOGY* (2017) 120: 4-7

COMPACT: Monkare, Juha et al. Development of PLGA nanoparticle loaded dissolving microneedles and comparison with hollow microneedles in intradermal vaccine delivery, *EUR J PHARM BIOPHARM* (2018) 129: 111-121

COMPACT: Nordin, Joel Z. et al. Ultrafiltration with size-exclusion liquid chromatography for high yield isolation of extracellular vesicles preserving intact biophysical and functional properties, *NANOMED-NANOTECHNOL* (2015) 11: 879-883

COMPACT: OLoughlin, Aisling J. et al. Functional Delivery of Lipid-Conjugated siRNA by Extracellular Vesicles, *MOL THER* (2017) 25: 1580-1587

COMPACT: Oswald, Mira et al. Targeting the Central Nervous System (CNS): A Review of Rabies Virus-Targeting Strategies, *MOL PHARMACEUT* (2017) 14: 2177-2196

COMPACT: Sanduleanu, Sebastian et al. Tracking tumor biology with radiomics: A systematic review utilizing a radiomics quality score, *RADIOTHER ONCOL* (2018) 127: 349-360

COMPACT: Sork, Helena et al. Heterogeneity and interplay of the extracellular vesicle small RNA transcriptome and proteome, *SCI REP-UK* (2018) 8:

COMPACT: Verdurmen, Wouter P. R. et al. Efficient cell-specific uptake of binding proteins into the cytoplasm through engineered modular transport systems, *J CONTROL RELEASE* (2015) 200: 13-22

COMPACT: Vermeulen, Lotte M. P. et al. Endosomal Size and Membrane Leakiness Influence Proton Sponge-Based Rupture of Endosomal Vesicles, *ACS NANO* (2018) 12: 2332-2345

COMPACT: Wiklander, Oscar P. B. et al. Extracellular vesicle in vivo biodistribution is determined by cell source, route of administration and targeting, *J EXTRACELL VESICLES* (2015) 4:

COMPACT: Willms, Eduard et al. Cells release subpopulations of exosomes with distinct molecular and biological properties, *SCI REP-UK* (2016) 6:

DDMoRe: Bender, Brendan C. et al. Population pharmacokinetic-pharmacodynamic modelling in oncology: a tool for predicting clinical response, *BRIT J CLIN PHARMACO* (2015) 79: 56-71

DDMoRe: Bergmann, Frank T. et al. COMBINE archive and OMEX format: one file to share all information to reproduce a modeling project, *BMC BIOINFORMATICS* (2014) 15:

DDMoRe: Buechel, Finja et al. Path2Models: large-scale generation of computational models from biochemical pathway maps, *BMC SYST BIOL* (2013) 7:

DDMoRe: Chelliah, Vijayalakshmi et al. BioModels: ten-year anniversary, *NUCLEIC ACIDS RES* (2015) 43: D542-D548

DDMoRe: Delattre, Maud et al. A note on BIC in mixed-effects models, *ELECTRON J STAT* (2014) 8: 456-475

DDMoRe: Dosne, Anne-Gaelle et al. Improving the estimation of parameter uncertainty distributions in nonlinear mixed effects models using sampling importance resampling, *J PHARMACOKINET PHAR* (2016) 43: 583-596

DDMoRe: Glont, Mihai et al. BioModels: expanding horizons to include more modelling approaches and formats, *NUCLEIC ACIDS RES* (2018) 46: D1248-D1253

DDMoRe: Malik-Sheriff, Rahuman S. et al. BioModels-15 years of sharing computational models in life science, *NUCLEIC ACIDS RES* (2020) 48: D407-D415

DDMoRe: McMurry, Julie A. et al. Identifiers for the 21st century: How to design, provision, and reuse persistent identifiers to maximize utility and impact of life science data, *PLOS BIOL* (2017) 15:

DDMoRe: Nielsen, Elisabet I. et al. Pharmacokinetic-Pharmacodynamic Modeling of Antibacterial Drugs, *PHARMACOL REV* (2013) 65: 1053-1090

DIRECT: Aguet, Francois et al. The GTEx Consortium atlas of genetic regulatory effects across human tissues, *SCIENCE* (2020) 369: 1318-1330

DIRECT: Ahmad, Shafqat et al. Gene x Physical Activity Interactions in Obesity: Combined Analysis of 111,421 Individuals of European Ancestry, *PLOS GENET* (2013) 9:

DIRECT: Allin, Kristine H. et al. Aberrant intestinal microbiota in individuals with prediabetes, *DIABETOLOGIA* (2018) 61: 810-820

DIRECT: Breier, Michaela et al. Targeted Metabolomics Identifies Reliable and Stable Metabolites in Human Serum and Plasma Samples, PLOS ONE (2014) 9:

DIRECT: Chung, Wendy K. et al. Precision Medicine in Diabetes: A Consensus Report From the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD), DIABETES CARE (2020) 43: 1617-1635

DIRECT: Demanelis, Kathryn et al. Determinants of telomere length across human tissues, SCIENCE (2020) 369: 1333-+

DIRECT: Dujic, T. et al. Variants in Pharmacokinetic Transporters and Glycemic Response to Metformin: A MetGen Meta-Analysis, CLIN PHARMACOL THER (2017) 101: 763-772

DIRECT: Ferraro, Nicole M. et al. Transcriptomic signatures across human tissues identify functional rare genetic variation, SCIENCE (2020) 369: 1334-+

DIRECT: Franks, Paul W. et al. Exposing the exposures responsible for type 2 diabetes and obesity, SCIENCE (2016) 354: 69-73

DIRECT: Fredolini, Claudia et al. Systematic assessment of antibody selectivity in plasma based on a resource of enrichment profiles, SCI REP-UK (2019) 9:

DIRECT: Haid, Mark et al. Long-Term Stability of Human Plasma Metabolites during Storage at -80 degrees C, J PROTEOME RES (2018) 17: 203-211

DIRECT: Hocher, Berthold et al. Metabolomics for clinical use and research in chronic kidney disease, NAT REV NEPHROL (2017) 13: 269-284

DIRECT: Ji, Yingjie et al. Genome-Wide and Abdominal MRI Data Provide Evidence That a Genetically Determined Favorable Adiposity Phenotype Is Characterized by Lower Ectopic Liver Fat and Lower Risk of Type 2 Diabetes, Heart Disease, and Hypertension, DIABETES (2019) 68: 207-219

DIRECT: McCarthy, Mark I. et al. Painting a new picture of personalised medicine for diabetes, DIABETOLOGIA (2017) 60: 793-799

DIRECT: Nica, Alexandra C. et al. Cell-type, allelic, and genetic signatures in the human pancreatic beta cell transcriptome, GENOME RES (2013) 23: 1554-1562

DIRECT: Oliva, Meritxell et al. The impact of sex on gene expression across human tissues, SCIENCE (2020) 369: 1331-+

DIRECT: Pasquali, Lorenzo et al. Pancreatic islet enhancer clusters enriched in type 2 diabetes risk-associated variants, NAT GENET (2014) 46: 136-+

DIRECT: Pearson, Ewan R. et al. Type 2 diabetes: a multifaceted disease, DIABETOLOGIA (2019) 62: 1107-1112

DIRECT: Pedersen, Helle Krogh et al. Human gut microbes impact host serum metabolome and insulin sensitivity, NATURE (2016) 535: 376-+

DIRECT: Shah, Nisha et al. Sharing data for future research-engaging participants views about data governance beyond the original project: a DIRECT Study, GENET MED (2019) 21: 1131-1138

DIRECT: Vinuela, Ana et al. Genetic variant effects on gene expression in human pancreatic islets and their implications for T2D, NAT COMMUN (2020) 11:

DIRECT: Wood, Andrew R. et al. A Genome-Wide Association Study of IVGTT-Based Measures of First-Phase Insulin Secretion Refines the Underlying Physiology of Type 2 Diabetes Variants, DIABETES (2017) 66: 2296-2309

DO->IT: Kalkman, Shona et al. Responsible data sharing in international health research: a systematic review of principles and norms, BMC MED ETHICS (2019) 20:

DRAGON: Hu, Shaoping et al. Weakly Supervised Deep Learning for COVID-19 Infection Detection and Classification From CT Images, *IEEE ACCESS* (2020) 8: 118869-118883

DRIVE: Alvarez-Uria, Gerardo et al. Global forecast of antimicrobial resistance in invasive isolates of *Escherichia coli* and *Klebsiella pneumoniae*, *INT J INFECT DIS* (2018) 68: 50-53

DRIVE: Panatto, Donatella et al. Influenza Vaccination in Italian Healthcare Workers (2018-2019 Season): Strengths and Weaknesses. Results of a Cohort Study in Two Large Italian Hospitals, *VACCINES-BASEL* (2020) 8:

DRIVE: Simon, Bruno et al. Whole Genome Sequencing of A(H3N2) Influenza Viruses Reveals Variants Associated with Severity during the 2016-2017 Season, *VIRUSES-BASEL* (2019) 11:

DRIVE-AB: Alvarez-Uria, Gerardo et al. Global forecast of antimicrobial resistance in invasive isolates of *Escherichia coli* and *Klebsiella pneumoniae*, *INT J INFECT DIS* (2018) 68: 50-53

DRIVE-AB: Baraldi, Enrico et al. Antibiotic Pipeline Coordinators, *J LAW MED ETHICS* (2018) 46: 25-31

DRIVE-AB: Benic, Mirjana Stanic et al. Metrics for quantifying antibiotic use in the hospital setting: results from a systematic review and international multidisciplinary consensus procedure, *J ANTIMICROB CHEMOTH* (2018) 73: 50-58

DRIVE-AB: de Kraker, M. E. A. et al. Good epidemiological practice: a narrative review of appropriate scientific methods to evaluate the impact of antimicrobial stewardship interventions, *CLIN MICROBIOL INFEC* (2017) 23: 819-825

DRIVE-AB: Deak, Dalia et al. Progress in the Fight Against Multidrug-Resistant Bacteria? A Review of US Food and Drug Administration-Approved Antibiotics, 2010-2015, *ANN INTERN MED* (2016) 165: 363-+

DRIVE-AB: Friedman, N. D. et al. The negative impact of antibiotic resistance, *CLIN MICROBIOL INFEC* (2016) 22: 416-422

DRIVE-AB: Harbarth, S. et al. Antibiotic research and development: business as usual?, *J ANTIMICROB CHEMOTH* (2015) 70: 1604-1607

DRIVE-AB: Huttner, Benedikt et al. How to improve antibiotic awareness campaigns: findings of a WHO global survey, *BMJ GLOB HEALTH* (2019) 4:

DRIVE-AB: Le Marechal, Marion et al. Quality indicators assessing antibiotic use in the outpatient setting: a systematic review followed by an international multidisciplinary consensus procedure, *J ANTIMICROB CHEMOTH* (2018) 73: 40-49

DRIVE-AB: Muller, Anouk E. et al. Therapeutic Drug Monitoring of Beta-Lactams and Other Antibiotics in the Intensive Care Unit: Which Agents, Which Patients and Which Infections?, *DRUGS* (2018) 78: 439-451

DRIVE-AB: Savic, Miloje et al. A Grant Framework as a Push Incentive to Stimulate Research and Development of New Antibiotics, *J LAW MED ETHICS* (2018) 46: 9-24

DRIVE-AB: Tacconelli, Evelina et al. STROBE-AMS: recommendations to optimise reporting of epidemiological studies on antimicrobial resistance and informing improvement in antimicrobial stewardship, *BMJ OPEN* (2016) 6:

DRIVE-AB: Teillant, Aude et al. Potential burden of antibiotic resistance on surgery and cancer chemotherapy antibiotic prophylaxis in the USA: a literature review and modelling study, *LANCET INFECT DIS* (2015) 15: 1429-1437

DRIVE-AB: Temkin, Elizabeth et al. Estimating the number of infections caused by antibiotic-resistant *Escherichia coli* and *Klebsiella pneumoniae* in 2014: a modelling study, *LANCET GLOB HEALTH* (2018) 6: E969-E979

DRIVE-AB: Zanichelli, V. et al. Patient-related determinants of antibiotic use: a systematic review, *CLIN MICROBIOL INFECTION* (2019) 25: 48-53

EBiSC: Cunningham, Fiona et al. Ensembl 2019, *NUCLEIC ACIDS RES* (2019) 47: D745-D751

EBiSC: De Sousa, Paul A. et al. Rapid establishment of the European Bank for induced Pluripotent Stem Cells (EBiSC) - the Hot Start experience, *STEM CELL RES* (2017) 20: 105-114

EBiSC: Falk, A. et al. Modeling psychiatric disorders: from genomic findings to cellular phenotypes, *MOL PSYCHIATR* (2016) 21: 1167-1179

EBiSC: Gerli, Mattia Francesco Maria et al. Combined Notch and PDGF Signaling Enhances Migration and Expression of Stem Cell Markers while Inducing Perivascular Cell Features in Muscle Satellite Cells, *STEM CELL REP* (2019) 12: 461-473

EBiSC: Hasselmann, Jonathan et al. Development of a Chimeric Model to Study and Manipulate Human Microglia In Vivo, *NEURON* (2019) 103: 1016-+

EBiSC: Laugsch, Magdalena et al. Modeling the Pathological Long-Range Regulatory Effects of Human Structural Variation with Patient-Specific hiPSCs, *CELL STEM CELL* (2019) 24: 736-+

EBiSC: Maffioletti, Sara Martina et al. Three-Dimensional Human iPSC-Derived Artificial Skeletal Muscles Model Muscular Dystrophies and Enable Multilineage Tissue Engineering, *CELL REP* (2018) 23: 899-908

EBiSC: OShea, Orla et al. Development and implementation of large-scale quality control for the European bank for induced Pluripotent Stem Cells, *STEM CELL RES* (2020) 45:

EBiSC: Zerbino, Daniel R. et al. Ensembl 2018, *NUCLEIC ACIDS RES* (2018) 46: D754-D761

EBiSC2: OShea, Orla et al. Development and implementation of large-scale quality control for the European bank for induced Pluripotent Stem Cells, *STEM CELL RES* (2020) 45:

EBODAC: Anywaine, Zacchaeus et al. Safety and Immunogenicity of a 2-Dose Heterologous Vaccination Regimen With Ad26.ZEBOV and MVA-BN-Filo Ebola Vaccines: 12-Month Data From a Phase 1 Randomized Clinical Trial in Uganda and Tanzania, *J INFECT DIS* (2019) 220: 46-56

EBODAC: Mutua, Gaudensia et al. Safety and Immunogenicity of a 2-Dose Heterologous Vaccine Regimen With Ad26.ZEBOV and MVA-BN-Filo Ebola Vaccines: 12-Month Data From a Phase 1 Randomized Clinical Trial in Nairobi, Kenya, *J INFECT DIS* (2019) 220: 57-67

EbolaMoDRAD: Forbes, Kristian M. et al. Bombali Virus in Mops condylurus Bat, Kenya, *EMERG INFECT DIS* (2019) 25: 955-957

EbolaMoDRAD: Guedj, Jeremie et al. Antiviral efficacy of favipiravir against Ebola virus: A translational study in cynomolgus macaques, *PLOS MED* (2018) 15:

EBOMAN: Anywaine, Zacchaeus et al. Safety and Immunogenicity of a 2-Dose Heterologous Vaccination Regimen With Ad26.ZEBOV and MVA-BN-Filo Ebola Vaccines: 12-Month Data From a Phase 1 Randomized Clinical Trial in Uganda and Tanzania, *J INFECT DIS* (2019) 220: 46-56

EBOMAN: Mutua, Gaudensia et al. Safety and Immunogenicity of a 2-Dose Heterologous Vaccine Regimen With Ad26.ZEBOV and MVA-BN-Filo Ebola Vaccines: 12-Month Data From a Phase 1 Randomized Clinical Trial in Nairobi, Kenya, *J INFECT DIS* (2019) 220: 57-67

EBOVAC: Huttner, Angela et al. Determinants of antibody persistence across doses and continents after single-dose rVSV-ZEBOV vaccination for Ebola virus disease: an observational cohort study, *LANCET INFECT DIS* (2018) 18: 738-748

EBOVAC1: Anywaine, Zacchaeus et al. Safety and Immunogenicity of a 2-Dose Heterologous Vaccination Regimen With Ad26.ZEBOV and MVA-BN-Filo Ebola Vaccines: 12-Month Data From a Phase 1 Randomized Clinical Trial in Uganda and Tanzania, *J INFECT DIS* (2019) 220: 46-56

EBOVAC1: Enria, Luisa et al. Power, fairness and trust: understanding and engaging with vaccine trial participants and communities in the setting up the EBOVAC-Salone vaccine trial in Sierra Leone, *BMC PUBLIC HEALTH* (2016) 16:

EBOVAC1: Funk, Sebastian et al. Assessing the performance of real-time epidemic forecasts: A case study of Ebola in the Western Area region of Sierra Leone, 2014-15, *PLOS COMPUT BIOL* (2019) 15:

EBOVAC1: Funk, Sebastian et al. Comparative Analysis of Dengue and Zika Outbreaks Reveals Differences by Setting and Virus, *PLOS NEGLECT TROP D* (2016) 10:

EBOVAC1: Funk, Sebastian et al. Real-time forecasting of infectious disease dynamics with a stochastic semi-mechanistic model, *EPIDEMICS-NETH* (2018) 22: 56-61

EBOVAC1: Kucharski, Adam J. et al. Effectiveness of Ring Vaccination as Control Strategy for Ebola Virus Disease, *EMERG INFECT DIS* (2016) 22: 105-108

EBOVAC1: Milligan, Iain D. et al. Safety and Immunogenicity of Novel Adenovirus Type 26-and Modified Vaccinia Ankara-Vectored Ebola Vaccines A Randomized Clinical Trial, *JAMA-J AM MED ASSOC* (2016) 315: 1610-1623

EBOVAC1: Mutua, Gaudensia et al. Safety and Immunogenicity of a 2-Dose Heterologous Vaccine Regimen With Ad26.ZEBOV and MVA-BN-Filo Ebola Vaccines: 12-Month Data From a Phase 1 Randomized Clinical Trial in Nairobi, Kenya, *J INFECT DIS* (2019) 220: 57-67

EBOVAC1: Sissoko, Daouda et al. Persistence and clearance of Ebola virus RNA from seminal fluid of Ebola virus disease survivors: a longitudinal analysis and modelling study, *LANCET GLOB HEALTH* (2017) 5: E80-E88

EBOVAC2: Anywaine, Zacchaeus et al. Safety and Immunogenicity of a 2-Dose Heterologous Vaccination Regimen With Ad26.ZEBOV and MVA-BN-Filo Ebola Vaccines: 12-Month Data From a Phase 1 Randomized Clinical Trial in Uganda and Tanzania, *J INFECT DIS* (2019) 220: 46-56

EBOVAC2: Goodier, Martin R. et al. CMV and natural killer cells: shaping the response to vaccination, *EUR J IMMUNOL* (2018) 48: 50-65

EBOVAC2: Mutua, Gaudensia et al. Safety and Immunogenicity of a 2-Dose Heterologous Vaccine Regimen With Ad26.ZEBOV and MVA-BN-Filo Ebola Vaccines: 12-Month Data From a Phase 1 Randomized Clinical Trial in Nairobi, Kenya, *J INFECT DIS* (2019) 220: 57-67

EBOVAC2: Rechten, Anne et al. Systems Vaccinology Identifies an Early Innate Immune Signature as a Correlate of Antibody Responses to the Ebola Vaccine rVSV-ZEBOV, *CELL REP* (2017) 20: 2251-2261

EHDEN: Lane, Jennifer C. E. et al. Risk of hydroxychloroquine alone and in combination with azithromycin in the treatment of rheumatoid arthritis: a multinational, retrospective study, *LANCET RHEUMATOL* (2020) 2: E698-E711

EHR4CR: Aarestrup, F. M. et al. Towards a European health research and innovation cloud (HRIC), *GENOME MED* (2020) 12:

EHR4CR: Coorevits, P. et al. Electronic health records: new opportunities for clinical research, *J INTERN MED* (2013) 274: 547-560

EHR4CR: De Moor, Georges et al. Using electronic health records for clinical research: The case of the EHR4CR project, *J BIOMED INFORM* (2015) 53: 162-173

ELF: Besnard, Jeremy et al. The Joint European Compound Library: boosting precompetitive research, *DRUG DISCOV TODAY* (2015) 20: 181-186

ELF: Domling, Alexander et al. Chemistry and Biology of SARS-CoV-2, *CHEM-US* (2020) 6: 1283-1295



ELF: Garcia-Castro, Miguel et al. Scaffold Diversity Synthesis and Its Application in Probe and Drug Discovery, *ANGEW CHEM INT EDIT* (2016) 55: 7586-7605

ELF: Karawajczyk, Anna et al. Expansion of chemical space for collaborative lead generation and drug discovery: the European Lead Factory Perspective, *DRUG DISCOV TODAY* (2015) 20: 1310-1316

ELF: Konstantinidou, Markella et al. Immune Checkpoint PD-1/PD-L1: Is There Life Beyond Antibodies?, *ANGEW CHEM INT EDIT* (2018) 57: 4840-4848

ELF: Krajnc, Alen et al. Bicyclic Boronate VNRX-5133 Inhibits Metallo- and Serine-beta-Lactamases, *J MED CHEM* (2019) 62: 8544-8556

ELF: Krajnc, Alen et al. Will morphing boron-based inhibitors beat the beta-lactamases?, *CURR OPIN CHEM BIOL* (2019) 50: 101-110

ELF: Langley, Gareth W. et al. Profiling interactions of vaborbactam with metallo-beta-lactamases, *BIOORG MED CHEM LETT* (2019) 29: 1981-1984

ELF: Liao, George P. et al. Versatile Multicomponent Reaction Macrocyclic Synthesis Using alpha-Isocyano-omega-carboxylic Acids, *ORG LETT* (2015) 17: 4980-4983

ELF: Mock, Elliot D. et al. Discovery of a NAPE-PLD inhibitor that modulates emotional behavior in mice, *NAT CHEM BIOL* (2020) 16: 667-+

ELF: Mueller, Gerhard et al. Charting Biologically Relevant Spirocyclic Compound Space, *CHEM-EUR J* (2017) 23: 703-710

ELF: Neochoritis, Constantinos G. et al. Efficient Isocyanide-less Isocyanide-Based Multicomponent Reactions, *ORG LETT* (2015) 17: 2002-2005

ELF: Patil, Pravin et al. De Novo Assembly of Highly Substituted Morpholines and Piperazines, *ORG LETT* (2017) 19: 642-645

ELF: Picazo, Edwige et al. Small molecule inhibitors of ebola virus infection, *DRUG DISCOV TODAY* (2015) 20: 277-286

ELF: Shaabani, Shabnam et al. A patent review on PD-1/PD-L1 antagonists: small molecules, peptides, and macrocycles (2015-2018), *EXPERT OPIN THER PAT* (2018) 28: 665-678

ELF: Surmiak, Ewa et al. Rational design and synthesis of 1,5-disubstituted tetrazoles as potent inhibitors of the MDM2-p53 interaction, *EUR J MED CHEM* (2017) 126: 384-407

ELF: Tselepis, Lucas et al. In vitro efficacy of imipenem-relebactam and cefepime-AAI101 against a global collection of ESBL-positive and carbapenemase-producing Enterobacteriaceae, *INT J ANTIMICROB AG* (2020) 56:

ELF: Zak, Krzysztof M. et al. Structural Biology of the Immune Checkpoint Receptor PD-1 and Its Ligands PD-L1/PD-L2, *STRUCTURE* (2017) 25: 1163-1174

ELF: Zarganes-Tzitzikas, Tryfon et al. Modern multicomponent reactions for better drug syntheses, *ORG CHEM FRONT* (2014) 1: 834-U178

ELF: Zarganes-Tzitzikas, Tryfon et al. Multicomponent Reactions, Union of MCRs and Beyond, *CHEM REC* (2015) 15: 981-996

EMIF: Aarestrup, F. M. et al. Towards a European health research and innovation cloud (HRIC), *GENOME MED* (2020) 12:

EMIF: Alexander, Myriam et al. Non-alcoholic fatty liver disease and risk of incident acute myocardial infarction and stroke: findings from matched cohort study of 18 million European adults, *BMJ-BRIT MED J* (2019) 367:

EMIF: Alshahrani, Mona et al. Neuro-symbolic representation learning on biological knowledge graphs, *BIOINFORMATICS* (2017) 33: 2723-2730

EMIF: Auffray, Charles et al. Making sense of big data in health research: Towards an EU action plan, *GENOME MED* (2016) 8:

EMIF: Barquissau, Valentin et al. Caloric Restriction and Diet-Induced Weight Loss Do Not Induce Browning of Human Subcutaneous White Adipose Tissue in Women and Men with Obesity, *CELL REP* (2018) 22: 1079-1089

EMIF: Bos, Isabelle et al. Cerebrospinal fluid biomarkers of neurodegeneration, synaptic integrity, and astroglial activation across the clinical Alzheimers disease spectrum, *ALZHEIMERS DEMENT* (2019) 15: 644-654

EMIF: Bridel, Claire et al. Diagnostic Value of Cerebrospinal Fluid Neurofilament Light Protein in Neurology: A Systematic Review and Meta-analysis, *JAMA NEUROL* (2019) 76: 1035-1048

EMIF: Brookes, Anthony J. et al. Human genotype-phenotype databases: aims, challenges and opportunities, *NAT REV GENET* (2015) 16: 702-715

EMIF: Chiasserini, Davide et al. Differential role of CSF fatty acid binding protein 3, alpha-synuclein, and Alzheimers disease core biomarkers in Lewy body disorders and Alzheimers dementia, *ALZHEIMERS RES THER* (2017) 9:

EMIF: Collij, Lyduine E. et al. Assessing Amyloid Pathology in Cognitively Normal Subjects Using F-18-Flutemetamol PET: Comparing Visual Reads and Quantitative Methods, *J NUCL MED* (2019) 60: 541-547

EMIF: Cuyvers, Elise et al. Genetic variations underlying Alzheimers disease: evidence from genome-wide association studies and beyond, *LANCET NEUROL* (2016) 15: 857-868

EMIF: De Vos, Ann et al. C-terminal neurogranin is increased in cerebrospinal fluid but unchanged in plasma in Alzheimers disease, *ALZHEIMERS DEMENT* (2015) 11: 1461-1469

EMIF: Dennis, John M. et al. Precision Medicine in Type 2 Diabetes: Clinical Markers of Insulin Resistance Are Associated With Altered Short- and Long-term Glycemic Response to DPP-4 Inhibitor Therapy, *DIABETES CARE* (2018) 41: 705-712

EMIF: Frisoni, Giovanni B. et al. Strategic roadmap for an early diagnosis of Alzheimers disease based on biomarkers, *LANCET NEUROL* (2017) 16: 661-676

EMIF: Gutierrez-Sacristan, Alba et al. PsyGeNET: a knowledge platform on psychiatric disorders and their genes, *BIOINFORMATICS* (2015) 31: 3075-3077

EMIF: Hagenbeek, Fiona A. et al. Heritability estimates for 361 blood metabolites across 40 genome-wide association studies, *NAT COMMUN* (2020) 11:

EMIF: Hansson, Oskar et al. Advantages and disadvantages of the use of the CSF Amyloid (A) 42/40 ratio in the diagnosis of Alzheimers Disease, *ALZHEIMERS RES THER* (2019) 11:

EMIF: Hansson, Oskar et al. The impact of preanalytical variables on measuring cerebrospinal fluid biomarkers for Alzheimers disease diagnosis: A review, *ALZHEIMERS DEMENT* (2018) 14: 1313-1333

EMIF: Hellmuth, Christian et al. Tyrosine Is Associated with Insulin Resistance in Longitudinal Metabolomic Profiling of Obese Children, *J DIABETES RES* (2016) 2016:

EMIF: Hellwig, Konstantin et al. Neurogranin and YKL-40: independent markers of synaptic degeneration and neuroinflammation in Alzheimers disease, *ALZHEIMERS RES THER* (2015) 7:

EMIF: Hess, Anne Lundby et al. Levels of Circulating miR-122 are Associated with Weight Loss and Metabolic Syndrome, *OBESITY* (2020) 28: 493-501

EMIF: Hye, Abdul et al. Plasma proteins predict conversion to dementia from prodromal disease, *ALZHEIMERS DEMENT* (2014) 10: 799-807

EMIF: Hyotylainen, Tuulia et al. Genome-scale study reveals reduced metabolic adaptability in patients with non-alcoholic fatty liver disease, *NAT COMMUN* (2016) 7:

EMIF: Hyysalo, Jenni et al. A population-based study on the prevalence of NASH using scores validated against liver histology, *J HEPATOL* (2014) 60: 839-846

EMIF: Iliodromiti, Stamatina et al. The impact of confounding on the associations of different adiposity measures with the incidence of cardiovascular disease: a cohort study of 296 535 adults of white European descent, *EUR HEART J* (2018) 39: 1514-+

EMIF: Isokuortti, Elina et al. Use of HOMA-IR to diagnose non-alcoholic fatty liver disease: a population-based and inter-laboratory study, *DIABETOLOGIA* (2017) 60: 1873-1882

EMIF: Jack, Clifford R., Jr. et al. Suspected non-Alzheimer disease pathophysiology - concept and controversy, *NAT REV NEUROL* (2016) 12: 117-124

EMIF: Jansen, Willemijn J. et al. Prevalence of Cerebral Amyloid Pathology in Persons Without Dementia A Meta-analysis, *JAMA-J AM MED ASSOC* (2015) 313: 1924-1938

EMIF: Jian, Ching et al. Quantitative PCR provides a simple and accessible method for quantitative microbiota profiling, *PLOS ONE* (2020) 15:

EMIF: Kim, Min et al. Primary fatty amides in plasma associated with brain amyloid burden, hippocampal volume, and memory in the European Medical Information Framework for Alzheimers Disease biomarker discovery cohort, *ALZHEIMERS DEMENT* (2019) 15: 817-827

EMIF: Kjolbaek, Louise et al. Arabinoxylan oligosaccharides and polyunsaturated fatty acid effects on gut microbiota and metabolic markers in overweight individuals with signs of metabolic syndrome: A randomized cross-over trial, *CLIN NUTR* (2020) 39: 67-79

EMIF: Kuhlmann, Julia et al. CSF A beta(1-42) - an excellent but complicated Alzheimers biomarker - a route to standardisation, *CLIN CHIM ACTA* (2017) 467: 27-33

EMIF: Lallukka, S. et al. Non-alcoholic fatty liver disease and risk of type 2 diabetes, *BEST PRACT RES CL EN* (2016) 30: 385-395

EMIF: Le Bastard, Nathalie et al. Importance and Impact of Preanalytical Variables on Alzheimer Disease Biomarker Concentrations in Cerebrospinal Fluid, *CLIN CHEM* (2015) 61: 734-743

EMIF: Lee, Sunjae et al. Integrated Network Analysis Reveals an Association between Plasma Mannose Levels and Insulin Resistance, *CELL METAB* (2016) 24: 172-184

EMIF: Lee, Sunjae et al. Network analyses identify liver-specific targets for treating liver diseases, *MOL SYST BIOL* (2017) 13:

EMIF: Legdeur, N. et al. Age dependency of risk factors for cognitive decline, *BMC GERIATR* (2018) 18:

EMIF: Lewczuk, Piotr et al. Cerebrospinal Fluid A beta(42/40) Corresponds Better than A beta(42) to Amyloid PET in Alzheimers Disease, *J ALZHEIMERS DIS* (2017) 55: 813-822

EMIF: Lewczuk, Piotr et al. Cerebrospinal fluid and blood biomarkers for neurodegenerative dementias: An update of the Consensus of the Task Force on Biological Markers in Psychiatry of the World Federation of Societies of Biological Psychiatry, *WORLD J BIOL PSYCHIA* (2018) 19: 244-328

EMIF: Lewczuk, Piotr et al. Plasma neurofilament light as a potential biomarker of neurodegeneration in Alzheimers disease, *ALZHEIMERS RES THER* (2018) 10:

EMIF: Loomis, A. Katrina et al. Body Mass Index and Risk of Nonalcoholic Fatty Liver Disease: Two Electronic Health Record Prospective Studies, *J CLIN ENDOCR METAB* (2016) 101: 945-952

EMIF: Lotta, Luca A. et al. Association of Genetic Variants Related to Gluteofemoral vs Abdominal Fat Distribution With Type 2 Diabetes, Coronary Disease, and Cardiovascular Risk Factors, *JAMA-J AM MED ASSOC* (2018) 320: 2553-2563

EMIF: Lotta, Luca A. et al. Genetic Predisposition to an Impaired Metabolism of the Branched-Chain Amino Acids and Risk of Type 2 Diabetes: A Mendelian Randomisation Analysis, *PLOS MED* (2016) 13:

EMIF: Lotta, Luca A. et al. Integrative genomic analysis implicates limited peripheral adipose storage capacity in the pathogenesis of human insulin resistance, *NAT GENET* (2017) 49: 17-26

EMIF: Lunnon, Katie et al. Mitochondrial genes are altered in blood early in Alzheimers disease, *NEUROBIOL AGING* (2017) 53: 36-47

EMIF: Luukkonen, Panu K. et al. Hepatic ceramides dissociate steatosis and insulin resistance in patients with non-alcoholic fatty liver disease, *J HEPATOL* (2016) 64: 1167-1175

EMIF: Luukkonen, Panu K. et al. Impaired hepatic lipid synthesis from polyunsaturated fatty acids in TM6SF2 E167K variant carriers with NAFLD, *J HEPATOL* (2017) 67: 128-136

EMIF: Luukkonen, Panu K. et al. Saturated Fat Is More Metabolically Harmful for the Human Liver Than Unsaturated Fat or Simple Sugars, *DIABETES CARE* (2018) 41: 1732-1739

EMIF: Mardinoglu, Adil et al. An Integrated Understanding of the Rapid Metabolic Benefits of a Carbohydrate-Restricted Diet on Hepatic Steatosis in Humans, *CELL METAB* (2018) 27: 559-+

EMIF: Mardinoglu, Adil et al. Personal model-assisted identification of NAD(+) and glutathione metabolism as intervention target in NAFLD, *MOL SYST BIOL* (2017) 13:

EMIF: Mardinoglu, Adil et al. Systems biology in hepatology: approaches and applications, *NAT REV GASTRO HEPAT* (2018) 15: 365-377

EMIF: Mroczko, Barbara et al. Amyloid beta oligomers (A beta Os) in Alzheimers disease, *J NEURAL TRANSM* (2018) 125: 177-191

EMIF: Nead, Kevin T. et al. Evidence of a Causal Association Between Insulinemia and Endometrial Cancer: A Mendelian Randomization Analysis, *JNCI-J NATL CANCER I* (2015) 107:

EMIF: Niemantsverdriet, Ellis et al. Alzheimers disease CSF biomarkers: clinical indications and rational use, *ACTA NEUROL BELG* (2017) 117: 591-602

EMIF: Niemantsverdriet, Ellis et al. The Cerebrospinal Fluid A beta(1-42)/A beta(1-40) Ratio Improves Concordance with Amyloid-PET for Diagnosing Alzheimers Disease in a Clinical Setting, *J ALZHEIMERS DIS* (2017) 60: 561-576

EMIF: Oeckl, Patrick et al. Glial Fibrillary Acidic Protein in Serum is Increased in Alzheimers Disease and Correlates with Cognitive Impairment, *J ALZHEIMERS DIS* (2019) 67: 481-488

EMIF: Ossenkoppele, Rik et al. Prevalence of Amyloid PET Positivity in Dementia Syndromes A Meta-analysis, *JAMA-J AM MED ASSOC* (2015) 313: 1939-1949

EMIF: Ostergaard, Soren D. et al. Associations between Potentially Modifiable Risk Factors and Alzheimer Disease: A Mendelian Randomization Study, *PLOS MED* (2015) 12:

EMIF: Payne, Felicity et al. Hypomorphism in human NSMCE2 linked to primordial dwarfism and insulin resistance, *J CLIN INVEST* (2014) 124: 4028-4038

EMIF: Payne, Felicity et al. Mutations disrupting the Kennedy phosphatidylcholine pathway in humans with congenital lipodystrophy and fatty liver disease, *P NATL ACAD SCI USA* (2014) 111: 8901-8906

EMIF: Perera, Gayan et al. Dementia prevalence and incidence in a federation of European Electronic Health Record databases: The European Medical Informatics Framework resource, *ALZHEIMERS DEMENT* (2018) 14: 130-139

EMIF: Pini, Lorenzo et al. Brain atrophy in Alzheimers Disease and aging, *AGEING RES REV* (2016) 30: 25-48

EMIF: Proitsi, Petroula et al. Association of blood lipids with Alzheimers disease: A comprehensive lipidomics analysis, *ALZHEIMERS DEMENT* (2017) 13: 140-151

EMIF: Queralt-Rosinach, Nuria et al. DisGeNET-RDF: harnessing the innovative power of the Semantic Web to explore the genetic basis of diseases, *BIOINFORMATICS* (2016) 32: 2236-2238

EMIF: Rowe, Emily R. et al. Conserved Amphipathic Helices Mediate Lipid Droplet Targeting of Perilipins 1-3, *J BIOL CHEM* (2016) 291: 6664-6678

EMIF: Sattar, Naveed et al. Type 2 diabetes as a disease of ectopic fat?, *BMC MED* (2014) 12:

EMIF: Sattar, Naveed et al. Type 2 diabetes in migrant south Asians: mechanisms, mitigation, and management, *LANCET DIABETES ENDO* (2015) 3: 1004-1016

EMIF: Skillback, Tobias et al. Cerebrospinal fluid tau and amyloid-beta(1-42) in patients with dementia, *BRAIN* (2015) 138: 2716-2731

EMIF: Slegers, Kristel et al. A 22-single nucleotide polymorphism Alzheimers disease risk score correlates with family history, onset age, and cerebrospinal fluid A beta(42), *ALZHEIMERS DEMENT* (2015) 11: 1452-1460

EMIF: Snowden, Stuart G. et al. Association between fatty acid metabolism in the brain and Alzheimer disease neuropathology and cognitive performance: A nontargeted metabolomic study, *PLOS MED* (2017) 14:

EMIF: Sood, Sanjana et al. A novel multi-tissue RNA diagnostic of healthy ageing relates to cognitive health status, *GENOME BIOL* (2015) 16:

EMIF: Struyfs, Hanne et al. Diagnostic Accuracy of Cerebrospinal Fluid Amyloid-beta Isoforms for Early and Differential Dementia Diagnosis, *J ALZHEIMERS DIS* (2015) 45: 813-822

EMIF: Suarez-Calvet, Marc et al. sTREM2 cerebrospinal fluid levels are a potential biomarker for microglia activity in early-stage Alzheimers disease and associate with neuronal injury markers, *EMBO MOL MED* (2016) 8: 466-476

EMIF: Swerdlow, Daniel I. et al. HMG-coenzyme A reductase inhibition, type 2 diabetes, and bodyweight: evidence from genetic analysis and randomised trials, *LANCET* (2015) 385: 351-361

EMIF: Tang, Eugene Y. H. et al. Current Developments in Dementia Risk Prediction Modelling: An Updated Systematic Review, *PLOS ONE* (2015) 10:

EMIF: ten Kate, Mara et al. Atrophy subtypes in prodromal Alzheimers disease are associated with cognitive decline, *BRAIN* (2018) 141: 3443-3456

EMIF: ten Kate, Mara et al. Clinical validity of medial temporal atrophy as a biomarker for Alzheimers disease in the context of a structured 5-phase development framework, *NEUROBIOL AGING* (2017) 52: 167-182

EMIF: Toledo, Jon B. et al. Alzheimers disease cerebrospinal fluid biomarker in cognitively normal subjects, *BRAIN* (2015) 138: 2701-2715

EMIF: Tsimihodimos, Vasilis et al. Hypertension and Diabetes Mellitus Coprediction and Time Trajectories, *HYPERTENSION* (2018) 71: 422-428

EMIF: van Bussell, Emma F. et al. Dementia incidence trend over 1992-2014 in the Netherlands: Analysis of primary care data, *PLOS MED* (2017) 14:

EMIF: Van Cauwenberghe, Caroline et al. The genetic landscape of Alzheimer disease: clinical implications and perspectives, *GENET MED* (2016) 18: 421-430

EMIF: van de Kreeke, Jacoba Alida et al. Optical coherence tomography angiography in preclinical Alzheimers disease, BRIT J OPHTHALMOL (2020) 104: 157-161

EMIF: Van der Mussele, Stefan et al. Depression in Mild Cognitive Impairment is associated with Progression to Alzheimers Disease: A Longitudinal Study, J ALZHEIMERS DIS (2014) 42: 1239-1250

EMIF: van Maurik, Ingrid S. et al. Biomarker-based prognosis for people with mild cognitive impairment (ABIDE): a modelling study, LANCET NEUROL (2019) 18: 1034-1044

EMIF: Vangipurapu, Jagadish et al. Nine Amino Acids Are Associated With Decreased Insulin Secretion and Elevated Glucose Levels in a 7.4-Year Follow-up Study of 5,181 Finnish Men, DIABETES (2019) 68: 1353-1358

EMIF: Vos, Stephanie J. B. et al. Modifiable Risk Factors for Prevention of Dementia in Midlife, Late Life and the Oldest-Old: Validation of the LIBRA Index, J ALZHEIMERS DIS (2017) 58: 537-547

EMIF: Vos, Stephanie J. B. et al. NIA-AA staging of preclinical Alzheimer disease: discordance and concordance of CSF and imaging biomarkers, NEUROBIOL AGING (2016) 44: 1-8

EMIF: Vos, Stephanie J. B. et al. Preclinical Alzheimers disease and its outcome: a longitudinal cohort study, LANCET NEUROL (2013) 12: 957-965

EMIF: Vos, Stephanie J. B. et al. Prevalence and prognosis of Alzheimers disease at the mild cognitive impairment stage, BRAIN (2015) 138: 1327-1338

EMIF: Wild, Sarah H. et al. Cardiovascular Disease, Cancer, and Mortality Among People With Type 2 Diabetes and Alcoholic or Nonalcoholic Fatty Liver Disease Hospital Admission, DIABETES CARE (2018) 41: 341-347

EMIF: Wittemans, Laura B. L. et al. Assessing the causal association of glycine with risk of cardio-metabolic diseases, NAT COMMUN (2019) 10:

EMIF: Yki-Jarvinen, Hannele et al. Diagnosis of non-alcoholic fatty liver disease (NAFLD), DIABETOLOGIA (2016) 59: 1104-1111

EMIF: Yki-Jarvinen, Hannele et al. Nutritional Modulation of Non-Alcoholic Fatty Liver Disease and Insulin Resistance, NUTRIENTS (2015) 7: 9127-9138

EMIF: Zhou, You et al. Circulating triacylglycerol signatures and insulin sensitivity in NAFLD associated with the E167K variant in TM6SF2, J HEPATOL (2015) 62: 657-663

EMIF: Zhou, You et al. Noninvasive Detection of Nonalcoholic Steatohepatitis Using Clinical Markers and Circulating Levels of Lipids and Metabolites, CLIN GASTROENTEROL H (2016) 14: 1463-+

ENABLE: Dilworth, Marvin V. et al. Microbial expression systems for membrane proteins, METHODS (2018) 147: 3-39

ENABLE: Hughes, Diarmaid et al. Evolutionary consequences of drug resistance: shared principles across diverse targets and organisms, NAT REV GENET (2015) 16: 459-471

ENABLE: Juhas, Mario et al. In vitro activity of apramycin against multidrug-, carbapenem- and aminoglycoside-resistant Enterobacteriaceae and Acinetobacter baumannii, J ANTIMICROB CHEMOTH (2019) 74: 944-952

ENABLE: Kitchen, Philip et al. Beyond water homeostasis: Diverse functional roles of mammalian aquaporins, BBA-GEN SUBJECTS (2015) 1850: 2410-2421

ENABLE: Krajnc, Alen et al. Bicyclic Boronate VNRX-5133 Inhibits Metallo- and Serine-beta-Lactamases, J MED CHEM (2019) 62: 8544-8556

ENABLE: Krajnc, Alen et al. Will morphing boron-based inhibitors beat the beta-lactamases?, CURR OPIN CHEM BIOL (2019) 50: 101-110

ENABLE: Langley, Gareth W. et al. Profiling interactions of vaborbactam with metallo-beta-lactamases, *BIOORG MED CHEM LETT* (2019) 29: 1981-1984

ENABLE: Moynie, Lucile et al. The complex of ferric-enterobactin with its transporter from *Pseudomonas aeruginosa* suggests a two-site model, *NAT COMMUN* (2019) 10:

ENABLE: Pantel, Lucile et al. Odilorhabdins, Antibacterial Agents that Cause Miscoding by Binding at a New Ribosomal Site, *MOL CELL* (2018) 70: 83-+

ENABLE: Rabanal, Francesc et al. A bioinspired peptide scaffold with high antibiotic activity and low in vivo toxicity, *SCI REP-UK* (2015) 5:

ENABLE: Rabanal, Francesc et al. Recent advances and perspectives in the design and development of polymyxins, *NAT PROD REP* (2017) 34: 886-908

ENABLE: Tselepis, Lucas et al. In vitro efficacy of imipenem-relebactam and cefepime-AAI101 against a global collection of ESBL-positive and carbapenemase-producing Enterobacteriaceae, *INT J ANTIMICROB AG* (2020) 56:

EPAD: Crous-Bou, Marta et al. Alzheimers disease prevention: from risk factors to early intervention, *ALZHEIMERS RES THER* (2017) 9:

EPAD: Milne, Richard et al. At, with and beyond risk: expectations of living with the possibility of future dementia, *SOCIOL HEALTH ILL* (2018) 40: 969-987

EPAD: Mortamais, Marion et al. Detecting cognitive changes in preclinical Alzheimers disease: A review of its feasibility, *ALZHEIMERS DEMENT* (2017) 13: 468-492

EPAD: Ritchie, Karen et al. Recommended cognitive outcomes in preclinical Alzheimers disease: Consensus statement from the European Prevention of Alzheimers Dementia project, *ALZHEIMERS DEMENT* (2017) 13: 186-195

EQIPD: Loescher, Wolfgang et al. Drug Resistance in Epilepsy: Clinical Impact, Potential Mechanisms, and New Innovative Treatment Options, *PHARMACOL REV* (2020) 72: 606-638

EQIPD: Voelkl, Bernhard et al. Reproducibility of animal research in light of biological variation, *NAT REV NEUROSCI* (2020) 21: 384-393

ERA4TB: Kar, Tamalika et al. A candidate multi-epitope vaccine against SARS-CoV-2, *SCI REP-UK* (2020) 10:

eTOX: Arighi, Cecilia N. et al. Overview of the BioCreative III Workshop, *BMC BIOINFORMATICS* (2011) 12:

eTOX: Bauer-Mehren, Anna et al. DisGeNET: a Cytoscape plugin to visualize, integrate, search and analyze gene-disease networks, *BIOINFORMATICS* (2010) 26: 2924-2926

eTOX: Bauer-Mehren, Anna et al. Gene-Disease Network Analysis Reveals Functional Modules in Mendelian, Complex and Environmental Diseases, *PLOS ONE* (2011) 6:

eTOX: Bento, A. Patricia et al. The ChEMBL bioactivity database: an update, *NUCLEIC ACIDS RES* (2014) 42: D1083-D1090

eTOX: Bravo, Alex et al. Extraction of relations between genes and diseases from text and large-scale data analysis: implications for translational research, *BMC BIOINFORMATICS* (2015) 16:

eTOX: Canzar, Stefan et al. Charge Group Partitioning in Biomolecular Simulation, *J COMPUT BIOL* (2013) 20: 188-198

eTOX: Carrio, Pau et al. Applicability Domain Analysis (ADAN): A Robust Method for Assessing the Reliability of Drug Property Predictions, *J CHEM INF MODEL* (2014) 54: 1500-1511

eTOX: Chiche, Johanna et al. In vivo pH in metabolic-defective Ras-transformed fibroblast tumors: Key role of the monocarboxylate transporter, MCT4, for inducing an alkaline intracellular pH, INT J CANCER (2012) 130: 1511-1520

eTOX: Enoch, S. J. et al. A review of the electrophilic reaction chemistry involved in covalent protein binding relevant to toxicity, CRIT REV TOXICOL (2011) 41: 783-802

eTOX: Furlong, Laura I. et al. Human diseases through the lens of network biology, TRENDS GENET (2013) 29: 150-159

eTOX: Garcia-Serna, Ricard et al. Large-Scale Predictive Drug Safety: From Structural Alerts to Biological Mechanisms, CHEM RES TOXICOL (2015) 28: 1875-1887

eTOX: Klepsch, Freya et al. Exhaustive Sampling of Docking Poses Reveals Binding Hypotheses for Propafenone Type Inhibitors of P-Glycoprotein, PLOS COMPUT BIOL (2011) 7:

eTOX: Klepsch, Freya et al. Ligand and Structure-Based Classification Models for Prediction of P-Glycoprotein Inhibitors, J CHEM INF MODEL (2014) 54: 218-229

eTOX: Krallinger, Martin et al. CHEMDNER: The drugs and chemical names extraction challenge, J CHEMINFORMATICS (2015) 7:

eTOX: Krallinger, Martin et al. The CHEMDNER corpus of chemicals and drugs and its annotation principles, J CHEMINFORMATICS (2015) 7:

eTOX: Mendez, David et al. ChEMBL: towards direct deposition of bioassay data, NUCLEIC ACIDS RES (2019) 47: D930-D940

eTOX: Obiol-Pardo, Cristian et al. A Multiscale Simulation System for the Prediction of Drug-Induced Cardiotoxicity, J CHEM INF MODEL (2011) 51: 483-492

eTOX: Oomen, Agnes G. et al. Concern-driven integrated approaches to nanomaterial testing and assessment - report of the NanoSafety Cluster Working Group 10, NANOTOXICOLOGY (2014) 8: 334-348

eTOX: Przybylak, Katarzyna R. et al. In silico models for drug-induced liver injury - current status, EXPERT OPIN DRUG MET (2012) 8: 201-217

eTOX: Queralt-Rosinach, Nuria et al. DisGeNET-RDF: harnessing the innovative power of the Semantic Web to explore the genetic basis of diseases, BIOINFORMATICS (2016) 32: 2236-2238

eTRANSafe: Hemmerich, Jennifer et al. COVER: conformational oversampling as data augmentation for molecules, J CHEMINFORMATICS (2020) 12:

eTRANSafe: Pinero, Janet et al. The DisGeNET knowledge platform for disease genomics: 2019 update, NUCLEIC ACIDS RES (2020) 48: D845-D855

eTRIKS: Aarestrup, F. M. et al. Towards a European health research and innovation cloud (HRIC), GENOME MED (2020) 12:

eTRIKS: Agusti, Alvar et al. Personalized Respiratory Medicine: Exploring the Horizon, Addressing the Issues Summary of a BRN-AJRCCM Workshop Held in Barcelona on June 12, 2014, AM J RESP CRIT CARE (2015) 191: 391-401

eTRIKS: Auffray, Charles et al. Making sense of big data in health research: Towards an EU action plan, GENOME MED (2016) 8:

eTRIKS: Debray, Thomas P. A. et al. Get real in individual participant data (IPD) meta-analysis: a review of the methodology, RES SYNTH METHODS (2015) 6: 293-309

eTRIKS: Efthimiou, Orestis et al. GetReal in network meta-analysis: a review of the methodology, RES SYNTH METHODS (2016) 7: 236-263



eTRIKS: Fleming, Louise et al. The burden of severe asthma in childhood and adolescence: results from the paediatric U-BIOPRED cohorts, *EUR RESPIR J* (2015) 46: 1322-1333

eTRIKS: Lefaudeux, Diane et al. U-BIOPRED clinical adult asthma clusters linked to a subset of sputum omics, *J ALLERGY CLIN IMMUN* (2017) 139: 1797-1807

eTRIKS: Lysenko, Artem et al. Representing and querying disease networks using graph databases, *BIODATA MIN* (2016) 9:

eTRIKS: Mazein, Alexander et al. Systems medicine disease maps: community-driven comprehensive representation of disease mechanisms, *NPJ SYST BIOL APPL* (2018) 4:

eTRIKS: McQuilton, Peter et al. BioSharing: curated and crowd-sourced metadata standards, databases and data policies in the life sciences, *DATABASE-OXFORD* (2016) :

eTRIKS: Nordon, Clementine et al. The Efficacy-Effectiveness Gap : Historical Background and Current Conceptualization, *VALUE HEALTH* (2016) 19: 75-81

eTRIKS: Ostaszewski, Marek et al. Community-driven roadmap for integrated disease maps, *BRIEF BIOINFORM* (2019) 20: 659-670

eTRIKS: Rocca-Serra, Philippe et al. Data standards can boost metabolomics research, and if there is a will, there is a way, *METABOLOMICS* (2016) 12:

eTRIKS: Rossios, Christos et al. Sputum transcriptomics reveal upregulation of IL-1 receptor family members in patients with severe asthma, *J ALLERGY CLIN IMMUN* (2018) 141: 560-570

eTRIKS: Schofield, James P. R. et al. Stratification of asthma phenotypes by airway proteomic signatures, *J ALLERGY CLIN IMMUN* (2019) 144: 70-82

eTRIKS: Shaw, Dominick E. et al. Clinical and inflammatory characteristics of the European U-BIOPRED adult severe asthma cohort, *EUR RESPIR J* (2015) 46: 1308-1321

Eu2P: Dreischulte, Tobias et al. Combined use of nonsteroidal anti-inflammatory drugs with diuretics and/or renin-angiotensin system inhibitors in the community increases the risk of acute kidney injury, *KIDNEY INT* (2015) 88: 396-403

EU-AIMS: Ajram, L. A. et al. Shifting brain inhibitory balance and connectivity of the prefrontal cortex of adults with autism spectrum disorder, *TRANSL PSYCHIAT* (2017) 7:

EU-AIMS: Arora, Manish et al. Fetal and postnatal metal dysregulation in autism, *NAT COMMUN* (2017) 8:

EU-AIMS: Ashwood, K. L. et al. Predicting the diagnosis of autism in adults using the Autism-Spectrum Quotient (AQ) questionnaire, *PSYCHOL MED* (2016) 46: 2595-2604

EU-AIMS: Auyeung, B. et al. Oxytocin increases eye contact during a real-time, naturalistic social interaction in males with and without autism, *TRANSL PSYCHIAT* (2015) 5:

EU-AIMS: Au-Yeung, Sheena K. et al. Experience of mental health diagnosis and perceived misdiagnosis in autistic, possibly autistic and non-autistic adults, *AUTISM* (2019) 23: 1508-1518

EU-AIMS: Babaev, Olga et al. Neurologin 2 deletion alters inhibitory synapse function and anxiety-associated neuronal activation in the amygdala, *NEUROPHARMACOLOGY* (2016) 100: 56-65

EU-AIMS: Bakker-Huvenaars, M. J. et al. Saliva oxytocin, cortisol, and testosterone levels in adolescent boys with autism spectrum disorder, oppositional defiant disorder/conduct disorder and typically developing individuals, *EUR NEUROPSYCHOPHARM* (2020) 30: 87-101

EU-AIMS: Baron-Cohen, Simon et al. Attenuation of Typical Sex Differences in 800 Adults with Autism vs. 3,900 Controls, *PLOS ONE* (2014) 9:

EU-AIMS: Basil, P. et al. Prenatal maternal immune activation causes epigenetic differences in adolescent mouse brain, *TRANSL PSYCHIAT* (2014) 4:

EU-AIMS: Baudouin, Stephane J. et al. Shared Synaptic Pathophysiology in Syndromic and Nonsyndromic Rodent Models of Autism, *SCIENCE* (2012) 338: 128-132

EU-AIMS: Berry-Kravis, Elizabeth M. et al. Drug development for neurodevelopmental disorders: lessons learned from fragile X syndrome, *NAT REV DRUG DISCOV* (2018) 17: 280-298

EU-AIMS: Bolte, Sven et al. Infants at risk for autism: a European perspective on current status, challenges and opportunities, *EUR CHILD ADOLES PSY* (2013) 22: 341-348

EU-AIMS: Bolte, Sven et al. The contribution of environmental exposure to the etiology of autism spectrum disorder, *CELL MOL LIFE SCI* (2019) 76: 1275-1297

EU-AIMS: Bourgeron, Thomas et al. From the genetic architecture to synaptic plasticity in autism spectrum disorder, *NAT REV NEUROSCI* (2015) 16: 551-563

EU-AIMS: Braun, Urs et al. Dynamic brain network reconfiguration as a potential schizophrenia genetic risk mechanism modulated by NMDA receptor function, *P NATL ACAD SCI USA* (2016) 113: 12568-12573

EU-AIMS: Budreck, Elaine C. et al. Neuroligin-1 controls synaptic abundance of NMDA-type glutamate receptors through extracellular coupling, *P NATL ACAD SCI USA* (2013) 110: 725-730

EU-AIMS: Bussu, G. et al. Prediction of Autism at 3 Years from Behavioural and Developmental Measures in High-Risk Infants: A Longitudinal Cross-Domain Classifier Analysis, *J AUTISM DEV DISORD* (2018) 48: 2418-2433

EU-AIMS: Camm-Crosbie, Louise et al. People like me dont get support: Autistic adults experiences of support and treatment for mental health difficulties, self-injury and suicidality, *AUTISM* (2019) 23: 1431-1441

EU-AIMS: Castellanos-Ryan, Natalie et al. Neural and Cognitive Correlates of the Common and Specific Variance Across Externalizing Problems in Young Adolescence, *AM J PSYCHIAT* (2014) 171: 1310-1319

EU-AIMS: Castellanos-Ryan, Natalie et al. The Structure of Psychopathology in Adolescence and Its Common Personality and Cognitive Correlates, *J ABNORM PSYCHOL* (2016) 125: 1039-1052

EU-AIMS: Catani, Marco et al. Frontal networks in adults with autism spectrum disorder, *BRAIN* (2016) 139: 616-630

EU-AIMS: Charman, Tony et al. The EU-AIMS Longitudinal European Autism Project (LEAP): clinical characterisation, *MOL AUTISM* (2017) 8:

EU-AIMS: Chatham, C. H. et al. Adaptive behavior in autism: Minimal clinically important differences on the Vineland-II, *AUTISM RES* (2018) 11: 270-283

EU-AIMS: Ching, Christopher R. K. et al. Mapping Subcortical Brain Alterations in 22q11.2 Deletion Syndrome: Effects of Deletion Size and Convergence With Idiopathic Neuropsychiatric Illness, *AM J PSYCHIAT* (2020) 177: 589-600

EU-AIMS: Constantino, John N. et al. Diagnosis of autism spectrum disorder: reconciling the syndrome, its diverse origins, and variation in expression, *LANCET NEUROL* (2016) 15: 279-291

EU-AIMS: Deans, P. J. Michael et al. Psychosis Risk Candidate ZNF804A Localizes to Synapses and Regulates Neurite Formation and Dendritic Spine Structure, *BIOL PSYCHIAT* (2017) 82: 49-61

EU-AIMS: Delorme, Richard et al. Progress toward treatments for synaptic defects in autism, *NAT MED* (2013) 19: 685-694

EU-AIMS: Di Lorenzo, Renata et al. Recommendations for motion correction of infant fNIRS data applicable to multiple data sets and acquisition systems, *NEUROIMAGE* (2019) 200: 511-527

EU-AIMS: Distler, Ute et al. In-depth protein profiling of the postsynaptic density from mouse hippocampus using data-independent acquisition proteomics, *PROTEOMICS* (2014) 14: 2607-2613

EU-AIMS: Ecker, C. et al. Relationship Between Cortical Gyrification, White Matter Connectivity, and Autism Spectrum Disorder, *CEREB CORTEX* (2016) 26: 3297-3309

EU-AIMS: Ecker, Christine et al. Association Between the Probability of Autism Spectrum Disorder and Normative Sex-Related Phenotypic Diversity in Brain Structure, *JAMA PSYCHIAT* (2017) 74: 329-338

EU-AIMS: Ecker, Christine et al. Neuroimaging in autism spectrum disorder: brain structure and function across the lifespan, *LANCET NEUROL* (2015) 14: 1121-1134

EU-AIMS: Ecker, Christine et al. Neuroimaging in autism-from basic science to translational research, *NAT REV NEUROL* (2014) 10: 82-91

EU-AIMS: El-Kordi, Ahmed et al. Development of an autism severity score for mice using *Nlgn4* null mutants as a construct-valid model of heritable monogenic autism, *BEHAV BRAIN RES* (2013) 251: 41-49

EU-AIMS: Ellie Wilson, C. et al. Does sex influence the diagnostic evaluation of autism spectrum disorder in adults?, *AUTISM* (2016) 20: 808-819

EU-AIMS: Elsabbagh, Mayada et al. Autism and the Social Brain: The First-Year Puzzle, *BIOL PSYCHIAT* (2016) 80: 94-99

EU-AIMS: Evangelou, Evangelos et al. New alcohol-related genes suggest shared genetic mechanisms with neuropsychiatric disorders, *NAT HUM BEHAV* (2019) 3: 950-961

EU-AIMS: Ey, Elodie et al. The Autism ProSAP1/Shank2 mouse model displays quantitative and structural abnormalities in ultrasonic vocalisations, *BEHAV BRAIN RES* (2013) 256: 677-689

EU-AIMS: Falck-Ytter, Terje et al. Reduced orienting to audiovisual synchrony in infancy predicts autism diagnosis at 3 years of age, *J CHILD PSYCHOL PSYC* (2018) 59: 872-880

EU-AIMS: Floris, Dorothea L. et al. Atypically Rightward Cerebral Asymmetry in Male Adults With Autism Stratifies Individuals With and Without Language Delay, *HUM BRAIN MAPP* (2016) 37: 230-253

EU-AIMS: Franke, Barbara et al. Genetic influences on schizophrenia and subcortical brain volumes: large-scale proof of concept, *NAT NEUROSCI* (2016) 19: 420-+

EU-AIMS: French, Leon et al. Early Cannabis Use, Polygenic Risk Score for Schizophrenia, and Brain Maturation in Adolescence, *JAMA PSYCHIAT* (2015) 72: 1002-1011

EU-AIMS: Gabriele, Stefano et al. Blood serotonin levels in autism spectrum disorder: A systematic review and meta-analysis, *EUR NEUROPSYCHOPHARM* (2014) 24: 919-929

EU-AIMS: Gevi, Federica et al. Urinary metabolomics of young Italian autistic children supports abnormal tryptophan and purine metabolism, *MOL AUTISM* (2016) 7:

EU-AIMS: Gliga, Teodora et al. Enhanced Visual Search in Infancy Predicts Emerging Autism Symptoms, *CURR BIOL* (2015) 25: 1727-1730

EU-AIMS: Heinrich, Angela et al. Prediction of alcohol drinking in adolescents: Personality-traits, behavior, brain responses, and genetic variations in the context of reward sensitivity, *BIOL PSYCHOL* (2016) 118: 79-87

EU-AIMS: Hillen, Anne E. J. et al. Cell adhesion and matricellular support by astrocytes of the tripartite synapse, *PROG NEUROBIOL* (2018) 165: 66-86

EU-AIMS: Holiga, Stefan et al. Patients with autism spectrum disorders display reproducible functional connectivity alterations, *SCI TRANSL MED* (2019) 11:

EU-AIMS: Holz, Nathalie E. et al. Resilience and the brain: a key role for regulatory circuits linked to social stress and support, *MOL PSYCHIATR* (2020) 25: 379-396

EU-AIMS: Horder, Jamie et al. Glutamate and GABA in autism spectrum disorder—a translational magnetic resonance spectroscopy study in man and rodent models, *TRANSL PSYCHIAT* (2018) 8:

EU-AIMS: Howells, Henrietta et al. Frontoparietal Tracts Linked to Lateralized Hand Preference and Manual Specialization, *CEREB CORTEX* (2018) 28: 2482-2494

EU-AIMS: Hsia, Yingfen et al. Psychopharmacological prescriptions for people with autism spectrum disorder (ASD): a multinational study, *PSYCHOPHARMACOLOGY* (2014) 231: 999-1009

EU-AIMS: Jedlicka, Peter et al. Neuroligin-1 regulates excitatory synaptic transmission, LTP and EPSP-spike coupling in the dentate gyrus in vivo, *BRAIN STRUCT FUNCT* (2015) 220: 47-58

EU-AIMS: Johnson, Mark H. et al. Annual Research Review: Infant development, autism, and ADHD - early pathways to emerging disorders, *J CHILD PSYCHOL PSYC* (2015) 56: 228-247

EU-AIMS: Johnson, Mark H. et al. Brain adaptation and alternative developmental trajectories, *DEV PSYCHOPATHOL* (2015) 27: 425-442

EU-AIMS: Jollans, Lee et al. Quantifying performance of machine learning methods for neuroimaging data, *NEUROIMAGE* (2019) 199: 351-365

EU-AIMS: Jones, Emily J. H. et al. Developmental pathways to autism: A review of prospective studies of infants at risk, *NEUROSCI BIOBEHAV R* (2014) 39: 1-33

EU-AIMS: Kas, Martien J. et al. Assessing behavioural and cognitive domains of autism spectrum disorders in rodents: current status and future perspectives, *PSYCHOPHARMACOLOGY* (2014) 231: 1125-1146

EU-AIMS: Kathuria, A. et al. Stem cell-derived neurons from autistic individuals with SHANK3 mutation show morphogenetic abnormalities during early development, *MOL PSYCHIATR* (2018) 23: 735-746

EU-AIMS: Kleijer, Kristel T. E. et al. Neurobiology of autism gene products: towards pathogenesis and drug targets, *PSYCHOPHARMACOLOGY* (2014) 231: 1037-1062

EU-AIMS: Kong, Augustine et al. Rate of de novo mutations and the importance of fathers age to disease risk, *NATURE* (2012) 488: 471-475

EU-AIMS: Lai, Meng-Chuan et al. Autism, *LANCET* (2014) 383: 896-910

EU-AIMS: Lai, Meng-Chuan et al. Biological sex affects the neurobiology of autism, *BRAIN* (2013) 136: 2799-2815

EU-AIMS: Lai, Meng-Chuan et al. Identifying the lost generation of adults with autism spectrum conditions, *LANCET PSYCHIAT* (2015) 2: 1013-1027

EU-AIMS: Lai, Meng-Chuan et al. Neural self-representation in autistic women and association with compensatory camouflaging, *AUTISM* (2019) 23: 1210-1223

EU-AIMS: Lai, Meng-Chuan et al. Quantifying and exploring camouflaging in men and women with autism, *AUTISM* (2017) 21: 690-702

EU-AIMS: Lai, Meng-Chuan et al. Sex/Gender Differences and Autism: Setting the Scene for Future Research, *J AM ACAD CHILD PSY* (2015) 54: 11-24

EU-AIMS: Leblond, Claire S. et al. Both rare and common genetic variants contribute to autism in the Faroe Islands, *NPJ GENOM MED* (2019) 4:

EU-AIMS: Lilja, Johanna et al. SHANK proteins limit integrin activation by directly interacting with Rap1 and R-Ras, *NAT CELL BIOL* (2017) 19: 292-+

EU-AIMS: Lombardo, Michael V. et al. Unsupervised data-driven stratification of mentalizing heterogeneity in autism, *SCI REP-UK* (2016) 6:

EU-AIMS: Loth, E. et al. Facial expression recognition as a candidate marker for autism spectrum disorder: how frequent and severe are deficits?, *MOL AUTISM* (2018) 9:

EU-AIMS: Loth, Eva et al. The EU-AIMS Longitudinal European Autism Project (LEAP): design and methodologies to identify and validate stratification biomarkers for autism spectrum disorders, *MOL AUTISM* (2017) 8:

EU-AIMS: Lukito, Steve et al. Comparative meta-analyses of brain structural and functional abnormalities during cognitive control in attention-deficit/hyperactivity disorder and autism spectrum disorder, *PSYCHOL MED* (2020) 50: 894-919

EU-AIMS: Luo, Qiang et al. Association of a Schizophrenia-Risk Nonsynonymous Variant With Putamen Volume in Adolescents A Voxelwise and Genome-Wide Association Study, *JAMA PSYCHIAT* (2019) 76: 435-445

EU-AIMS: Mackey, Scott et al. Brain Regions Related to Impulsivity Mediate the Effects of Early Adversity on Antisocial Behavior, *BIOL PSYCHIAT* (2017) 82: 275-282

EU-AIMS: Man, Kenneth K. C. et al. Exposure to selective serotonin reuptake inhibitors during pregnancy and risk of autism spectrum disorder in children: A systematic review and meta-analysis of observational studies, *NEUROSCI BIOBEHAV R* (2015) 49: 82-89

EU-AIMS: Maricic, Lea Mascarell et al. The IMAGEN study: a decade of imaging genetics in adolescents, *MOL PSYCHIATR* (2020) 25: 2648-2671

EU-AIMS: McDonald, Nicole M. et al. Developmental Trajectories of Infants With Multiplex Family Risk for Autism A Baby Siblings Research Consortium Study, *JAMA NEUROL* (2020) 77: 73-81

EU-AIMS: Meyer-Lindenberg, Andreas et al. Neural mechanisms of social risk for psychiatric disorders, *NAT NEUROSCI* (2012) 15: 663-668

EU-AIMS: Mielenz, D. et al. EFhd2/Swiprosin-1 is a common genetic determinant for sensation-seeking/low anxiety and alcohol addiction, *MOL PSYCHIATR* (2018) 23: 1303-1319

EU-AIMS: Murphy, Clodagh M. et al. Autism spectrum disorder in adults: diagnosis, management, and health services development, *NEUROPSYCH DIS TREAT* (2016) 12: 1669-1686

EU-AIMS: Murray, Macey L. et al. Pharmacological treatments prescribed to people with autism spectrum disorder (ASD) in primary health care, *PSYCHOPHARMACOLOGY* (2014) 231: 1011-1021

EU-AIMS: Naaijen, J. et al. Glutamatergic and GABAergic gene sets in attention-deficit/hyperactivity disorder: association to overlapping traits in ADHD and autism, *TRANSL PSYCHIAT* (2017) 7:

EU-AIMS: Nystrom, Par et al. Enhanced pupillary light reflex in infancy is associated with autism diagnosis in toddlerhood, *NAT COMMUN* (2018) 9:

EU-AIMS: Oguro-Ando, Asami et al. A current view on contactin-4,-5, and-6: Implications in neurodevelopmental disorders, *MOL CELL NEUROSCI* (2017) 81: 72-83

EU-AIMS: OHalloran, Laura et al. Neural circuitry underlying sustained attention in healthy adolescents and in ADHD symptomatology, *NEUROIMAGE* (2018) 169: 395-406

EU-AIMS: Oldehinkel, Marianne et al. Altered Connectivity Between Cerebellum, Visual, and Sensory-Motor Networks in Autism Spectrum Disorder: Results from the EU-AIMS Longitudinal European Autism Project, *BIOL PSYCHIAT-COGN N* (2019) 4: 260-270

EU-AIMS: Orekhova, Elena V. et al. EEG hyper-connectivity in high-risk infants is associated with later autism, *J NEURODEV DISORD* (2014) 6:

EU-AIMS: Orr, Catherine et al. Grey Matter Volume Differences Associated with Extremely Low Levels of Cannabis Use in Adolescence, *J NEUROSCI* (2019) 39: 1817-1827

EU-AIMS: Ortuno-Sierra, Javier et al. New evidence of factor structure and measurement invariance of the SDQ across five European nations, *EUR CHILD ADOLES PSY* (2015) 24: 1523-1534

EU-AIMS: Persico, Antonio M. et al. Autism genetics, *BEHAV BRAIN RES* (2013) 251: 95-112

EU-AIMS: Persico, Antonio M. et al. Unmet needs in paediatric psychopharmacology: Present scenario and future perspectives, *EUR NEUROPSYCHOPHARM* (2015) 25: 1513-1531

EU-AIMS: Persico, Antonio M. et al. Urinary p-cresol in autism spectrum disorder, *NEUROTOXICOL TERATOL* (2013) 36: 82-90

EU-AIMS: Peter, Sasa et al. Dysfunctional cerebellar Purkinje cells contribute to autism-like behaviour in Shank2-deficient mice, *NAT COMMUN* (2016) 7:

EU-AIMS: Pijl, M. K. J. et al. Temperament as an Early Risk Marker for Autism Spectrum Disorders? A Longitudinal Study of High-Risk and Low-Risk Infants, *J AUTISM DEV DISORD* (2019) 49: 1825-1836

EU-AIMS: Piras, I. S. et al. Anti-brain antibodies are associated with more severe cognitive and behavioral profiles in Italian children with Autism Spectrum Disorder, *BRAIN BEHAV IMMUN* (2014) 38: 91-99

EU-AIMS: Postema, Merel C. et al. Altered structural brain asymmetry in autism spectrum disorder in a study of 54 datasets, *NAT COMMUN* (2019) 10:

EU-AIMS: Pretzsch, Charlotte Marie et al. Effects of cannabidiol on brain excitation and inhibition systems, a randomised placebo-controlled single dose trial during magnetic resonance spectroscopy in adults with and without autism spectrum disorder, *NEUROPSYCHOPHARMACOL* (2019) 44: 1398-1405

EU-AIMS: Richards, Gareth et al. Autistic traits in adults who have attempted suicide, *MOL AUTISM* (2019) 10:

EU-AIMS: Richiardi, Jonas et al. Correlated gene expression supports synchronous activity in brain networks, *SCIENCE* (2015) 348: 1241-1244

EU-AIMS: Robbins, J. P. et al. Human induced pluripotent stem cells as a research tool in Alzheimers disease, *PSYCHOL MED* (2017) 47: 2587-2592

EU-AIMS: Ruggeri, Barbara et al. Biomarkers in autism spectrum disorder: the old and the new, *PSYCHOPHARMACOLOGY* (2014) 231: 1201-1216

EU-AIMS: Sacco, Roberto et al. Head circumference and brain size in autism spectrum disorder: A systematic review and meta-analysis, *PSYCHIAT RES-NEUROIM* (2015) 234: 239-251

EU-AIMS: Salomone, Erica et al. Prevalence and correlates of use of complementary and alternative medicine in children with autism spectrum disorder in Europe, *EUR J PEDIATR* (2015) 174: 1277-1285

EU-AIMS: Salomone, Erica et al. Use of early intervention for young children with autism spectrum disorder across Europe, *AUTISM* (2016) 20: 233-249

EU-AIMS: Schmeisser, Michael J. et al. Translational neurobiology in Shank mutant mice - Model systems for neuropsychiatric disorders, *ANN ANAT* (2015) 200: 115-117

EU-AIMS: Schreiner, Dietmar et al. Targeted Combinatorial Alternative Splicing Generates Brain Region-Specific Repertoires of Neurexins, *NEURON* (2014) 84: 386-398

EU-AIMS: Scott, Ricardo et al. Loss of Cntnap2 Causes Axonal Excitability Deficits, Developmental Delay in Cortical Myelination, and Abnormal Stereotyped Motor Behavior, CEREB CORTEX (2019) 29: 586-597

EU-AIMS: Sethna, Vaheshta et al. Mother-infant interactions and regional brain volumes in infancy: an MRI study, BRAIN STRUCT FUNCT (2017) 222: 2379-2388

EU-AIMS: Shephard, Elizabeth et al. Mid-childhood outcomes of infant siblings at familial high-risk of autism spectrum disorder, AUTISM RES (2017) 10: 546-557

EU-AIMS: Shum, Carole et al. Delta(9)-tetrahydrocannabinol and 2-AG decreases neurite outgrowth and differentially affects ERK1/2 and Akt signaling in hiPSC-derived cortical neurons, MOL CELL NEUROSCI (2020) 103:

EU-AIMS: Siddiqui, Tabrez J. et al. An LRRTM4-HSPG Complex Mediates Excitatory Synapse Development on Dentate Gyrus Granule Cells, NEURON (2013) 79: 680-695

EU-AIMS: Silva, Ana, I et al. Reciprocal White Matter Changes Associated With Copy Number Variation at 15q11.2 BP1-BP2: A Diffusion Tensor Imaging Study, BIOL PSYCHIAT (2019) 85: 563-572

EU-AIMS: Sokolova, Elena et al. A Causal and Mediation Analysis of the Comorbidity Between Attention Deficit Hyperactivity Disorder (ADHD) and Autism Spectrum Disorder (ASD), J AUTISM DEV DISORD (2017) 47: 1595-1604

EU-AIMS: Spooren, Will et al. Synapse dysfunction in autism: a molecular medicine approach to drug discovery in neurodevelopmental disorders, TRENDS PHARMACOL SCI (2012) 33: 669-684

EU-AIMS: Stamouli, Sofia et al. Copy Number Variation Analysis of 100 Twin Pairs Enriched for Neurodevelopmental Disorders, TWIN RES HUM GENET (2018) 21: 1-11

EU-AIMS: Stein, Jason L. et al. Identification of common variants associated with human hippocampal and intracranial volumes, NAT GENET (2012) 44: 552-+

EU-AIMS: Stringaris, Argyris et al. The Brains Response to Reward Anticipation and Depression in Adolescence: Dimensionality, Specificity, and Longitudinal Predictions in a Community-Based Sample, AM J PSYCHIAT (2015) 172: 1215-1223

EU-AIMS: Thompson, Abigail et al. Impaired Communication Between the Motor and Somatosensory Homunculus Is Associated With Poor Manual Dexterity in Autism Spectrum Disorder, BIOL PSYCHIAT (2017) 81: 211-219

EU-AIMS: Tillmann, J. et al. Evaluating Sex and Age Differences in ADI-R and ADOS Scores in a Large European Multi-site Sample of Individuals with Autism Spectrum Disorder, J AUTISM DEV DISORD (2018) 48: 2490-2505

EU-AIMS: Tillmann, Julian et al. Investigating the factors underlying adaptive functioning in autism in the EU-AIMS Longitudinal European Autism Project, AUTISM RES (2019) 12: 645-657

EU-AIMS: Tost, Heike et al. Environmental influence in the brain, human welfare and mental health, NAT NEUROSCI (2015) 18: 1421-1431

EU-AIMS: Tost, Heike et al. Neural correlates of individual differences in affective benefit of real-life urban green space exposure, NAT NEUROSCI (2019) 22: 1389-+

EU-AIMS: Traunmuller, Lisa et al. Control of neuronal synapse specification by a highly dedicated alternative splicing program, SCIENCE (2016) 352: 982-986

EU-AIMS: Ulfarsson, M. O. et al. 15q11.2 CNV affects cognitive, structural and functional correlates of dyslexia and dyscalculia, TRANSL PSYCHIAT (2017) 7:

EU-AIMS: van den Berk-Smeekens, Iris et al. Adherence and acceptability of a robot-assisted Pivotal Response Treatment protocol for children with autism spectrum disorder, SCI REP-UK (2020) 10:

EU-AIMS: van Rooij, Daan et al. Cortical and Subcortical Brain Morphometry Differences Between Patients With Autism Spectrum Disorder and Healthy Individuals Across the Lifespan: Results From the ENIGMA ASD Working Group, *AM J PSYCHIAT* (2018) 175: 359-369

EU-AIMS: Vicidomini, C. et al. Pharmacological enhancement of mGlu5 receptors rescues behavioral deficits in SHANK3 knock-out mice, *MOL PSYCHIATR* (2017) 22: 689-702

EU-AIMS: Visser, Janne C. et al. Autism spectrum disorder and attention-deficit/hyperactivity disorder in early childhood: A review of unique and shared characteristics and developmental antecedents, *NEUROSCI BIOBEHAV R* (2016) 65: 229-263

EU-AIMS: Visser, Janne C. et al. Variation in the Early Trajectories of Autism Symptoms Is Related to the Development of Language, Cognition, and Behavior Problems, *J AM ACAD CHILD PSY* (2017) 56: 659-668

EU-AIMS: Wass, Sam V. et al. Shorter spontaneous fixation durations in infants with later emerging autism, *SCI REP-UK* (2015) 5:

EU-AIMS: Webb, Sara Jane et al. The motivation for very early intervention for infants at high risk for autism spectrum disorders, *INT J SPEECH-LANG PA* (2014) 16: 36-42

EU-AIMS: Whelan, Robert et al. Adolescent impulsivity phenotypes characterized by distinct brain networks, *NAT NEUROSCI* (2012) 15: 920-U153

EU-AIMS: Whelan, Robert et al. Neuropsychosocial profiles of current and future adolescent alcohol misusers, *NATURE* (2014) 512: 185-+

EU-AIMS: Wilson, C. Ellie et al. The Neuropsychology of Male Adults With High-Functioning Autism or Asperger Syndrome, *AUTISM RES* (2014) 7: 568-581

EU-AIMS: Wolfers, Thomas et al. Mapping the Heterogeneous Phenotype of Schizophrenia and Bipolar Disorder Using Normative Models, *JAMA PSYCHIAT* (2018) 75: 1146-1155

EU-AIMS: Yorke, Isabel et al. The Association Between Emotional and Behavioral Problems in Children with Autism Spectrum Disorder and Psychological Distress in Their Parents: A Systematic Review and Meta-analysis, *J AUTISM DEV DISORD* (2018) 48: 3393-3415

EU-AIMS: Zabihi, Mariam et al. Dissecting the Heterogeneous Cortical Anatomy of Autism Spectrum Disorder Using Normative Models, *BIOL PSYCHIAT-COGN N* (2019) 4: 567-578

EU-AIMS: Zuko, Amila et al. Contactins in the neurobiology of autism, *EUR J PHARMACOL* (2013) 719: 63-74

EUbOPEN: Deniston, C. K. et al. Structure of LRRK2 in Parkinsons disease and model for microtubule interaction, *NATURE* (2020) 588:

EU-PEARL: Stallard, Nigel et al. Efficient Adaptive Designs for Clinical Trials of Interventions for COVID-19, *STAT BIOPHARM RES* (2020) 12: 483-497

EUROPAIN: Aasvang, Eske K. et al. Predictive Risk Factors for Persistent Postherniotomy Pain, *ANESTHESIOLOGY* (2010) 112: 957-969

EUROPAIN: Andersen, Kenneth Geving et al. Persistent Pain After Breast Cancer Treatment: A Critical Review of Risk Factors and Strategies for Prevention, *J PAIN* (2011) 12: 725-746

EUROPAIN: Andersen, Kenneth Geving et al. Predictive factors for the development of persistent pain after breast cancer surgery, *PAIN* (2015) 156: 2413-2422

EUROPAIN: Andrews, N. et al. Spontaneous burrowing behaviour in the rat is reduced by peripheral nerve injury or inflammation associated pain, *EUR J PAIN* (2012) 16: 485-495



EUROPAIN: Baastrup, Cathrine et al. Spinal-, brainstem- and cerebrally mediated responses at- and below-level of a spinal cord contusion in rats: Evaluation of pain-like behavior, PAIN (2010) 151: 670-679

EUROPAIN: Bannister, Kirsty et al. Neuropathic Pain: Mechanism-Based Therapeutics, ANNU REV PHARMACOL (2020) 60: 257-274

EUROPAIN: Baron, Ralf et al. Subgrouping of patients with neuropathic pain according to pain-related sensory abnormalities: a first step to a stratified treatment approach, LANCET NEUROL (2012) 11: 999-1005

EUROPAIN: Baskozos, Georgios et al. Comprehensive analysis of long noncoding RNA expression in dorsal root ganglion reveals cell-type specificity and dysregulation after nerve injury, PAIN (2019) 160: 463-485

EUROPAIN: Calvo, Margarita et al. The role of the immune system in the generation of neuropathic pain, LANCET NEUROL (2012) 11: 629-642

EUROPAIN: Caspani, Ombretta et al. Tramadol reduces anxiety-related and depression-associated behaviors presumably induced by pain in the chronic constriction injury model of neuropathic pain in rats, PHARMACOL BIOCHEM BE (2014) 124: 290-296

EUROPAIN: Colloca, Luana et al. Neuropathic pain, NAT REV DIS PRIMERS (2017) 3:

EUROPAIN: Dawes, John M. et al. CXCL5 Mediates UVB Irradiation-Induced Pain, SCI TRANSL MED (2011) 3:

EUROPAIN: Demant, Dyveke T. et al. Pain relief with lidocaine 5% patch in localized peripheral neuropathic pain in relation to pain phenotype: a randomised, double-blind, and placebo-controlled, phenotype panel study, PAIN (2015) 156: 2234-2244

EUROPAIN: Demant, Dyveke T. et al. The effect of oxcarbazepine in peripheral neuropathic pain depends on pain phenotype: A randomised, double-blind, placebo-controlled phenotype-stratified study, PAIN (2014) 155: 2263-2273

EUROPAIN: Denk, Franziska et al. HDAC inhibitors attenuate the development of hypersensitivity in models of neuropathic pain, PAIN (2013) 154: 1668-1679

EUROPAIN: Derry, Sheena et al. Topical capsaicin (high concentration) for chronic neuropathic pain in adults, COCHRANE DB SYST REV (2013) :

EUROPAIN: Dworkin, Robert H. et al. Interventional management of neuropathic pain: NeuPSIG recommendations, PAIN (2013) 154: 2249-2261

EUROPAIN: Eijkelkamp, N. et al. A role for Piezo2 in EPAC1-dependent mechanical allodynia, NAT COMMUN (2013) 4:

EUROPAIN: Ellis, A. et al. Neuroinflammation and the generation of neuropathic pain, BRIT J ANAESTH (2013) 111: 26-37

EUROPAIN: Finnerup, Nanna B. et al. Neuropathic pain clinical trials: factors associated with decreases in estimated drug efficacy, PAIN (2018) 159: 2339-2346

EUROPAIN: Finnerup, Nanna B. et al. Neuropathic pain: an updated grading system for research and clinical practice, PAIN (2016) 157: 1599-1606

EUROPAIN: Finnerup, Nanna Brix et al. Spinal Cord Injury Pain: Mechanisms and Management, CURR PAIN HEADACHE R (2012) 16: 207-216

EUROPAIN: Finnerup, Nanna Brix et al. The evidence for pharmacological treatment of neuropathic pain, PAIN (2010) 150: 573-581

EUROPAIN: Forstenpointner, Julia et al. Individualized neuropathic pain therapy based on phenotyping: are we there yet?, *PAIN* (2018) 159: 569-575

EUROPAIN: Gierthmuehlen, Janne et al. Mechanism-based treatment in complex regional pain syndromes, *NAT REV NEUROL* (2014) 10: 518-528

EUROPAIN: Gierthmuehlen, Janne et al. Who is healthy? Aspects to consider when including healthy volunteers in QST-based studies-a consensus statement by the EUROPAIN and NEUROPAIN consortia, *PAIN* (2015) 156: 2203-2211

EUROPAIN: Gilron, Ian et al. Combination pharmacotherapy for management of chronic pain: from bench to bedside, *LANCET NEUROL* (2013) 12: 1084-1095

EUROPAIN: Haeuser, Winfried et al. The Role of Antidepressants in the Management of Fibromyalgia Syndrome A Systematic Review and Meta-Analysis, *CNS DRUGS* (2012) 26: 297-307

EUROPAIN: Haroutiunian, Simon et al. The neuropathic component in persistent postsurgical pain: A systematic literature review, *PAIN* (2013) 154: 95-102

EUROPAIN: Haroutounian, Simon et al. Primary afferent input critical for maintaining spontaneous pain in peripheral neuropathy, *PAIN* (2014) 155: 1272-1279

EUROPAIN: Huang, Wenlong et al. A clinically relevant rodent model of the HIV antiretroviral drug stavudine induced painful peripheral neuropathy, *PAIN* (2013) 154: 560-575

EUROPAIN: Jensen, Troels S. et al. Allodynia and hyperalgesia in neuropathic pain: clinical manifestations and mechanisms, *LANCET NEUROL* (2014) 13: 924-935

EUROPAIN: Kemp, Harriet I. et al. Use of Corneal Confocal Microscopy to Evaluate Small Nerve Fibers in Patients With Human Immunodeficiency Virus, *JAMA OPHTHALMOL* (2017) 135: 795-799

EUROPAIN: Kosek, Eva et al. Do we need a third mechanistic descriptor for chronic pain states?, *PAIN* (2016) 157: 1382-1386

EUROPAIN: Marinus, Johan et al. Clinical features and pathophysiology of complex regional pain syndrome, *LANCET NEUROL* (2011) 10: 637-648

EUROPAIN: McDonnell, Aoibhinn et al. Inherited erythromelalgia due to mutations in SCN9A: natural history, clinical phenotype and somatosensory profile, *BRAIN* (2016) 139: 1052-1065

EUROPAIN: Mejdahl, Mathias Kvist et al. Persistent pain and sensory disturbances after treatment for breast cancer: six year nationwide follow-up study, *BMJ-BRIT MED J* (2013) 346:

EUROPAIN: Minett, Michael S. et al. Pain without Nociceptors? Nav1.7-Independent Pain Mechanisms, *CELL REP* (2014) 6: 301-312

EUROPAIN: Petersen, Gitte L. et al. Expectations and positive emotional feelings accompany reductions in ongoing and evoked neuropathic pain following placebo interventions, *PAIN* (2014) 155: 2687-2698

EUROPAIN: Petersen, Gitte Laue et al. Placebo manipulations reduce hyperalgesia in neuropathic pain, *PAIN* (2012) 153: 1292-1300

EUROPAIN: Petersen, Gitte Laue et al. The magnitude of nocebo effects in pain: A meta-analysis, *PAIN* (2014) 155: 1426-1434

EUROPAIN: Phillips, Tudor J. C. et al. Pharmacological Treatment of Painful HIV-Associated Sensory Neuropathy: A Systematic Review and Meta-Analysis of Randomised Controlled Trials, *PLOS ONE* (2010) 5:

EUROPAIN: Quick, Kathryn et al. TRPC3 and TRPC6 are essential for normal mechanotransduction in subsets of sensory neurons and cochlear hair cells, *OPEN BIOL* (2012) 2:

EUROPAIN: Rutten, K. et al. Burrowing as a non-reflex behavioural readout for analgesic action in a rat model of sub-chronic knee joint inflammation, *EUR J PAIN* (2014) 18: 204-212

EUROPAIN: Segerdahl, Andrew R. et al. A brain-based pain facilitation mechanism contributes to painful diabetic polyneuropathy, *BRAIN* (2018) 141: 357-364

EUROPAIN: Segerdahl, Andrew R. et al. The dorsal posterior insula subserves a fundamental role in human pain, *NAT NEUROSCI* (2015) 18: 499-+

EUROPAIN: Serra, Jordi et al. Hyperexcitable C nociceptors in fibromyalgia, *ANN NEUROL* (2014) 75: 196-208

EUROPAIN: Serra, Jordi et al. Microneurographic identification of spontaneous activity in C-nociceptors in neuropathic pain states in humans and rats, *PAIN* (2012) 153: 42-55

EUROPAIN: Sikandar, Shafaq et al. Neural coding of nociceptive stimuli-from rat spinal neurones to human perception, *PAIN* (2013) 154: 1263-1273

EUROPAIN: Sikandar, Shafaq et al. Visceral pain: the ins and outs, the ups and downs, *CURR OPIN SUPPORT PA* (2012) 6: 17-26

EUROPAIN: Sisignano, Marco et al. Mechanism-based treatment for chemotherapy-induced peripheral neuropathic pain, *NAT REV NEUROL* (2014) 10: 694-707

EUROPAIN: Treede, Rolf-Detlef et al. A classification of chronic pain for ICD-11, *PAIN* (2015) 156: 1003-1007

EUROPAIN: Treede, Rolf-Detlef et al. The role of quantitative sensory testing in the prediction of chronic pain, *PAIN* (2019) 160: S66-S69

EUROPAIN: van Hecke, Oliver et al. Neuropathic pain phenotyping by international consensus (NeuroPPIC) for genetic studies: a NeuPSIG systematic review, Delphi survey, and expert panel recommendations, *PAIN* (2015) 156: 2337-2353

EUROPAIN: Vase, Lene et al. Placebo, nocebo, and neuropathic pain, *PAIN* (2016) 157: S98-S105

EUROPAIN: Vase, Lene et al. Predictors of the placebo analgesia response in randomized controlled trials of chronic pain: a meta-analysis of the individual data from nine industrially sponsored trials, *PAIN* (2015) 156: 1795-1802

EUROPAIN: Venzel, Lise et al. Chemotherapy-induced pain and neuropathy: a prospective study in patients treated with adjuvant oxaliplatin or docetaxel, *PAIN* (2016) 157: 560-568

EUROPAIN: Vollert, Jan et al. Pathophysiological mechanisms of neuropathic pain: comparison of sensory phenotypes in patients and human surrogate pain models, *PAIN* (2018) 159: 1090-1102

EUROPAIN: Vollert, Jan et al. Quantitative sensory testing using DFNS protocol in Europe: an evaluation of heterogeneity across multiple centers in patients with peripheral neuropathic pain and healthy subjects, *PAIN* (2016) 157: 750-758

EUROPAIN: Vollert, Jan et al. Stratifying patients with peripheral neuropathic pain based on sensory profiles: algorithm and sample size recommendations, *PAIN* (2017) 158: 1446-1455

EUROPAIN: Wanigasekera, V. et al. Disambiguating pharmacological mechanisms from placebo in neuropathic pain using functional neuroimaging, *BRIT J ANAESTH* (2018) 120: 299-307

EUROPAIN: Wijayasinghe, Nelun et al. Ultrasound Guided Intercostobrachial Nerve Blockade in Patients with Persistent Pain after Breast Cancer Surgery: A Pilot Study, *PAIN PHYSICIAN* (2016) 19: E309-E317

EUROPAIN: Wildgaard, K. et al. Consequences of persistent pain after lung cancer surgery: a nationwide questionnaire study, *ACTA ANAESTH SCAND* (2011) 55: 60-68

EUROPAIN: Wildgaard, K. et al. Persistent postsurgical pain after video-assisted thoracic surgery - an observational study, *ACTA ANAESTH SCAND* (2016) 60: 650-658

EUROPAIN: Wodarski, Rachel et al. Cross-centre replication of suppressed burrowing behaviour as an ethologically relevant pain outcome measure in the rat: a prospective multicentre study, *PAIN* (2016) 157: 2350-2365

FAIRplus: Rodriguez-Espigares, Ismael et al. GPCRmd uncovers the dynamics of the 3D-GPCRome, *NAT METHODS* (2020) 17: 777-+

FLUCOP: de Vries, Rory D. et al. Influenza virus-specific antibody dependent cellular cytotoxicity induced by vaccination or natural infection, *VACCINE* (2017) 35: 238-247

FLUCOP: de Vries, Rory D. et al. Primary Human Influenza B Virus Infection Induces Cross-Lineage Hemagglutinin Stalk-Specific Antibodies Mediating Antibody-Dependent Cellular Cytotoxicity, *J INFECT DIS* (2018) 217: 3-11

FLUCOP: Lartey, Sarah et al. Live-Attenuated Influenza Vaccine Induces Tonsillar Follicular T Helper Cell Responses That Correlate With Antibody Induction, *J INFECT DIS* (2020) 221: 21-32

FLUCOP: Madsen, Anders et al. Prospects and Challenges in the Development of Universal Influenza Vaccines, *VACCINES-BASEL* (2020) 8:

FLUCOP: Mohn, Kristin G. I. et al. Boosting of Cross-Reactive and Protection-Associated T Cells in Children After Live Attenuated Influenza Vaccination, *J INFECT DIS* (2017) 215: 1527-1535

FLUCOP: Mohn, Kristin G. -I. et al. Immune responses after live attenuated influenza vaccination, *HUM VACC IMMUNOTHER* (2018) 14: 571-578

FLUCOP: Pebody, R. et al. Effectiveness of seasonal influenza vaccine for adults and children in preventing laboratory-confirmed influenza in primary care in the United Kingdom: 2015/16 end-of-season results, *EUROSURVEILLANCE* (2016) 21: 41-51

FLUCOP: Sridhar, Saranya et al. Influenza Vaccination Strategies: Comparing Inactivated and Live Attenuated Influenza Vaccines, *VACCINES* (2015) 3: 373-389

GETREAL: Debray, Thomas P. A. et al. An overview of methods for network meta-analysis using individual participant data: when do benefits arise?, *STAT METHODS MED RES* (2018) 27: 1351-1364

GETREAL: Efthimiou, Orestis et al. Combining randomized and nonrandomized evidence in network meta-analysis, *STAT MED* (2017) 36: 1210-1226

GETREAL: Efthimiou, Orestis et al. GetReal in network meta-analysis: a review of the methodology, *RES SYNTH METHODS* (2016) 7: 236-263

GETREAL: Makady, Amr et al. Policies for Use of Real-World Data in Health Technology Assessment (HTA): A Comparative Study of Six HTA Agencies, *VALUE HEALTH* (2017) 20: 520-532

GETREAL: Makady, Amr et al. What Is Real-World Data? A Review of Definitions Based on Literature and Stakeholder Interviews, *VALUE HEALTH* (2017) 20: 858-865

GETREAL: Nordon, Clementine et al. The Efficacy-Effectiveness Gap: Historical Background and Current Conceptualization, *VALUE HEALTH* (2016) 19: 75-81

GETREAL: Rengerink, Katrien Oude et al. Series: Pragmatic trials and real world evidence: Paper 3. Patient selection challenges and consequences, *J CLIN EPIDEMIOL* (2017) 89: 173-180

GETREAL: Zuidgeest, Mira G. P. et al. Series: Pragmatic trials and real world evidence: Paper 1. Introduction, *J CLIN EPIDEMIOL* (2017) 88: 7-13

HARMONY: Malcikova, J. et al. ERIC recommendations for TP53 mutation analysis in chronic lymphocytic leukemia-update on methodological approaches and results interpretation, *LEUKEMIA* (2018) 32: 1070-1080

Hypo-RESOLVE: Cherkas, Andriy et al. Glucose as a Major Antioxidant: When, What for and Why It Fails?, *ANTIOXIDANTS-BASEL* (2020) 9:

iABC: Aliberti, Stefano et al. Research priorities in bronchiectasis: a consensus statement from the EMBARC Clinical Research Collaboration, *EUR RESPIR J* (2016) 48: 632-647

iABC: Schaedle, Thomas et al. Mid-Infrared Waveguides: A Perspective, *APPL SPECTROSC* (2016) 70: 1625-1638

IMIDIA: Bosco, Domenico et al. CONNEXINS: KEY MEDIATORS OF ENDOCRINE FUNCTION, *PHYSIOL REV* (2011) 91: 1393-1445

IMIDIA: Broichhagen, Johannes et al. Optical control of insulin release using a photoswitchable sulfonylurea, *NAT COMMUN* (2014) 5:

IMIDIA: Campana, Melanie et al. Inhibition of central de novo ceramide synthesis restores insulin signaling in hypothalamus and enhances beta-cell function of obese Zucker rats, *MOL METAB* (2018) 8: 23-36

IMIDIA: Chabosseau, Pauline et al. Mitochondrial and ER-Targeted eCALWY Probes Reveal High Levels of Free Zn<sup>2+</sup>, *ACS CHEM BIOL* (2014) 9: 2111-2120

IMIDIA: Chabosseau, Pauline et al. Zinc and diabetes, *ARCH BIOCHEM BIOPHYS* (2016) 611: 79-85

IMIDIA: Chakravarthy, Harini et al. Converting Adult Pancreatic Islet alpha Cells into beta Cells by Targeting Both Dnmt1 and Arx, *CELL METAB* (2017) 25: 622-634

IMIDIA: Cohrs, Christian M. et al. Dysfunction of Persisting beta Cells Is a Key Feature of Early Type 2 Diabetes Pathogenesis, *CELL REP* (2020) 31:

IMIDIA: Damond, Nicolas et al. Blockade of glucagon signaling prevents or reverses diabetes onset only if residual beta-cells persist, *ELIFE* (2016) 5:

IMIDIA: Fine, Nicholas H. F. et al. Glucocorticoids Reprogram beta-Cell Signaling to Preserve Insulin Secretion, *DIABETES* (2018) 67: 278-290

IMIDIA: Gerber, Philipp A. et al. The Role of Oxidative Stress and Hypoxia in Pancreatic Beta-Cell Dysfunction in Diabetes Mellitus, *ANTIOXID REDOX SIGN* (2017) 26: 501-+

IMIDIA: Gonzalez, Claudio D. et al. The emerging role of autophagy in the pathophysiology of diabetes mellitus, *AUTOPHAGY* (2011) 7: 2-11

IMIDIA: Hodson, David J. et al. ADCY5 Couples Glucose to Insulin Secretion in Human Islets, *DIABETES* (2014) 63: 3009-3021

IMIDIA: Hodson, David J. et al. Lipotoxicity disrupts incretin-regulated human beta cell connectivity, *J CLIN INVEST* (2013) 123: 4182-4194

IMIDIA: Huch, Meritxell et al. Unlimited in vitro expansion of adult bi-potent pancreas progenitors through the Lgr5/R-spondin axis, *EMBO J* (2013) 32: 2708-2721

IMIDIA: Johnston, Natalie R. et al. Beta Cell Hubs Dictate Pancreatic Islet Responses to Glucose, *CELL METAB* (2016) 24: 389-401

IMIDIA: Kone, Marina et al. LKB1 and AMPK differentially regulate pancreatic beta-cell identity, *FASEB J* (2014) 28: 4972-4985

IMIDIA: Lenzen, Sigurd et al. A Fresh View of Glycolysis and Glucokinase Regulation: History and Current Status, *J BIOL CHEM* (2014) 289: 12189-12194

IMIDIA: Marselli, Lorella et al. Are we overestimating the loss of beta cells in type 2 diabetes?, *DIABETOLOGIA* (2014) 57: 362-365

IMIDIA: Mitchell, Ryan K. et al. Molecular Genetic Regulation of Slc30a8/ZnT8 Reveals a Positive Association With Glucose Tolerance, *MOL ENDOCRINOL* (2016) 30: 77-91

IMIDIA: Mitchell, Ryan K. et al. Selective disruption of Tcf7l2 in the pancreatic beta cell impairs secretory function and lowers beta cell mass, *HUM MOL GENET* (2015) 24: 1390-1399

IMIDIA: Ravassard, Philippe et al. A genetically engineered human pancreatic beta cell line exhibiting glucose-inducible insulin secretion, *J CLIN INVEST* (2011) 121: 3589-3597

IMIDIA: Roggli, Elodie et al. Changes in MicroRNA Expression Contribute to Pancreatic beta-Cell Dysfunction in Prediabetic NOD Mice, *DIABETES* (2012) 61: 1742-1751

IMIDIA: Roggli, Elodie et al. Involvement of MicroRNAs in the Cytotoxic Effects Exerted by Proinflammatory Cytokines on Pancreatic beta-Cells, *DIABETES* (2010) 59: 978-986

IMIDIA: Rutter, Guy A. et al. Pancreatic beta-cell identity, glucose sensing and the control of insulin secretion, *BIOCHEM J* (2015) 466: 203-218

IMIDIA: Rutter, Guy A. et al. SLC30A8 mutations in type 2 diabetes, *DIABETOLOGIA* (2015) 58: 31-36

IMIDIA: Santiago, Marcelo F. et al. Targeting Pannexin1 Improves Seizure Outcome, *PLOS ONE* (2011) 6:

IMIDIA: Scharfmann, Raphael et al. Development of a conditionally immortalized human pancreatic beta cell line, *J CLIN INVEST* (2014) 124: 2087-2098

IMIDIA: Solimena, Michele et al. Systems biology of the IMIDIA biobank from organ donors and pancreatectomised patients defines a novel transcriptomic signature of islets from individuals with type 2 diabetes, *DIABETOLOGIA* (2018) 61: 641-657

IMIDIA: Wigger, Leonore et al. Plasma Dihydroceramides Are Diabetes Susceptibility Biomarker Candidates in Mice and Humans, *CELL REP* (2017) 18: 2269-2279

IMIDIA: Woodfin, Abigail et al. The junctional adhesion molecule JAM-C regulates polarized transendothelial migration of neutrophils in vivo, *NAT IMMUNOL* (2011) 12: 761-U145

IMI-PainCare: Treede, Rolf-Detlef et al. The role of quantitative sensory testing in the prediction of chronic pain, *PAIN* (2019) 160: S66-S69

IMPRiND: Alam, Parvez et al. alpha-synuclein oligomers and fibrils: a spectrum of species, a spectrum of toxicities, *J NEUROCHEM* (2019) 150: 522-534

IMPRiND: Bieri, Gregor et al. LRRK2 modifies alpha-syn pathology and spread in mouse models and human neurons, *ACTA NEUROPATHOL* (2019) 137: 961-980

IMPRiND: Falcon, Benjamin et al. Novel tau filament fold in chronic traumatic encephalopathy encloses hydrophobic molecules, *NATURE* (2019) 568: 420-+

IMPRiND: Falcon, Benjamin et al. Structures of filaments from Picks disease reveal a novel tau protein fold, *NATURE* (2018) 561: 137-+

IMPRiND: Falcon, Benjamin et al. Tau filaments from multiple cases of sporadic and inherited Alzheimers disease adopt a common fold, *ACTA NEUROPATHOL* (2018) 136: 699-708

IMPRiND: Fenyi, Alexis et al. Detection of alpha-synuclein aggregates in gastrointestinal biopsies by protein misfolding cyclic amplification, *NEUROBIOL DIS* (2019) 129: 38-43

IMPRiND: Fitzpatrick, Anthony W. P. et al. Cryo-EM structures of tau filaments from Alzheimers disease, *NATURE* (2017) 547: 185-+

IMPRiND: Gribaudo, Simona et al. Propagation of alpha-Synuclein Strains within Human Reconstructed Neuronal Network, *STEM CELL REP* (2019) 12: 230-244

IMPRiND: Guerrero-Ferreira, Ricardo et al. Two new polymorphic structures of human full-length alpha-synuclein fibrils solved by cryo-electron microscopy, *ELIFE* (2019) 8:

IMPRiND: Jucker, Mathias et al. Propagation and spread of pathogenic protein assemblies in neurodegenerative diseases, *NAT NEUROSCI* (2018) 21: 1341-1349

IMPRiND: Kundel, Franziska et al. Measurement of Tau Filament Fragmentation Provides Insights into Prion-like Spreading, *ACS CHEM NEUROSCI* (2018) 9: 1276-1282

IMPRiND: Mavroei, Panagiota et al. Endogenous oligodendroglial alpha-synuclein and TPPP/p25 alpha orchestrate alpha-synuclein pathology in experimental multiple system atrophy models, *ACTA NEUROPATHOL* (2019) 138: 415-441

IMPRiND: McInnes, Joseph et al. Synaptogyrin-3 Mediates Presynaptic Dysfunction Induced by Tau, *NEURON* (2018) 97: 823-+

IMPRiND: Nachman, Eliana et al. Disassembly of Tau fibrils by the human Hsp70 disaggregation machinery generates small seeding-competent species, *J BIOL CHEM* (2020) 295: 9676-9690

IMPRiND: Peelaerts, W. et al. E-Synuclein strains and seeding in Parkinsons disease, incidental Lewy body disease, dementia with Lewy bodies and multiple system atrophy: similarities and differences, *CELL TISSUE RES* (2018) 373: 195-212

IMPRiND: Rey, Nolwen L. et al. alpha-Synuclein conformational strains spread, seed and target neuronal cells differentially after injection into the olfactory bulb, *ACTA NEUROPATHOL COM* (2019) 7:

IMPRiND: Roesler, Thomas W. et al. Four-repeat tauopathies, *PROG NEUROBIOL* (2019) 180:

IMPRiND: Shrivastava, Amulya Nidhi et al. Cell biology and dynamics of Neuronal Na<sup>+</sup>/K<sup>+</sup>-ATPase in health and diseases, *NEUROPHARMACOLOGY* (2020) 169:

IMPRiND: Shrivastava, Amulya Nidhi et al. Clustering of Tau fibrils impairs the synaptic composition of alpha 3-Na<sup>+</sup>/K<sup>+</sup>-ATPase and AMPA receptors, *EMBO J* (2019) 38:

IMPRiND: Shrivastava, Amulya Nidhi et al. Differential Membrane Binding and Seeding of Distinct alpha-Synuclein Fibrillar Polymorphs, *BIOPHYS J* (2020) 118: 1301-1320

IMPRiND: Teil, Margaux et al. Targeting alpha-Synuclein for PD Therapeutics: A Pursuit on All Fronts, *BIOMOLECULES* (2020) 10:

IMPRiND: Van der Perren, Anke et al. The structural differences between patient-derived alpha-synuclein strains dictate characteristics of Parkinsons disease, multiple system atrophy and dementia with Lewy bodies, *ACTA NEUROPATHOL* (2020) 139: 977-1000

IMPRiND: Vasili, Eftychia et al. Spreading of alpha-Synuclein and Tau: A Systematic Comparison of the Mechanisms Involved, *FRONT MOL NEUROSCI* (2019) 12:

IMPRiND: Wilkinson, Mark D. et al. Comment: A design framework and exemplar metrics for FAIRness, *SCI DATA* (2018) 5:

IMPRiND: Zhang, Wenjuan et al. Heparin-induced tau filaments are polymorphic and differ from those in Alzheimers and Picks diseases, *ELIFE* (2019) 8:

IMPRiND: Zhang, Wenjuan et al. Novel tau filament fold in corticobasal degeneration, *NATURE* (2020) 580: 283-+

INNODIA HARVEST: Mallone, Roberto et al. Presumption of innocence for beta cells: why are they vulnerable autoimmune targets in type 1 diabetes?, *DIABETOLOGIA* (2020) 63: 1999-2006

INNODIA: Atkinson, Mark A. et al. The challenge of modulating beta-cell autoimmunity in type 1 diabetes, *LANCET DIABETES ENDO* (2019) 7: 52-64

INNODIA: Balboa, Diego et al. Concise Review: Human Pluripotent Stem Cells for the Modeling of Pancreatic beta-Cell Pathology, *STEM CELLS* (2019) 37: 33-41

INNODIA: Balboa, Diego et al. Insulin mutations impair beta-cell development in a patient-derived iPSC model of neonatal diabetes, *ELIFE* (2018) 7:

INNODIA: Boss, Marti et al. PET-Based Human Dosimetry of Ga-68-NODAGA-Exendin-4, a Tracer for beta-Cell Imaging, *J NUCL MED* (2020) 61: 112-116

INNODIA: Charalampopoulos, Dimitrios et al. Exploring Variation in Glycemic Control Across and Within Eight High-Income Countries: A Cross-sectional Analysis of 64,666 Children and Adolescents With Type 1 Diabetes, *DIABETES CARE* (2018) 41: 1180-1187

INNODIA: Cohrs, Christian M. et al. Dysfunction of Persisting beta Cells Is a Key Feature of Early Type 2 Diabetes Pathogenesis, *CELL REP* (2020) 31:

INNODIA: Colli, Maikel L. et al. An integrated multi-omics approach identifies the landscape of interferon-alpha-mediated responses of human pancreatic beta cells, *NAT COMMUN* (2020) 11:

INNODIA: Colli, Maikel L. et al. PDL1 is expressed in the islets of people with type 1 diabetes and is up-regulated by interferons-alpha and-gamma via IRF1 induction, *EBIOMEDICINE* (2018) 36: 367-375

INNODIA: Culina, Slobodan et al. Islet-reactive CD8(+) T cell frequencies in the pancreas, but not in blood, distinguish type 1 diabetic patients from healthy donors, *SCI IMMUNOL* (2018) 3:

INNODIA: Danne, Thomas et al. International Consensus on Risk Management of Diabetic Ketoacidosis in Patients With Type 1 Diabetes Treated With Sodium-Glucose Cotransporter (SGLT) Inhibitors, *DIABETES CARE* (2019) 42: 1147-1154

INNODIA: Demine, Stephane et al. Pro-inflammatory cytokines induce cell death, inflammatory responses, and endoplasmic reticulum stress in human iPSC-derived beta cells, *STEM CELL RES THER* (2020) 11:

INNODIA: DeSalvo, Daniel J. et al. Continuous glucose monitoring and glycemic control among youth with type 1 diabetes: International comparison from the T1D Exchange and DPV Initiative, *PEDIATR DIABETES* (2018) 19: 1271-1275

INNODIA: Eizirik, Decio L. et al. Pancreatic beta-cells in type 1 and type 2 diabetes mellitus: different pathways to failure, *NAT REV ENDOCRINOL* (2020) 16: 349-362

INNODIA: Gonzalez-Duque, Sergio et al. Conventional and Neo-antigenic Peptides Presented by beta Cells Are Targeted by Circulating Naive CD8+T Cells in Type 1 Diabetic and Healthy Donors, *CELL METAB* (2018) 28: 946-+

INNODIA: Grieco, Fabio Arturo et al. MicroRNAs miR-23a-3p, miR-23b-3p, and miR-149-5p Regulate the Expression of Proapoptotic BH3-Only Proteins DP5 and PUMA in Human Pancreatic beta-Cells, *DIABETES* (2017) 66: 100-112

INNODIA: Hakonen, Elina et al. MANF protects human pancreatic beta cells against stress-induced cell death, *DIABETOLOGIA* (2018) 61: 2202-2214

INNODIA: Henriksson, Johan et al. Genome-wide CRISPR Screens in T Helper Cells Reveal Pervasive Crosstalk between Activation and Differentiation, *CELL* (2019) 176: 882-+

INNODIA: Marroqui, Laura et al. Interferon-alpha mediates human beta cell HLA class I overexpression, endoplasmic reticulum stress and apoptosis, three hallmarks of early human type 1 diabetes, *DIABETOLOGIA* (2017) 60: 656-667

INNODIA: Nakayasu, Ernesto S. et al. Comprehensive Proteomics Analysis of Stressed Human Islets Identifies GDF15 as a Target for Type 1 Diabetes Intervention, *CELL METAB* (2020) 31: 363-+



INNODIA: Piga, Isabella et al. Ultra-high resolution MALDI-FTICR-MSI analysis of intact proteins in mouse and human pancreas tissue, *INT J MASS SPECTROM* (2019) 437: 10-16

INNODIA: Ramos-Rodriguez, Mireia et al. The impact of proinflammatory cytokines on the beta-cell regulatory landscape provides insights into the genetics of type 1 diabetes, *NAT GENET* (2019) 51: 1588-+

INNODIA: Reinehr, Thomas et al. Worse Metabolic Control and Dynamics of Weight Status in Adolescent Girls Point to Eating Disorders in the First Years after Manifestation of Type 1 Diabetes Mellitus: Findings from the Diabetes Patienten Verlaufsdokumentation Registry, *J PEDIATR-US* (2019) 207: 205-212

INNODIA: Roep, Bart O. et al. Antigen-based immune modulation therapy for type 1 diabetes: the era of precision medicine, *LANCET DIABETES ENDO* (2019) 7: 65-74

INNODIA: Schwandt, Anke et al. Comparison of MDRD, CKD-EPI, and Cockcroft-Gault equation in relation to measured glomerular filtration rate among a large cohort with diabetes, *J DIABETES COMPLICAT* (2017) 31: 1376-1383

INNODIA: Schwandt, Anke et al. Longitudinal Trajectories of Metabolic Control From Childhood to Young Adulthood in Type 1 Diabetes From a Large German/Austrian Registry: A Group-Based Modeling Approach, *DIABETES CARE* (2017) 40: 309-316

INNODIA: Thomaidou, Sofia et al. beta-Cell Stress Shapes CTL Immune Recognition of Preproinsulin Signal Peptide by Posttranscriptional Regulation of Endoplasmic Reticulum Aminopeptidase 1, *DIABETES* (2020) 69: 670-680

iPiE: Bittner, Lisa et al. Influence of pH on the uptake and toxicity of beta-blockers in embryos of zebrafish, *Danio rerio*, *AQUAT TOXICOL* (2018) 201: 129-137

iPiE: Burns, Emily E. et al. Temporal and spatial variation in pharmaceutical concentrations in an urban river system, *WATER RES* (2018) 137: 72-85

iPiE: Escher, Beate I. et al. General baseline toxicity QSAR for nonpolar, polar and ionisable chemicals and their mixtures in the bioluminescence inhibition assay with *Aliivibrio fischeri*, *ENVIRON SCI-PROC IMP* (2017) 19: 414-428

iPiE: Gunnarsson, Lina et al. Pharmacology beyond the patient - The environmental risks of human drugs, *ENVIRON INT* (2019) 129: 320-332

iPiE: Kluever, Nils et al. Development of a general baseline toxicity QSAR model for the fish embryo acute toxicity test, *CHEMOSPHERE* (2016) 164: 164-173

iPiE: Kluever, Nils et al. QSAR for baseline toxicity and classification of specific modes of action of ionizable organic chemicals in the zebrafish embryo toxicity test, *AQUAT TOXICOL* (2019) 207: 110-119

iPiE: Miller, Thomas H. et al. A review of the pharmaceutical exposome in aquatic fauna, *ENVIRON POLLUT* (2018) 239: 129-146

iPiE: Miller, Thomas H. et al. Prediction of bioconcentration factors in fish and invertebrates using machine learning, *SCI TOTAL ENVIRON* (2019) 648: 80-89

iPiE: Nolte, Tom M. et al. Disentanglement of the chemical, physical, and biological processes aids the development of quantitative structure-biodegradation relationships for aerobic wastewater treatment, *SCI TOTAL ENVIRON* (2020) 708:

iPiE: Queralt-Rosinach, Nuria et al. DisGeNET-RDF: harnessing the innovative power of the Semantic Web to explore the genetic basis of diseases, *BIOINFORMATICS* (2016) 32: 2236-2238

ITCC-P4: Theruvath, Johanna et al. Locoregionally administered B7-H3-targeted CAR T cells for treatment of atypical teratoid/rhabdoid tumors, *NAT MED* (2020) 26: 712-+

K4DD: Bruce, Neil J. et al. New approaches for computing ligand-receptor binding kinetics, CURR OPIN STRUC BIOL (2018) 49: 1-10

K4DD: Cheng, Robert K. Y. et al. Structures of Human A(1) and A(2A) Adenosine Receptors with Xanthines Reveal Determinants of Selectivity, STRUCTURE (2017) 25: 1275-+

K4DD: de Witte, Wilhelmus E. A. et al. In vivo Target Residence Time and Kinetic Selectivity: The Association Rate Constant as Determinant, TRENDS PHARMACOL SCI (2016) 37: 831-842

K4DD: Forster, Michael et al. Selective JAK3 Inhibitors with a Covalent Reversible Binding Mode Targeting a New Induced Fit Binding Pocket, CELL CHEM BIOL (2016) 23: 1335-1340

K4DD: Hoffmann, C. et al. Ligand Residence Time at G-protein-Coupled Receptors-Why We Should Take Our Time To Study It, MOL PHARMACOL (2015) 88: 552-560

K4DD: Hothersall, J. Daniel et al. Can residence time offer a useful strategy to target agonist drugs for sustained GPCR responses?, DRUG DISCOV TODAY (2016) 21: 90-96

K4DD: Kokh, Daria B. et al. Estimation of Drug-Target Residence Times by tau-Random Acceleration Molecular Dynamics Simulations, J CHEM THEORY COMPUT (2018) 14: 3859-3869

K4DD: Rucktooa, Prakash et al. Towards high throughput GPCR crystallography: In Meso soaking of Adenosine A(2A) Receptor crystals, SCI REP-UK (2018) 8:

K4DD: Schuetz, Doris A. et al. Kinetics for Drug Discovery: an industry-driven effort to target drug residence time, DRUG DISCOV TODAY (2017) 22: 896-911

K4DD: Schuetz, Doris A. et al. Ligand Desolvation Steers On-Rate and Impacts Drug Residence Time of Heat Shock Protein 90 (Hsp90) Inhibitors, J MED CHEM (2018) 61: 4397-4411

K4DD: Schuetz, Doris A. et al. Predicting Residence Time and Drug Unbinding Pathway through Scaled Molecular Dynamics, J CHEM INF MODEL (2019) 59: 535-549

K4DD: Segala, Elena et al. Controlling the Dissociation of Ligands from the Adenosine A(2A) Receptor through Modulation of Salt Bridge Strength, J MED CHEM (2016) 59: 6470-6479

K4DD: Stank, Antonia et al. Protein Binding Pocket Dynamics, ACCOUNTS CHEM RES (2016) 49: 809-815

K4DD: Stoddart, Leigh A. et al. Development of novel fluorescent histamine H-1-receptor antagonists to study ligand-binding kinetics in living cells, SCI REP-UK (2018) 8:

K4DD: Stoddart, Leigh A. et al. NanoBRET Approaches to Study Ligand Binding to GPCRs and RTKs, TRENDS PHARMACOL SCI (2018) 39: 136-147

K4DD: Sykes, David A. et al. Binding kinetics of ligands acting at GPCRs, MOL CELL ENDOCRINOL (2019) 485: 9-19

K4DD: Yuan, Jui-Hung et al. Druggability Assessment in TRAPP Using Machine Learning Approaches, J CHEM INF MODEL (2020) 60: 1685-1699

LITMUS: Aron-Wisniewsky, Judith et al. Gut microbiota and human NAFLD: disentangling microbial signatures from metabolic disorders, NAT REV GASTRO HEPAT (2020) 17: 279-297

LITMUS: Azzu, Vian et al. Adipose Tissue-Liver Cross Talk in the Control of Whole-Body Metabolism: Implications in Nonalcoholic Fatty Liver Disease, GASTROENTEROLOGY (2020) 158: 1899-1912

LITMUS: Gehrke, Nadine et al. Metabolic Inflammation-A Role for Hepatic Inflammatory Pathways as Drivers of Comorbidities in Nonalcoholic Fatty Liver Disease?, GASTROENTEROLOGY (2020) 158: 1929-+

LITMUS: Karsdal, Morten A. et al. Assessment of liver fibrosis progression and regression by a serological collagen turnover profile, AM J PHYSIOL-GASTR L (2019) 316: G25-G31

LITMUS: Lazarus, Jeffrey, V et al. A cross-sectional study of the public health response to non-alcoholic fatty liver disease in Europe, *J HEPATOL* (2020) 72: 14-24

LITMUS: Luukkonen, Panu K. et al. Effect of a ketogenic diet on hepatic steatosis and hepatic mitochondrial metabolism in nonalcoholic fatty liver disease, *P NATL ACAD SCI USA* (2020) 117: 7347-7354

LITMUS: Luukkonen, Panu K. et al. Human PNPLA3-I148M variant increases hepatic retention of polyunsaturated fatty acids, *JCI INSIGHT* (2019) 4:

LITMUS: Luukkonen, Panu K. et al. Hydroxysteroid 17-beta dehydrogenase 13 variant increases phospholipids and protects against fibrosis in nonalcoholic fatty liver disease, *JCI INSIGHT* (2020) 5:

LITMUS: Stols-Goncalves, Daniela et al. NAFLD and Atherosclerosis: Two Sides of the Same Dysmetabolic Coin?, *TRENDS ENDOCRIN MET* (2019) 30: 891-902

LITMUS: Vali, Yasaman et al. Enhanced liver fibrosis test for the non-invasive diagnosis of fibrosis in patients with NAFLD: A systematic review and meta-analysis, *J HEPATOL* (2020) 73: 252-262

MACUSTAR: Finger, Robert P. et al. MACUSTAR: Development and Clinical Validation of Functional, Structural, and Patient-Reported Endpoints in Intermediate Age-Related Macular Degeneration, *OPHTHALMOLOGICA* (2019) 241: 61-72

MARCAR: Luisier, Raphaelle et al. Phenobarbital Induces Cell Cycle Transcriptional Responses in Mouse Liver Humanized for Constitutive Androstane and Pregnane X Receptors, *TOXICOL SCI* (2014) 139: 501-511

MARCAR: Meehan, Richard R. et al. DNA methylation as a genomic marker of exposure to chemical and environmental agents, *CURR OPIN CHEM BIOL* (2018) 45: 48-56

MARCAR: Nestor, Colm E. et al. Rapid reprogramming of epigenetic and transcriptional profiles in mammalian culture systems, *GENOME BIOL* (2015) 16:

MARCAR: Reddington, James P. et al. Redistribution of H3K27me3 upon DNA hypomethylation results in de-repression of Polycomb target genes, *GENOME BIOL* (2013) 14:

MARCAR: Sproul, Duncan et al. Genomic insights into cancer-associated aberrant CpG island hypermethylation, *BRIEF FUNCT GENOMICS* (2013) 12: 174-190

MARCAR: Treindl, Fridolin et al. A bead-based western for high-throughput cellular signal transduction analyses, *NAT COMMUN* (2016) 7:

MIP-DILI: Bachour-EI Azzi, Pamela et al. Comparative Localization and Functional Activity of the Main Hepatobiliary Transporters in HepaRG Cells and Primary Human Hepatocytes, *TOXICOL SCI* (2015) 145: 157-168

MIP-DILI: Bell, Catherine C. et al. Characterization of primary human hepatocyte spheroids as a model system for drug-induced liver injury, liver function and disease, *SCI REP-UK* (2016) 6:

MIP-DILI: Bell, Catherine C. et al. Comparison of Hepatic 2D Sandwich Cultures and 3D Spheroids for Long-term Toxicity Applications: A Multicenter Study, *TOXICOL SCI* (2018) 162: 655-666

MIP-DILI: Bell, Catherine C. et al. Transcriptional, Functional, and Mechanistic Comparisons of Stem Cell-Derived Hepatocytes, HepaRG Cells, and Three-Dimensional Human Hepatocyte Spheroids as Predictive In Vitro Systems for Drug-Induced Liver Injury, *DRUG METAB DISPOS* (2017) 45: 419-429

MIP-DILI: Burbank, Matthew G. et al. Early Alterations of Bile Canaliculi Dynamics and the Rho Kinase/Myosin Light Chain Kinase Pathway Are Characteristics of Drug-Induced Intrahepatic Cholestasis, *DRUG METAB DISPOS* (2016) 44: 1780-+

MIP-DILI: Fredriksson, Lisa et al. Drug-Induced Endoplasmic Reticulum and Oxidative Stress Responses Independently Sensitize Toward TNF alpha-Mediated Hepatotoxicity, TOXICOL SCI (2014) 140: 144-159

MIP-DILI: Goldring, Christopher et al. Stem Cell-Derived Models to Improve Mechanistic Understanding and Prediction of Human Drug-Induced Liver Injury, HEPATOLOGY (2017) 65: 710-721

MIP-DILI: Hendriks, Delilah F. G. et al. Hepatic 3D spheroid models for the detection and study of compounds with cholestatic liability, SCI REP-UK (2016) 6:

MIP-DILI: Ivanov, M. et al. Epigenomics and Interindividual Differences in Drug Response, CLIN PHARMACOL THER (2012) 92: 727-736

MIP-DILI: Ivanov, Maxim et al. Epigenetic mechanisms of importance for drug treatment, TRENDS PHARMACOL SCI (2014) 35: 384-396

MIP-DILI: Kamalian, Laleh et al. The utility of HepG2 cells to identify direct mitochondrial dysfunction in the absence of cell death, TOXICOL IN VITRO (2015) 29: 732-740

MIP-DILI: Kim, Seung-Hyun et al. Characterization of amoxicillin- and clavulanic acid-specific T cells in patients with amoxicillin-clavulanate-induced liver injury, HEPATOLOGY (2015) 62: 887-899

MIP-DILI: Lauschke, Volker M. et al. Massive rearrangements of cellular MicroRNA signatures are key drivers of hepatocyte dedifferentiation, HEPATOLOGY (2016) 64: 1743-1756

MIP-DILI: Lauschke, Volker M. et al. Novel 3D Culture Systems for Studies of Human Liver Function and Assessments of the Hepatotoxicity of Drugs and Drug Candidates, CHEM RES TOXICOL (2016) 29: 1936-1955

MIP-DILI: Lauschke, Volker M. et al. The Importance of Patient-Specific Factors for Hepatic Drug Response and Toxicity, INT J MOL SCI (2016) 17:

MIP-DILI: Maiwald, Tim et al. Driving the Model to Its Limit: Profile Likelihood Based Model Reduction, PLOS ONE (2016) 11:

MIP-DILI: Oorts, Marlies et al. Drug-induced cholestasis risk assessment in sandwich-cultured human hepatocytes, TOXICOL IN VITRO (2016) 34: 179-186

MIP-DILI: Proctor, William R. et al. Utility of spherical human liver microtissues for prediction of clinical drug-induced liver injury, ARCH TOXICOL (2017) 91: 2849-2863

MIP-DILI: Sharanek, Ahmad et al. Different Dose-Dependent Mechanisms Are Involved in Early Cyclosporine A-Induced Cholestatic Effects in HepaRG Cells, TOXICOL SCI (2014) 141: 244-253

MIP-DILI: Sharanek, Ahmad et al. Rho-kinase/myosin light chain kinase pathway plays a key role in the impairment of bile canaliculi dynamics induced by cholestatic drugs, SCI REP-UK (2016) 6:

MIP-DILI: Sison-Young, Rowena L. C. et al. Comparative Proteomic Characterization of 4 Human Liver-Derived Single Cell Culture Models Reveals Significant Variation in the Capacity for Drug Disposition, Bioactivation, and Detoxication, TOXICOL SCI (2015) 147: 412-424

MIP-DILI: Sison-Young, Rowena L. et al. A multicenter assessment of single-cell models aligned to standard measures of cell health for prediction of acute hepatotoxicity, ARCH TOXICOL (2017) 91: 1385-1400

MIP-DILI: Sutherland, Jeffrey J. et al. Assessing Concordance of Drug-Induced Transcriptional Response in Rodent Liver and Cultured Hepatocytes, PLOS COMPUT BIOL (2016) 12:

MIP-DILI: Vorrink, Sabine U. et al. Endogenous and xenobiotic metabolic stability of primary human hepatocytes in long-term 3D spheroid cultures revealed by a combination of targeted and untargeted metabolomics, FASEB J (2017) 31: 2696-2708

MIP-DILI: Vorrink, Sabine U. et al. Prediction of Drug-Induced Hepatotoxicity Using Long-Term Stable Primary Hepatic 3D Spheroid Cultures in Chemically Defined Conditions, *TOXICOL SCI* (2018) 163: 655-665

MIP-DILI: Weaver, Richard J. et al. Managing the challenge of drug-induced liver injury: a roadmap for the development and deployment of preclinical predictive models, *NAT REV DRUG DISCOV* (2020) 19: 131-148

MIP-DILI: Wink, Steven et al. Dynamic imaging of adaptive stress response pathway activation for prediction of drug induced liver injury, *ARCH TOXICOL* (2018) 92: 1797-1814

MIP-DILI: Wink, Steven et al. Quantitative High Content Imaging of Cellular Adaptive Stress Response Pathways in Toxicity for Chemical Safety Assessment, *CHEM RES TOXICOL* (2014) 27: 338-355

MOBILISE-D: Flachenecker, Felix et al. Objective sensor-based gait measures reflect motor impairment in multiple sclerosis patients: Reliability and clinical validation of a wearable sensor device, *MULT SCLER RELAT DIS* (2020) 39:

MOBILISE-D: Gassner, Heiko et al. Gait variability as digital biomarker of disease severity in Huntingtons disease, *J NEUROL* (2020) 267: 1594-1601

MOBILISE-D: Shema-Shiratzky, Shirley et al. A wearable sensor identifies alterations in community ambulation in multiple sclerosis: contributors to real-world gait quality and physical activity, *J NEUROL* (2020) 267: 1912-1921

MOBILISE-D: Viceconti, Marco et al. Credibility of In Silico Trial Technologies-A Theoretical Framing, *IEEE J BIOMED HEALTH* (2020) 24: 4-13

MOBILISE-D: Warmerdam, Elke et al. Long-term unsupervised mobility assessment in movement disorders, *LANCET NEUROL* (2020) 19: 462-470

MOPEAD: Moreno-Grau, Sonia et al. Genome-wide association analysis of dementia and its clinical endophenotypes reveal novel loci associated with Alzheimers disease and three causality networks: The GR@ACE project, *ALZHEIMERS DEMENT* (2019) 15: 1333-1347

ND4BB: Abu Kwaik, Yousef et al. Microbial quest for food in vivo: Nutritional virulence as an emerging paradigm, *CELL MICROBIOL* (2013) 15: 882-890

ND4BB: Kostyanov, T. et al. The Innovative Medicines Initiatives New Drugs for Bad Bugs programme: European public-private partnerships for the development of new strategies to tackle antibiotic resistance, *J ANTIMICROB CHEMOTH* (2016) 71: 290-295

NEWMEDS: Anacker, Christoph et al. Role for the kinase SGK1 in stress, depression, and glucocorticoid effects on hippocampal neurogenesis, *P NATL ACAD SCI USA* (2013) 110: 8708-8713

NEWMEDS: Artigas, Francesc et al. Developments in the field of antidepressants, where do we go now?, *EUR NEUROPSYCHOPHARM* (2015) 25: 657-670

NEWMEDS: Artigas, Francesc et al. Serotonin receptors involved in antidepressant effects, *PHARMACOL THERAPEUT* (2013) 137: 119-131

NEWMEDS: Bortolozzi, A. et al. Selective siRNA-mediated suppression of 5-HT1A autoreceptors evokes strong anti-depressant-like effects, *MOL PSYCHIATR* (2012) 17: 612-623

NEWMEDS: Braun, Urs et al. Dynamic reconfiguration of frontal brain networks during executive cognition in humans, *P NATL ACAD SCI USA* (2015) 112: 11678-11683

NEWMEDS: Braun, Urs et al. Test-retest reliability of resting-state connectivity network characteristics using fMRI and graph theoretical measures, *NEUROIMAGE* (2012) 59: 1404-1412

NEWMEDS: Bussey, T. J. et al. New translational assays for preclinical modelling of cognition in schizophrenia: The touchscreen testing method for mice and rats, *NEUROPHARMACOLOGY* (2012) 62: 1191-1203

NEWMEDS: Cao, Hengyi et al. Test-retest reliability of fMRI-based graph theoretical properties during working memory, emotion processing, and resting state, *NEUROIMAGE* (2014) 84: 888-900

NEWMEDS: Coleman, Jonathan R., I et al. The Genetics of the Mood Disorder Spectrum: Genome-wide Association Analyses of More Than 185,000 Cases and 439,000 Controls, *BIOL PSYCHIAT* (2020) 88: 169-184

NEWMEDS: Direk, Nese et al. An Analysis of Two Genome-wide Association Meta-analyses Identifies a New Locus for Broad Depression Phenotype, *BIOL PSYCHIAT* (2017) 82: 322-329

NEWMEDS: Doyle, O. M. et al. Quantifying the Attenuation of the Ketamine Pharmacological Magnetic Resonance Imaging Response in Humans: A Validation Using Antipsychotic and Glutamatergic Agents, *J PHARMACOL EXP THER* (2013) 345: 151-160

NEWMEDS: Fejgin, Kim et al. A Mouse Model that Recapitulates Cardinal Features of the 15q13.3 Microdeletion Syndrome Including Schizophrenia- and Epilepsy-Related Alterations, *BIOL PSYCHIAT* (2014) 76: 128-137

NEWMEDS: Gastambide, Francois et al. Selective Remediation of Reversal Learning Deficits in the Neurodevelopmental MAM Model of Schizophrenia by a Novel mGlu5 Positive Allosteric Modulator, *NEUROPSYCHOPHARMACOL* (2012) 37: 1057-1066

NEWMEDS: Gilmour, Gary et al. NMDA receptors, cognition and schizophrenia - Testing the validity of the NMDA receptor hypofunction hypothesis, *NEUROPHARMACOLOGY* (2012) 62: 1401-1412

NEWMEDS: Godsil, Bill P. et al. The hippocampal-prefrontal pathway: The weak link in psychiatric disorders?, *EUR NEUROPSYCHOPHARM* (2013) 23: 1165-1181

NEWMEDS: Grandjean, Joanes et al. Common functional networks in the mouse brain revealed by multi-centre resting-state fMRI analysis, *NEUROIMAGE* (2020) 205:

NEWMEDS: Grimm, Oliver et al. Acute ketamine challenge increases resting state prefrontal-hippocampal connectivity in both humans and rats, *PSYCHOPHARMACOLOGY* (2015) 232: 4231-4241

NEWMEDS: Holz, Nathalie E. et al. Resilience and the brain: a key role for regulatory circuits linked to social stress and support, *MOL PSYCHIATR* (2020) 25: 379-396

NEWMEDS: Horner, Alexa E. et al. The touchscreen operant platform for testing learning and memory in rats and mice, *NAT PROTOC* (2013) 8: 1961-1984

NEWMEDS: Ingason, Andres et al. Maternally Derived Microduplications at 15q11-q13: Implication of Imprinted Genes in Psychotic Illness, *AM J PSYCHIAT* (2011) 168: 408-417

NEWMEDS: Iniesta, R. et al. Machine learning, statistical learning and the future of biological research in psychiatry, *PSYCHOL MED* (2016) 46: 2455-2465

NEWMEDS: Iniesta, Raquel et al. Combining clinical variables to optimize prediction of antidepressant treatment outcomes, *J PSYCHIATR RES* (2016) 78: 94-102

NEWMEDS: Jacquemont, Sebastien et al. Mirror extreme BMI phenotypes associated with gene dosage at the chromosome 16p11.2 locus, *NATURE* (2011) 478: 97-U111

NEWMEDS: Kapur, S. et al. Why has it taken so long for biological psychiatry to develop clinical tests and what to do about it?, *MOL PSYCHIATR* (2012) 17: 1174-1179

NEWMEDS: Keeler, J. F. et al. Translating cognition from animals to humans, *BIOCHEM PHARMACOL* (2011) 81: 1356-1366

NEWMEDS: Kim, Chi Hun et al. The continuous performance test (rCPT) for mice: a novel operant touchscreen test of attentional function, *PSYCHOPHARMACOLOGY* (2015) 232: 3947-3966

NEWMEDS: Kirov, G. et al. De novo CNV analysis implicates specific abnormalities of postsynaptic signalling complexes in the pathogenesis of schizophrenia, *MOL PSYCHIATR* (2012) 17: 142-153

NEWMEDS: Llado-Pelfort, Laia et al. 5-HT<sub>1A</sub> Receptor Agonists Enhance Pyramidal Cell Firing in Prefrontal Cortex Through a Preferential Action on GABA Interneurons, *CEREB CORTEX* (2012) 22: 1487-1497

NEWMEDS: Lo, Min-Tzu et al. Genome-wide analyses for personality traits identify six genomic loci and show correlations with psychiatric disorders, *NAT GENET* (2017) 49: 152-156

NEWMEDS: Lustig, C. et al. CNTRICS final animal model task selection: Control of attention, *NEUROSCI BIOBEHAV R* (2013) 37: 2099-2110

NEWMEDS: Lyon, L. et al. Spontaneous object recognition and its relevance to schizophrenia: a review of findings from pharmacological, genetic, lesion and developmental rodent models, *PSYCHOPHARMACOLOGY* (2012) 220: 647-672

NEWMEDS: Mar, Adam C. et al. The touchscreen operant platform for assessing executive function in rats and mice, *NAT PROTOC* (2013) 8: 1985-2005

NEWMEDS: Meyer-Lindenberg, Andreas et al. From maps to mechanisms through neuroimaging of schizophrenia, *NATURE* (2010) 468: 194-202

NEWMEDS: Meyer-Lindenberg, Andreas et al. Neural mechanisms of social risk for psychiatric disorders, *NAT NEUROSCI* (2012) 15: 663-668

NEWMEDS: Meyer-Lindenberg, Andreas et al. Oxytocin and vasopressin in the human brain: social neuropeptides for translational medicine, *NAT REV NEUROSCI* (2011) 12: 524-538

NEWMEDS: Nord, Magdalena et al. Effect of a single dose of escitalopram on serotonin concentration in the non-human and human primate brain, *INT J NEUROPSYCHOPH* (2013) 16: 1577-1586

NEWMEDS: Oomen, Charlotte A. et al. The touchscreen operant platform for testing working memory and pattern separation in rats and mice, *NAT PROTOC* (2013) 8: 2006-2021

NEWMEDS: Paloyelis, Yannis et al. A Spatiotemporal Profile of In Vivo Cerebral Blood Flow Changes Following Intranasal Oxytocin in Humans, *BIOL PSYCHIAT* (2016) 79: 693-705

NEWMEDS: Plichta, Michael M. et al. Amygdala habituation: A reliable fMRI phenotype, *NEUROIMAGE* (2014) 103: 383-390

NEWMEDS: Plichta, Michael M. et al. Test-retest reliability of evoked BOLD signals from a cognitive-emotive fMRI test battery, *NEUROIMAGE* (2012) 60: 1746-1758

NEWMEDS: Power, Robert A. et al. Polygenic risk scores for schizophrenia and bipolar disorder predict creativity, *NAT NEUROSCI* (2015) 18: 953-+

NEWMEDS: Silva, Ana, I et al. Reciprocal White Matter Changes Associated With Copy Number Variation at 15q11.2 BP1-BP2: A Diffusion Tensor Imaging Study, *BIOL PSYCHIAT* (2019) 85: 563-572

NEWMEDS: Smith, Janice W. et al. A comparison of the effects of ketamine and phencyclidine with other antagonists of the NMDA receptor in rodent assays of attention and working memory, *PSYCHOPHARMACOLOGY* (2011) 217: 255-269

NEWMEDS: Stefansson, Hreinn et al. CNVs conferring risk of autism or schizophrenia affect cognition in controls, *NATURE* (2014) 505: 361-+

NEWMEDS: Sullivan, Patrick F. et al. A mega-analysis of genome-wide association studies for major depressive disorder, *MOL PSYCHIATR* (2013) 18: 497-511

NEWMEDS: Tansey, Katherine E. et al. Contribution of Common Genetic Variants to Antidepressant Response, *BIOL PSYCHIAT* (2013) 73: 679-682

NEWMEDS: Tansey, Katherine E. et al. Genetic Predictors of Response to Serotonergic and Noradrenergic Antidepressants in Major Depressive Disorder: A Genome-Wide Analysis of Individual-Level Data and a Meta-Analysis, *PLOS MED* (2012) 9:

NEWMEDS: Tost, Heike et al. Neural correlates of individual differences in affective benefit of real-life urban green space exposure, *NAT NEUROSCI* (2019) 22: 1389-+

NEWMEDS: Uher, R. et al. Depression symptom dimensions as predictors of antidepressant treatment outcome: replicable evidence for interest-activity symptoms, *PSYCHOL MED* (2012) 42: 967-980

NEWMEDS: Uher, Rudolf et al. Gene-environment interactions in common mental disorders: an update and strategy for a genome-wide search, *SOC PSYCH PSYCH EPID* (2014) 49: 3-14

NEWMEDS: Uher, Rudolf et al. SELF-REPORT AND CLINICIAN-RATED MEASURES OF DEPRESSION SEVERITY: CAN ONE REPLACE THE OTHER?, *DEPRESS ANXIETY* (2012) 29: 1043-1049

NEWMEDS: Ulfarsson, M. O. et al. 15q11.2 CNV affects cognitive, structural and functional correlates of dyslexia and dyscalculia, *TRANSL PSYCHIAT* (2017) 7:

NEWMEDS: Zink, Caroline F. et al. Human neuroimaging of oxytocin and vasopressin in social cognition, *HORM BEHAV* (2012) 61: 400-409

Onco Track: Algar, W. Russ et al. Quantum Dots as Simultaneous Acceptors and Donors in Time-Gated Forster Resonance Energy Transfer Relays: Characterization and Biosensing, *J AM CHEM SOC* (2012) 134: 1876-1891

Onco Track: Bettermann, Kira et al. SUMOylation in carcinogenesis, *CANCER LETT* (2012) 316: 113-125

Onco Track: Boehnke, Karsten et al. Assay Establishment and Validation of a High-Throughput Screening Platform for Three-Dimensional Patient-Derived Colon Cancer Organoid Cultures, *J BIOMOL SCREEN* (2016) 21: 931-941

Onco Track: Butcher, Lee M. et al. Probe Lasso: A novel method to rope in differentially methylated regions with 450K DNA methylation data, *METHODS* (2015) 72: 21-28

Onco Track: Feber, Andrew et al. Using high-density DNA methylation arrays to profile copy number alterations, *GENOME BIOL* (2014) 15:

Onco Track: Geissler, Daniel et al. Lanthanides and Quantum Dots as Forster Resonance Energy Transfer Agents for Diagnostics and Cellular Imaging, *INORG CHEM* (2014) 53: 1824-1838

Onco Track: Golob-Schwarzl, Nicole et al. New liver cancer biomarkers: PI3K/AKT/mTOR pathway members and eukaryotic translation initiation factors, *EUR J CANCER* (2017) 83: 56-70

Onco Track: Hildebrandt, Niko et al. Biofunctional Quantum Dots: Controlled Conjugation for Multiplexed Biosensors, *ACS NANO* (2011) 5: 5286-5290

Onco Track: Hoetzer, Benjamin et al. Fluorescence in Nanobiotechnology: Sophisticated Fluorophores for Novel Applications, *SMALL* (2012) 8: 2297-2326

Onco Track: Jin, Zongwen et al. A Rapid, Amplification-Free, and Sensitive Diagnostic Assay for Single-Step Multiplexed Fluorescence Detection of MicroRNA, *ANGEW CHEM INT EDIT* (2015) 54: 10024-10029

Onco Track: Jin, Zongwen et al. Semiconductor quantum dots for in vitro diagnostics and cellular imaging, *TRENDS BIOTECHNOL* (2012) 30: 394-403



Onco Track: Kargl, J. et al. GPR55 promotes migration and adhesion of colon cancer cells indicating a role in metastasis, *BRIT J PHARMACOL* (2016) 173: 142-154

Onco Track: Ke, Rongqin et al. In situ sequencing for RNA analysis in preserved tissue and cells, *NAT METHODS* (2013) 10: 857-+

Onco Track: Lechner, Matthias et al. Identification and functional validation of HPV-mediated hypermethylation in head and neck squamous cell carcinoma, *GENOME MED* (2013) 5:

Onco Track: Morris, Tiffany J. et al. ChAMP: 450k Chip Analysis Methylation Pipeline, *BIOINFORMATICS* (2014) 30: 428-430

Onco Track: Qiu, Xue et al. Multiplexed Nucleic Acid Hybridization Assays Using Single-FRET-Pair Distance-Tuning, *SMALL* (2017) 13:

Onco Track: Qiu, Xue et al. Rapid and Multiplexed MicroRNA Diagnostic Assay Using Quantum Dot-Based Forster Resonance Energy Transfer, *ACS NANO* (2015) 9: 8449-8457

Onco Track: Schuette, Moritz et al. Molecular dissection of colorectal cancer in pre-clinical models identifies biomarkers predicting sensitivity to EGFR inhibitors, *NAT COMMUN* (2017) 8:

Onco Track: Taiwo, Oluwatosin et al. Methylome analysis using MeDIP-seq with low DNA concentrations, *NAT PROTOC* (2012) 7: 617-636

Onco Track: Wegner, K. David et al. Nanobodies and Nanocrystals: Highly Sensitive Quantum Dot-Based Homogeneous FRET Immunoassay for Serum-Based EGFR Detection, *SMALL* (2014) 10: 734-740

Onco Track: Wegner, K. David et al. Quantum dots: bright and versatile in vitro and in vivo fluorescence imaging biosensors, *CHEM SOC REV* (2015) 44: 4792-4834

Onco Track: Wegner, K. David et al. Quantum-Dot-Based Forster Resonance Energy Transfer Immunoassay for Sensitive Clinical Diagnostics of Low-Volume Serum Samples, *ACS NANO* (2013) 7: 7411-7419

Open PHACTS: Alshahrani, Mona et al. Neuro-symbolic representation learning on biological knowledge graphs, *BIOINFORMATICS* (2017) 33: 2723-2730

Open PHACTS: Bento, A. Patricia et al. The ChEMBL bioactivity database: an update, *NUCLEIC ACIDS RES* (2014) 42: D1083-D1090

Open PHACTS: Dumontier, Michel et al. The Semanticscience Integrated Ontology (SIO) for biomedical research and knowledge discovery, *J BIOMED SEMANT* (2014) 5:

Open PHACTS: Furlong, Laura I. et al. Human diseases through the lens of network biology, *TRENDS GENET* (2013) 29: 150-159

Open PHACTS: Gaulton, Anna et al. The ChEMBL database in 2017, *NUCLEIC ACIDS RES* (2017) 45: D945-D954

Open PHACTS: Gray, Alasdair J. G. et al. Applying linked data approaches to pharmacology: Architectural decisions and implementation, *SEMANT WEB* (2014) 5: 101-113

Open PHACTS: Jupp, Simon et al. The EBI RDF platform: linked open data for the life sciences, *BIOINFORMATICS* (2014) 30: 1338-1339

Open PHACTS: Kringelum, Jens et al. ChemProt-3.0: a global chemical biology diseases mapping, *DATABASE-OXFORD* (2016) :

Open PHACTS: Kutmon, Martina et al. WikiPathways: capturing the full diversity of pathway knowledge, *NUCLEIC ACIDS RES* (2016) 44: D488-D494

Open PHACTS: Lizio, Marina et al. Gateways to the FANTOM5 promoter level mammalian expression atlas, *GENOME BIOL* (2015) 16:

Open PHACTS: Moreau, Luc et al. The rationale of PROV, *J WEB SEMANT* (2015) 35: 235-257

Open PHACTS: Pinero, Janet et al. DisGeNET: a comprehensive platform integrating information on human disease-associated genes and variants, *NUCLEIC ACIDS RES* (2017) 45: D833-D839

Open PHACTS: Pinero, Janet et al. DisGeNET: a discovery platform for the dynamical exploration of human diseases and their genes, *DATABASE-OXFORD* (2015) :

Open PHACTS: Queralt-Rosinach, Nuria et al. DisGeNET-RDF: harnessing the innovative power of the Semantic Web to explore the genetic basis of diseases, *BIOINFORMATICS* (2016) 32: 2236-2238

Open PHACTS: Slenter, Denise N. et al. WikiPathways: a multifaceted pathway database bridging metabolomics to other omics research, *NUCLEIC ACIDS RES* (2018) 46: D661-D667

Open PHACTS: Williams, Antony J. et al. Open PHACTS: semantic interoperability for drug discovery, *DRUG DISCOV TODAY* (2012) 17: 1188-1198

Open PHACTS: Williams, Antony J. et al. Towards a gold standard: regarding quality in public domain chemistry databases and approaches to improving the situation, *DRUG DISCOV TODAY* (2012) 17: 685-701

ORBITO: Andreas, Cord J. et al. Mechanistic investigation of the negative food effect of modified release zolpidem, *EUR J PHARM SCI* (2017) 102: 284-298

ORBITO: Augustijns, Patrick et al. A review of drug solubility in human intestinal fluids: Implications for the prediction of oral absorption, *EUR J PHARM SCI* (2014) 57: 322-332

ORBITO: Berben, Philippe et al. Drug permeability profiling using cell-free permeation tools: Overview and applications, *EUR J PHARM SCI* (2018) 119: 219-233

ORBITO: Bergstrom, Christel A. S. et al. Early pharmaceutical profiling to predict oral drug absorption: Current status and unmet needs, *EUR J PHARM SCI* (2014) 57: 173-199

ORBITO: Butler, James et al. In vitro models for the prediction of in vivo performance of oral dosage forms: Recent progress from partnership through the IMI OrBiTo collaboration, *EUR J PHARM BIOPHARM* (2019) 136: 70-83

ORBITO: Couto, Narciso et al. Quantitative Proteomics of Clinically Relevant Drug-Metabolizing Enzymes and Drug Transporters and Their Intercorrelations in the Human Small Intestine, *DRUG METAB DISPOS* (2020) 48: 245-254

ORBITO: Dahlgren, D. et al. The effects of three absorption-modifying critical excipients on the in vivo intestinal absorption of six model compounds in rats and dogs, *INT J PHARMACEUT* (2018) 547: 158-168

ORBITO: Dahlgren, David et al. Direct In Vivo Human Intestinal Permeability (P-eff) Determined with Different Clinical Perfusion and Intubation Methods, *J PHARM SCI-US* (2015) 104: 2702-2726

ORBITO: Dahlgren, David et al. Regional Intestinal Permeability of Three Model Drugs in Human, *MOL PHARMACEUT* (2016) 13: 3013-3021

ORBITO: Grimm, Michael et al. Gastric Emptying and Small Bowel Water Content after Administration of Grapefruit Juice Compared to Water and Isocaloric Solutions of Glucose and Fructose: A Four-Way Crossover MRI Pilot Study in Healthy Subjects, *MOL PHARMACEUT* (2018) 15: 548-559

ORBITO: Grimm, Michael et al. Interindividual and intraindividual variability of fasted state gastric fluid volume and gastric emptying of water, *EUR J PHARM BIOPHARM* (2018) 127: 309-317

ORBITO: Harwood, M. D. et al. Application of an LC-MS/MS method for the simultaneous quantification of human intestinal transporter proteins absolute abundance using a QconCAT technique, J PHARMACEUT BIOMED (2015) 110: 27-33

ORBITO: Hens, Bart et al. Exploring gastrointestinal variables affecting drug and formulation behavior: Methodologies, challenges and opportunities, INT J PHARMACEUT (2017) 519: 79-97

ORBITO: Hens, Bart et al. Gastrointestinal behavior of nano- and microsized fenofibrate: In vivo evaluation in man and in vitro simulation by assessment of the permeation potential, EUR J PHARM SCI (2015) 77: 40-47

ORBITO: Hens, Bart et al. Gastrointestinal transfer: In vivo evaluation and implementation in in vitro and in silico predictive tools, EUR J PHARM SCI (2014) 63: 233-242

ORBITO: Hens, Bart et al. In Silico Modeling Approach for the Evaluation of Gastrointestinal Dissolution, Supersaturation, and Precipitation of Posaconazole, MOL PHARMACEUT (2017) 14: 4321-4333

ORBITO: Hofmann, Michael et al. In vitro prediction of in vivo absorption of ibuprofen from suspensions through rational choice of dissolution conditions, EUR J PHARM BIOPHARM (2020) 149: 229-237

ORBITO: Hossain, Shakhawath et al. Molecular simulation as a computational pharmaceuticals tool to predict drug solubility, solubilization processes and partitioning, EUR J PHARM BIOPHARM (2019) 137: 46-55

ORBITO: Khadra, Ibrahim et al. Statistical investigation of simulated intestinal fluid composition on the equilibrium solubility of biopharmaceutics classification system class II drugs, EUR J PHARM SCI (2015) 67: 65-75

ORBITO: Kostewicz, Edmund S. et al. In vitro models for the prediction of in vivo performance of oral dosage forms, EUR J PHARM SCI (2014) 57: 342-366

ORBITO: Kostewicz, Edmund S. et al. PBPK models for the prediction of in vivo performance of oral dosage forms, EUR J PHARM SCI (2014) 57: 300-321

ORBITO: Kourentas, Alexandros et al. An in vitro biorelevant gastrointestinal transfer (BioGIT) system for forecasting concentrations in the fasted upper small intestine: Design, implementation, and evaluation, EUR J PHARM SCI (2016) 82: 106-114

ORBITO: Koziolok, M. et al. Intragastric pH and pressure profiles after intake of the high-caloric, high-fat meal as used for food effect studies, J CONTROL RELEASE (2015) 220: 71-78

ORBITO: Koziolok, Mirko et al. Intragastric Volume Changes after Intake of a High-Caloric, High-Fat Standard Breakfast in Healthy Human Subjects Investigated by MRI, MOL PHARMACEUT (2014) 11: 1632-1639

ORBITO: Koziolok, Mirko et al. Investigation of pH and Temperature Profiles in the GI Tract of Fasted Human Subjects Using the Intellicap((R)) System, J PHARM SCI-US (2015) 104: 2855-2863

ORBITO: Koziolok, Mirko et al. Navigating the human gastrointestinal tract for oral drug delivery: Uncharted waters and new frontiers, ADV DRUG DELIVER REV (2016) 101: 75-88

ORBITO: Lennernas, H. et al. In Vivo Predictive Dissolution (IPD) and Biopharmaceutical Modeling and Simulation: Future Use of Modern Approaches and Methodologies in a Regulatory Context, MOL PHARMACEUT (2017) 14: 1307-1314

ORBITO: Mann, James et al. Validation of Dissolution Testing with Biorelevant Media: An OrBiTo Study, MOL PHARMACEUT (2017) 14: 4192-4201

ORBITO: Margolskee, Alison et al. IMI - oral biopharmaceutics tools project - evaluation of bottom-up PBPK prediction success part 1: Characterisation of the OrBiTo database of compounds, EUR J PHARM SCI (2017) 96: 598-609

ORBITO: Margolskee, Alison et al. IMI - Oral biopharmaceutics tools project - Evaluation of bottom-up PBPK prediction success part 2: An introduction to the simulation exercise and overview of results, EUR J PHARM SCI (2017) 96: 610-625

ORBITO: Markopoulos, Constantinos et al. In-vitro simulation of luminal conditions for evaluation of performance of oral drug products: Choosing the appropriate test media, EUR J PHARM BIOPHARM (2015) 93: 173-182

ORBITO: Palmelund, Henrik et al. Studying the Propensity of Compounds to Supersaturate: A Practical and Broadly Applicable Approach, J PHARM SCI-US (2016) 105: 3021-3029

ORBITO: Ruff, Aaron et al. Prediction of Ketoconazole absorption using an updated in vitro transfer model coupled to physiologically based pharmacokinetic modelling, EUR J PHARM SCI (2017) 100: 42-55

ORBITO: Schneider, Felix et al. Resolving the physiological conditions in bioavailability and bioequivalence studies: Comparison of fasted and fed state, EUR J PHARM BIOPHARM (2016) 108: 214-219

ORBITO: Sjogren, Erik et al. In vivo methods for drug absorption - Comparative physiologies, model selection, correlations with in vitro methods (IVIVC), and applications for formulation/API/excipient characterization including food effects, EUR J PHARM SCI (2014) 57: 99-151

ORBITO: Van den Abeele, Jens et al. The dynamic gastric environment and its impact on drug and formulation behaviour, EUR J PHARM SCI (2017) 96: 207-231

ORBITO: Van Den Abeele, Jens et al. The effect of reduced gastric acid secretion on the gastrointestinal disposition of a ritonavir amorphous solid dispersion in fasted healthy volunteers: an in vivo-in vitro investigation., EUR J PHARM SCI (2020) 151:

ORBITO: Verwei, Miriam et al. Evaluation of two dynamic in vitro models simulating fasted and fed state conditions in the upper gastrointestinal tract (TIM-1 and tiny-TIM) for investigating the bioaccessibility of pharmaceutical compounds from oral dosage forms, INT J PHARMACEUT (2016) 498: 178-186

PD-MitoQUANT: Alam, Parvez et al. alpha-synuclein oligomers and fibrils: a spectrum of species, a spectrum of toxicities, J NEUROCHEM (2019) 150: 522-534

PD-MitoQUANT: Jacoupy, M. et al. The PINK1 kinase-driven ubiquitin ligase Parkin promotes mitochondrial protein import through the presequence pathway in living cells, SCI REP-UK (2019) 9:

PD-MitoQUANT: Rey, Nolwen L. et al. alpha-Synuclein conformational strains spread, seed and target neuronal cells differentially after injection into the olfactory bulb, ACTA NEUROPATHOL COM (2019) 7:

PD-MitoQUANT: Shrivastava, Amulya Nidhi et al. Differential Membrane Binding and Seeding of Distinct alpha-Synuclein Fibrillar Polymorphs, BIOPHYS J (2020) 118: 1301-1320

PERISCOPE: Botafogo, Vitor et al. Age Distribution of Multiple Functionally Relevant Subsets of CD4+T Cells in Human Blood Using a Standardized and Validated 14-Color EuroFlow Immune Monitoring Tube, FRONT IMMUNOL (2020) 11:

PERISCOPE: de Graaf, Hans et al. Controlled Human Infection With Bordetella pertussis Induces Asymptomatic, Immunizing Colonization, CLIN INFECT DIS (2020) 71: 403-411

PERISCOPE: Wilk, Mieszko M. et al. Immunization with whole cell but not acellular pertussis vaccines primes CD4 T-RM cells that sustain protective immunity against nasal colonization with Bordetella pertussis, EMERG MICROBES INFEC (2019) 8: 169-185

PHAGO: Boza-Serrano, Antonio et al. Galectin-3, a novel endogenous TREM2 ligand, detrimentally regulates inflammatory response in Alzheimers disease, ACTA NEUROPATHOL (2019) 138: 251-273

PHAGO: Brown, Guy C. et al. The endotoxin hypothesis of neurodegeneration, *J NEUROINFLAMM* (2019) 16:

PHAGO: Garcia-Reitboeck, Pablo et al. Human Induced Pluripotent Stem Cell-Derived Microglia-Like Cells Harboring TREM2 Missense Mutations Show Specific Deficits in Phagocytosis, *CELL REP* (2018) 24: 2300-2311

PHAGO: Houtman, Judith et al. Beclin1-driven autophagy modulates the inflammatory response of microglia via NLRP3, *EMBO J* (2019) 38:

PHAGO: Linnartz-Gerlach, Bettina et al. TREM2 triggers microglial density and age-related neuronal loss, *GLIA* (2019) 67: 539-550

PHAGO: Parhizkar, Samira et al. Loss of TREM2 function increases amyloid seeding but reduces plaque-associated ApoE, *NAT NEUROSCI* (2019) 22: 191-+

PHAGO: Piers, Thomas M. et al. A locked immunometabolic switch underlies TREM2 R47H loss of function in human iPSC-derived microglia, *FASEB J* (2019) 34: 2436-2450

PHAGO: Schlepckow, Kai et al. An Alzheimer-associated TREM2 variant occurs at the ADAM cleavage site and affects shedding and phagocytic function, *EMBO MOL MED* (2017) 9: 1356-1365

PHAGO: Schlepckow, Kai et al. Enhancing protective microglial activities with a dual function TREM2 antibody to the stalk region, *EMBO MOL MED* (2020) 12:

PHAGO: Thornton, Peter et al. TREM2 shedding by cleavage at the H157-S158 bond is accelerated for the Alzheimers disease-associated H157Y variant, *EMBO MOL MED* (2017) 9: 1366-1378

PHAGO: Xiang, Xianyuan et al. The Trem2 R47H Alzheimers risk variant impairs splicing and reduces Trem2 mRNA and protein in mice but not in humans, *MOL NEURODEGENER* (2018) 13:

Pharma-Cog: Albi, Angela et al. Free water elimination improves test-retest reproducibility of diffusion tensor imaging indices in the brain: A longitudinal multisite study of healthy elderly subjects, *HUM BRAIN MAPP* (2017) 38: 12-26

Pharma-Cog: Babiloni, Claudio et al. Resting state cortical electroencephalographic rhythms are related to gray matter volume in subjects with mild cognitive impairment and Alzheimers disease, *HUM BRAIN MAPP* (2013) 34: 1427-1446

Pharma-Cog: Carrillo, Maria C. et al. Worldwide Alzheimers Disease Neuroimaging Initiative, *ALZHEIMERS DEMENT* (2012) 8: 337-342

Pharma-Cog: Frisoni, Giovanni B. et al. The clinical use of structural MRI in Alzheimer disease, *NAT REV NEUROL* (2010) 6: 67-77

Pharma-Cog: Galluzzi, S. et al. Clinical and biomarker profiling of prodromal Alzheimers disease in workpackage 5 of the Innovative Medicines Initiative PharmaCog project: a European ADNI study, *J INTERN MED* (2016) 279: 576-591

Pharma-Cog: Jovicich, Jorge et al. Brain morphometry reproducibility in multi-center 3 T MRI studies: A comparison of cross-sectional and longitudinal segmentations, *NEUROIMAGE* (2013) 83: 472-484

Pharma-Cog: Jovicich, Jorge et al. Longitudinal reproducibility of default-mode network connectivity in healthy elderly participants: A multicentric resting-state fMRI study, *NEUROIMAGE* (2016) 124: 442-454

Pharma-Cog: Jovicich, Jorge et al. Multisite longitudinal reliability of tract-based spatial statistics in diffusion tensor imaging of healthy elderly subjects, *NEUROIMAGE* (2014) 101: 390-403

Pharma-Cog: Languille, S. et al. The grey mouse lemur: A non-human primate model for ageing studies, *AGEING RES REV* (2012) 11: 150-162

Pharma-Cog: Lim, Chai K. et al. Involvement of the kynurenine pathway in the pathogenesis of Parkinsons disease, *PROG NEUROBIOL* (2017) 155: 76-95

Pharma-Cog: Nathan, Pradeep J. et al. Association between CSF biomarkers, hippocampal volume and cognitive function in patients with amnesic mild cognitive impairment (MCI), *NEUROBIOL AGING* (2017) 53: 1-10

Pharma-Cog: Pini, Lorenzo et al. Brain atrophy in Alzheimers Disease and aging, *AGEING RES REV* (2016) 30: 25-48

PIONEER: Aarestrup, F. M. et al. Towards a European health research and innovation cloud (HRIC), *GENOME MED* (2020) 12:

PRECISESADS: Acosta-Herrera, Marialbert et al. Genome-wide meta-analysis reveals shared new loci in systemic seropositive rheumatic diseases, *ANN RHEUM DIS* (2019) 78: 311-319

PRECISESADS: Alvarez-Errico, Damiana et al. Epigenetic control of myeloid cell differentiation, identity and function, *NAT REV IMMUNOL* (2015) 15: 7-17

PRECISESADS: Barturen, Guillermo et al. Moving towards a molecular taxonomy of autoimmune rheumatic diseases, *NAT REV RHEUMATOL* (2018) 14: 75-93

PRECISESADS: Fernandez-Ochoa, Alvaro et al. Urinary and plasma metabolite differences detected by HPLC-ESI-QTOF-MS in systemic sclerosis patients, *J PHARMACEUT BIOMED* (2019) 162: 82-90

PRECISESADS: Teruel, Maria et al. The genetic basis of systemic lupus erythematosus: What are the risk factors and what have we learned, *J AUTOIMMUN* (2016) 74: 161-175

PRECISESADS: Toro-Dominguez, Daniel et al. Stratification of Systemic Lupus Erythematosus Patients Into Three Groups of Disease Activity Progression According to Longitudinal Gene Expression, *ARTHRITIS RHEUMATOL* (2018) 70: 2025-2035

Predict: Arandkar, Sharathchandra et al. Altered p53 functionality in cancer-associated fibroblasts contributes to their cancer-supporting features, *P NATL ACAD SCI USA* (2018) 115: 6410-6415

Predict: Blom, Sami et al. Systems pathology by multiplexed immunohistochemistry and whole-slide digital image analysis, *SCI REP-UK* (2017) 7:

Predict: Davies, Emma et al. Capturing complex tumour biology in vitro: histological and molecular characterisation of precision cut slices, *SCI REP-UK* (2015) 5:

Predict: de Jong, Marion et al. Imaging preclinical tumour models: improving translational power, *NAT REV CANCER* (2014) 14: 481-493

Predict: de Witte, Samantha F. H. et al. Cytokine treatment optimises the immunotherapeutic effects of umbilical cord-derived MSC for treatment of inflammatory liver disease, *STEM CELL RES THER* (2017) 8:

Predict: Dobrolecki, Lacey E. et al. Patient-derived xenograft (PDX) models in basic and translational breast cancer research, *CANCER METAST REV* (2016) 35: 547-573

Predict: Estrada, Marta F. et al. Modelling the tumour microenvironment in long-term microencapsulated 3D co-cultures recapitulates phenotypic features of disease progression, *BIOMATERIALS* (2016) 78: 50-61

Predict: Gualda, Emilio J. et al. SPIM-fluid: open source light-sheet based platform for high-throughput imaging, *BIOMED OPT EXPRESS* (2015) 6: 4447-4456

Predict: Hickman, John A. et al. Three-dimensional models of cancer for pharmacology and cancer cell biology: Capturing tumor complexity in vitro/ex vivo, *BIOTECHNOL J* (2014) 9: 1115-1128

Predict: Metsalu, Tauno et al. ClustVis: a web tool for visualizing clustering of multivariate data using Principal Component Analysis and heatmap, *NUCLEIC ACIDS RES* (2015) 43: W566-W570

Predelect: Nieminen, Anni I. et al. Myc-induced AMPK-phospho p53 pathway activates Bak to sensitize mitochondrial apoptosis, *P NATL ACAD SCI USA* (2013) 110: E1839-E1848

Predelect: Rebelo, Sofia P. et al. 3D-3-culture: A tool to unveil macrophage plasticity in the tumour microenvironment, *BIOMATERIALS* (2018) 163: 185-197

Predelect: Santo, Vitor E. et al. Drug screening in 3D in vitro tumor models: overcoming current pitfalls of efficacy read-outs, *BIOTECHNOL J* (2017) 12:

Predelect: Sflomos, George et al. A Preclinical Model for ER alpha-Positive Breast Cancer Points to the Epithelial Microenvironment as Determinant of Luminal Phenotype and Hormone Response, *CANCER CELL* (2016) 29: 407-422

Predelect: Stock, Kristin et al. Capturing tumor complexity in vitro: Comparative analysis of 2D and 3D tumor models for drug discovery, *SCI REP-UK* (2016) 6:

Predelect: Tanos, Tamara et al. Progesterone/RANKL Is a Major Regulatory Axis in the Human Breast, *SCI TRANSL MED* (2013) 5:

PreDiCT-TB: Ates, Louis S. et al. Essential Role of the ESX-5 Secretion System in Outer Membrane Permeability of Pathogenic Mycobacteria, *PLOS GENET* (2015) 11:

PreDiCT-TB: Baranowski, Catherine et al. Maturing Mycobacterium smegmatis peptidoglycan requires non-canonical crosslinks to maintain shape, *ELIFE* (2018) 7:

PreDiCT-TB: Boritsch, Eva C. et al. Key experimental evidence of chromosomal DNA transfer among selected tuberculosis-causing mycobacteria, *P NATL ACAD SCI USA* (2016) 113: 9876-9881

PreDiCT-TB: Boritsch, Eva C. et al. pks5-recombination-mediated surface remodelling in Mycobacterium tuberculosis emergence, *NAT MICROBIOL* (2016) 1:

PreDiCT-TB: Hu, Yanmin et al. High-dose rifampicin kills persisters, shortens treatment duration, and reduces relapse rate in vitro and in vivo, *FRONT MICROBIOL* (2015) 6:

PreDiCT-TB: Kaufmann, Stefan H. E. et al. Host-directed therapies for bacterial and viral infections, *NAT REV DRUG DISCOV* (2018) 17: 35-56

PreDiCT-TB: Kaufmann, Stefan H. E. et al. Molecular Determinants in Phagocyte-Bacteria Interactions, *IMMUNITY* (2016) 44: 476-491

PreDiCT-TB: Lipworth, S. et al. Defining dormancy in mycobacterial disease, *TUBERCULOSIS* (2016) 99: 131-142

PreDiCT-TB: Manina, Giulia et al. Stress and Host Immunity Amplify Mycobacterium tuberculosis Phenotypic Heterogeneity and Induce Nongrowing Metabolically Active Forms, *CELL HOST MICROBE* (2015) 17: 32-46

PreDiCT-TB: McReynolds, Naomi et al. Multimodal discrimination of immune cells using a combination of Raman spectroscopy and digital holographic microscopy, *SCI REP-UK* (2017) 7:

PreDiCT-TB: Sisniega, A. et al. Monte Carlo study of the effects of system geometry and antiscatter grids on cone-beam CT scatter distributions, *MED PHYS* (2013) 40:

PreDiCT-TB: Svensson, Elin M. et al. Model-Based Estimates of the Effects of Efavirenz on Bedaquiline Pharmacokinetics and Suggested Dose Adjustments for Patients Coinfected with HIV and Tuberculosis, *ANTIMICROB AGENTS CH* (2013) 57: 2780-2787

PreDiCT-TB: Svensson, Elin M. et al. Rifampicin and rifapentine significantly reduce concentrations of bedaquiline, a new anti-TB drug, *J ANTIMICROB CHEMOTH* (2015) 70: 1106-1114

PreDiCT-TB: Svensson, Robin J. et al. A Population Pharmacokinetic Model Incorporating Saturable Pharmacokinetics and Autoinduction for High Rifampicin Doses, *CLIN PHARMACOL THER* (2018) 103: 674-683

PreDiCT-TB: Svensson, Robin J. et al. Greater Early Bactericidal Activity at Higher Rifampicin Doses Revealed by Modeling and Clinical Trial Simulations, *J INFECT DIS* (2018) 218: 991-999

PreDiCT-TB: Zumla, Alimuddin I. et al. New antituberculosis drugs, regimens, and adjunct therapies: needs, advances, and future prospects, *LANCET INFECT DIS* (2014) 14: 327-340

PREFER: Russo, Selena et al. Understanding Patients Preferences: A Systematic Review of Psychological Instruments Used in Patients Preference and Decision Studies, *VALUE HEALTH* (2019) 22: 491-501

PREFER: Soekhai, Vikas et al. Methods for exploring and eliciting patient preferences in the medical product lifecycle: a literature review, *DRUG DISCOV TODAY* (2019) 24: 1324-1331

PREFER: van Overbeeke, Eline et al. Factors and situations influencing the value of patient preference studies along the medical product lifecycle: a literature review, *DRUG DISCOV TODAY* (2019) 24: 57-68

PRISM: Arango, Celso et al. Preventive strategies for mental health, *LANCET PSYCHIAT* (2018) 5: 591-604

PRISM: Bralten, J. et al. Autism spectrum disorders and autistic traits share genetics and biology, *MOL PSYCHIATR* (2018) 23: 1205-1212

PRISM: de Pablo, Gonzalo Salazar et al. Impact of coronavirus syndromes on physical and mental health of health care workers: Systematic review and meta-analysis, *J AFFECT DISORDERS* (2020) 275: 48-57

PRISM: Downs, Johnny et al. Negative Symptoms in Early-Onset Psychosis and Their Association With Antipsychotic Treatment Failure, *SCHIZOPHRENIA BULL* (2019) 45: 69-79

PRISM: Fraguas, David et al. Oxidative Stress and Inflammation in First-Episode Psychosis: A Systematic Review and Meta-analysis, *SCHIZOPHRENIA BULL* (2019) 45: 742-751

PRISM: Galderisi, Silvana et al. Negative symptoms of schizophrenia: new developments and unanswered research questions, *LANCET PSYCHIAT* (2018) 5: 664-677

PRISM: Hornix, Betty E. et al. Multisensory cortical processing and dysfunction across the neuropsychiatric spectrum, *NEUROSCI BIOBEHAV R* (2019) 97: 138-151

PRISM: Kas, Martien J. et al. A quantitative approach to neuropsychiatry: The why and the how, *NEUROSCI BIOBEHAV R* (2019) 97: 3-9

PRISM: Moreno, Carmen et al. How mental health care should change as a consequence of the COVID-19 pandemic, *LANCET PSYCHIAT* (2020) 7: 813-824

PRISM: Porcelli, Stefano et al. Social brain, social dysfunction and social withdrawal, *NEUROSCI BIOBEHAV R* (2019) 97: 10-33

PRISM: Saris, I. M. J. et al. Social functioning in patients with depressive and anxiety disorders, *ACTA PSYCHIAT SCAND* (2017) 136: 352-361

PRISM: van Heukelum, Sabrina et al. Where is Cingulate Cortex? A Cross-Species View, *TRENDS NEUROSCI* (2020) 43: 285-299

PRISM: Winsky-Sommerer, Raphaelle et al. Disturbances of sleep quality, timing and structure and their relationship with other neuropsychiatric symptoms in Alzheimers disease and schizophrenia: Insights from studies in patient populations and animal models, *NEUROSCI BIOBEHAV R* (2019) 97: 112-137

PROACTIVE: Demeyer, H. et al. Physical activity is increased by a 12-week semiautomated telecoaching programme in patients with COPD: a multicentre randomised controlled trial, *THORAX* (2017) 72: 415-423



PROACTIVE: Demeyer, Heleen et al. Standardizing the Analysis of Physical Activity in Patients With COPD Following a Pulmonary Rehabilitation Program, CHEST (2014) 146: 318-327

PROACTIVE: Demeyer, Heleen et al. The Minimal Important Difference in Physical Activity in Patients with COPD, PLOS ONE (2016) 11:

PROACTIVE: Gimeno-Santos, Elena et al. Determinants and outcomes of physical activity in patients with COPD: a systematic review, THORAX (2014) 69: 731-739

PROACTIVE: Gimeno-Santos, Elena et al. The PROactive instruments to measure physical activity in patients with chronic obstructive pulmonary disease, EUR RESPIR J (2015) 46: 988-1000

PROACTIVE: Rabinovich, Roberto A. et al. Validity of physical activity monitors during daily life in patients with COPD, EUR RESPIR J (2013) 42: 1205-1215

PROACTIVE: Van Remoortel, Hans et al. Validity of activity monitors in health and chronic disease: a systematic review, INT J BEHAV NUTR PHY (2012) 9:

PROACTIVE: Van Remoortel, Hans et al. Validity of Six Activity Monitors in Chronic Obstructive Pulmonary Disease: A Comparison with Indirect Calorimetry, PLOS ONE (2012) 7:

PROTECT: Abbing-Karahagopian, V. et al. Antidepressant prescribing in five European countries: application of common definitions to assess the prevalence, clinical observations, and methodological implications, EUR J CLIN PHARMACOL (2014) 70: 849-857

PROTECT: Ali, M. Sanni et al. Reporting of covariate selection and balance assessment in propensity score analysis is suboptimal: a systematic review, J CLIN EPIDEMIOL (2015) 68: 122-131

PROTECT: Candore, Gianmario et al. Comparison of Statistical Signal Detection Methods Within and Across Spontaneous Reporting Databases, DRUG SAFETY (2015) 38: 577-587

PROTECT: Lalmohamed, Arief et al. Risk of fracture after bariatric surgery in the United Kingdom: population based, retrospective cohort study, BMJ-BRIT MED J (2012) 345:

PROTECT: Mt-Isa, Shahrul et al. Balancing benefit and risk of medicines: a systematic review and classification of available methodologies, PHARMACOEPIDEM DR S (2014) 23: 667-678

PROTECT: Nixon, Richard et al. A case study using the ProACT-URL and BRAT frameworks for structured benefit risk assessment, BIOMETRICAL J (2016) 58: 8-27

PROTECT: Ryan, Patrick B. et al. A Comparison of the Empirical Performance of Methods for a Risk Identification System, DRUG SAFETY (2013) 36: S143-S158

PROTECT: Ryan, Patrick B. et al. Defining a Reference Set to Support Methodological Research in Drug Safety, DRUG SAFETY (2013) 36: S33-S47

PROTECT: van Staa, T. P. et al. Glucose-lowering agents and the patterns of risk for cancer: a study with the General Practice Research Database and secondary care data, DIABETOLOGIA (2012) 55: 654-665

PROTECT: Wisniewski, Antoni F. Z. et al. Good Signal Detection Practices: Evidence from IMI PROTECT, DRUG SAFETY (2016) 39: 469-490

Quic-Concept: Aerts, Hugo J. W. L. et al. Decoding tumour phenotype by noninvasive imaging using a quantitative radiomics approach, NAT COMMUN (2014) 5:

Quic-Concept: Asselin, Marie-Claude et al. Quantifying heterogeneity in human tumours using MRI and PET, EUR J CANCER (2012) 48: 447-455

Quic-Concept: Bollineni, V. R. et al. A systematic review on [F-18]FLT-PET uptake as a measure of treatment response in cancer patients, EUR J CANCER (2016) 55: 81-97

Quic-Concept: Carvalho, Sara et al. F-18-fluorodeoxyglucose positron-emission tomography (FDG-PET)-Radiomics of metastatic lymph nodes and primary tumor in non-small cell lung cancer (NSCLC) - A prospective externally validated study, PLOS ONE (2018) 13:

Quic-Concept: Challapalli, Amarnath et al. F-18-ICMT-11, a Caspase-3-Specific PET Tracer for Apoptosis: Biodistribution and Radiation Dosimetry, J NUCL MED (2013) 54: 1551-1556

Quic-Concept: Coroller, Thibaud P. et al. CT-based radiomic signature predicts distant metastasis in lung adenocarcinoma, RADIOTHER ONCOL (2015) 114: 345-350

Quic-Concept: Deist, Timo M. et al. Machine learning algorithms for outcome prediction in (chemo)radiotherapy: An empirical comparison of classifiers, MED PHYS (2018) 45: 3449-3459

Quic-Concept: deSouza, N. M. et al. Implementing diffusion-weighted MRI for body imaging in prospective multicentre trials: current considerations and future perspectives, EUR RADIOL (2018) 28: 1118-1131

Quic-Concept: Dubash, S. R. et al. Clinical translation of [F-18]ICMT-11 for measuring chemotherapy-induced caspase 3/7 activation in breast and lung cancer, EUR J NUCL MED MOL I (2018) 45: 2285-2299

Quic-Concept: Dubois, Ludwig J. et al. New ways to image and target tumour hypoxia and its molecular responses, RADIOTHER ONCOL (2015) 116: 352-357

Quic-Concept: Frings, Virginie et al. Repeatability of Metabolically Active Tumor Volume Measurements with FDG PET/CT in Advanced Gastrointestinal Malignancies: A Multicenter Study, RADIOLOGY (2014) 273: 539-548

Quic-Concept: Grossmann, Patrick et al. Defining the biological basis of radiomic phenotypes in lung cancer, ELIFE (2017) 6:

Quic-Concept: Huizinga, W. et al. PCA-based groupwise image registration for quantitative MRI, MED IMAGE ANAL (2016) 29: 65-78

Quic-Concept: Lambin, Philippe et al. Decision support systems for personalized and participative radiation oncology, ADV DRUG DELIVER REV (2017) 109: 131-153

Quic-Concept: Lambin, Philippe et al. Predicting outcomes in radiation oncology-multifactorial decision support systems, NAT REV CLIN ONCOL (2013) 10: 27-40

Quic-Concept: Lambin, Philippe et al. Radiomics: Extracting more information from medical images using advanced feature analysis, EUR J CANCER (2012) 48: 441-446

Quic-Concept: Lambin, Philippe et al. Radiomics: the bridge between medical imaging and personalized medicine, NAT REV CLIN ONCOL (2017) 14: 749-762

Quic-Concept: Lambin, Philippe et al. Rapid Learning health care in oncology - An approach towards decision support systems enabling customised radiotherapy, RADIOTHER ONCOL (2013) 109: 159-164

Quic-Concept: Larue, Ruben T. H. M. et al. 4DCT imaging to assess radiomics feature stability: An investigation for thoracic cancers, RADIOTHER ONCOL (2017) 125: 147-153

Quic-Concept: Leijenaar, Ralph T. H. et al. Development and validation of a radiomic signature to predict HPV (p16) status from standard CT imaging: a multicenter study, BRIT J RADIOL (2018) 91:

Quic-Concept: Leijenaar, Ralph T. H. et al. External validation of a prognostic CT-based radiomic signature in oropharyngeal squamous cell carcinoma, ACTA ONCOL (2015) 54: 1423-1429

Quic-Concept: Leijenaar, Ralph T. H. et al. Stability of FDG-PET Radiomics features: An integrated analysis of test-retest and inter-observer variability, ACTA ONCOL (2013) 52: 1391-1397

Quic-Concept: Leijenaar, Ralph T. H. et al. The effect of SUV discretization in quantitative FDG-PET Radiomics: the need for standardized methodology in tumor texture analysis, *SCI REP-UK* (2015) 5:

Quic-Concept: OConnor, James P. B. et al. Imaging biomarker roadmap for cancer studies, *NAT REV CLIN ONCOL* (2017) 14: 169-186

Quic-Concept: Panth, Kranthi Marella et al. Is there a causal relationship between genetic changes and radiomics-based image features? An in vivo preclinical experiment with doxycycline inducible GADD34 tumor cells, *RADIOTHER ONCOL* (2015) 116: 462-466

Quic-Concept: Parmar, Chintan et al. Robust Radiomics Feature Quantification Using Semiautomatic Volumetric Segmentation, *PLOS ONE* (2014) 9:

Quic-Concept: Peerlings, Jurgen et al. Stability of radiomics features in apparent diffusion coefficient maps from a multi-centre test-retest trial, *SCI REP-UK* (2019) 9:

Quic-Concept: Peeters, Sarah G. J. A. et al. TH-302 in Combination with Radiotherapy Enhances the Therapeutic Outcome and Is Associated with Pretreatment [F-18]HX4 Hypoxia PET Imaging, *CLIN CANCER RES* (2015) 21: 2984-2992

Quic-Concept: Sanduleanu, Sebastian et al. Tracking tumor biology with radiomics: A systematic review utilizing a radiomics quality score, *RADIOTHER ONCOL* (2018) 127: 349-360

Quic-Concept: van der Heide, Uulke A. et al. Functional MRI for radiotherapy dose painting, *MAGN RESON IMAGING* (2012) 30: 1216-1223

Quic-Concept: van Stiphout, Ruud G. P. M. et al. Nomogram predicting response after chemoradiotherapy in rectal cancer using sequential PETCT imaging: A multicentric prospective study with external validation, *RADIOTHER ONCOL* (2014) 113: 215-222

Quic-Concept: van Timmeren, Janna E. et al. Survival prediction of non-small cell lung cancer patients using radiomics analyses of cone-beam CT images, *RADIOTHER ONCOL* (2017) 123: 363-369

Quic-Concept: Velazquez, Emmanuel Rios et al. A semiautomatic CT-based ensemble segmentation of lung tumors: Comparison with oncologists delineations and with the surgical specimen, *RADIOTHER ONCOL* (2012) 105: 167-173

Quic-Concept: Velazquez, Emmanuel Rios et al. Volumetric CT-based segmentation of NSCLC using 3D-Slicer, *SCI REP-UK* (2013) 3:

Quic-Concept: Zegers, Catharina M. L. et al. Evaluation of tumour hypoxia during radiotherapy using [F-18]HX4 PET imaging and blood biomarkers in patients with head and neck cancer, *EUR J NUCL MED MOL I* (2016) 43: 2139-2146

Quic-Concept: Zwanenburg, Alex et al. The Image Biomarker Standardization Initiative: Standardized Quantitative Radiomics for High-Throughput Image-based Phenotyping, *RADIOLOGY* (2020) 295: 328-338

RADAR-AD: Stavropoulos, Thanos G. et al. IoT Wearable Sensors and Devices in Elderly Care: A Literature Review, *SENSORS-BASEL* (2020) 20:

RADAR-CNS: Bruno, Elisa et al. Wearable technology in epilepsy: The views of patients, caregivers, and healthcare professionals, *EPILEPSY BEHAV* (2018) 85: 141-149

RADAR-CNS: Difrancesco, Sonia et al. Sleep, circadian rhythm, and physical activity patterns in depressive and anxiety disorders: A 2-week ambulatory assessment study, *DEPRESS ANXIETY* (2019) 36: 975-986

RADAR-CNS: Matcham, F. et al. Remote assessment of disease and relapse in major depressive disorder (RADAR-MDD): a multi-centre prospective cohort study protocol, *BMC PSYCHIATRY* (2019) 19:

RADAR-CNS: Polhemus, Ashley Marie et al. Human-Centered Design Strategies for Device Selection in mHealth Programs: Development of a Novel Framework and Case Study, JMIR MHEALTH UHEALTH (2020) 8:

RADAR-CNS: Ranjan, Yatharth et al. RADAR-Base: Open Source Mobile Health Platform for Collecting, Monitoring, and Analyzing Data Using Sensors, Wearables, and Mobile Devices, JMIR MHEALTH UHEALTH (2019) 7:

RADAR-CNS: Rintala, Aki et al. Response Compliance and Predictors Thereof in Studies Using the Experience Sampling Method, PSYCHOL ASSESSMENT (2019) 31: 226-235

RADAR-CNS: Simblett, Sara et al. Barriers to and Facilitators of Engagement With mHealth Technology for Remote Measurement and Management of Depression: Qualitative Analysis, JMIR MHEALTH UHEALTH (2019) 7:

RADAR-CNS: Simblett, Sara et al. Barriers to and Facilitators of Engagement With Remote Measurement Technology for Managing Health: Systematic Review and Content Analysis of Findings, J MED INTERNET RES (2018) 20:

RADAR-CNS: Simblett, Sara Katherine et al. Patients experience of wearing multimodal sensor devices intended to detect epileptic seizures: A qualitative analysis, EPILEPSY BEHAV (2020) 102:

RADAR-CNS: van Genugten, Claire R. et al. Experienced Burden of and Adherence to Smartphone-Based Ecological Momentary Assessment in Persons with Affective Disorders, J CLIN MED (2020) 9:

RADAR-CNS: Vancampfort, Davy et al. Sedentary behavior and anxiety-induced sleep disturbance among 181,093 adolescents from 67 countries: a global perspective, SLEEP MED (2019) 58: 19-26

RADAR-CNS: Zhang, Zixing et al. Snore-GANs: Improving Automatic Snore Sound Classification With Synthesized Data, IEEE J BIOMED HEALTH (2020) 24: 300-310

RAPP-ID: Afshari, Arash et al. Bench-to-bedside review: Rapid molecular diagnostics for bloodstream infection - a new frontier?, CRIT CARE (2012) 16:

RAPP-ID: Faridi, Muhammad Asim et al. Elasto-inertial microfluidics for bacteria separation from whole blood for sepsis diagnostics, J NANOBIOELECTRON (2017) 15:

RAPP-ID: Knez, Karel et al. Emerging technologies for hybridization based single nucleotide polymorphism detection, ANALYST (2014) 139: 353-370

RAPP-ID: Leirs, Karen et al. Bioassay Development for Ultrasensitive Detection of Influenza A Nucleoprotein Using Digital ELISA, ANAL CHEM (2016) 88: 8450-8458

RAPP-ID: Schechner, Vered et al. Epidemiological Interpretation of Studies Examining the Effect of Antibiotic Usage on Resistance, CLIN MICROBIOL REV (2013) 26: 289-307

RESCEU: Kirolos, Amir et al. A Systematic Review of Clinical Practice Guidelines for the Diagnosis and Management of Bronchiolitis, J INFECT DIS (2020) 222: S672-S679

RESCEU: Li, You et al. Global patterns in monthly activity of influenza virus, respiratory syncytial virus, parainfluenza virus, and metapneumovirus: a systematic analysis, LANCET GLOB HEALTH (2019) 7: E1031-E1045

RESCEU: Lin, Gu-Lung et al. Epidemiology and Immune Pathogenesis of Viral Sepsis, FRONT IMMUNOL (2018) 9:

RESCEU: Shi, Ting et al. Association Between Respiratory Syncytial Virus-Associated Acute Lower Respiratory Infection in Early Life and Recurrent Wheeze and Asthma in Later Childhood, J INFECT DIS (2020) 222: S628-S633

RESCEU: Shi, Ting et al. Global and Regional Burden of Hospital Admissions for Pneumonia in Older Adults: A Systematic Review and Meta-Analysis, J INFECT DIS (2020) 222: S570-S576

RESCEU: Shi, Ting et al. Global Disease Burden Estimates of Respiratory Syncytial Virus-Associated Acute Respiratory Infection in Older Adults in 2015: A Systematic Review and Meta-Analysis, *J INFECT DIS* (2020) 222: S577-S583

RESCEU: Shi, Ting et al. The Etiological Role of Common Respiratory Viruses in Acute Respiratory Infections in Older Adults: A Systematic Review and Meta-analysis, *J INFECT DIS* (2020) 222: S563-S569

RESCEU: Wang, Xin et al. Global burden of respiratory infections associated with seasonal influenza in children under 5 years in 2018: a systematic review and modelling study, *LANCET GLOB HEALTH* (2020) 8: E497-E510

RHAPSODY: Akalestou, Elina et al. Glucocorticoid Metabolism in Obesity and Following Weight Loss, *FRONT ENDOCRINOL* (2020) 11:

RHAPSODY: Chung, Wendy K. et al. Precision Medicine in Diabetes: A Consensus Report From the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD), *DIABETES CARE* (2020) 43: 1617-1635

RHAPSODY: Cohrs, Christian M. et al. Dysfunction of Persisting beta Cells Is a Key Feature of Early Type 2 Diabetes Pathogenesis, *CELL REP* (2020) 31:

RHAPSODY: Diedisheim, Marc et al. Modeling human pancreatic beta cell dedifferentiation, *MOL METAB* (2018) 10: 74-86

RHAPSODY: Eizirik, Decio L. et al. Pancreatic beta-cells in type 1 and type 2 diabetes mellitus: different pathways to failure, *NAT REV ENDOCRINOL* (2020) 16: 349-362

RHAPSODY: Falcon, Benjamin et al. Structures of filaments from Picks disease reveal a novel tau protein fold, *NATURE* (2018) 561: 137-+

RHAPSODY: Falcon, Benjamin et al. Tau filaments from multiple cases of sporadic and inherited Alzheimers disease adopt a common fold, *ACTA NEUROPATHOL* (2018) 136: 699-708

RHAPSODY: Fang, Zijian et al. The Influence of Peptide Context on Signaling and Trafficking of Glucagon-like Peptide-1 Receptor Biased Agonists, *ACS PHARMACOL TRANSL* (2020) 3: 345-360

RHAPSODY: Franks, Paul W. et al. Exposing the exposures responsible for type 2 diabetes and obesity, *SCIENCE* (2016) 354: 69-73

RHAPSODY: Georgiadou, Eleni et al. The pore-forming subunit MCU of the mitochondrial Ca<sup>2+</sup> uniporter is required for normal glucose-stimulated insulin secretion in vitro and in vivo in mice, *DIABETOLOGIA* (2020) 63: 1368-1381

RHAPSODY: Lucey, Maria et al. Disconnect between signalling potency and in vivo efficacy of pharmacokinetically optimised biased glucagon-like peptide-1 receptor agonists, *MOL METAB* (2020) 37:

RHAPSODY: Lytrivi, Maria et al. Recent Insights Into Mechanisms of beta-Cell Lipo- and Glucolipotoxicity in Type 2 Diabetes, *J MOL BIOL* (2020) 432: 1514-1534

RHAPSODY: McCarthy, Mark I. et al. Painting a new picture of personalised medicine for diabetes, *DIABETOLOGIA* (2017) 60: 793-799

RHAPSODY: Salem, Victoria et al. Leader beta-cells coordinate Ca<sup>2+</sup> dynamics across pancreatic islets in vivo, *NAT METAB* (2019) 1: 615-629

RHAPSODY: Schmid, Vera et al. Safety of intranasal human insulin: A review, *DIABETES OBES METAB* (2018) 20: 1563-1577

RHAPSODY: Xavier, Gabriela Da Silva et al. Metabolic and Functional Heterogeneity in Pancreatic beta Cells, *J MOL BIOL* (2020) 432: 1395-1406

ROADMAP: Ponjoan, Anna et al. Epidemiology of dementia: prevalence and incidence estimates using validated electronic health records from primary care, *CLIN EPIDEMIOL* (2019) 11: 217-228

RTCure: Adam, Susanne et al. JAK inhibition increases bone mass in steady-state conditions and ameliorates pathological bone loss by stimulating osteoblast function, *SCI TRANSL MED* (2020) 12:

RTCure: Chemin, Karine et al. Effector Functions of CD4+T Cells at the Site of Local Autoimmune Inflammation-Lessons From Rheumatoid Arthritis, *FRONT IMMUNOL* (2019) 10:

RTCure: Cossarizza, Andrea et al. Guidelines for the use of flow cytometry and cell sorting in immunological studies (second edition), *EUR J IMMUNOL* (2019) 49: 1457-1973

RTCure: Culemann, Stephan et al. Locally renewing resident synovial macrophages provide a protective barrier for the joint, *NATURE* (2019) 572: 670-+

RTCure: Daniel, Christoph et al. Extracellular DNA traps in inflammation, injury and healing, *NAT REV NEPHROL* (2019) 15: 559-575

RTCure: Engdahl, Cecilia et al. Estrogen induces St6gal1 expression and increases IgG sialylation in mice and patients with rheumatoid arthritis: a potential explanation for the increased risk of rheumatoid arthritis in postmenopausal women, *ARTHRITIS RES THER* (2018) 20:

RTCure: Eriksson, Kaja et al. Periodontal Health and Oral Microbiota in Patients with Rheumatoid Arthritis, *J CLIN MED* (2019) 8:

RTCure: Grueeneboom, Anika et al. A network of trans-cortical capillaries as mainstay for blood circulation in long bones, *NAT METAB* (2019) 1: 236-250

RTCure: Hafkenscheid, Lise et al. N-Linked Glycans in the Variable Domain of IgG Anti-Citrullinated Protein Antibodies Predict the Development of Rheumatoid Arthritis, *ARTHRITIS RHEUMATOL* (2019) 71: 1626-1633

RTCure: Kampstra, Arieke Suzanna Berendina et al. Different classes of anti-modified protein antibodies are induced on exposure to antigens expressing only one type of modification, *ANN RHEUM DIS* (2019) 78: 908-916

RTCure: Kissel, T. et al. Antibodies and B cells recognising citrullinated proteins display a broad cross-reactivity towards other post-translational modifications, *ANN RHEUM DIS* (2020) 79: 472-480

RTCure: Klareskog, L. et al. The importance of differences, On environment and its interactions with genes and immunity in the causation of rheumatoid arthritis, *J INTERN MED* (2020) 287: 514-533

RTCure: Lloyd, Katy A. et al. Differential ACPA Binding to Nuclear Antigens Reveals a PAD-Independent Pathway and a Distinct Subset of Acetylation Cross-Reactive Autoantibodies in Rheumatoid Arthritis, *FRONT IMMUNOL* (2019) 9:

RTCure: Mosanya, Chijioke H. et al. Tolerising cellular therapies: what is their promise for autoimmune disease?, *ANN RHEUM DIS* (2019) 78: 297-310

RTCure: Nemeth, Tamas et al. Neutrophils as emerging therapeutic targets, *NAT REV DRUG DISCOV* (2020) 19: 253-275

RTCure: Perucha, Esperanza et al. The cholesterol biosynthesis pathway regulates IL-10 expression in human Th1 cells, *NAT COMMUN* (2019) 10:

RTCure: Rauber, Simon et al. Resolution of inflammation by interleukin-9-producing type 2 innate lymphoid cells, *NAT MED* (2017) 23: 938-+

RTCure: Schett, Georg et al. COVID-19 revisiting inflammatory pathways of arthritis, *NAT REV RHEUMATOL* (2020) 16: 465-470

RTCure: Schulz, Axel R. et al. Stabilizing Antibody Cocktails for Mass Cytometry, *CYTOM PART A* (2019) 95A: 910-916

RTCure: Simon, David et al. Patients with immune-mediated inflammatory diseases receiving cytokine inhibitors have low prevalence of SARS-CoV-2 seroconversion, NAT COMMUN (2020) 11:

RTCure: Steffen, Ulrike et al. IgA subclasses have different effector functions associated with distinct glycosylation profiles, NAT COMMUN (2020) 11:

RTCure: Tajik, Narges et al. Targeting zonulin and intestinal epithelial barrier function to prevent onset of arthritis, NAT COMMUN (2020) 11:

RTCure: Vletter, Esther M. et al. A Comparison of Immunoglobulin Variable Region N-Linked Glycosylation in Healthy Donors, Autoimmune Disease and Lymphoma, FRONT IMMUNOL (2020) 11:

RTCure: Wohlfahrt, Thomas et al. PU.1 controls fibroblast polarization and tissue fibrosis, NATURE (2019) 566: 344-+

SafeSciMET: Heslop, James A. et al. Concise Review: Workshop Review: Understanding and Assessing the Risks of Stem Cell-Based Therapies, STEM CELL TRANSL MED (2015) 4: 389-400

SAFE-T: Church, Rachel J. et al. Candidate biomarkers for the diagnosis and prognosis of drug-induced liver injury: An international collaborative effort, HEPATOLOGY (2019) 69: 760-773

SAFE-T: Robles-Diaz, Mercedes et al. Use of Hys Law and a New Composite Algorithm to Predict Acute Liver Failure in Patients With Drug-Induced Liver Injury, GASTROENTEROLOGY (2014) 147: 109-U204

SOPHIA: Chung, Wendy K. et al. Precision Medicine in Diabetes: A Consensus Report From the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD), DIABETES CARE (2020) 43: 1617-1635

SPRINTT: Angulo, Javier et al. Physical activity and exercise: Strategies to manage frailty, REDOX BIOL (2020) 35:

SPRINTT: Auffray, Charles et al. Making sense of big data in health research: Towards an EU action plan, GENOME MED (2016) 8:

SPRINTT: Calvani, Riccardo et al. A Distinct Pattern of Circulating Amino Acids Characterizes Older Persons with Physical Frailty and Sarcopenia: Results from the BIOSPHERE Study, NUTRIENTS (2018) 10:

SPRINTT: Calvani, Riccardo et al. Biomarkers for physical frailty and sarcopenia, AGING CLIN EXP RES (2017) 29: 29-34

SPRINTT: Calvani, Riccardo et al. Biomarkers for physical frailty and sarcopenia: state of the science and future developments, J CACHEXIA SARCOPENI (2015) 6: 278-286

SPRINTT: Calvani, Riccardo et al. Identification of a Circulating Amino Acid Signature in Frail Older Persons with Type 2 Diabetes Mellitus: Results from the Metabofrail Study, NUTRIENTS (2020) 12:

SPRINTT: Calvani, Riccardo et al. Of Microbes and Minds: A Narrative Review on the Second Brain Aging, FRONT MED-LAUSANNE (2018) 5:

SPRINTT: Calvani, Riccardo et al. The BIOMarkers associated with Sarcopenia and PHysical frailty in EldeRly pErsons (BIOSPHERE) study: Rationale, design and methods, EUR J INTERN MED (2018) 56: 19-25

SPRINTT: Cesari, Matteo et al. Rationale for a preliminary operational definition of physical frailty and sarcopenia in the SPRINTT trial, AGING CLIN EXP RES (2017) 29: 81-88

SPRINTT: Clark, Richard V. et al. Creatine (methyl-d(3)) dilution in urine for estimation of total body skeletal muscle mass: accuracy and variability vs. MRI and DXA, J APPL PHYSIOL (2018) 124: 1-9

SPRINTT: Coelho-Junior, Helio J. et al. Protein-Related Dietary Parameters and Frailty Status in Older Community-Dwellers across Different Frailty Instruments, NUTRIENTS (2020) 12:

SPRINTT: Collamati, Agnese et al. Sarcopenia in heart failure: mechanisms and therapeutic strategies, J GERIATR CARDIOL (2016) 13: 615-624

SPRINTT: Cruz-Jentoft, Alfonso J. et al. Nutrition, frailty, and sarcopenia, AGING CLIN EXP RES (2017) 29: 43-48

SPRINTT: Landi, F. et al. The association between sarcopenia and functional outcomes among older patients with hip fracture undergoing in-hospital rehabilitation, OSTEOPOROSIS INT (2017) 28: 1569-1576

SPRINTT: Landi, Francesco et al. Age-Related Variations of Muscle Mass, Strength, and Physical Performance in Community-Dwellers: Results From the Milan EXPO Survey, J AM MED DIR ASSOC (2017) 18:

SPRINTT: Landi, Francesco et al. Anorexia of Aging: Risk Factors, Consequences, and Potential Treatments, NUTRIENTS (2016) 8:

SPRINTT: Landi, Francesco et al. Impact of physical function impairment and multimorbidity on mortality among community-living older persons with sarcopaenia: results from the iSIRENTE prospective cohort study, BMJ OPEN (2016) 6:

SPRINTT: Landi, Francesco et al. Protein Intake and Muscle Health in Old Age: From Biological Plausibility to Clinical Evidence, NUTRIENTS (2016) 8:

SPRINTT: Landi, Francesco et al. Sarcopenia as the Biological Substrate of Physical Frailty, CLIN LIVER DIS (2015) 19: 367-+

SPRINTT: Landi, Francesco et al. Sarcopenia: An Overview on Current Definitions, Diagnosis and Treatment, CURR PROTEIN PEPT SC (2018) 19: 633-638

SPRINTT: Landi, Francesco et al. The Sarcopenia and Physical fRailty IN older people: multi-component Treatment strategies (SPRINTT) randomized controlled trial: design and methods, AGING CLIN EXP RES (2017) 29: 89-100

SPRINTT: Martone, Anna Maria et al. Exercise and Protein Intake: A Synergistic Approach against Sarcopenia, BIOMED RES INT (2017) 2017:

SPRINTT: Marzetti, E. et al. INNOVATIVE MEDICINES INITIATIVE: THE SPRINTT PROJECT, J FRALITY AGING (2015) 4: 207-208

SPRINTT: Marzetti, Emanuele et al. Altered mitochondrial quality control signaling in muscle of old gastric cancer patients with cachexia, EXP GERONTOL (2017) 87: 92-99

SPRINTT: Marzetti, Emanuele et al. Inflammatory signatures in older persons with physical frailty and sarcopenia: The frailty cytokinome at its core, EXP GERONTOL (2019) 122: 129-138

SPRINTT: Marzetti, Emanuele et al. Physical activity and exercise as countermeasures to physical frailty and sarcopenia, AGING CLIN EXP RES (2017) 29: 35-42

SPRINTT: Marzetti, Emanuele et al. Sarcopenia: an overview, AGING CLIN EXP RES (2017) 29: 11-17

SPRINTT: Marzetti, Emanuele et al. The Sarcopenia and Physical fRailty IN older people: multi-component Treatment strategies (SPRINTT) randomized controlled trial: Case finding, screening and characteristics of eligible participants, EXP GERONTOL (2018) 113: 48-57

SPRINTT: Picca, Anna et al. Circulating Mitochondrial DNA at the Crossroads of Mitochondrial Dysfunction and Inflammation During Aging and Muscle Wasting Disorders, REJUV RES (2018) 21: 350-359

SPRINTT: Picca, Anna et al. Fueling Inflamm-Aging through Mitochondrial Dysfunction: Mechanisms and Molecular Targets, INT J MOL SCI (2017) 18:



SPRINTT: Picca, Anna et al. Generation and Release of Mitochondrial-Derived Vesicles in Health, Aging and Disease, *J CLIN MED* (2020) 9:

SPRINTT: Picca, Anna et al. Gut Dysbiosis and Muscle Aging: Searching for Novel Targets against Sarcopenia, *MEDIAT INFLAMM* (2018) 2018:

SPRINTT: Picca, Anna et al. Gut Microbial, Inflammatory and Metabolic Signatures in Older People with Physical Frailty and Sarcopenia: Results from the BIOSPHERE Study, *NUTRIENTS* (2020) 12:

SPRINTT: Picca, Anna et al. Inter-Organelle Membrane Contact Sites and Mitochondrial Quality Control during Aging: A Geroscience View, *CELLS-BASEL* (2020) 9:

SPRINTT: Picca, Anna et al. Mitochondrial Dysfunction and Aging: Insights from the Analysis of Extracellular Vesicles, *INT J MOL SCI* (2019) 20:

SPRINTT: Picca, Anna et al. Mitochondrial Dysfunction, Oxidative Stress, and Neuroinflammation: Intertwined Roads to Neurodegeneration, *ANTIOXIDANTS-BASEL* (2020) 9:

SPRINTT: Picca, Anna et al. Mitochondrial quality control mechanisms as molecular targets in cardiac ageing, *NAT REV CARDIOL* (2018) 15: 543-554

SPRINTT: Picca, Anna et al. Mitochondrial Signatures in Circulating Extracellular Vesicles of Older Adults with Parkinsons Disease: Results from the EXosomes in PArkiNsons Disease (EXPAND) Study, *J CLIN MED* (2020) 9:

SPRINTT: Picca, Anna et al. Mitochondrial-Derived Vesicles as Candidate Biomarkers in Parkinsons Disease: Rationale, Design and Methods of the EXosomes in PArkiNson Disease (EXPAND) Study, *INT J MOL SCI* (2019) 20:

SPRINTT: Picca, Anna et al. Update on mitochondria and muscle aging: all wrong roads lead to sarcopenia, *BIOL CHEM* (2018) 399: 421-436

SPRINTT: Ravesteijn, Bastian et al. The wear and tear on health: What is the role of occupation?, *HEALTH ECON* (2018) 27: E69-E86

SPRINTT: Sirven, Nicolas et al. The cost of frailty in France, *EUR J HEALTH ECON* (2017) 18: 243-253

SPRINTT: Tosato, Matteo et al. Measurement of muscle mass in sarcopenia: from imaging to biochemical markers, *AGING CLIN EXP RES* (2017) 29: 19-27

SPRINTT: von Haehling, Stephan et al. Muscle wasting and cachexia in heart failure: mechanisms and therapies, *NAT REV CARDIOL* (2017) 14: 323-341

SPRINTT: von Haehling, Stephan et al. The wasting continuum in heart failure: from sarcopenia to cachexia, *P NUTR SOC* (2015) 74: 367-377

STEMBANCC: Badger, J. L. et al. Parkinsons disease in a dish - Using stem cells as a molecular tool, *NEUROPHARMACOLOGY* (2014) 76: 88-96

STEMBANCC: Baskozos, Georgios et al. Comprehensive analysis of long noncoding RNA expression in dorsal root ganglion reveals cell-type specificity and dysregulation after nerve injury, *PAIN* (2019) 160: 463-485

STEMBANCC: Bennett, David L. et al. THE ROLE OF VOLTAGE-GATED SODIUM CHANNELS IN PAIN SIGNALING, *PHYSIOL REV* (2019) 99: 1079-1151

STEMBANCC: Booth, Heather D. E. et al. RNA sequencing reveals MMP2 and TGFB1 downregulation in LRRK2 G2019S Parkinsons iPSC-derived astrocytes, *NEUROBIOL DIS* (2019) 129: 56-66

STEMBANCC: Brownjohn, Philip W. et al. Functional Studies of Missense TREM2 Mutations in Human Stem Cell-Derived Microglia, *STEM CELL REP* (2018) 10: 1294-1307

STEMBANCC: Cao, Lishuang et al. Pharmacological reversal of a pain phenotype in iPSC-derived sensory neurons and patients with inherited erythromelalgia, *SCI TRANSL MED* (2016) 8:

STEMBANCC: Christoffersson, Jonas et al. Fabrication of modular hyaluronan-PEG hydrogels to support 3D cultures of hepatocytes in a perfused liver-on-a-chip device, *BIOFABRICATION* (2019) 11:

STEMBANCC: Ciampi, Osele et al. Generation of functional podocytes from human induced pluripotent stem cells, *STEM CELL RES* (2016) 17: 130-139

STEMBANCC: Clark, Alex J. et al. Co-cultures with stem cell-derived human sensory neurons reveal regulators of peripheral myelination, *BRAIN* (2017) 140: 898-913

STEMBANCC: Delsing, Louise et al. Barrier Properties and Transcriptome Expression in Human iPSC-Derived Models of the Blood-Brain Barrier, *STEM CELLS* (2018) 36: 1816-1827

STEMBANCC: Fernandes, Hugo J. R. et al. ER Stress and Autophagic Perturbations Lead to Elevated Extracellular alpha-Synuclein in GBA-N370S LEParkinsons iPSC-Derived Dopamine Neurons, *STEM CELL REP* (2016) 6: 342-356

STEMBANCC: Haenseler, Walther et al. A Highly Efficient Human Pluripotent Stem Cell Microglia Model Displays a Neuronal-Co-culture-Specific Expression Profile and Inflammatory Response, *STEM CELL REP* (2017) 8: 1727-1742

STEMBANCC: Halloin, Caroline et al. Continuous WNT Control Enables Advanced hPSC Cardiac Processing and Prognostic Surface Marker Identification in Chemically Defined Suspension Culture, *STEM CELL REP* (2019) 13: 366-379

STEMBANCC: Handel, Adam E. et al. Assessing similarity to primary tissue and cortical layer identity in induced pluripotent stem cell-derived cortical neurons through single-cell transcriptomics, *HUM MOL GENET* (2016) 25: 989-1000

STEMBANCC: Hartlova, Anetta et al. LRRK2 is a negative regulator of Mycobacterium tuberculosis phagosome maturation in macrophages, *EMBO J* (2018) 37:

STEMBANCC: Heman-Ackah, Sabrina M. et al. Alpha-synuclein induces the unfolded protein response in Parkinsons disease SNCA triplication iPSC-derived neurons, *HUM MOL GENET* (2017) 26: 4441-4450

STEMBANCC: Heywood, Wendy E. et al. Identification of novel CSF biomarkers for neurodegeneration and their validation by a high-throughput multiplexed targeted proteomic assay, *MOL NEURODEGENER* (2015) 10:

STEMBANCC: Hocher, Berthold et al. Metabolomics for clinical use and research in chronic kidney disease, *NAT REV NEPHROL* (2017) 13: 269-284

STEMBANCC: Kathuria, A. et al. Stem cell-derived neurons from autistic individuals with SHANK3 mutation show morphogenetic abnormalities during early development, *MOL PSYCHIATR* (2018) 23: 735-746

STEMBANCC: Kaye, Jane et al. Dynamic consent: a patient interface for twenty-first century research networks, *EUR J HUM GENET* (2015) 23: 141-146

STEMBANCC: Kempf, Henning et al. Cardiac differentiation of human pluripotent stem cells in scalable suspension culture, *NAT PROTOC* (2015) 10: 1345-1361

STEMBANCC: Kempf, Henning et al. Controlling Expansion and Cardiomyogenic Differentiation of Human Pluripotent Stem Cells in Scalable Suspension Culture, *STEM CELL REP* (2014) 3: 1132-1146

STEMBANCC: Kempf, Henning et al. Large-scale production of human pluripotent stem cell derived cardiomyocytes, *ADV DRUG DELIVER REV* (2016) 96: 18-30

STEMBANCC: Koch, Lothar et al. Laser bioprinting of human induced pluripotent stem cells-the effect of printing and biomaterials on cell survival, pluripotency, and differentiation, *BIOFABRICATION* (2018) 10:

STEMBANCC: Kropp, Christina et al. Impact of Feeding Strategies on the Scalable Expansion of Human Pluripotent Stem Cells in Single-Use Stirred Tank Bioreactors, *STEM CELL TRANSL MED* (2016) 5: 1289-1301

STEMBANCC: Kropp, Christina et al. Progress and challenges in large-scale expansion of human pluripotent stem cells, *PROCESS BIOCHEM* (2017) 59: 244-254

STEMBANCC: Kuijlaars, Jacobine et al. Sustained synchronized neuronal network activity in a human astrocyte co-culture system, *SCI REP-UK* (2016) 6:

STEMBANCC: Lang, Charmaine et al. Single-Cell Sequencing of iPSC-Dopamine Neurons Reconstructs Disease Progression and Identifies HDAC4 as a Regulator of Parkinson Cell Phenotypes, *CELL STEM CELL* (2019) 24: 93-+

STEMBANCC: Lee, Heyne et al. LRRK2 in peripheral and central nervous system innate immunity: its link to Parkinsons disease, *BIOCHEM SOC T* (2017) 45: 131-139

STEMBANCC: Lee, Heyne et al. LRRK2 Is Recruited to Phagosomes and Co-recruits RAB8 and RAB10 in Human Pluripotent Stem Cell-Derived Macrophages, *STEM CELL REP* (2020) 14: 940-955

STEMBANCC: Little, Daniel et al. Using stem cell-derived neurons in drug screening for neurological diseases, *NEUROBIOL AGING* (2019) 78: 130-141

STEMBANCC: Ludtmann, Marthe H. R. et al. alpha-synuclein oligomers interact with ATP synthase and open the permeability transition pore in Parkinsons disease, *NAT COMMUN* (2018) 9:

STEMBANCC: McDermott, Lucy A. et al. Defining the Functional Role of Na(v)1.7 in Human Nociception, *NEURON* (2019) 101: 905-+

STEMBANCC: Morrison, Michael et al. A good collaboration is based on unique contributions from each side: assessing the dynamics of collaboration in stem cell science, *LIFE SCI SOC POLICY* (2017) 13:

STEMBANCC: Paillusson, Sebastien et al. alpha-Synuclein binds to the ER-mitochondria tethering protein VAPB to disrupt Ca<sup>2+</sup> homeostasis and mitochondrial ATP production, *ACTA NEUROPATHOL* (2017) 134: 129-149

STEMBANCC: Patsch, Christoph et al. Generation of vascular endothelial and smooth muscle cells from human pluripotent stem cells, *NAT CELL BIOL* (2015) 17: 994-U294

STEMBANCC: Pettingill, Philippa et al. A causal role for TRESK loss of function in migraine mechanisms, *BRAIN* (2019) 142: 3852-3867

STEMBANCC: Ramond, Cyrille et al. Understanding human fetal pancreas development using subpopulation sorting, RNA sequencing and single-cell profiling, *DEVELOPMENT* (2018) 145:

STEMBANCC: Sandor, Cynthia et al. Transcriptomic profiling of purified patient-derived dopamine neurons identifies convergent perturbations and therapeutics for Parkinsons disease, *HUM MOL GENET* (2017) 26: 552-566

STEMBANCC: Viereck, Janika et al. Long noncoding RNA Chast promotes cardiac remodeling, *SCI TRANSL MED* (2016) 8:

STEMBANCC: Volpato, Viola et al. Reproducibility of Molecular Phenotypes after Long-Term Differentiation to Human iPSC-Derived Neurons: A Multi-Site Omics Study, *STEM CELL REP* (2018) 11: 897-911

STEMBANCC: Zambon, Federico et al. Cellular alpha-synuclein pathology is associated with bioenergetic dysfunction in Parkinsons iPSC-derived dopamine neurons, HUM MOL GENET (2019) 28: 2001-2013

SUMMIT: Boekholdt, S. Matthijs et al. Association of LDL Cholesterol, Non-HDL Cholesterol, and Apolipoprotein B Levels With Risk of Cardiovascular Events Among Patients Treated With Statins A Meta-analysis, JAMA-J AM MED ASSOC (2012) 307: 1302-1309

SUMMIT: Boni, Enrico et al. A Reconfigurable and Programmable FPGA-Based System for Nonstandard Ultrasound Methods, IEEE T ULTRASON FERR (2012) 59: 1378-1385

SUMMIT: Colombo, Marco et al. Serum kidney injury molecule 1 and (2)-microglobulin perform as well as larger biomarker panels for prediction of rapid decline in renal function in type 2 diabetes, DIABETOLOGIA (2019) 62: 156-168

SUMMIT: De Marinis, Yang et al. Epigenetic regulation of the thioredoxin-interacting protein (TXNIP) gene by hyperglycemia in kidney, KIDNEY INT (2016) 89: 342-353

SUMMIT: Edsfeldt, Andreas et al. Sphingolipids Contribute to Human Atherosclerotic Plaque Inflammation, ARTERIOSCL THROM VAS (2016) 36: 1132-+

SUMMIT: Fadista, Joao et al. LoFtool: a gene intolerance score based on loss-of-function variants in 60 706 individuals, BIOINFORMATICS (2017) 33: 471-474

SUMMIT: Fall, Tove et al. The Role of Adiposity in Cardiometabolic Traits: A Mendelian Randomization Analysis, PLOS MED (2013) 10:

SUMMIT: Goncalves, Isabel et al. Elevated Plasma Levels of MMP-12 Are Associated With Atherosclerotic Burden and Symptomatic Cardiovascular Disease in Subjects With Type 2 Diabetes, ARTERIOSCL THROM VAS (2015) 35: 1723-1731

SUMMIT: Justice, Anne E. et al. Genome-wide meta-analysis of 241,258 adults accounting for smoking behaviour identifies novel loci for obesity traits, NAT COMMUN (2017) 8:

SUMMIT: Looker, Helen C. et al. Biomarkers of rapid chronic kidney disease progression in type 2 diabetes, KIDNEY INT (2015) 88: 888-896

SUMMIT: Meng, W. et al. A genome-wide association study suggests an association of Chr8p21.3 (GFRA2) with diabetic neuropathic pain, EUR J PAIN (2015) 19: 392-399

SUMMIT: Natali, Andrea et al. Metformin is the key factor in elevated plasma growth differentiation factor-15 levels in type 2 diabetes: A nested, case-control study, DIABETES OBES METAB (2019) 21: 412-416

SUMMIT: Patrono, Carlo et al. Low-dose aspirin in primary prevention: cardioprotection, chemoprevention, both, or neither?, EUR HEART J (2013) 34: 3403-U17

SUMMIT: Patrono, Carlo et al. The Multifaceted Clinical Readouts of Platelet Inhibition by Low-Dose Aspirin, J AM COLL CARDIOL (2015) 66: 74-85

SUMMIT: Pollack, Samuela et al. Multiethnic Genome-Wide Association Study of Diabetic Retinopathy Using Liability Threshold Modeling of Duration of Diabetes and Glycemic Control, DIABETES (2019) 68: 441-456

SUMMIT: Postmus, Iris et al. Pharmacogenetic meta-analysis of genome-wide association studies of LDL cholesterol response to statins, NAT COMMUN (2014) 5:

SUMMIT: Rocca, B. et al. The recovery of platelet cyclooxygenase activity explains interindividual variability in responsiveness to low-dose aspirin in patients with and without diabetes, J THROMB HAEMOST (2012) 10: 1220-1230

SUMMIT: Salem, Rany M. et al. Genome-Wide Association Study of Diabetic Kidney Disease Highlights Biology Involved in Glomerular Basement Membrane Collagen, *J AM SOC NEPHROL* (2019) 30: 2000-2016

SUMMIT: Sandholm, Niina et al. New Susceptibility Loci Associated with Kidney Disease in Type 1 Diabetes, *PLOS GENET* (2012) 8:

SUMMIT: Sandholm, Niina et al. The Genetic Landscape of Renal Complications in Type 1 Diabetes, *J AM SOC NEPHROL* (2017) 28: 557-574

SUMMIT: van Zuydam, Natalie R. et al. A Genome-Wide Association Study of Diabetic Kidney Disease in Subjects With Type 2 Diabetes, *DIABETES* (2018) 67: 1414-1427

SUMMIT: Wain, Louise V. et al. Novel Blood Pressure Locus and Gene Discovery Using Genome-Wide Association Study and Expression Data Sets From Blood and the Kidney, *HYPERTENSION* (2017) 70: E4-+

SUMMIT: Zhou, Kaixin et al. Heritability of variation in glycaemic response to metformin: a genome-wide complex trait analysis, *LANCET DIABETES ENDO* (2014) 2: 481-487

TRANSLOCATION: Abellon-Ruiz, Javier et al. Structural basis for maintenance of bacterial outer membrane lipid asymmetry, *NAT MICROBIOL* (2017) 2: 1616-1623

TRANSLOCATION: Acosta-Gutierrez, Silvia et al. Getting Drugs into Gram-Negative Bacteria: Rational Rules for Permeation through General Porins, *ACS INFECT DIS* (2018) 4: 1487-1498

TRANSLOCATION: Anes, Joao et al. The ins and outs of RND efflux pumps in *Escherichia coli*, *FRONT MICROBIOL* (2015) 6:

TRANSLOCATION: Arunmanee, Wanatchaporn et al. Gram-negative trimeric porins have specific LPS binding sites that are essential for porin biogenesis, *P NATL ACAD SCI USA* (2016) 113: E5034-E5043

TRANSLOCATION: Auffray, Charles et al. Making sense of big data in health research: Towards an EU action plan, *GENOME MED* (2016) 8:

TRANSLOCATION: Bafna, Jayesh Arun et al. Kanamycin Uptake into *Escherichia coli* Is Facilitated by OmpF and OmpC Porin Channels Located in the Outer Membrane, *ACS INFECT DIS* (2020) 6: 1855-1865

TRANSLOCATION: Basciu, Andrea et al. Holo-like and Druggable Protein Conformations from Enhanced Sampling of Binding Pocket Volume and Shape, *J CHEM INF MODEL* (2019) 59: 1515-1528

TRANSLOCATION: Bhamidimarri, Satya Prathyusha et al. A Multidisciplinary Approach toward Identification of Antibiotic Scaffolds for *Acinetobacter baumannii*, *STRUCTURE* (2019) 27: 268-+

TRANSLOCATION: Bhamidimarri, Satya Prathyusha et al. Role of Electroosmosis in the Permeation of Neutral Molecules: CymA and Cyclodextrin as an Example, *BIOPHYS J* (2016) 110: 600-611

TRANSLOCATION: Cama, Jehangir et al. Breaching the Barrier: Quantifying Antibiotic Permeability across Gram-negative Bacterial Membranes, *J MOL BIOL* (2019) 431: 3531-3546

TRANSLOCATION: Daury, Laetitia et al. Tripartite assembly of RND multidrug efflux pumps, *NAT COMMUN* (2016) 7:

TRANSLOCATION: Davin-Regli, Anne et al. *Enterobacter aerogenes* and *Enterobacter cloacae*, versatile bacterial pathogens confronting antibiotic treatment, *FRONT MICROBIOL* (2015) 6:

TRANSLOCATION: Davin-Regli, Anne et al. *Enterobacter* spp.: Update on Taxonomy, Clinical Aspect, and Emerging Antimicrobial Resistance, *CLIN MICROBIOL REV* (2019) 32:

TRANSLOCATION: Dreier, Juerg et al. Interaction of antibacterial compounds with RND efflux pumps in *Pseudomonas aeruginosa*, *FRONT MICROBIOL* (2015) 6:

TRANSLOCATION: Du, Dijun et al. Multidrug efflux pumps: structure, function and regulation, *NAT REV MICROBIOL* (2018) 16: 523-539

TRANSLOCATION: Du, Dijun et al. Structure, mechanism and cooperation of bacterial multidrug transporters, *CURR OPIN STRUC BIOL* (2015) 33: 76-91

TRANSLOCATION: Eicher, Thomas et al. Coupling of remote alternating-access transport mechanisms for protons and substrates in the multidrug efflux pump AcrB, *ELIFE* (2014) 3:

TRANSLOCATION: Gasser, Veronique et al. Cellular organization of siderophore biosynthesis in *Pseudomonas aeruginosa*: Evidence for siderosomes, *J INORG BIOCHEM* (2015) 148: 27-34

TRANSLOCATION: Ghai, Ishan et al. General Method to Determine the Flux of Charged Molecules through Nanopores Applied to beta-Lactamase Inhibitors and OmpF, *J PHYS CHEM LETT* (2017) 8: 1295-1301

TRANSLOCATION: Glenwright, Amy J. et al. Structural basis for nutrient acquisition by dominant members of the human gut microbiota, *NATURE* (2017) 541: 407-+

TRANSLOCATION: Gutschmann, Thomas et al. Protein reconstitution into freestanding planar lipid membranes for electrophysiological characterization, *NAT PROTOC* (2015) 10: 188-198

TRANSLOCATION: Masi, Muriel et al. Mechanisms of envelope permeability and antibiotic influx and efflux in Gram-negative bacteria, *NAT MICROBIOL* (2017) 2:

TRANSLOCATION: Mislin, Gaetan L. A. et al. Siderophore-dependent iron uptake systems as gates for antibiotic Trojan horse strategies against *Pseudomonas aeruginosa*, *METALLOMICS* (2014) 6: 408-420

TRANSLOCATION: Moynie, Lucile et al. Structure and Function of the PiuA and PirA Siderophore-Drug Receptors from *Pseudomonas aeruginosa* and *Acinetobacter baumannii*, *ANTIMICROB AGENTS CH* (2017) 61:

TRANSLOCATION: Moynie, Lucile et al. The complex of ferric-enterobactin with its transporter from *Pseudomonas aeruginosa* suggests a two-site model, *NAT COMMUN* (2019) 10:

TRANSLOCATION: Perraud, Quentin et al. Phenotypic Adaption of *Pseudomonas aeruginosa* by Hacking Siderophores Produced by Other Microorganisms, *MOL CELL PROTEOMICS* (2020) 19: 589-607

TRANSLOCATION: Ruggerone, Paolo et al. RND Efflux Pumps: Structural Information Translated into Function and Inhibition Mechanisms, *CURR TOP MED CHEM* (2013) 13: 3079-3100

TRANSLOCATION: Sjuts, Hanno et al. Molecular basis for inhibition of AcrB multidrug efflux pump by novel and powerful pyranopyridine derivatives, *P NATL ACAD SCI USA* (2016) 113: 3509-3514

TRANSLOCATION: Tam, Heng-Keat et al. Binding and Transport of Carboxylated Drugs by the Multidrug Transporter AcrB, *J MOL BIOL* (2020) 432: 861-877

TRANSLOCATION: Vargiu, Attilio Vittorio et al. Water-mediated interactions enable smooth substrate transport in a bacterial efflux pump, *BBA-GEN SUBJECTS* (2018) 1862: 836-845

TRANSLOCATION: Vergalli, Julia et al. Spectrofluorimetric quantification of antibiotic drug concentration in bacterial cells for the characterization of translocation across bacterial membranes, *NAT PROTOC* (2018) 13: 1348-1361

TransQST: Albrecht, Wiebke et al. Prediction of human drug-induced liver injury (DILI) in relation to oral doses and blood concentrations, *ARCH TOXICOL* (2019) 93: 1609-1637

TransQST: del-Toro, N. et al. Capturing variation impact on molecular interactions in the IMEx Consortium mutations data set, *NAT COMMUN* (2019) 10:

TransQST: Leishman, Derek J. et al. Improving prediction of torsadogenic risk in the CiPA in silico model by appropriately accounting for clinical exposure, *J PHARMACOL TOX MET* (2020) 101:

TransQST: Liu, Jun et al. Integration of epidemiologic, pharmacologic, genetic and gut microbiome data in a drug-metabolite atlas, *NAT MED* (2020) 26: 110-+

TransQST: Malik-Sheriff, Rahuman S. et al. BioModels-15 years of sharing computational models in life science, *NUCLEIC ACIDS RES* (2020) 48: D407-D415

TransQST: Passini, Elisa et al. Human In Silico Drug Trials Demonstrate Higher Accuracy than Animal Models in Predicting Clinical Pro-Arrhythmic Cardiotoxicity, *FRONT PHYSIOL* (2017) 8:

TransQST: Pinero, Janet et al. The DisGeNET knowledge platform for disease genomics: 2019 update, *NUCLEIC ACIDS RES* (2020) 48: D845-D855

TransQST: Sachinidis, Agapios et al. Road Map for Development of Stem Cell-Based Alternative Test Methods, *TRENDS MOL MED* (2019) 25: 470-481

TRISTAN: de Vries, Elisabeth G. E. et al. Integrating molecular nuclear imaging in clinical research to improve anticancer therapy, *NAT REV CLIN ONCOL* (2019) 16: 241-255

TRISTAN: Heskamp, Sandra et al. Zr-89-Immuno-Positron Emission Tomography in Oncology: State-of-the-Art Zr-89 Radiochemistry, *BIOCONJUGATE CHEM* (2017) 28: 2211-2223

TRISTAN: Raave, Rene et al. Direct comparison of the in vitro and in vivo stability of DFO, DFO\* and DFOcyclo\* for Zr-89-immunoPET, *EUR J NUCL MED MOL I* (2019) 46: 1966-1977

TRISTAN: Skeoch, Sarah et al. Drug-Induced Interstitial Lung Disease: A Systematic Review, *J CLIN MED* (2018) 7:

U-BIOPRED: Aarestrup, F. M. et al. Towards a European health research and innovation cloud (HRIC), *GENOME MED* (2020) 12:

U-BIOPRED: Auffray, Charles et al. An Integrative Systems Biology Approach to Understanding Pulmonary Diseases, *CHEST* (2010) 137: 1410-1416

U-BIOPRED: Auffray, Charles et al. Making sense of big data in health research: Towards an EU action plan, *GENOME MED* (2016) 8:

U-BIOPRED: Balgoma, David et al. Linoleic acid-derived lipid mediators increase in a female-dominated subphenotype of COPD, *EUR RESPIR J* (2016) 47: 1645-1656

U-BIOPRED: Bel, Elisabeth H. et al. Diagnosis and definition of severe refractory asthma: an international consensus statement from the Innovative Medicine Initiative (IMI), *THORAX* (2011) 66: 910-917

U-BIOPRED: Bigler, Jeannette et al. A Severe Asthma Disease Signature from Gene Expression Profiling of Peripheral Blood from U-BIOPRED Cohorts, *AM J RESP CRIT CARE* (2017) 195: 1311-1320

U-BIOPRED: Bousquet, Jean et al. Systems medicine and integrated care to combat chronic noncommunicable diseases, *GENOME MED* (2011) 3:

U-BIOPRED: Brinkman, Paul et al. Exhaled volatile organic compounds as markers for medication use in asthma, *EUR RESPIR J* (2020) 55:

U-BIOPRED: Brinkman, Paul et al. Identification and prospective stability of electronic nose (eNose)-derived inflammatory phenotypes in patients with severe asthma, *J ALLERGY CLIN IMMUN* (2019) 143: 1811-+

U-BIOPRED: Carraro, S. et al. Asthma severity in childhood and metabolomic profiling of breath condensate, *ALLERGY* (2013) 68: 110-117

U-BIOPRED: Durham, Andrew L. et al. Targeted anti-inflammatory therapeutics in asthma and chronic obstructive lung disease, *TRANSL RES* (2016) 167: 192-203

U-BIOPRED: Harris, Jennifer R. et al. Toward a roadmap in global biobanking for health, *EUR J HUM GENET* (2012) 20: 1105-1111

U-BIOPRED: Hekking, Pieter-Paul et al. Pathway discovery using transcriptomic profiles in adult-onset severe asthma, *J ALLERGY CLIN IMMUN* (2018) 141: 1280-1290

U-BIOPRED: James, Anna J. et al. Increased YKL-40 and Chitotriosidase in Asthma and Chronic Obstructive Pulmonary Disease, *AM J RESP CRIT CARE* (2016) 193: 131-142

U-BIOPRED: Jevnikar, Zala et al. Epithelial IL-6 trans-signaling defines a new asthma phenotype with increased airway inflammation, *J ALLERGY CLIN IMMUN* (2019) 143: 577-590

U-BIOPRED: Kuo, Chih-Hsi Scott et al. A Transcriptome-driven Analysis of Epithelial Brushings and Bronchial Biopsies to Define Asthma Phenotypes in U-BIOPRED, *AM J RESP CRIT CARE* (2017) 195: 443-455

U-BIOPRED: Kuo, Chih-Hsi Scott et al. T-helper cell type 2 (Th2) and non-Th2 molecular phenotypes of asthma using sputum transcriptomics in U-BIOPRED, *EUR RESPIR J* (2017) 49:

U-BIOPRED: Lambrecht, Bart N. et al. Allergens and the airway epithelium response: Gateway to allergic sensitization, *J ALLERGY CLIN IMMUN* (2014) 134: 499-507

U-BIOPRED: Lefaudeux, Diane et al. U-BIOPRED clinical adult asthma clusters linked to a subset of sputum omics, *J ALLERGY CLIN IMMUN* (2017) 139: 1797-1807

U-BIOPRED: Loza, Matthew J. et al. Validated and longitudinally stable asthma phenotypes based on cluster analysis of the ADEPT study, *RESP RES* (2016) 17:

U-BIOPRED: Lysenko, Artem et al. Representing and querying disease networks using graph databases, *BIODATA MIN* (2016) 9:

U-BIOPRED: Mazein, Alexander et al. Systems medicine disease maps: community-driven comprehensive representation of disease mechanisms, *NPJ SYST BIOL APPL* (2018) 4:

U-BIOPRED: Montuschi, Paolo et al. The Electronic Nose in Respiratory Medicine, *RESPIRATION* (2013) 85: 72-84

U-BIOPRED: Ostaszewski, Marek et al. Community-driven roadmap for integrated disease maps, *BRIEF BIOINFORM* (2019) 20: 659-670

U-BIOPRED: Pavlidis, Stelios et al. T2-high in severe asthma related to blood eosinophil, exhaled nitric oxide and serum periostin, *EUR RESPIR J* (2019) 53:

U-BIOPRED: Ravanetti, Lara et al. IL-33 drives influenza-induced asthma exacerbations by halting innate and adaptive antiviral immunity, *J ALLERGY CLIN IMMUN* (2019) 143: 1355-+

U-BIOPRED: Rossios, Christos et al. Sputum transcriptomics reveal upregulation of IL-1 receptor family members in patients with severe asthma, *J ALLERGY CLIN IMMUN* (2018) 141: 560-570

U-BIOPRED: Schofield, James P. R. et al. Stratification of asthma phenotypes by airway proteomic signatures, *J ALLERGY CLIN IMMUN* (2019) 144: 70-82

U-BIOPRED: Schuijjs, Martijn J. et al. ALLERGY Farm dust and endotoxin protect against allergy through A20 induction in lung epithelial cells, *SCIENCE* (2015) 349: 1106-1110

U-BIOPRED: Shrine, Nick et al. Moderate-to-severe asthma in individuals of European ancestry: a genome-wide association study, *LANCET RESP MED* (2019) 7: 20-34

U-BIOPRED: Takahashi, Kentaro et al. Sputum proteomics and airway cell transcripts of current and ex-smokers with severe asthma in U-BIOPRED: an exploratory analysis, *EUR RESPIR J* (2018) 51:



U-BIOPRED: Wheelock, Craig E. et al. Application of omics technologies to biomarker discovery in inflammatory lung diseases, *EUR RESPIR J* (2013) 42: 802-825

U-BIOPRED: Wolkenhauer, Olaf et al. The road from systems biology to systems medicine, *PEDIATR RES* (2013) 73: 502-507

ULTRA-DD: Abeywickrama-Samarakoon, Natali et al. Hepatitis Delta Virus histone mimicry drives the recruitment of chromatin remodelers for viral RNA replication, *NAT COMMUN* (2020) 11:

ULTRA-DD: Alam, Mahmood M. et al. Validation of the protein kinase PfCLK3 as a multistage cross-species malarial drug target, *SCIENCE* (2019) 365: 884-+

ULTRA-DD: Al-Mossawi, M. H. et al. Unique transcriptome signatures and GM-CSF expression in lymphocytes from patients with spondyloarthritis, *NAT COMMUN* (2017) 8:

ULTRA-DD: Asquith, Christopher R. M. et al. Design of a Cyclin G Associated Kinase (GAK)/Epidermal Growth Factor Receptor (EGFR) Inhibitor Set to Interrogate the Relationship of EGFR and GAK in Chordoma, *J MED CHEM* (2019) 62: 4772-4778

ULTRA-DD: Asquith, Christopher R. M. et al. Identification and Optimization of 4-Anilinoquinolines as Inhibitors of CyclinG Associated Kinase, *CHEMMEDCHEM* (2018) 13: 48-66

ULTRA-DD: Asquith, Christopher R. M. et al. SGC-GAK-1: A Chemical Probe for Cyclin G Associated Kinase (GAK), *J MED CHEM* (2019) 62: 2830-2836

ULTRA-DD: Asquith, Christopher R. M. et al. Utilizing comprehensive and mini-kinome panels to optimize the selectivity of quinoline inhibitors for cyclin G associated kinase (GAK), *BIOORG MED CHEM LETT* (2019) 29: 1727-1731

ULTRA-DD: Ayelen Carabajal, Maria et al. Quinazoline-Based Antivirulence Compounds Selectively Target Salmonella PhoP/PhoQ Signal Transduction System, *ANTIMICROB AGENTS CH* (2020) 64:

ULTRA-DD: Babault, Nicolas et al. Discovery of Bisubstrate Inhibitors of Nicotinamide N-Methyltransferase (NNMT), *J MED CHEM* (2018) 61: 1541-1551

ULTRA-DD: Barnash, Kimberly D. et al. Discovery of Peptidomimetic Ligands of EED as Allosteric Inhibitors of PRC2, *ACS COMB SCI* (2017) 19: 161-172

ULTRA-DD: Bataille, Carole J. R. et al. Thiazolidine derivatives as potent and selective inhibitors of the PIM kinase family, *BIOORGAN MED CHEM* (2017) 25: 2657-2665

ULTRA-DD: Bavetsias, Vassilios et al. 8-Substituted Pyrido[3,4-d]pyrimidin-4(3H)-one Derivatives As Potent, Cell Permeable, KDM4 (JMJD2) and KDM5 (JARID1) Histone Lysine Demethylase Inhibitors, *J MED CHEM* (2016) 59: 1388-1409

ULTRA-DD: Bergqvist, Filip et al. A review on mPGES-1 inhibitors: From preclinical studies to clinical applications, *PROSTAG OTH LIPID M* (2020) 147:

ULTRA-DD: Bonday, Zahid Q. et al. LLY-283, a Potent and Selective Inhibitor of Arginine Methyltransferase 5, PRMT5, with Antitumor Activity, *ACS MED CHEM LETT* (2018) 9: 612-617

ULTRA-DD: Caplan, Tavia et al. Overcoming Fungal Echinocandin Resistance through Inhibition of the Non-essential Stress Kinase Yck2, *CELL CHEM BIOL* (2020) 27: 269-+

ULTRA-DD: Carter, Adrian J. et al. Target 2035: probing the human proteome, *DRUG DISCOV TODAY* (2019) 24: 2111-2115

ULTRA-DD: Carvalho, Diana et al. ALK2 inhibitors display beneficial effects in preclinical models of ACVR1 mutant diffuse intrinsic pontine glioma, *COMMUN BIOL* (2019) 2:

ULTRA-DD: Celis-Gutierrez, Javier et al. Quantitative Interactomics in Primary T Cells Provides a Rationale for Concomitant PD-1 and BTLA Coinhibitor Blockade in Cancer Immunotherapy, *CELL REP* (2019) 27: 3315-+

ULTRA-DD: Chaikuad, Apirat et al. The Cysteinome of Protein Kinases as a Target in Drug Development, *ANGEW CHEM INT EDIT* (2018) 57: 4372-4385

ULTRA-DD: Christott, Thomas et al. Discovery of a Selective Inhibitor for the YEATS Domains of ENL/AF9, *SLAS DISCOV* (2019) 24: 133-141

ULTRA-DD: Clerici, Marcello et al. Structural basis of AAUAAA polyadenylation signal recognition by the human CPSF complex, *NAT STRUCT MOL BIOL* (2018) 25: 135-+

ULTRA-DD: Dahlin, Jayme L. et al. Assay interference and off-target liabilities of reported histone acetyltransferase inhibitors, *NAT COMMUN* (2017) 8:

ULTRA-DD: de Freitas, Renato Ferreira et al. A systematic analysis of atomic protein-ligand interactions in the PDB, *MEDCHEMCOMM* (2017) 8: 1970-1981

ULTRA-DD: de Witte, Wilhelmus E. A. et al. In vivo Target Residence Time and Kinetic Selectivity: The Association Rate Constant as Determinant, *TRENDS PHARMACOL SCI* (2016) 37: 831-842

ULTRA-DD: Dong, Cheng et al. Molecular basis of GID4-mediated recognition of degrons for the Pro/N-end rule pathway, *NAT CHEM BIOL* (2018) 14: 466-+

ULTRA-DD: Douangamath, Alice et al. Crystallographic and electrophilic fragment screening of the SARS-CoV-2 main protease, *NAT COMMUN* (2020) 11:

ULTRA-DD: Drewry, David H. et al. Progress towards a public chemogenomic set for protein kinases and a call for contributions, *PLOS ONE* (2017) 12:

ULTRA-DD: Ebrahimi, Ayyub et al. Bromodomain inhibition of the coactivators CBP/EP300 facilitate cellular reprogramming, *NAT CHEM BIOL* (2019) 15: 519-+

ULTRA-DD: Eggert, Erik et al. Discovery and Characterization of a Highly Potent and Selective Aminopyrazoline-Based in Vivo Probe (BAY-598) for the Protein Lysine Methyltransferase SMYD2, *J MED CHEM* (2016) 59: 4578-4600

ULTRA-DD: Eram, Mohammad S. et al. A Potent, Selective, and Cell-Active Inhibitor of Human Type I Protein Arginine Methyltransferases, *ACS CHEM BIOL* (2016) 11: 772-781

ULTRA-DD: Faini, Marco et al. The Evolving Contribution of Mass Spectrometry to Integrative Structural Biology, *J AM SOC MASS SPECTR* (2016) 27: 966-974

ULTRA-DD: Fang, Hai et al. A genetics-led approach defines the drug target landscape of 30 immune-related traits, *NAT GENET* (2019) 51: 1082-+

ULTRA-DD: Favalli, Nicholas et al. A DNA-Encoded Library of Chemical Compounds Based on Common Scaffolding Structures Reveals the Impact of Ligand Geometry on Protein Recognition, *CHEMMEDCHEM* (2018) 13: 1303-1307

ULTRA-DD: Fernandez-Montalvan, Amaury E. et al. Isoform-Selective ATAD2 Chemical Probe with Novel Chemical Structure and Unusual Mode of Action, *ACS CHEM BIOL* (2017) 12: 2730-2736

ULTRA-DD: Fong, Jia Yi et al. Therapeutic Targeting of RNA Splicing Catalysis through Inhibition of Protein Arginine Methylation, *CANCER CELL* (2019) 36: 194-+

ULTRA-DD: Forster, Michael et al. Selective JAK3 Inhibitors with a Covalent Reversible Binding Mode Targeting a New Induced Fit Binding Pocket, *CELL CHEM BIOL* (2016) 23: 1335-1340

ULTRA-DD: Fortin, Jerome et al. Mutant ACVR1 Arrests Glial Cell Differentiation to Drive Tumorigenesis in Pediatric Gliomas, *CANCER CELL* (2020) 37: 308-+

ULTRA-DD: Fox, Nicholas G. et al. Structure of the human frataxin-bound iron-sulfur cluster assembly complex provides insight into its activation mechanism, *NAT COMMUN* (2019) 10:

ULTRA-DD: Fujisawa, Takao et al. Functions of bromodomain-containing proteins and their roles in homeostasis and cancer, *NAT REV MOL CELL BIO* (2017) 18: 246-262

ULTRA-DD: Fulcher, Luke J. et al. The DUF1669 domain of FAM83 family proteins anchor casein kinase 1 isoforms, *SCI SIGNAL* (2018) 11:

ULTRA-DD: Gray, Janine L. et al. Targeting the Small GTPase Superfamily through Their Regulatory Proteins, *ANGEW CHEM INT EDIT* (2020) 59: 6342-6366

ULTRA-DD: Grieben, Mariana et al. Structure of the polycystic kidney disease TRP channel Polycystin-2 (PC2), *NAT STRUCT MOL BIOL* (2017) 24: 114-+

ULTRA-DD: Halabelian, Levon et al. Structural basis of HMCES interactions with abasic DNA and multivalent substrate recognition, *NAT STRUCT MOL BIOL* (2019) 26: 607-+

ULTRA-DD: Hammitzsch, Ariane et al. CBP30, a selective CBP/p300 bromodomain inhibitor, suppresses human Th17 responses, *P NATL ACAD SCI USA* (2015) 112: 10768-10773

ULTRA-DD: Hauri, Simon et al. A High-Density Map for Navigating the Human Polycomb Complexome, *CELL REP* (2016) 17: 583-595

ULTRA-DD: He, Yupeng et al. The EED protein-protein interaction inhibitor A-395 inactivates the PRC2 complex, *NAT CHEM BIOL* (2017) 13: 389-+

ULTRA-DD: Huang, Ling et al. Ductal pancreatic cancer modeling and drug screening using human pluripotent stem cell- and patient-derived tumor organoids, *NAT MED* (2015) 21: 1364-1371

ULTRA-DD: Hudson, Liam et al. Novel Quinazolinone Inhibitors of ALK2 Flip between Alternate Binding Modes: Structure-Activity Relationship, Structural Characterization, Kinase Profiling, and Cellular Proof of Concept, *J MED CHEM* (2018) 61: 7261-7272

ULTRA-DD: Igoe, Niall et al. Design of a Biased Potent Small Molecule Inhibitor of the Bromodomain and PHD Finger-Containing (BRPF) Proteins Suitable for Cellular and in Vivo Studies, *J MED CHEM* (2017) 60: 668-680

ULTRA-DD: Imrie, Fergus et al. Protein Family-Specific Models Using Deep Neural Networks and Transfer Learning Improve Virtual Screening and Highlight the Need for More Data, *J CHEM INF MODEL* (2018) 58: 2319-2330

ULTRA-DD: Kagoya, Yuki et al. BET bromodomain inhibition enhances T cell persistence and function in adoptive immunotherapy models, *J CLIN INVEST* (2016) 126: 3479-3494

ULTRA-DD: Kalkat, Manpreet et al. MYC Protein Interactome Profiling Reveals Functionally Distinct Regions that Cooperate to Drive Tumorigenesis, *MOL CELL* (2018) 72: 836-+

ULTRA-DD: Kasinath, Vignesh et al. Structures of human PRC2 with its cofactors AEBP2 and JARID2, *SCIENCE* (2018) 359: 940-944

ULTRA-DD: Klatt, Felix et al. A precisely positioned MED12 activation helix stimulates CDK8 kinase activity, *P NATL ACAD SCI USA* (2020) 117: 2894-2905

ULTRA-DD: Kock, Anna et al. Inhibition of Microsomal Prostaglandin E Synthase-1 in Cancer-Associated Fibroblasts Suppresses Neuroblastoma Tumor Growth, *EBIOMEDICINE* (2018) 32: 84-92

ULTRA-DD: Lafita, Aleix et al. BioJava 5: A community driven open-source bioinformatics library, *PLOS COMPUT BIOL* (2019) 15:

ULTRA-DD: Lambert, Jean-Philippe et al. Interactome Rewiring Following Pharmacological Targeting of BET Bromodomains, *MOL CELL* (2019) 73: 621-+

ULTRA-DD: Leitner, Alexander et al. Crosslinking and Mass Spectrometry: An Integrated Technology to Understand the Structure and Function of Molecular Machines, *TRENDS BIOCHEM SCI* (2016) 41: 20-32

ULTRA-DD: Liu, Lihua et al. UbiHub: a data hub for the explorers of ubiquitination pathways, *BIOINFORMATICS* (2019) 35: 2882-2884

ULTRA-DD: McAllister, Tom E. et al. Recent Progress in Histone Demethylase Inhibitors, *J MED CHEM* (2016) 59: 1308-1329

ULTRA-DD: Michealraj, Kulandaimanuel Antony et al. Metabolic Regulation of the Epigenome Drives Lethal Infantile Ependymoma, *CELL* (2020) 181: 1329-+

ULTRA-DD: Moustakim, Moses et al. Chemical probes and inhibitors of bromodomains outside the BET family, *MEDCHEMCOMM* (2016) 7: 2246-2264

ULTRA-DD: OByrne, Sean N. et al. In Depth Analysis of Kinase Cross Screening Data to Identify CAMKK2 Inhibitory Scaffolds, *MOLECULES* (2020) 25:

ULTRA-DD: Ostrom, Quinn T. et al. Risk factors for childhood and adult primary brain tumors, *NEURO-ONCOLOGY* (2019) 21: 1357-1375

ULTRA-DD: Picaud, Sarah et al. Promiscuous targeting of bromodomains by bromosporine identifies BET proteins as master regulators of primary transcription response in leukemia, *SCI ADV* (2016) 2:

ULTRA-DD: Resnick, Efrat et al. Rapid Covalent-Probe Discovery by Electrophile-Fragment Screening, *J AM CHEM SOC* (2019) 141: 8951-8968

ULTRA-DD: Reynoird, Nicolas et al. Coordination of stress signals by the lysine methyltransferase SMYD2 promotes pancreatic cancer, *GENE DEV* (2016) 30: 772-785

ULTRA-DD: Rocklin, Gabriel J. et al. Global analysis of protein folding using massively parallel design, synthesis, and testing, *SCIENCE* (2017) 357: 168-174

ULTRA-DD: Rodstrom, Karin E. J. et al. A lower X-gate in TASK channels traps inhibitors within the vestibule, *NATURE* (2020) :

ULTRA-DD: Schapira, Matthieu et al. Targeted protein degradation: expanding the toolbox, *NAT REV DRUG DISCOV* (2019) 18: 949-963

ULTRA-DD: Schapira, Matthieu et al. WD40 repeat domain proteins: a novel target class?, *NAT REV DRUG DISCOV* (2017) 16: 773-786

ULTRA-DD: Scheer, Sebastian et al. A chemical biology toolbox to study protein methyltransferases and epigenetic signaling, *NAT COMMUN* (2019) 10:

ULTRA-DD: Schewe, Marcus et al. A pharmacological master key mechanism that unlocks the selectivity filter gate in K<sup>+</sup> channels, *SCIENCE* (2019) 363: 875-+

ULTRA-DD: Shen, Yudao et al. Discovery of a Potent, Selective, and Cell-Active Dual Inhibitor of Protein Arginine Methyltransferase 4 and Protein Arginine Methyltransferase 6, *J MED CHEM* (2016) 59: 9124-9139

ULTRA-DD: Shigesu, Nina et al. The association between endometriosis and autoimmune diseases: a systematic review and meta-analysis, *HUM REPROD UPDATE* (2019) 25: 486-503

ULTRA-DD: Shukla, Vipul et al. HMCES Functions in the Alternative End-Joining Pathway of the DNA DSB Repair during Class Switch Recombination in B Cells, *MOL CELL* (2020) 77: 384-+

ULTRA-DD: Stoesser, Nicole et al. Performance characteristics of five immunoassays for SARS-CoV-2: a head-to-head benchmark comparison, *LANCET INFECT DIS* (2020) 20: 1390-1400

ULTRA-DD: Teyra, Joan et al. Comprehensive Analysis of the Human SH3 Domain Family Reveals a Wide Variety of Non-canonical Specificities, *STRUCTURE* (2017) 25: 1598-+

ULTRA-DD: Tumber, Anthony et al. Potent and Selective KDM5 Inhibitor Stops Cellular Demethylation of H3K4me3 at Transcription Start Sites and Proliferation of MM1S Myeloma Cells, *CELL CHEM BIOL* (2017) 24: 371-380

ULTRA-DD: Urbanucci, Alfonso et al. Androgen Receptor Deregulation Drives Bromodomain-Mediated Chromatin Alterations in Prostate Cancer, *CELL REP* (2017) 19: 2045-2059

ULTRA-DD: Vasta, James D. et al. Quantitative, Wide-Spectrum Kinase Profiling in Live Cells for Assessing the Effect of Cellular ATP on Target Engagement, *CELL CHEM BIOL* (2018) 25: 206-+

ULTRA-DD: Vaz, Bruno et al. Metalloprotease SPRTN/DVC1 Orchestrates Replication-Coupled DNA-Protein Crosslink Repair, *MOL CELL* (2016) 64: 704-719

ULTRA-DD: Veschi, Veronica et al. Epigenetic siRNA and Chemical Screens Identify SETD8 Inhibition as a Therapeutic Strategy for p53 Activation in High-Risk Neuroblastoma, *CANCER CELL* (2017) 31: 50-63

ULTRA-DD: Villasenor, Rodrigo et al. ChromID identifies the protein interactome at chromatin marks, *NAT BIOTECHNOL* (2020) 38: 728-+

ULTRA-DD: Ward, Jennifer A. et al. Re-Evaluating the Mechanism of Action of alpha,beta-Unsaturated Carbonyl DUB Inhibitors b-AP15 and VLX1570: A Paradigmatic Example of Unspecific Protein Cross-linking with Michael Acceptor Motif-Containing Drugs, *J MED CHEM* (2020) 63: 3756-3762

ULTRA-DD: Wilkes, Martin et al. Molecular insights into lipid-assisted Ca<sup>2+</sup> regulation of the TRP channel Polycystin-2, *NAT STRUCT MOL BIOL* (2017) 24: 123-+

ULTRA-DD: Wu, Qin et al. A chemical toolbox for the study of bromodomains and epigenetic signaling, *NAT COMMUN* (2019) 10:

ULTRA-DD: Xiong, Yan et al. Discovery of Potent and Selective Inhibitors for G9a-Like Protein (GLP) Lysine Methyltransferase, *J MED CHEM* (2017) 60: 1876-1891

ULTRA-DD: Xu, Chao et al. DNA Sequence Recognition of Human CXXC Domains and Their Structural Determinants, *STRUCTURE* (2018) 26: 85-+

ULTRA-DD: Xu, Chao et al. Structural Basis for the Discriminative Recognition of N-6-Methyladenosine RNA by the Human YT521-B Homology Domain Family of Proteins, *J BIOL CHEM* (2015) 290: 24902-24913

ULTRA-DD: Zhang, Wei et al. System-Wide Modulation of HECT E3 Ligases with Selective Ubiquitin Variant Probes, *MOL CELL* (2016) 62: 121-136

VITAL: Wagner, Angelika et al. Vaccines to Prevent Infectious Diseases in the Older Population: Immunological Challenges and Future Perspectives, *FRONT IMMUNOL* (2020) 11:

VSV-EBOPPLUS: Alter, Galit et al. Antibody glycosylation in inflammation, disease and vaccination, *SEMIN IMMUNOL* (2018) 39: 102-110

VSV-EBOVAC: Huttner, Angela et al. A dose-dependent plasma signature of the safety and immunogenicity of the rVSV-Ebola vaccine in Europe and Africa, *SCI TRANSL MED* (2017) 9:

WEB-RADR: Caster, Ola et al. Assessment of the Utility of Social Media for Broad-Ranging Statistical Signal Detection in Pharmacovigilance: Results from the WEB-RADR Project, *DRUG SAFETY* (2018) 41: 1355-1369

WEB-RADR: Pierce, Carrie E. et al. Evaluation of Facebook and Twitter Monitoring to Detect Safety Signals for Medical Products: An Analysis of Recent FDA Safety Alerts, *DRUG SAFETY* (2017) 40: 317-331

WEB-RADR: Pierce, Carrie E. et al. Recommendations on the Use of Mobile Applications for the Collection and Communication of Pharmaceutical Product Safety Information: Lessons from IMI WEB-RADR, *DRUG SAFETY* (2019) 42: 477-489

WEB-RADR: Powell, Gregory E. et al. Social Media Listening for Routine Post-Marketing Safety Surveillance, *DRUG SAFETY* (2016) 39: 443-454

WEB-RADR: Sloane, Richard et al. Social media and pharmacovigilance: A review of the opportunities and challenges, *BRIT J CLIN PHARMACO* (2015) 80: 910-920

ZAPI: Becares, Martina et al. Mutagenesis of Coronavirus nsp14 Reveals Its Potential Role in Modulation of the Innate Immune Response, *J VIROL* (2016) 90: 5399-5414

ZAPI: Canton, Javier et al. MERS-CoV 4b protein interferes with the NF-kappa B-dependent innate immune response during infection, *PLOS PATHOG* (2018) 14:

ZAPI: Castano-Rodriguez, Carlos et al. Role of Severe Acute Respiratory Syndrome Coronavirus Viroporins E, 3a, and 8a in Replication and Pathogenesis, *MBIO* (2018) 9:

ZAPI: Haagmans, Bart L. et al. An orthopoxvirus-based vaccine reduces virus excretion after MERS-CoV infection in dromedary camels, *SCIENCE* (2016) 351: 77-81

ZAPI: Li, Wentao et al. Identification of sialic acid-binding function for the Middle East respiratory syndrome coronavirus spike glycoprotein, *P NATL ACAD SCI USA* (2017) 114: E8508-E8517

ZAPI: Ludlow, Martin et al. Neurotropic virus infections as the cause of immediate and delayed neuropathology, *ACTA NEUROPATHOL* (2016) 131: 159-184

ZAPI: Morales, Lucia et al. SARS-CoV-Encoded Small RNAs Contribute to Infection-Associated Lung Pathology, *CELL HOST MICROBE* (2017) 21: 344-355

ZAPI: Munyua, Peninah et al. No Serologic Evidence of Middle East Respiratory Syndrome Coronavirus Infection among Camel Farmers Exposed to Highly Seropositive Camel Herds: A Household Linked Study, Kenya, 2013, *AM J TROP MED HYG* (2017) 96: 1318-1324

ZAPI: Okba, Nisreen M. A. et al. Middle East respiratory syndrome coronavirus vaccines: current status and novel approaches, *CURR OPIN VIROL* (2017) 23: 49-58

ZAPI: Okba, Nisreen M. A. et al. Sensitive and Specific Detection of Low-Level Antibody Responses in Mild Middle East Respiratory Syndrome Coronavirus Infections, *EMERG INFECT DIS* (2019) 25: 1868-1877

ZAPI: Okba, Nisreen M. A. et al. Severe Acute Respiratory Syndrome Coronavirus 2-Specific Antibody Responses in Coronavirus Disease Patients, *EMERG INFECT DIS* (2020) 26: 1478-1488

ZAPI: Raj, V. Stalin et al. Chimeric camel/human heavy-chain antibodies protect against MERS-CoV infection, *SCI ADV* (2018) 4:

ZAPI: Rey, Felix A. et al. Common Features of Enveloped Viruses and Implications for Immunogen Design for Next-Generation Vaccines, *CELL* (2018) 172: 1319-1334

ZAPI: Siu, Kam-Leung et al. Severe acute respiratory syndrome coronavirus ORF3a protein activates the NLRP3 inflammasome by promoting TRAF3-dependent ubiquitination of ASC, *FASEB J* (2019) 33: 8865-8877

ZAPI: Vergara-Alert, Julia et al. Livestock Susceptibility to Infection with Middle East Respiratory Syndrome Coronavirus, *EMERG INFECT DIS* (2017) 23: 232-240

ZAPI: Wang, Chunyan et al. A human monoclonal antibody blocking SARS-CoV-2 infection, *NAT COMMUN* (2020) 11:

ZAPI: Wernike, Kerstin et al. The N-terminal domain of Schmallenberg virus envelope protein Gc is highly immunogenic and can provide protection from infection, *SCI REP-UK* (2017) 7:

ZAPI: Widagdo, W. et al. Differential Expression of the Middle East Respiratory Syndrome Coronavirus Receptor in the Upper Respiratory Tracts of Humans and Dromedary Camels, *J VIROL* (2016) 90: 4838-4842

ZAPI: Widagdo, W. et al. MERS-coronavirus: From discovery to intervention, *ONE HEALTH-AMSTERDAM* (2017) 3: 11-16

ZAPI: Widagdo, W. et al. Species-Specific Colocalization of Middle East Respiratory Syndrome Coronavirus Attachment and Entry Receptors, *J VIROL* (2019) 93:

ZAPI: Widjaja, Ivy et al. Towards a solution to MERS: protective human monoclonal antibodies targeting different domains and functions of the MERS-coronavirus spike glycoprotein, *EMERG MICROBES INFECTION* (2019) 8: 516-530

Unassigned: Ahlqvist, Emma et al. Novel subgroups of adult-onset diabetes and their association with outcomes: a data-driven cluster analysis of six variables, *LANCET DIABETES ENDO* (2018) 6: 361-369

Unassigned: Attal, Nadine et al. Diagnosis and assessment of neuropathic pain through questionnaires, *LANCET NEUROL* (2018) 17: 456-466

Unassigned: Bachert, Claus et al. Staphylococcus aureus and its IgE-inducing enterotoxins in asthma: current knowledge, *EUR RESPIR J* (2020) 55:

Unassigned: Carey, Iain M. et al. Are noise and air pollution related to the incidence of dementia? A cohort study in London, England, *BMJ OPEN* (2018) 8:

Unassigned: Dhar, Raja et al. Bronchiectasis in India: results from the European Multicentre Bronchiectasis Audit and Research Collaboration (EMBARC) and Respiratory Research Network of India Registry, *LANCET GLOB HEALTH* (2019) 7: E1269-E1279

Unassigned: Dumas, G. et al. The Human Dynamic Clamp Reveals the Fronto-Parietal Network Linking Real-Time Social Coordination and Cognition, *CEREB CORTEX* (2020) 30: 3271-3285

Unassigned: Gallagher, Arlene M. et al. The accuracy of date of death recording in the Clinical Practice Research Datalink GOLD database in England compared with the Office for National Statistics death registrations, *PHARMACOEPIDEM DRUG SAFETY* (2019) 28: 563-569

Unassigned: Generaal, Ellen et al. Neighbourhood characteristics and prevalence and severity of depression: pooled analysis of eight Dutch cohort studies, *BRIT J PSYCHIATRY* (2019) 215: 468-475

Unassigned: Heerspink, Hidde J. L. et al. Canagliflozin reduces inflammation and fibrosis biomarkers: a potential mechanism of action for beneficial effects of SGLT2 inhibitors in diabetic kidney disease, *DIABETOLOGIA* (2019) 62: 1154-1166

Unassigned: Piot, Peter et al. Immunization: vital progress, unfinished agenda, *NATURE* (2019) 575: 119-129

Unassigned: Visscher, Peter M. et al. 10 Years of GWAS Discovery: Biology, Function, and Translation, *AM J HUM GENET* (2017) 101: 5-22

Unassigned: Williams, Tim et al. Recent advances in the utility and use of the General Practice Research Database as an example of a UK Primary Care Data resource, *THER ADV DRUG SAFETY* (2012) 3: 89-99